U.S. patent application number 12/911442 was filed with the patent office on 2011-03-31 for c-met modulators and method of use.
This patent application is currently assigned to Exelixis, Inc.. Invention is credited to Lynne Canne Bannen, Diva Sze-Ming Chan, Jeff Chen, Lisa Esther Dalrymple, Timothy Patrick Forsyth, Tai Phat Huynh, Vasu Jammalamadaka, Richard George Khoury, James William Leahy, Morrison B. Mac, Grace Mann, Larry W. Mann, John M. Nuss, Jason Jevious Parks, Craig Stacy Takeuchi, Yong Wang, Wei Xu.
Application Number | 20110077233 12/911442 |
Document ID | / |
Family ID | 34397024 |
Filed Date | 2011-03-31 |
United States Patent
Application |
20110077233 |
Kind Code |
A1 |
Bannen; Lynne Canne ; et
al. |
March 31, 2011 |
C-Met Modulators and Method of Use
Abstract
The present invention provides compounds for modulating protein
kinase enzymatic activity for modulating cellular activities such
as proliferation, differentiation, programmed cell death, migration
and chemoinvasion. More specifically, the invention provides
quinazolines and quinolines which inhibit, regulate, and/or
modulate kinase receptor, particularly c-Met, KDF, c-Kit, flt-3 and
flt-4, signal transduction pathways related to the changes in
cellular activities as mentioned above, compositions which contain
these compounds, and methods of using them to treat
kinase-dependent diseases and conditions. The present invention
also provides methods for making compounds as mentioned above, and
compositions which contain these compounds.
Inventors: |
Bannen; Lynne Canne;
(Pacifica, CA) ; Chan; Diva Sze-Ming; (San
Francisco, CA) ; Chen; Jeff; (San Francisco, CA)
; Dalrymple; Lisa Esther; (Seattle, WA) ; Forsyth;
Timothy Patrick; (Hayward, CA) ; Huynh; Tai Phat;
(Oakland, CA) ; Jammalamadaka; Vasu; (Pleasanton,
CA) ; Khoury; Richard George; (San Mateo, CA)
; Leahy; James William; (San Leandro, CA) ; Mac;
Morrison B.; (San Francisco, CA) ; Mann; Grace;
(San Mateo, CA) ; Mann; Larry W.; (Richland,
MI) ; Nuss; John M.; (Danville, CA) ; Parks;
Jason Jevious; (Sacramento, CA) ; Takeuchi; Craig
Stacy; (Burlingame, CA) ; Wang; Yong; (Foster
City, CA) ; Xu; Wei; (Danville, CA) |
Assignee: |
Exelixis, Inc.
South San Francisco
CA
|
Family ID: |
34397024 |
Appl. No.: |
12/911442 |
Filed: |
October 25, 2010 |
Related U.S. Patent Documents
|
|
|
|
|
|
Application
Number |
Filing Date |
Patent Number |
|
|
11753462 |
May 24, 2007 |
|
|
|
12911442 |
|
|
|
|
11586751 |
Oct 26, 2006 |
|
|
|
11753462 |
|
|
|
|
10573336 |
Sep 18, 2006 |
|
|
|
PCT/US04/31523 |
Sep 24, 2004 |
|
|
|
11586751 |
|
|
|
|
60577384 |
Jun 4, 2004 |
|
|
|
60535377 |
Jan 9, 2004 |
|
|
|
60506181 |
Sep 26, 2003 |
|
|
|
Current U.S.
Class: |
514/210.18 ;
435/15; 435/375; 514/234.5; 514/235.2; 514/266.21; 514/266.23;
514/266.4; 514/312; 544/119; 544/128; 544/287; 544/293;
546/153 |
Current CPC
Class: |
A61P 9/10 20180101; C07D
405/14 20130101; C07D 401/14 20130101; A61P 1/00 20180101; A61P
43/00 20180101; A61K 31/505 20130101; A61P 37/02 20180101; A61P
17/02 20180101; C12Q 1/485 20130101; C07D 413/14 20130101; Y02A
50/30 20180101; A61K 31/4709 20130101; A61P 29/00 20180101; A61P
37/06 20180101; C07D 417/12 20130101; A61P 1/04 20180101; A61K
31/501 20130101; A61P 3/10 20180101; A61P 19/00 20180101; C07D
215/36 20130101; A61K 31/4725 20130101; A61K 31/517 20130101; C07D
401/12 20130101; A61K 31/496 20130101; A61K 31/506 20130101; A61P
37/00 20180101; A61P 35/02 20180101; C07D 239/88 20130101; C07D
403/12 20130101; A61P 35/00 20180101; A61K 31/5377 20130101; C07D
239/94 20130101; C07D 215/22 20130101; C07D 215/46 20130101; G01N
2500/04 20130101; A61P 19/02 20180101; A61P 27/02 20180101; A61K
31/47 20130101; C07D 413/12 20130101; A61P 9/00 20180101; C07D
215/38 20130101; A61P 37/08 20180101; C07D 295/15 20130101; A61P
25/00 20180101; C07D 215/233 20130101; A61P 17/06 20180101 |
Class at
Publication: |
514/210.18 ;
546/153; 514/312; 544/287; 514/266.23; 544/293; 514/266.4;
514/266.21; 544/128; 514/235.2; 544/119; 514/234.5; 435/15;
435/375 |
International
Class: |
A61K 31/517 20060101
A61K031/517; C07D 401/12 20060101 C07D401/12; A61K 31/4709 20060101
A61K031/4709; C07D 417/12 20060101 C07D417/12; C07D 403/12 20060101
C07D403/12; C07D 239/94 20060101 C07D239/94; A61K 31/47 20060101
A61K031/47; C07D 413/12 20060101 C07D413/12; A61K 31/5377 20060101
A61K031/5377; A61P 35/00 20060101 A61P035/00; A61P 9/00 20060101
A61P009/00; A61P 37/02 20060101 A61P037/02; A61P 29/00 20060101
A61P029/00; C12Q 1/48 20060101 C12Q001/48; C12N 5/02 20060101
C12N005/02 |
Claims
1. A compound of formula I, ##STR00548## or a pharmaceutically
acceptable salt, hydrate, or prodrug thereof, wherein, R.sup.1 is
selected from --H, halogen, --OR.sup.3, --NO.sub.2, --NH.sub.2,
--NR.sup.3R.sup.4 and optionally substituted lower alkyl; A.sup.1
is selected from .dbd.N-- and .dbd.C(H)--; Z is --O--; Ar is either
a group of formula II, or of formula III, ##STR00549## wherein,
R.sup.2 is selected from --H, halogen, trihalomethyl, --CN,
--NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3 and optionally
substituted lower alkyl; q is 0 to 4; G is selected from:
##STR00550## ##STR00551## ##STR00552## each E is selected from
--O--, --N(R.sup.13)--, --CH.sub.2-- and --S(O).sub.0-2--; M is
selected from --O--, --N(R.sup.13)--, --CH.sub.2-- and
--C(.dbd.O)N(R.sup.13)--; each V is independently either .dbd.N--
or .dbd.C(H)--; each methylene in any of the above formulae is
independently optionally substituted with one or two R.sup.25;
R.sup.25 is selected from halogen, trihalomethyl, --CN, --NO.sub.2,
--NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
arylalkyl, heteroarylalkyl and optionally substituted lower alkyl;
or two of R.sup.25, together with the carbon or carbons to which
they are attached, can combine to form a three- to seven-membered
alicyclic or heteroalicyclic; or two of R.sup.25 on a single carbon
can be oxo; J is selected from --S(O).sub.0-2-, --O--, and
--NR.sup.5--; R.sup.3 is --H or R.sup.4; R.sup.4 is selected from
optionally substituted lower alkyl, optionally substituted aryl,
optionally substituted lower arylalkyl, optionally substituted
heterocyclyl and optionally substituted lower heterocyclylalkyl; or
R.sup.3 and R.sup.4, when taken together with a common nitrogen to
which they are attached, form an optionally substituted five- to
seven-membered heterocyclyl, said optionally substituted five- to
seven-membered heterocyclyl optionally containing at least one
additional annular heteroatom selected from N, O, S and P; A.sup.2
and A.sup.3 are each independently selected from .dbd.N-- and
.dbd.C(R.sup.2)--; D is selected from --O--, --S(O).sub.0-2-- and
--NR.sup.15--; R.sup.50 is R.sup.3; R.sup.13 is selected from --H,
--C(.dbd.O)R.sup.3, --C(.dbd.O)OR.sup.3, --C(.dbd.O)SR.sup.3,
--SO.sub.2R.sup.4, --C(.dbd.O)N(R.sup.3)R.sup.3 and optionally
substituted lower alkyl; or, two R.sup.13, together with the atom
or atoms to which they are attached, can combine to form a
heteroalicyclic optionally substituted with between one and four of
R.sup.60, said heteroalicyclic can have up to four annular
heteroatoms, and said heteroalicyclic can have an aryl or
heteroaryl fused thereto, in which case said aryl or heteroaryl is
optionally substituted with an additional one to four of R.sup.60;
R.sup.14 is selected from --H, --NO.sub.2, --NH.sub.2,
--N(R.sup.3)R.sup.4, --CN, --OR.sup.3, optionally substituted lower
alkyl, optionally substituted heteroalicyclylalkyl, optionally
substituted aryl, optionally substituted arylallyl and optionally
substituted heteroalicyclic; R.sup.15 is a group -M.sup.1-M.sup.2,
wherein M.sup.1 is selected from absent, --C(.dbd.S)N(R.sup.13)--,
--C(.dbd.NR.sup.14)N(R.sup.13)--, SO.sub.2N(R.sup.13)--,
--SO.sub.2--, --C(.dbd.O)N(R.sup.13)--,
--C(.dbd.O)C(.dbd.O)N(R.sup.13)--, --C.sub.0-4alkylene-,
--C(.dbd.O)-- and an optionally substituted four to six-membered
heterocyclyl annular containing between one and three heteratoms
including at least one nitrogen; and M.sup.2 is selected from --H,
--C.sub.0-6alkyl, alkoxy, --C(.dbd.O)C.sub.0-4alkylQ,
--C.sub.0-4alkylQ, --OC.sub.0-4alkylQ-,
--N(R.sup.13)C.sub.0-4alkylQ- and
--C(.dbd.O)N(R.sup.13)C.sub.0-4alkylQ; Q is a five- to ten-membered
ring system, optionally substituted with between zero and four of
R.sup.20; R.sup.20 is selected from -H, halogen, trihalomethyl,
--CN, --NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3, --N(R.sup.3)
SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3 and optionally
substituted lower alkyl; and R.sup.60 is selected from --H,
halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted lower alkyl, optionally
substituted aryl, optionally substituted heteroarylalkyl and
optionally substituted arylalkyl; or two of R.sup.60, when attached
to a non-aromatic carbon, can be oxo; with the proviso that the
conditions of: Z is -O--; Ar is according to formula II; and the
portion of G directly attached to Ar selected from the table below:
##STR00553## are not met at the same time; and with the proviso
that when Ar is phenylene or substituted phenylene, then the
portion of G directly attached to Ar cannot contain ##STR00554##
wherein R.sup.70 is selected from --H, C.sub.1-4alkyl, and
C.sub.1-4alkoxyl.
2. The compound according to claim 1, wherein Ar is according to
one of formula IIa, IIb and IIIa: ##STR00555##
3. The compound according to claim 1, wherein A.sup.1 is
.dbd.C(H)--.
4. The compound according to claim 2, wherein Ar is of formula IIa
and A.sup.1 is .dbd.N--.
5. The compound according to claim 2, wherein D is --O-- and
R.sup.1 is -OR.sup.3.
6. The compound according to claim 5, wherein --O--R.sup.50 and
R.sup.1 are interchangeably located at the 6-position and
7-position of the quinazoline or quinoline according to formula
I.
7. The compound according to claim 6, wherein R.sup.1 is --OH or
--OC.sub.1-6alkyl.
8. The compound according to claim 7, wherein G is selected from:
##STR00556## wherein Q, R.sup.13, E and R.sup.60 are as defined
above; each methylene in any of the above formulae, other than
those in a depicted ring, is independently optionally substituted
with one or two R.sup.25; and R.sup.25 is selected from halogen,
trihalomethyl, oxo, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
arylalkyl, heteroarylalkyl and optionally substituted lower alkyl;
or two of R.sup.25, together with the carbon or carbons to which
they are attached, can combine to form a three- to seven-membered
alicyclic or heteroalicyclic.
9. The compound according to claim 8, wherein Q is selected from:
##STR00557## wherein R.sup.20 is defined as above, and P is a five-
to seven-membered ring, including the two shared carbons of the
aromatic ring to which P is fused, P optionally containing between
one and three heteroatoms.
10. The compound according to claim 9, wherein Ar is according to
formula IIb, and G is selected from: ##STR00558## wherein Q,
R.sup.13, E, and R.sup.60 are as defined above, and each methylene
in any of the above foimulae, other than those depicted in a ring,
is independently optionally substituted with one or two R.sup.25;
and R.sup.25 is selected from halogen, trihalomethyl, oxo, --CN,
--NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3, optionally substituted
aryl, optionally substituted arylalkyl, heteroarylalkyl and
optionally substituted lower alkyl; or two of R.sup.25, together
with the carbon or carbons to which they are attached, can combine
to form a three- to seven-membered alicyclic or
heteroalicyclic.
11. The compound according to claim 10, wherein the methylene
between the two carbonyls of G is di-substituted with either
optionally substituted lower alkyl, or an optionally substituted
spirocycle.
12. The compound according to claim 10, wherein R.sup.50 is a
heteroalicylic or a C.sub.1-6alkyl-heteroalicylic.
13. The compound according to claim 12, wherein at least one of
R.sup.2 is halogen.
14. The compound according to claim 1, selected from one of the
following compounds: TABLE-US-00006 Name Structure N-{[(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3- fluorophenyl)(methyl)amino]
carbonothioyl}-2- phenylacetamide ##STR00559## 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3 -fluorophenyl)
imidazolidin-2-one ##STR00560## N'-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N- methyl-N-(2-
phenylethyl)sulfamide ##STR00561## 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3- fluorophenyl)piperidin-2-one
##STR00562## N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-4- phenyl-1,3-thiazol-2-amine ##STR00563##
4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluoro-N-
(phenylmethyl) benzenesulfonamide ##STR00564## 4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluoro-N-(2- phenylethyl)
benzenesulfonamide ##STR00565## 4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluoro-N-(3- phenylpropyl) benzenesulfonamide
##STR00566## 4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}phenyl
(phenylmethyl)carbamate ##STR00567## 4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluoro-N-methyl-N-
(3-phenylpropyl) benzenesulfonamide ##STR00568## N-[(Z)-[(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3- fluorophenyl)amino](imino)
methyl]-2-phenylacetamide ##STR00569## N,N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-bis-
(3-phenylpropane-1- sulfonamide) ##STR00570## N2-[(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3- fluorophenyl)sulfonyl]-N1-
phenylglycinamide ##STR00571## N-{[(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-
yl)amino]carbonothioyl}-2- phenylacetamide ##STR00572## 6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-1,3 -
benzothiazol-2-amine ##STR00573## benzyl-{[4-(6,7-dimethoxy-
quinolin-4-yloxy)-3-fluoro- phenylcarbamoyl]-methyl}- carbamic acid
tert-butyl ester ##STR00574## N2-acetyl-N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxyl -3-fluorophenyl)-N2-
(phenylmethyl)glycinamide ##STR00575## benzyl-{[6-(6,7-dimethoxy-
quinolin-4-yloxy)-pyridin-3- ylcarbamoyl]-methyl}- carbamic acid
tert-butyl ester ##STR00576## N2-acetyl-N1-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-yl)-N2-
(phenylmethyl)glycinamide ##STR00577## N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-yl)-4- phenylbutanamide
##STR00578## N1-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N2- methyl-N2- (phenylmethyl)glycinamide
##STR00579## N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-fluoro-1,3- benzothiazol-2-yl)-3- phenylpropanamide
##STR00580## N'-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N- (2-phenylethyl)-N-
(phenylmethyl)sulfamide ##STR00581## N-{[4-(6,7-dimethoxy-
quinolin-4-yloxy)-3-fluoro- phenylcarbamoyl]-methyl}- benzamide
##STR00582## N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N,N'- bis(phenylmethyl)sulfamide
##STR00583## N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-chloropyridin-3- yl)-N'-(4- fluorophenyl)propanediamide
##STR00584## 1-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-3- [(4-methylphenyl)sulfonyl]-4-
(phenylmethyl)imidazolidin- 2-one ##STR00585## N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-2-[3-(trifluoromethyl) phenyl]acetamide ##STR00586## 6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-N-(2-
piperidin-1-ylethyl)-1,3- benzothiazol-2-amine ##STR00587##
6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-N-(2-
pyrrolidin-1-ylethyl)-1,3- benzothiazol-2-amine ##STR00588##
6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-N-{2-[3 -
(trifluoromethyl)phenyl]ethyl}- 1,3-benzothiazol-2-amine
##STR00589## N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-fluoro-1,3- benzothiazol-2-yl)-2-[3- (trifluoromethyl)
phenyl]acetamide ##STR00590## N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N2-
(2-phenylethyl)glycinamide ##STR00591## benzyl-{[5-chloro-6-(6,7-
dimethoxy-quinolin-4-yloxy)- pyridin-3-ylcarbamoyl]-
methyl}-carbamic acid tert- butyl ester ##STR00592## N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-1,3-
benzothiazol-2-yl)-2-[3,5- bis(trifluoromethyl) phenyl]acetamide
##STR00593## N1-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N2- methyl-N2-{[3- (trifluoromethyl)
phenyl]methyl}glycinamide ##STR00594## N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N2- methyl-N2-(2-
phenylethyl)glycinamide ##STR00595## N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}pyridazin-3-yl)-N'-(4-
fluorophenyl)propanediamide ##STR00596## N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3- yl)-N'-(3-
chlorophenyl)propanediamide ##STR00597## N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3- yl)-N'-(4-
chlorophenyl)propanediamide ##STR00598## (2E)-N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-2- [(ethyloxy)imino]
propanamide ##STR00599## N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}phenyl)-1- (phenylmethyl)prolinamide ##STR00600##
1-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}phenyl)-4-
(phenylmethyl) imidazolidin-2-one ##STR00601##
6,7-bis(methyloxy)-4-({4-[4- (phenylmethyl)piperazin-1-
yl]phenyl}oxy)quinoline ##STR00602## N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N2-
(phenylmethyl)alaninamide ##STR00603## N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N2-
(phenylmethyl)leucinamide ##STR00604## N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N2-
(phenylmethyl)valinamide ##STR00605## 2-(Benzyl-methyl-amino)-N-
[4-(6,7-dimethoxy-quinolin-4- yloxy)-phenyl]-3-methyl- butyramide
(note: Alphabetic order of prefixes ignored while selecting parent
chain) ##STR00606## 2-Benzyloxyimino-N-[4-(6,7-
dimethoxy-quinolin-4-yloxy)- phenyl]-2-phenyl-acetamide
##STR00607## 4-(4-{3-Chloro-5-[2-(4- fluoro-phenylcarbamoyl)-
acetylamino]-pyridin-2- yloxy}-6-methoxy-quinolin-7-
yloxymethyl)-piperidine-1- carboxylic acid tert-butyl ester
##STR00608## N-{5-Chloro-6-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-pyridin-3-yl}-N'-(4-
fluoro-phenyl)-malonamide ##STR00609## N- [5-Chloro-6-(6,7-
dimethoxy-quinolin-4-yloxy)- pyridin-3-yl]-N'-(2,4-difluoro-
phenyl)-malonarnide ##STR00610## N-{5-Chloro-6-[6-methoxy-7-
(3-piperidin-1-yl-propoxy)- quinolin-4-yloxy]-pyridin-3-
yl}-N'-(4-fluoro-phenyl)- malonamide ##STR00611##
N-{5-Chloro-6-[7-(3- diethylamino-propoxy)-6-
methoxy-quinolin-4-yloxy]- pyridin-3-yl}-N'-(4-fluoro-
phenyl)-malonamide ##STR00612## N-[5-Chloro-6-(6,7-
dimethoxy-quinolin-4-yloxy)- pyridin-3-yl]-N'-phenyl- malonamide
##STR00613##
15. A compound of formula A-B-C, or a pharmaceutically acceptable
salt, hydrate, or prodrug thereof, wherein: A is selected from:
##STR00614## B is selected from: ##STR00615## and C is selected
from: ##STR00616## wherein: R.sup.2 is selected from --H, halogen,
trihalomethyl, --CN, --NH.sub.2, --NO.sub.2, --OR.sup.3,
--NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3
and optionally substituted lower alkyl; q is 0 to 2; each R.sup.3
is independently selected from --H, optionally substituted lower
alkyl, optionally substituted aryl, optionally substituted
arylalkyl and optionally substituted heteroarylalkyl; or, two
R.sup.3, together with the nitrogen to which they are attached,
form a four- to seven-membered heteroalicyclic, said four- to
seven-membered heteroalicyclic optionally containing one additional
heteroatom; when one said additional heteroatom is a nitrogen, then
said nitrogen is optionally substituted with a group selected from
--H, trihalomethyl, --SO.sub.2R.sup.5, --SO.sub.2NR.sup.5R.sup.5,
--CO.sub.2R.sup.5, --C(O)NR.sup.5R.sup.5, --C(O)R.sup.5 and
optionally substituted lower alkyl; each R.sup.35 is independently
selected from --H, --C(.dbd.O)R.sup.3, --C(.dbd.O)OR.sup.3,
--C(.dbd.O)SR.sup.3, --SO.sub.2R.sup.3,
--C(.dbd.O)N(R.sup.3)R.sup.3, and optionally substituted lower
alkyl; or, two R.sup.35, together with the nitrogen to which they
are attached, can combine to form a heteroalicyclic optionally
substituted with between one and four of R.sup.60, said
heteroalicyclic may have an additional annular heteroatom, and said
heteroalicyclic may have an aryl fused thereto, said aryl
optionally substituted with an additional one to four of R.sup.60;
A.sup.1 is selected from .dbd.N-- and .dbd.C(H)--; A.sup.2 is
either .dbd.N-- or .dbd.C(H)--; R.sup.5 is --H or optionally
substituted lower alkyl; R.sup.8 is selected from R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3 and --C(O)R.sup.3, or an
R.sup.8 is absent and the alkylene linker of A is covalently bonded
to the nitrogen atom in which R.sup.8 is absent; E.sup.1 is
selected from --O--, --CH.sub.2--, --N(R.sup.5)-- and
--S(O).sub.0-2--; Q is a five- to ten-membered ring system,
optionally substituted with between zero and four of R.sup.20;
R.sup.20 is selected from --H, halogen, trihalomethyl, --CN,
--NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.3,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3 and optionally
substituted lower alkyl; R.sup.60 is selected from --H, halogen,
trihalomethyl, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted lower alkyl, optionally
substituted aryl, optionally substituted heteroarylalkyl and
optionally substituted arylalkyl; or, two of R.sup.60, when
attached to a non-aromatic carbon, can be oxo; each methylene in
any of the above formulae is independently optionally substituted
with one or two R.sup.25; and each R.sup.25 is independently
selected from halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2,
--OR.sup.3, --NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
arylalkyl, heteroarylalkyl and optionally substituted lower alkyl;
or two of R.sup.25, together with the carbon or carbons to which
they are attached, can combine to form a three- to seven-membered
alicyclic or heteroalicyclic; or two of R.sup.25 on a single carbon
can be oxo; with the proviso that the conditions of: C contains
##STR00617## and the remaining portion of C contains one of:
##STR00618## are not met at the same time; and with the proviso
that when C contains ##STR00619## directly attached to ##STR00620##
and R.sup.70 is selected from --H, C.sub.1-4alkyl, and
C.sub.1-4alkoxyl, then A.sup.2 is N.
16. The compound according to claim 15, wherein Q is selected from
phenyl, napthyl, 1,2,3,4-tetrahydronaphthyl, indanyl,
benzodioxanyl, benzofuranyl, phenazinyl, phenothiazinyl,
phenoxazinyl, tetrahydroisoquinolyl, pyrrolyl, pyrazolyl,
pyrazolidinyl, imidazolyl, imidazolinyl, imidazolidinyl,
tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl,
isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl, thiazolidinyl,
isothiazolyl, isothiazolidinyl, indolyl, isoindolyl, indolinyl,
isoindolinyl, octahydroindolyl, octahydroisoindolyl, quinolyl,
isoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl,
benzothiazolyl, benzoxazolyl, furyl, thienyl, benzothieliyl and
oxadiazolyl; each optionally substituted with between one and four
of R.sup.20; wherein each R.sup.20 is independently selected from
--H, halogen, trihalomethyl, --CN, --NO.sub.2, --OR.sup.3,
--NR.sup.3R.sup.3, --CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3 and optionally
substituted lower alkyl.
17. The compound according to claim 16, wherein B is: ##STR00621##
wherein A.sup.1 is .dbd.N-- or .dbd.C(H)--.
18. The compound according to claim 17, wherein R.sup.3 is
methyl.
19. The compound according to claim 18, wherein C is selected from:
##STR00622## ##STR00623##
20. The compound according to claim 19, wherein R.sup.2 is selected
from halogen, trihalomethyl, --CN, --NO.sub.2, --OR.sup.3,
--NR.sup.3R.sup.3, --CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3
and optionally substituted lower alkyl.
21. The compound according to claim 20, wherein R.sup.2 is
halogen.
22. The compound according to claim 21, wherein R.sup.2 is fluorine
or chlorine.
23. A compound according to Formula XI, ##STR00624## or a
pharmaceutically acceptable salt, hydrate, or prodrug thereof,
wherein: each R.sup.1 is independently selected from halogen,
--OR.sup.3, --NO.sub.2, --NH.sub.2, --NR.sup.3R.sup.4, -D-R.sup.50
and optionally substituted C.sub.1-6alkyl; Q is selected from
.dbd.N-- or .dbd.C(H)--; Z is --O--; Ar is either a five- or
six-membered arylene or a five- or six-membered heteroarylene
containing between one and three heteroatoms; G is either an
optionally substituted cycloalkyl or an optionally substituted
heteroalicyclic; each R.sup.2 is independently selected from
halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3
and optionally substituted C.sub.1-6alkyl; each R.sup.3 is
independently --H or R.sup.4; each R.sup.4 is independently
selected from optionally substituted C.sub.1-6alkyl, optionally
substituted aryl, optionally substituted aryl C.sub.1-6alkyl,
optionally substituted heterocyclyl and optionally substituted
heterocyclyl C.sub.1-6alkyl; or R.sup.3 and R.sup.4, when taken
together with a common nitrogen to which they are attached, form an
optionally substituted five- to seven-membered heterocyclyl, said
optionally substituted five- to seven-membered heterocyclyl
optionally containing at least one additional annular heteroatom
selected from N, O, S and P; R.sup.5 is --H or optionally
substituted C.sub.1-6alkyl; each D is independently selected from
--O--, --S(O).sub.0-2-- and --NR.sup.S--; each R.sup.30 is
independently selected from halogen, trihalomethyl, --CN,
--NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3 and optionally
substituted C.sub.1-6alkyl; each R.sup.50 is R.sup.3; and R.sup.70
is selected from --H, halogen, --OR.sup.3, --S(O).sub.0-2R.sup.3,
--NO.sub.2, --NH.sub.2, --NR.sup.3R.sup.4 and optionally
substituted C.sub.1-6alkyl.
24. The compound according to claim 23, wherein R.sup.70 is
hydrogen.
25. The compound according to claim 24, wherein at least one of
R.sup.1 is -D-R.sup.50.
26. The compound according to claim 25, wherein D is --O-- and at
least one other R.sup.1 is -OR.sup.3.
27. The compound according to claim 26, of formula XIIIa or XIIIb:
##STR00625## wherein Q.sup.1 is either .dbd.N-- or .dbd.C(H)--,
R.sup.3ais C.sub.1-6alkyl, and --N(R.sup.3b)R.sup.4 is selected
from the following: ##STR00626## wherein: J is a five- to
ten-membered ring, optionally substituted with between zero and
five of R.sup.20, wherein each R.sup.20 is independently selected
from --H, halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2,
--OR.sup.3, --NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted C.sub.1-6alkyl, optionally
substituted aryl, optionally substituted aryl C.sub.1-6alkyl,
optionally substituted heterocyclyl and optionally substituted
heterocyclyl C.sub.1-6alkyl, or two of R.sup.20, together with the
atom or atoms to which they are attached, combine to form an
optionally substituted three- to seven-membered heteroalicyclic,
said optionally substituted three- to seven-membered
heteroalicyclic either spiro- to J or fused to J; E is selected
from --O--, --N(R.sup.5)--, --CH.sub.2-- and --S(O).sub.0-2--; each
R.sup.60 is independently selected from halogen, trihalomethyl,
--CN, --NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
heteroaryl C.sub.1-6alkyl and optionally substituted aryl
C.sub.1-6alkyl; each methylene in any of the above formulae, other
than those in a depicted ring, is independently optionally
substituted with one or two R.sup.25, wherein R.sup.25 is selected
from halogen, trihalomethyl, oxo, --CN, --NO.sub.2, --NH.sub.2,
--OR.sup.3, --NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
aryl C.sub.1-6alkyl, heteroaryl C.sub.1-6allyl and optionally
substituted C.sub.1-6alkyl; or two of R.sup.25, together with the
carbon or carbons to which they are attached, can combine to form a
three- to seven-membered alicyclic or heteroalicyclic; and R.sup.3b
has the same meaning as R.sup.3.
28. The compound according to claim 27, wherein R.sup.50 is
selected from C.sub.1-6alkyl optionally substituted with at least
one of optionally substituted amino, optionally substituted
C.sub.1-6alkyl amino, optionally substituted C.sub.1-6dialkyl
amino, optionally substituted heteroalicylic and a group of formula
XII.
29. The compound according to claim 28, wherein G is selected from
cyclopropyl, aziradine, cyclobutyl and azetidine, each optionally
substituted with between zero and four of R.sup.30.
30. The compound according to claim 29, wherein R.sup.2 is selected
from --H, halogen, C.sub.1-6 alkyl and perfluoro C.sub.1-6
alkyl.
31. The compound of claim 23, wherein (R.sup.30).sub.0-4 is
(R.sup.30).sub.0 or methyl.
32. The compound according to claim 30, of formula XIVa or XIVb:
##STR00627## wherein R.sup.50 is C.sub.1-6alkyl substituted with a
group selected from optionally substituted amino, optionally
substituted alkylamino, optionally substituted dialkylamino and
optionally substituted heteroalicylic.
33. The compound according to claim 32, wherein Q is --CH.dbd..
34. The compound according to claim 33, wherein the heteroalicyclic
portion of R.sup.50 is selected from piperidine, piperazine,
morpholine, thiomorpholine, thiomorpholine 1-oxide, thiomorpholine
1,1-dioxide, 2-oxo-morpholine, pyrrolidine and azepine.
35. The compound according to claim 33, wherein (R.sup.30).sub.0-4
is (R.sup.30).sub.0 or methyl.
36. The compound according to claim 33 or 34, wherein R.sup.2 is
selected from C.sub.1-6 alkyl, perfluoro C.sub.1-6 alkyl, hydrogen
and halogen.
37. The compound according to claim 34, wherein R.sup.2 is
halogen.
38. The compound according to claim 34, wherein R.sup.2 is
hydrogen.
39. The compound according to claim 33 or 34, wherein R.sup.20 is
selected from halogen, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3, optionally
substituted heterocyclyl and optionally substituted heterocyclyl
C.sub.1-6alkyl, and (two of R.sup.20) together with the atom or
atoms to which they are attached, an optionally substituted three-
to six-membered heteroalicyclic, said optionally substituted three-
to six-membered heteroalicyclic fused to the phenyl as in XIVa or
XIVb.
40. The compound according to claim 39, wherein R.sup.20 is
selected from halogen, --NR.sup.3R.sup.4, optionally substituted
heterocyclyl and optionally substituted heterocyclyl
C.sub.1-6alkyl, and (two of R.sup.20) together with the atom or
atoms to which they are attached, an optionally substituted five-
to six-membered heteroalicyclic, said optionally substituted five-
to six-membered heteroalicyclic fused to the phenyl as in XIVa or
XIVb.
41. The compound according to claim 40, wherein R.sup.2 is selected
from C.sub.1-6 alkyl, perfluoro C.sub.1-6 alkyl and halogen.
42. The compound according to claim 41, wherein R.sup.2 is selected
from perfluoro C.sub.1-3 alkyl and halogen.
43. The compound according to claim 23 selected from the following:
TABLE-US-00007 Name Structure 1,1-dimethylethyl 4-(3-
{[4-[(2-fluoro-4-{[(1-{[(4- fluorophenyl)amino]
carbonyl}cyclopropyl) carbonyl]amino} phenyl)oxy]-6-
(methyloxy)quinolin-7- yl]oxy}propyl)piperazine- 1-carboxylate
##STR00628## N-(4-{[7-{[3- (diethylamino)propyl]oxy}-
6-(methyloxy)quinazolin- 4-yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl) cyclopropane- 1,1-dicarboxamide ##STR00629##
N-(4-{[7-{[3-(4- acetylpiperazin-1- yl)propyl]oxy}-6-
(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl)
cyclopropane- 1,1-dicarboxamide ##STR00630##
N-(3-fluoro-4-{[7-({3-[4- (1-methylethyl)piperazin-
1-yl]propyl}oxy)6- (methyloxy)quinolin-4- yl]oxy}phenyl)-N'-(4-
fluorophenyl) cyclopropane- 1,1-dicarboxamide ##STR00631##
N-(4-{[7-{[3- (diethylamino)propyl]oxy}- 6-(methyloxy)quinazolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00632## N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinazolin- 4-yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl) cyclobutane- 1,1-dicarboxamide ##STR00633##
N-[3-fluoro-4-({6- (methyloxy)-7-[(3- morpholin-4-ylpropyl)
oxy]quinazolin- 4-yl}oxy)phenyl]-N'-(4- fluorophenyl)cyclobutane-
1,1-dicarboxamide ##STR00634## N-(4-{[7-{[3-
(diethylamino)propyl]oxy}- 6-(methyloxy) quinolin-4-yl]oxy}-3-
fluorophenyl)-N'-(4- fluorophenyl)-2,2- dimethylcyclopropane-
1,1-dicarboxamide ##STR00635## N-[3-fluoro-4-({6-
(methyloxy)-7-[(3- morpholin-4-ylpropyl) oxy]quinazolin-
4-yl}oxy)phenyl]-N'-(4- fluorophenyl)-2,2- dimethylcyclopropane-
1,1-dicarboxamide ##STR00636## N-(4-{[7-{[2-
(diethylamino)ethyl]oxy}- 6-(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00637##
(1R,2R,3S)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00638## N-[3-fluoro-4-({6- (methyloxy)-7-[(3-
morpholin-4-ylpropyl) oxy]quinolin-4- yl}oxy)phenyl]-N'-(4-
fluorophenyl)-2,2- dimethylcyclopropane- 1,1-dicarboxamide
##STR00639## N-(4-{[7-{[2- (diethylamino)ethyl] oxy}-6-(methyloxy)
quinazolin-4-yl]oxy}- 3-fluorophenyl)-N'-(4- fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00640## N-(4-{[7-{[3-
(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00641## N-(4-{[7-{[3-
(diethylamino)propyl] oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-
3-fluorophenyl)-N'-(4- fluorophenyl)cyclobutane- 1,1-dicarboxamide
##STR00642## N-{3-fluoro-4-[(6- (methyloxy)-7-{[3-(4-
methylpiperazin-1-yl) propyl]oxy}quinazolin-
4-yl)oxy]phenyl}-N'-(4- fluorophenyl)cyclobutane- 1,1-dicarboxamide
##STR00643## N-[3-fluoro-4-({6- (methyloxy)-7-[(3-
piperazin-1-ylpropyl) oxy]quinazolin-4-yl} oxy)phenyl]-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00644##
N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00645##
N-{3-fluoro-4-[(6- (methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinolin-4- yl)oxy]phenyl}-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00646##
N-[3-fluoro-4-({6- (methyloxy)-7-[(3- morpholin-4-ylpropyl)
oxy]quinolin-4-yl} oxy)phenyl]-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00647## N-[3-fluoro-4-({6-
(methyloxy)-7-[(3- piperidin-1-ylpropyl)oxy] quinolin-4-yl}oxy)
phenyl]-N'-(4- fluorophenyl)cyclopropane- 1,1-dicarboxamide
##STR00648## N-[3-fluoro-4-({6- (methyloxy)-7-[(3-
piperidin-1-ylpropyl)oxy] quinolin-4-yl}oxy) phenyl]-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00649##
N-[3-fluoro-4-({6- (methyloxy)-7-[(3- morpholin-4-ylpropyl)
oxy]quinazolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00650## N-{5-chloro-6-[(6-
(methyloxy)-7-{[(1- methylpiperidin-4-yl) methyl]oxy}quinolin-4-
yl)oxy]pyridin-3-yl}-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00651## N-[5-chloro-6-({6-
(methyloxy)-7-[(piperidin- 4-ylmethyl)oxy]quinolin-4-
yl}oxy)pyridin-3-yl]-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00652## N-[5-chloro-6-({6- (methyloxy)-7-
[(phenylmethyl)oxy] quinolin-4-yl}oxy) pyridin-3-yl]-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00653##
N-(4-{[7-{[2- (diethylamino)ethyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}- 3-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00654##
N-(4-{[7-{[2- (diethylamino)ethyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00655##
N-{3-fluoro-4-[(6- (methyloxy)-7-{[(1- methylpiperidin-4-yl)
methyl]oxy}quinazolin- 4-yl)oxy]phenyl}-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00656##
N-(4-fluorophenyl)-N'- [2-methyl-6-({6- (methyloxy)-7-[(3-
morpholin-4- ylpropyl)oxy]quinolin- 4-yl}oxy)pyridin-3-yl]
cyclopropane- 1,1-dicarboxamide ##STR00657## N-[3-fluoro-4-({7-
(methyloxy)-6-[(3- morpholin-4- ylpropyl)oxy]quinazolin-
4-yl}oxy)phenyl]-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00658## N-[3-fluoro-4-({7-
(methyloxy)-6-[(3- morpholin-4- ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]-N'-(4- fluorophenyl)cyclopropane- 1,1-dicarboxamide
##STR00659## N-{3-fluoro-4-[(6- (methyloxy)-7-(2-methyl
octahydrocyclo- penta[c]pyrrol-5- ylmethoxy)quinazolin-4-
yl)oxy]phenyl}-N'-(4- fluorophenyl)cyclopropane- 1,1-dicarboxamide
##STR00660## N-{3-fluoro-4-[(7- (methloxy)-6-{[(1-
methylpiperidin-4- yl)methyl]oxy}quinazolin- 4-yl)oxy]phenyl-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00661##
N-[5-fluoro-2-methyl-4- ({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00662##
N-(4-fluorophenyl)-N'-[2- methyl-4-({6-(methyloxy)-
7-[(3-morpholin-4-ylpropyl) oxy]quinolin-4-yl}
oxy)phenyl]cyclopropane- 1,1-dicarboxamide ##STR00663##
N-[3-fluoro-4-({6- (methyloxy)-7-[(3- piperazin-1-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00664##
N-{3-fluoro-4-[(6- (methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinazolin- 4-yl)oxy]phenyl}-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00665##
N-{3-fluoro-4-[(6- (methyloxy)-7-{[(1- methylpiperidin-4-
yl)methyl]oxy}quinolin- 4-yl)oxy]phenyl}-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00666##
N-(4-fluorophenyl)-N'-[4- ({6-(methyloxy)-7-[(3-
morpholin-4-ylpropyl)oxy] quinolin-4-yl}oxy)phenyl] cyclopropane-
1,1-dicarboxamide ##STR00667## N-(4-{[7-{[3-
(diethylamino)propyl]oxy}- 6-(methyloxy)quinolin-4-yl]
oxy}-3-fluorophenyl)-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00668## N-(4-{[6-{[3-
(diethylamino)propyl]oxy}- 7-(methyloxy)quinolin-4-yl]
oxy}-3-fluorophenyl)-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00669## N-(4-{[6-{[2-
(diethylamino)ethyl]oxy}- 7-(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00670##
44. The compound according to claim 23 selected from the following:
TABLE-US-00008 (1S,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3-
morpholin-4-ylpropyl) oxy]quinolin-4-yl}oxy) phenyl]-N'-(4-fluoro-
phenyl)-2-methylcyclo- propane-1,1- dicarboxamide ##STR00671##
(1R,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3- morpholin-4-ylpropyl)
oxy]quinolin-4-yl}oxy) phenyl]-N'-(4-fluorophenyl)-
2-methylcyclopropane-1,1- dicarboxamide ##STR00672##
(1R,2R)-N-[3-fluoro-4-({6- (methyloxy)-7-[(3-morpholin-
4-ylpropyl)oxy]quinazolin-4- yl}oxy)phenyl]-N'-(4-fluoro-
phenyl)-2-methylcyclopropane- 1,1-dicarboxamide ##STR00673##
(1R,2R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinazolin- 4-yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide
##STR00674## 1,1-dimethylethyl 4-(3- {[4-[(2-fluoro-4-{[((1R,2R)-
1-{[(4-fluorophenyl)amino] carbonyl}-2-methylcyclopropyl)
carbonyl]amino}phenyl)oxy]-6- (methyloxy)quinolin-7-yl]oxy}
propyl)piperazine-1-carboxylate ##STR00675## (1R,2S)-N-{3-fluoro-4-
[(6-(methyloxy)-7-{[3-(4- methylpiperazin-1-yl)propyl]
oxy}quinolin-4-yl)oxy]phenyl}- N'-(4-fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00676##
(1R,2R)-N-{3-fluoro-4- [(6-(methyloxy)-7-{[3-(4-
methy]piperazin-1-yl)propyl] oxy}quinolin-4-yl)oxy]phenyl}-
N'-(4-fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide
##STR00677## (1R,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3-
piperazin-1-ylpropyl) oxy]quinolin-4-yl}oxy)
phenyl]-N'-(4-fluorophenyl)- 2-methylcyclopropane-1,1-
dicarboxamide ##STR00678## (1R,2R)-N-(4-{[7-{[3-
(diethylamino)propyl]oxy}- 6-(methyloxy)quinolin-
4-yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00679##
(1R,2R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide
##STR00680## (1R,2S)-N-(4-{[7-{[3- (diethylamino)propyl]oxy}-6-
(methyloxy)quinolin-4-yl] oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide ##STR00681##
(1R,2S)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide
##STR00682## (1R,2S)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3-
piperazin-1-ylpropyl) oxy]quinolin-4- yl}oxy)phenyl]-N'-(4-
fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide ##STR00683##
(1R,2R,3S)-N-[3-fluoro- 4-({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2,3-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00684##
(1R,2R,3S)-N-{3-fluoro- 4-[(6-(methyloxy)-7-{[3-
(4-methylpiperazin-1- yl)propyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4- fluorophenyl)-2,3- dimethylcyclopropane-
1,1-dicarboxamide ##STR00685## (1R,2R,3S)-N-[3-fluoro-
4-({6-(methyloxy)-7-[(3- morpholin-4-ylpropyl)oxy]
quinazolin-4-yl}oxy)phenyl]- N'-(4-fluorophenyl)-2,3-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00686##
(1R,2R,3S)-N-{3-fluoro- 4-[(6-(methyloxy)-7-{[3-
(4-methylpiperazin-1- yl)propyl]oxy}quinazolin-
4-yl)oxy]phenyl}-N'-(4- fluorophenyl)-2,3- dimethylcyclopropane-
1,1-dicarboxamide ##STR00687## (2R,3R)-N-[3-fluoro-4-
({6-(methyloxy)-7-[(3- morpholin-4-ylpropyl)oxy]
quinolin-4-yl}oxy)phenyl]- N'-(4-fluorophenyl)-2,3-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00688##
(2R,3R)-N-(4-{[7-{[3- (diethylamino)propyl]oxy}-
6-(methyloxy)quinolin- 4-yl]oxy}-3-fluoropheny)-
N'-(4-fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00689## (1R,2R,3S)-N-(4-{[7-{[3- (diethylamino)propyl]oxy}-
6-(methyloxy)quinolin- 4-yl]oxy}-3- fluorophenyl)N'-(4-
fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00690## (2R,3R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3-
morpholin-4-ylpropyl) oxy]quinazolin-4-yl} oxy)phenyl]-N'-(4-
fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00691## (1R,2R)-N-(4-{[7-{[3- (diethylamino)propyl]
oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide ##STR00692##
(1R,2R)-N-{3-fluoro-4- [(6-(methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinazolin- 4-yl)oxy]phenyl}-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00693##
(2R,3R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinazolin- 4-yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00694## (2R,3R)-N-(4-{[7-{[3- (diethylamino)propyl]
oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fIuorophenyl)-N'-(4-
fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00695## (lR,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3-
piperazin-1-ylpropyl) oxy]quinazolin-4- yl}oxy)phenyl]-N'-(4-
fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide ##STR00696##
(2R,3R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00697##
45. The compound according to claim 33 selected from the following:
TABLE-US-00009 Name Structure N-(3-fluoro-4-{[7-({3-[4-
(1-methylethyl)piperazin- 1-yl]propyl}oxy)-6-
(methyloxy)quinolin-4- yl]oxy}phenyl)-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00698##
(1R,2R)-N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2-
methylcyclopropane- 1,1-dicarboxamide ##STR00699##
(1R,2R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)-2- methylcyclopropane- 1,1-dicarboxamide ##STR00700##
(1R,2S)-N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2-
methylcyclopropane- 1,1-dicarboxamide ##STR00701##
(1R,2S)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)- N'-(4-
fluorophenyl)-2- methylcyclopropane- 1,1-dicarboxamide ##STR00702##
(1R,2S)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3- piperazin-1-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2-
methylcyclopropane- 1,1-dicarboxamide ##STR00703##
(1R,2R,3S)-N-[3-fluoro- 4-({6-(methyloxy)-7-[(3-
morpholin-4-ylpropyl) oxy]quinolin-4- yl}oxy)phenyl]-N'-(4-
fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00704## (1R,2R,3S)-N-{3-fluoro- 4-[(6-(methyloxy)-7-{[3-
(4-methylpiperazin-1- yl)propyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4- fluorophenyl)-2,3- dimethylcyclopropane-
1,1-dicarboxamide ##STR00705## (2R,3R)-N-[3-fluoro-4-
({6-(methyloxy)-7-[(3- morpholin-4-ylpropyl) oxy]quinolin-4-yl}
oxy)phenyl]-N'-(4- fluorophenyl)-2,3- dimethylcyclopropane-
1,1-dicarboxamide ##STR00706## (2R,3R)-N-(4-{[7-{[3-
(diethylamino)propyl] oxy}-6-(methyloxy) quinolin-4-yl]oxy}-3-
fluorophenyl)-N'-(4- fluorophenyl)-2,3- dimethylcyclopropane-
1,1-dicarboxamide ##STR00707## N-(4-{[7-{[3- (diethylamino)propyl]
oxy}-6-(methyloxy) quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)-2,2- dimethylcyclopropane- 1,1-dicarboxamide
##STR00708## (1R,2R,3S)-N-(4-{[7-{[3- (diethylamino)propyl]
oxy}-6-(methyloxy) quinolin-4-yl]oxy}-3- fluorophenyl-N'-(4-
fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00709## N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)- N'-(4-
fluorophenyl)-2,2- dimethylcyclopropane- 1,1-dicarboxamide
##STR00710## (1R,2R,4S)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00711## N-[3-fluoro-4-({6- (methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]- N'-(4-fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00712##
(2R,3R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00713## N-[3-fluoro-4-({6- (methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]- N'-(4-fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00714## N-[3-fluoro-4-({6-
(methyloxy)-7-[(3- piperidin-1-ylpropyl) oxy]quinolin-4-
yl}oxy)phenyl]- N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00715## N-{5-chloro-6-[(6- (methyloxy)-7-{[1-
methylpiperidin-4- yl)methyl]oxy}quinolin- 4-yl)oxy]pyridin-3-yl}-
N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00716##
N-[5-chloro-6-({6- (methyloxy)-7- [(piperidin-4-
ylmethyl)oxy]quinolin-4- yl}oxy)pyridin-3-yl]- N'-(4-fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00717## N-[5-chloro-6-({6-
(methyloxy)-7- [(phenylmethyl)oxy] quinolin-4-yl}oxy)pyridin-
3-yl]-N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00718## N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00719##
N-(4-fluorophenyl)-N'-[2- methyl-6-({6- (methyloxy)-7-[(3-
morpholin-4- ylpropyl)oxy]quinolin-4- yl}oxy)pyridin-3-
yl]cyclopropane-1,1- dicarboxamide ##STR00720## N-[3-fluoro-4-({7-
(methyloxy)-6-[(3- morpholin-4- ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]- N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00721## N-{3-fluoro-4-[(6- (methyloxy)-7-(2-methyl
octahydrocyclo- penta[c]pyrrol-5- ylmethoxy)quinazolin-4-
yl)oxy]phenyl}- N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00722## N-[5-fluoro-2-methyl-4- ({6-(methyloxy)-7-[(3-
morpholin-4- ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-
N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00723##
N-(4-fluorophenyl)-N'-[2- methyl-4-({6- (methyloxy)-7-[(3-
morpholin-4- ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]cyclo-
propane-1,1-dicarboxamide ##STR00724## N-[3-fluoro-4-({6-
(methyloxy)-7-[(3- piperazin-1- ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]- N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00725## N-{3-fluoro-4-[(6- (methyloxy)-7-{[3-(4-
methylpiperazin-1- yl)propyl]oxy}quinolin-4- yl)oxy]phenyl}-
N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00726##
N-{3-fluoro-4-[(6- (methyloxy)-7-{[(1- methylpiperidin-4-
yl)methyl]oxy]quinolin- 4-yl)oxy]phenyl}- N'-(4-fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00727##
N-(4-fluorophenyl)-N'-[4- ({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]cyclo-
propane-1,1-dicarboxamide ##STR00728## N-(4-{[7-{[3-
(diethylamino)propyl] oxy}-6-(methyloxy) quinolin-4-yl]oxy}-3-
fluorophenyl)-N'- (4-fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00729## (1S,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3-
morpholin-4- ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-
N'-(4-fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide
##STR00730## (1R,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3-
morpholin-4- ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-
N'-(4-fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide
##STR00731## N-(4-{[6-{[3- (diethylamino)propyl] oxy}-7-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane- 1,1-dicarboxamide ##STR00732##
N-(4-{[6-{[2- (diethylamino)ethyl]oxy}- 7-(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00733## 1,1-dimethylethyl 4-(3-
{[4-[(2-fluoro-4-{[(1- {[(4-fluorophenyl) amino]carbonyl}cyclo-
propyl)carbonyl]amino} phenyl)oxy]-6-(methyloxy) quinolin-7-yl]oxy}
propyl)piperazine-1- carboxylate ##STR00734## N-(4-{[7-{[3-(4-
acetylpiperazin-1- yl)propyl]oxy}-6- (methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00735## 1,1-dimethylethyl 4-(3-
{[4-{(2-fluoro-4- {[((1R,2R)-1-{[(4- fluorophenyl)amino]
carbonyl}-2- methylcyclopropyl) carbonyl]amino}phenyl}
oxy]-6-(methyloxy) quinolin-7-yl]oxy} propyl)piperazine-1-
carboxylate ##STR00736## (1R,2S)-N-{3-fluoro-4-
[(6-(methyloxy)-7-{[3-(4- methylpiperazin-1-yl)
propyl]oxy}quinolin-4-yl) oxy]phenyl}-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00737##
(1R,2R)-N-{3-fluoro-4- [(6-(methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinolin-4- yl)oxy]phenyl}-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00738##
(1R,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3- piperazin-1-ylpropyl)
oxy]quinolin-4-yl}oxy) phenyl]-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00739##
46. A pharmaceutical composition comprising a compound according to
claim 1, 15 or 23, and a pharmaceutically acceptable carrier.
47. A metabolite of the compound according to claim 1, 15 or
23.
48. A method of modulating the in vivo activity of a kinase, the
method comprising administering to a subject a therapeutically
effective amount of the compound according to claim 1, 15 or 23, or
a composition containing a therapeutically effective amount of the
compound.
49. The method according to claim 48, wherein modulating the in
vivo activity of the kinase comprises inhibition of said
kinase.
50. The method according to claim 49, wherein the kinase is at
least one of c-Met, KDR, c-Kit, flt-3, and flt-4.
51. The method according to claim 50, wherein the kinase is
c-Met.
52. A method of treating diseases or disorders associated with
uncontrolled, abnormal, and/or unwanted cellular activities, the
method comprising administering, to a mammal in need thereof, a
therapeutically effective amount of the compound according to claim
1, 15 or 23, or a composition containing a therapeutically
effective amount of the compound.
53. A method of screening for a modulator of a kinase, said kinase
selected from c-Met, KDR, c-Kit, flt-3, and flt-4, the method
comprising comparing the kinase modulating activity of a compound
according to claim 1, 15 or 23 with the modulating activity of at
least one candidate agent, and determining the relative effect of
the candidate agent on the activity of said kinase.
54. A method of inhibiting proliferative activity in a cell, the
method comprising administering an effective amount of a
composition comprising a cell proliferation inhibiting-effective
amount of a compound according to claim 1, 15 or 23 to a cell or a
plurality of cells.
Description
CROSS-REFERENCE TO RELATED APPLICATIONS
[0001] This application is a continuation of copending U.S. patent
application Ser. No. 11/586,751, filed on Oct. 26, 2006, which is a
continuation of U.S. patent application Ser. No. 10/573,336, filed
on Sep. 16, 2006, now abandoned, which is a national phase
application under 35 U.S.C. .sctn.371 of International Patent
Application No. PCT/US2004/031523, filed on Sep. 24, 2004, which
claims the benefit of U.S. Provisional Patent Application
60/506,181 filed on Sep. 26, 2003, and which also claims the
benefit of U.S. Provisional Patent Application No. 60/535,377 filed
on Jan. 9, 2004, and which also claims the benefit of U.S.
Provisional Patent Application No. 60/577,384 filed on Jun. 4,
2004, each of which is hereby incorporated by reference in its
entirety for all purposes.
FIELD OF THE INVENTION
[0002] This invention relates to compounds for modulating protein
kinase enzymatic activity for modulating cellular activities such
as proliferation, differentiation, programmed cell death, migration
and chemoinvasion. Even more specifically, the invention relates to
quinazolines and quinolines which inhibit, regulate and/or modulate
kinase receptor signal transduction pathways related to the changes
in cellular activities as mentioned above, compositions which
contain these compounds, methods of using them to treat
kinase-dependent diseases and conditions, synthesis of the
compounds as well as processes for formulating the compounds for
pharmaceutical purposes.
BACKGROUND OF THE INVENTION
[0003] Improvements in the specificity of agents used to treat
cancer is of considerable interest because of the therapeutic
benefits which would be realized if the side effects associated
with the administration of these agents could be reduced.
Traditionally, dramatic improvements in the treatment of cancer are
associated with identification of therapeutic agents acting through
novel mechanisms.
[0004] Protein kinases are enzymes that catalyze the
phosphorylation of proteins, in particular, hydroxy groups on
tyrosine, serine and threonine residues of proteins. The
consequences of this seemingly simple activity are staggering; cell
differentiation and proliferation; i.e., virtually all aspects of
cell life in one-way or another depend on protein kinase activity.
Furthermore, abnormal protein kinase activity has been related to a
host of disorders, ranging from relatively non-life threatening
diseases such as psoriasis to extremely virulent diseases such as
glioblastoma (brain cancer).
[0005] Protein kinases can be categorized as receptor type or
non-receptor type. Receptor-type tyrosine kinases have an
extracellular, a transmembrane, and an intracellular portion, while
non-receptor type tyrosine kinases are wholly intracellular.
[0006] Receptor-type tyrosine kinases are comprised of a large
number of transmembrane receptors with diverse biological activity.
In fact, about 20 different subfamilies of receptor-type tyrosine
kinases have been identified. One tyrosine kinase subfamily,
designated the HER subfamily, is comprised of EGFR (HER1), HER2,
HER3, and HER4. Ligands of this subfamily of receptors identified
so far include epithelial growth factor, TGF-alpha, amphiregulin,
HB-EGF, betacellulin and heregulin. Another subfamily of these
receptor-type tyrosine kinases is the insulin subfamily, which
includes INS-R, IGF-IR, and IR-R. The PDGF subfamily includes the
PDGF-alpha and beta receptors, CSFIR, c-Kit and FLK-II. Then there
is the FLK family, which is comprised of the kinase insert domain
receptor (KDR), fetal liver kinase-1 (FLK-1), fetal liver kinase-4
(FLK-4) and the fms-like tyrosine kinase-1 (flt-1). The PDGF and
FLK families are usually considered together due to the
similarities of the two groups. For a detailed discussion of the
receptor-type tyrosine kinases, see Plowman et al., DN&P 7(6):
334-339, 1994, which is hereby incorporated by reference.
[0007] The non-receptor type of tyrosine kinases is also comprised
of numerous subfamilies, including Src, Frk, Btk, Csk, Abl, Zap70,
Fes/Fps, Fak, Jak, Ack, and LIMK. Each of these subfamilies is
further sub-divided into varying receptors. For example, the Src
subfamily is one of the largest and includes Src, Yes, Fyn, Lyn,
Lck, Blk, Hck, Fgr, and Yrk. The Src subfamily of enzymes has been
linked to oncogenesis. For a more detailed discussion of the
non-receptor type of tyrosine kinases, see Bolen, Oncogene,
8:2025-2031 (1993), which is hereby incorporated by reference.
[0008] Since protein kinases and their ligands play critical roles
in various cellular activities, deregulation of protein kinase
enzymatic activity can lead to altered cellular properties, such as
uncontrolled cell growth associated with cancer. In addition to
oncological indications, altered kinase signaling is implicated in
numerous other pathological diseases. These include, but are not
limited to: immunological disorders, cardiovascular diseases,
inflammatory diseases, and degenerative diseases. Therefore, both
receptor and non-receptor protein kinases are attractive targets
for small molecule drug discovery.
[0009] One particularly attractive goal for therapeutic use of
kinase modulation relates to oncological indications. For example,
modulation of protein kinase activity for the treatment of cancer
has been demonstrated successfully with the FDA approval of
Gleevec.RTM. (imatinib mesylate, produced by Novartis
Pharmaceutical Corporation of East Hanover, N.J.) for the treatment
of Chronic Myeloid Leukemia (CML) and gastrointestinal stroma
cancers (GIST). Gleevec is a c-Kit and Abl kinase inhibitor.
[0010] Modulation (particularly inhibition) of cell proliferation
and angiogenesis, two key cellular processes needed for tumor
growth and survival (Matter A. Drug Disc Technol 2001 6,
1005-1024), is an attractive goal for development of small-molecule
drugs. Anti-angiogenic therapy represents a potentially important
approach for the treatment of solid tumors and other diseases
associated with dysregulated vascularization, including ischemic
coronary artery disease, diabetic retinopathy, psoriasis and
rheumatoid arthritis. As well, cell antiproliferative agents are
desirable to slow or stop the growth of tumors.
[0011] One particularly attractive target for small-molecule
modulation, with respect to antiangiogenic and antiproliferative
activity is c-Met. The kinase, c-Met, is the prototypic member of a
subfamily of heterodimeric receptor tyrosine kinases (RTKs) which
include Met, Ron and Sea. Expression of c-Met occurs in a wide
variety of cell types including epithelial, endothelial and
mesenchymal cells where activation of the receptor induces cell
migration, invasion, proliferation and other biological activities
associated with "invasive cell growth." As such, signal
transduction through c-Met receptor activation is responsible for
many of the characteristics of tumor cells.
[0012] The endogenous ligand for c-Met is the hepatocyte growth
factor (HGF), a potent inducer of angiogenesis, also known as
"scatter factor" (SF). Binding of HGF to c-Met induces activation
of the receptor via autophosphorylation resulting in an increase of
receptor dependent signaling, which promotes cell growth and
invasion. Anti-HGF antibodies or HGF antagonists have been shown to
inhibit tumor metastasis in vivo (See: Maulik et al Cytokine &
Growth Factor Reviews 2002 13, 41-59).
[0013] Tumor growth progression requires the recruitment of new
blood vessels into the tumor from preexisting vessels as well as
invasion, adhesion and proliferation of malignant cells.
Accordingly, c-Met overexpression has been demonstrated on a wide
variety of tumor types including breast, colon, renal, lung,
squamous cell myeloid leukemia, hemangiomas, melanomas,
astrocytomas, and glioblastomas. Additionally activating mutations
in the kinase domain of c-Met have been identified in hereditary
and sporadic renal papilloma and squamous cell carcinoma. (See:
Maulik et al Cytokine & growth Factor reviews 2002 13, 41-59;
Longati et al Curr Drug Targets 2001, 2, 41-55; Funakoshi et al
Clinica Chimica Acta 2003 1-23). Thus modulation of c-Met is
desirable as a means to treat cancer and cancer-related
disease.
[0014] The Eph receptors comprise the largest family of receptor
tyrosine kinases and are divided into two groups, EphA and EphB,
based on their sequence homology. The ligands for the Eph receptors
are ephrin, which are membrane anchored. Ephrin A ligands bind
preferentially to EphA receptors whilst ephrin B ligands bind to
EphB receptors. Binding of ephrin to Eph receptors causes receptor
autophosphorylation and typically requires a cell-cell interaction
since both receptor and ligand are membrane bound.
[0015] Overexpression of Eph receptors has been linked to increased
cell proliferation in a variety of tumors (Zhou R 1998 Pharmacol
Ther. 77, 151-181; Kiyokawa E, Takai S, Tanaka M et al 1994 Cancer
Res 54, 3645-3650; Takai N Miyazaki T, Fujisawa K, Nasu K and
Miyakawa. 2001 Oncology reports 8, 567-573). The family of Eph
receptor tyrosine kinases and their ephrin ligands play important
roles in a variety of processes during embryonic development and
also in pathological angiogenesis and potentially metastasis.
Therefore modulation of Eph receptor kinase activity should provide
means to treat or prevent disease states associated with abnormal
cell proliferation such as those described above.
[0016] Inhibition of EGF, VEGF and ephrin signal transduction will
prevent cell proliferation and angiogenesis, two key cellular
processes needed for tumor growth and survival (Matter A. Drug
Disc. Technol. 20016, 1005-1024). EGF and VEGF receptors are
previously described targets for small molecule inhibition. KDR and
flt-4 are both VEGF receptors.
[0017] One particularly attractive target for small-molecule
modulation is c-Kit. The protooncogene c-Kit was first identified
as the oncogenic component of the acutely transforming
Hardy-Zuckerman 4-feline sarcoma virus (Besmer et al Nature 1986
320:415-421). c-Kit (also called stem cell factor receptor or steel
factor receptor) is a type 3 receptor tyrosine kinase (RTK)
belonging to the platelet-derived growth factor receptor subfamily.
c-Kit binds the ligand stem cell factor (SCF), and triggers its
multiple signal transduction pathways including Src family kinases,
phosphatidyl-inositol 3 kinase, the Ras-Raf-Map kinase cascade, and
phospholipase C (Broudy et al Blood 1999 94: 1979-1986; Lennartsson
et al Oncogene 1999 18: 5546-5553; Timokhina et al EMBO J. 1998 17;
6250-6262; Chian et al Blood 2001 98(5)1365-1373; Blume-Jensen et
al Curr Biol 1998 8:779-782; Kissel et al EMBO J. 2000
19:1312-1326; Lennartsson et al. Oncogene 1999 18: 5546-5553; Sue
et al Blood, 199892:1242-1149; Lev et al EMBO J. 1991 10:647-654).
c-Kit is required for normal hematopoiesis, melanonogenesis, and
gametogenesis. c-Kit is expressed in mast cells, immature myeloid
cells, melanocytes, epithelial breast cells and the interstitial
cells of Cajal (ICC). In mast cells, it is required not only for
the differentiation, maturation, chemotaxis, and haptotaxis but
also for the promotion of survival and proliferation.
[0018] Mutations in c-Kit have been implicated in human disease.
Mutations in the juxtamembrane domain are found in many human
gastrointestinal stromal tumors, and mutations in the kinase domain
are found in mastocytosis, germ cell tumors, acute myeloid leukemia
(AML), NK lymphoma, and other hematologic disorders (Hirota et al
Science 1998 279:577-580; Singer et al J Clin Oncol 2002
203898-3905; Longley et al Proc Natl Aca Sci USA 1999: 1609-1614;
Tian et al Am J Pathol 1999 154: 1643-1647; Beghini et al Blood
2000 95:726-727; Hongyo et al Cancer Res 2000 60:2345-2347). These
mutations result in ligand-independent tyrosine kinase activity,
autophosphorylation of c-Kit, uncontrolled cell proliferation, and
stimulation of downstream signaling pathways. Overexpression of
c-Kit and c-Kit ligand have also been described in other tumors
including small-cell lung cancer, neuroblastomas, gynecological
tumors, and colon carcinoma, which might result in autocrine or
paracrine c-Kit activation.
[0019] The overexpression of c-Kit has also been implicated in the
development of neoplasia associated with neurofibromatosis type 1
(NF1). Mutations in the tumor suppressor gene NF1 lead to a
deficiency in neurofibromin, a GTPase-activating protein for Ras.
This deficiency results in abnormal proliferation of Schwann cells
in the peripheral nervous system, and predisposes affected
individuals to peripheral nerve sheath tumors (neurofibromas),
astrocytomas (optic pathway gliomas), learning disabilities,
seizures, strokes, macrocephaly, vascular abnormalities, and
juvenile myelomonocytic leukemia (Lynch & Gutmann Neurol Clin
2002 20:841-865). Genetic experiments in mice demonstrate that
haploinsufficiency at NF1 partially rescues some of the phenotypes
associated with mutations in the gene for c-Kit, indicating that
these genes function along a common developmental pathway (Ingram,
et al. J. Exp Med 2000 191:181-187). Also, c-Kit is expressed in
schwannoma cells from NF1 patients, but not in normal schwann cells
(Ryan et al. J Neurosci Res 1994 37:415-432). These data indicate
that elevated c-Kit expression and sensitivity to stem cell factor
may play important roles in the development of proliferative
disorders associated with NF-1. Therefore, c-Kit inhibitors may be
effective chemotherapeutic agents for treating patients with
NF-1.
[0020] GISTs are the most common mesenchymal tumors of the
gastrointestinal tract, and they are generally resistant to
chemotherapy and radiation therapy. However, recent results with
the c-Kit/BCR-Abl inhibitor STI571 indicate that targeting c-Kit
may be an effective therapeutic strategy for this disease
(Eisenberg & Mehren Expert Opin Pharmacother 2003 4:869-874).
Malignant mast cell disease often suggests an extremely poor
prognosis, and no reliable effective chemotherapeutic agents have
been identified (Marone et al Leuk Res 2001 25:583-594). Systemic
mast cell disorders have been treated with interferon-alpha,
although the effectiveness of this therapy has been variable
(Lehmann & Lammle Ann Hematol 1999 78:483-484; Butterfield Br J
Dermatol 1998 138: 489-495). Therefore, activated c-Kit might serve
as a therapeutic target in GISTs and mast cell disease, as well as
other disorders associated with activated c-Kit.
[0021] Flt-3 is normally expressed on hematopoietic progenitor
cells and a subset of mature myeloid and lymphoid cells, where it
modulates cell survival and proliferation. Flt-3 is constitutively
activated via mutation, either in the juxtamembrane region or in
the activation loop of the kinase domain, in a large proportion of
patients with AML (Reilly Leuk Lymphoma 2003 44: 1-7). Also,
mutations in flt-3 are significantly correlated with poor prognosis
in AML patients (Sawyers Cancer Cell 2002 1: 413-415).
[0022] Accordingly, the identification of small-molecule compounds
that specifically inhibit, regulate and/or modulate the signal
transduction of kinases, particularly including c-Met, KDR, c-Kit,
flt-3, and flt-4, is desirable as a means to treat or prevent
disease states associated with abnormal cell proliferation and
angiogenesis, and is an object of this invention.
[0023] Quinolines and quinazolines bearing substitution, for
example at the two, four, six and seven positions of their fused
ring system have been shown to be particularly attractive targets
for kinase inhibition by a number of groups. Conventional quinoline
and quinazoline kinase inhibitors typically have fairly simple
substitution about the quinoline or quinazoline fused ten-membered
ring system, but recently more complex molecules are being
disclosed. For example, we have previously disclosed, in U.S.
provisional patent applications 60/506,181 and 60/535,377 which are
both incorporated by reference herein in their entirety for all
purposes, that certain quinolines and quinazolines are particularly
well suited as kinase modulators, more particularly inhibitors of
for example c-Met, KDR, c-Kit, flt-3, and flt-4. These molecules in
some cases are particularly complex and although they can be made
via conventional methods, more efficient routes are desirable,
especially in a pharmaceutical setting.
[0024] International patent application publication no. WO 01/21597
discloses substituted quinazolines linked, via a heteroatom, to an
optionally substituted aromatic ring containing at least one
nitrogen atom. WO 01/21597 states that the disclosed compounds
inhibit aurora 2 kinase and are useful in the treatment of
proliferative disease such as cancer. U.S. patent application
publication no. US 2004/0242603 discloses substituted quinolines
and quinazolines linked, via a heteroatom, to a substituted
phenylene. US 2004/0242603 states that the disclosed compounds have
autophosphorylation inhibitory activity and antitumor activity.
[0025] International patent application publication no. WO
2005/005389 discloses bivalent malonamide derivatives, including
derivatives in which substituted aryl substituents are bonded
directly to the nitrogen atoms on either side of the malonamide
moiety. WO 2005/005389 states that the disclosed compounds are
inhibitors of raf kinase.
[0026] Conventional methods of making quinolines and quinazolines
with the aforementioned substitution patterns usually involve
linear construction of a quinoline or quinazoline template upon
which relatively simple substitutions are appended. With the advent
of more complex substitution about such quinolines and quinazolines
(vide supra), for example side chains containing cyclic and
bicyclic systems with multiple functional groups, conventional
methods of synthesis become problematic due to the linear or serial
reactions used. Indeed, as such molecules become more complex and
the utility of such complex groups is realized, the quinoline and
quinazoline ring system becomes more of a sub-structure than a main
structure of such inhibitors. Thus it is desirable to find more
efficient methods of synthesis, particularly convergent syntheses
which are an object of this invention.
SUMMARY OF THE INVENTION
[0027] In one aspect, the present invention provides compounds for
modulating kinase activity and methods of treating diseases
mediated by kinase activity utilizing the compounds and
pharmaceutical compositions thereof. Diseases mediated by kinase
activity include, but are not limited to, diseases characterized in
part by migration, invasion, proliferation and other biological
activities associated with invasive cell growth. In particular to
this invention is modulation, even more particularly inhibition, of
c-Met, KDR, c-Kit, flt-3, and flt-4.
[0028] In another aspect, the invention provides methods of
screening for modulators of c-Met, KDR, c-Kit, flt-3, and flt-4
activity. The methods comprise combining a composition of the
invention, a kinase, e.g. c-Met, KDR, c-Kit, flt-3, or flt-4, and
at least one candidate agent and determining the effect of the
candidate agent on the c-Met, KDR, c-Kit, flt-3, or flt-4,
activity.
[0029] In yet another aspect, the invention also provides
pharmaceutical kits comprising one or more containers filled with
one or more of the ingredients of pharmaceutical compounds and/or
compositions of the present invention, including, one or more
kinase, e.g. c-Met, KDR, c-Kit, flt-3, or flt-4, enzyme activity
modulators as described herein. Such kits can also include, for
example, other compounds and/or compositions (e.g., diluents,
permeation enhancers, lubricants, and the like), a device(s) for
administering the compounds and/or compositions, and written
instructions in a form prescribed by a governmental agency
regulating the manufacture, use or sale of pharmaceuticals or
biological products, which instructions can also reflects approval
by the agency of manufacture, use or sale for human
administration.
[0030] In another aspect, the invention also provides a diagnostic
agent comprising a compound of the invention and, optionally,
pharmaceutically acceptable adjuvants and excipients.
[0031] In still yet another aspect, the present invention provides
processes for making compounds, and pharmaceutical compositions
thereof, for modulating kinase activity and treating diseases
mediated by kinase activity. In particular to this invention are
methods for making quinolines and quinazolines used for modulation
of kinase activity, even more particularly inhibition of kinase
activity, and yet even more particularly inhibition of c-Met, KDR,
c-Kit, flt-3, and flt-4.
[0032] These and other features and advantages of the present
invention will be described in more detail below with reference to
the associated drawings.
DETAILED DESCRIPTION OF THE INVENTION
[0033] The compositions of the invention are used to treat diseases
associated with abnormal and or unregulated cellular activities.
Disease states which can be treated by the methods and compositions
provided herein include, but are not limited to, cancer (further
discussed below), immunological disorders such as rheumatoid
arthritis, graft-host diseases, multiple sclerosis, psoriasis;
cardiovascular diseases such as artherosclerosis,
myocardioinfarction, ischemia, stroke and restenosis; other
inflammatory and degenerative diseases such as interbowel diseases,
osteoarthritus, macular degeneration, diabetic retinopathy.
[0034] It is appreciated that in some cases the cells may not be in
a hyper- or hypo-proliferative and/or migratory state (abnormal
state) and still require treatment. For example, during wound
healing, the cells may be proliferating "normally", but
proliferation and migration enhancement may be desired.
Alternatively, reduction in "normal" cell proliferation and/or
migration rate may be desired.
[0035] Thus, in one aspect the present invention comprises a
compound for modulating kinase activity according to Formula I,
##STR00001##
or a pharmaceutically acceptable salt, hydrate, or prodrug thereof,
wherein, R.sup.1 is selected from --H, halogen, --OR.sup.3,
--NO.sub.2, --NH.sub.2, --NR.sup.3R.sup.4, and optionally
substituted lower alkyl; A.sup.1 is selected from .dbd.N--,
.dbd.C(H)--, and .dbd.C(CN)--; Z is selected from --S(O).sub.0-2--,
--O--, and --NR.sup.5--; Ar is either a group of formula II, or of
formula III,
##STR00002##
wherein, R.sup.2 is selected from --H, halogen, trihalomethyl,
--CN, --NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3, and optionally
substituted lower alkyl; q is 0 to 4; G is a group --B-L-T, wherein
[0036] B is selected from absent, --N(R.sup.13)--,
--N(SO.sub.2R.sup.13)--, --O--, --S(O).sub.0-2--, and
--C(.dbd.O)--; [0037] L is selected from absent,
--C(.dbd.S)N(R.sup.13)--, --C(.dbd.NR.sup.14)N(R.sup.13)--,
--SO.sub.2N(R.sup.13)--, --SO.sub.2--, --C(.dbd.O)N(R.sup.13)--,
--N(R.sup.13)--, --C(.dbd.O)C.sub.1-2alkylN(R.sup.13)--,
--N(R.sup.13)C.sub.1-2alkylC(.dbd.O)--,
--C(.dbd.O)C.sub.0-1alkylC(.dbd.O)N(R.sup.13)--,
--C.sub.0-4alkylene-, --C(.dbd.O)C.sub.0-1alkylC(.dbd.O)OR.sup.3--,
--C(.dbd.NR.sup.14)C.sub.0-1alkylC(.dbd.O)--, --C(.dbd.O)--,
--C(.dbd.O)C.sub.0-1alkylC(.dbd.O)--, and an optionally substituted
four to six-membered heterocyclyl containing between one and three
annular heteroatoms including at least one nitrogen; and [0038] T
is selected from --H, --R.sup.3, --C.sub.0-4alkyl,
--C.sub.0-4alkylQ, --OC.sub.0-4alkylQ, --C.sub.0-4alkylOQ,
--N(R.sup.13)C.sub.0-4alkylQ, --SO.sub.2C.sub.0-4alkylQ,
--C(.dbd.O)C.sub.0-4alkylQ, --C.sub.0-4alkylN(R.sup.13)Q, and
--C(.dbd.O)N(R.sup.13)C.sub.0-4alkylQ, wherein each of the
aforementioned C.sub.0-4alkyl is optionally substituted; J is
selected from --S(O).sub.0-2--, --O--, and --NR.sup.15--;
R.sup.3 is --H or R.sup.4;
[0039] R.sup.4 is selected from optionally substituted lower alkyl,
optionally substituted aryl, optionally substituted lower
arylalkyl, optionally substituted heterocyclyl, and optionally
substituted lower heterocyclylalkyl; or R.sup.3 and R.sup.4, when
taken together with a common nitrogen to which they are attached,
form an optionally substituted five- to seven-membered
heterocyclyl, said optionally substituted five- to seven-membered
heterocyclyl optionally containing at least one additional annular
heteroatom selected from N, O, S, and P; A.sup.2 and A.sup.3 are
each independently selected from .dbd.N--, .dbd.C(R.sup.2)--;
R.sup.5 is --H or optionally substituted lower alkyl; D is selected
from --O--, --S(O).sub.0-2--, and --NR.sup.15--; R.sup.50 is either
R.sup.3, or according to formula IV;
##STR00003##
wherein X.sup.1, X.sup.2, and optionally X.sup.3, represent the
atoms of a saturated bridged ring system, said saturated bridged
ring system comprising up to four annular heteroatoms represented
by any of X.sup.1, X.sup.2, and X.sup.3; wherein, [0040] each
X.sup.1 is independently selected from --C(R.sup.6)R.sup.7--,
--O--, --S(O).sub.0-2--, and --NR.sup.8--; [0041] each X.sup.2 is
independently an optionally substituted bridgehead methine or a
bridgehead nitrogen; [0042] each X.sup.3 is independently selected
from --C(R.sup.6)R.sup.7--, --O--, --S(O).sub.0-2--, and
--NR.sup.8--; Y is either: [0043] an optionally substituted lower
alkylene linker, between D and either 1) any annular atom of the
saturated bridged ring system, except X.sup.2 when X.sup.2 is a
bridgehead nitrogen, or 2) any heteroatom, represented by any of
R.sup.6 or R.sup.7; provided there are at least two carbon atoms
between D and any annular heteroatom of the saturated bridged ring
system or any heteroatom represented by any of R.sup.6 or R.sup.7;
[0044] or Y is absent, when Y is absent, said saturated bridged
ring system, is directly attached to D via an annular carbon of
said saturated bridged ring system, unless D is --SO.sub.2--, in
which case said saturated bridged ring system, is directly attached
to D via an any annular atom of said saturated bridged ring system;
m and p are each independently 1-4; n is 0-2, when n=0, then there
is a single bond between the two bridgehead X.sup.2's; R.sup.6 and
R.sup.7 are each independently selected from --H, halogen,
trihalomethyl, --CN, --NH.sub.2, --NO.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.4,
--SO.sub.2NR.sup.3R.sup.4, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.4, --N(R.sup.3)SO.sub.2R.sup.4,
--N(R.sup.3)C(O)R.sup.3, --NCO.sub.2R.sup.3, --C(O)R.sup.3,
optionally substituted lower alkyl, optionally substituted aryl,
optionally substituted lower arylalkyl, optionally substituted
heterocyclyl, optionally substituted lower heterocyclylalkyl, and a
bond to either Y or D; or R.sup.6 and R.sup.7, when taken together
are oxo; or R.sup.6 and R.sup.7, when taken together with a common
carbon to which they are attached, form a optionally substituted
three- to seven-membered spirocyclyl, said optionally substituted
three- to seven-membered spirocyclyl optionally containing at least
one additional annular heteroatom selected from N, O, S, and P;
R.sup.8 is selected from --R.sup.3, Y, --SO.sub.2NR.sup.3R.sup.4,
--CO.sub.2R.sup.4, --C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.4, and
--C(O)R.sup.3; R.sup.13 is selected from --H, --C(.dbd.O)R.sup.3,
--C(.dbd.O)OR.sup.3, --C(.dbd.O)SR.sup.3, --SO.sub.2R.sup.4,
--C(.dbd.O)N(R.sup.3)R.sup.3, and optionally substituted lower
alkyl, two R.sup.13, together with the atom or atoms to which they
are attached, can combine to form a heteroalicyclic optionally
substituted with between one and four of R.sup.60, said
heteroalicyclic can have up to four annular heteroatoms, and said
heteroalicyclic can have an aryl or heteroaryl fused thereto, in
which case said aryl or heteroaryl is optionally substituted with
an additional one to four of R.sup.60; R.sup.14 is selected from
--H, --NO.sub.2, --NH.sub.2, --N(R.sup.3)R.sup.4, --CN, --OR.sup.3,
optionally substituted lower alkyl, optionally substituted
heteroalicyclylalkyl, optionally substituted aryl, optionally
substituted arylalkyl and optionally substituted heteroalicyclic;
R.sup.15 is a group -M.sup.1-M.sup.2, wherein M.sup.1 is selected
from absent, --C(.dbd.S)N(R.sup.13)--,
--C(.dbd.NR.sup.14)N(R.sup.13)--, --SO.sub.2N(R.sup.13)--,
--SO.sub.2--, --C(.dbd.O)N(R.sup.13)--,
--C(.dbd.O)C(.dbd.O)N(R.sup.13)--, --C.sub.0-4alkylene-,
--C(.dbd.O)--, and an optionally substituted four to six-membered
heterocyclyl annular containing between one and three heteroatoms
including at least one nitrogen; and M.sup.2 is selected from --H,
--C.sub.0-6alkyl, alkoxy, --C(.dbd.O)C.sub.0-4alkylQ,
--C.sub.0-4alkylQ, --OC.sub.0-4alkylQ-,
--N(R.sup.13)C.sub.0-4alkylQ-, and
--C(.dbd.O)N(R.sup.13)C.sub.0-4alkylQ; and Q is a five- to
ten-membered ring system, optionally substituted with between zero
and four of R.sup.20; R.sup.20 is selected from --H, halogen,
trihalomethyl, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3
and optionally substituted lower alkyl; R.sup.60 is selected from
--H, halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2,
--OR.sup.3, --NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted lower alkyl, optionally
substituted aryl, optionally substituted heteroarylalkyl, and
optionally substituted arylalkyl; two of R.sup.60, when attached to
a non-aromatic carbon, can be oxo; with the proviso, only when Ar
is according to formula II, if Y is a C.sub.1-6 alkylene; Z is
--NH-- or --N(CH.sub.3)--; R.sup.1 is a C.sub.1-6alkyl optionally
substituted in the 2-position by --OH or a C.sub.1-4alkoxy group;
R.sup.2 is --H or halogen; n=0; and the atoms, X.sup.1, of one
bridge of the saturated bridged ring system, when combined with
both bridgehead atoms, X.sup.2, of the saturated bridged ring
system, represent: [0045] 1) either a pyrrolidine or a piperidine,
and any atom, X.sup.1 or X.sup.2, of either of said pyrrolidine or
said piperidine is attached to Y, then the other bridge of said
saturated bridged ring system cannot be any one of
--OC(O)CH.sub.2--, --CH.sub.2OC(O)--, --OC(O)CH.sub.2CH.sub.2--,
--CH.sub.2OC(O)CH.sub.2--, --CH.sub.2CH.sub.2OC(O)--,
--OC(O)CH.sub.2NH--, --OC(O)CH.sub.2N(C.sub.1-4alkyl)-, and
--OC(O)CH.sub.2O--; or [0046] 2) either a piperazine or a
4-(C.sub.1-4alkyl)-piperazine, and any atom, X.sup.1 or X.sup.2, of
either of said piperazine or said 4-(C.sub.1-4alkyl)-piperazine is
attached to Y, then the other bridge of said saturated bridged ring
system, only when attached via the 2- and the 3-position of either
of said piperazine or said 4-(C.sub.1-4alkyl)-piperazine, cannot be
one of --CH.sub.2OC(O)CH.sub.2--, --CH.sub.2CH.sub.2OC(O)--, and
either of the two aforementioned bridges optionally substituted by
one or two C.sub.1-2alkyl groups; or [0047] 3) a piperazine, and
any atom, X.sup.1 or X.sup.2, of said piperazine is attached to Y,
then the other bridge of said saturated bridged ring system, only
when attached via the 3- and the 4-position of said piperazine,
cannot be one of --C(O)OCH.sub.2CH.sub.2--,
--CH.sub.2OC(O)CH.sub.2--, and either of the two aforementioned
bridges optionally substituted by one or two C.sub.1-2alkyl groups,
and only when either of the two aforementioned bridges are attached
to the 3-position of said piperazine via their left-hand end as
depicted above; or [0048] 4) a 2-oxomorpholine, said
2-oxomorpholine attached to Y via its 4-position, then the other
bridge of said saturated bridged ring system, only when attached
via the 5- and the 6-position of said 2-oxomorpholine, cannot be
one of --(CH.sub.2).sub.g--, --CH.sub.2WCH.sub.2--,
--CH.sub.2WCH.sub.2CH.sub.2--, and --CH.sub.2CH.sub.2WCH.sub.2--,
wherein W is --O--, --S(O).sub.0-2--, --NH--, or
--N(C.sub.1-4alkyl)- wherein g is 2, 3, or 4; and with the proviso
that when Z is --O--, Ar is according to formula II, and the
portion of G directly attached to Ar is selected from:
##STR00004##
[0048] then R.sup.50 must be of formula IV; and with the proviso
that when Ar is phenylene or substituted phenylene, Z is
--S(O).sub.0-2-- or --O--, then the portion of G directly attached
to Ar cannot contain
##STR00005##
when R.sup.70 is selected from --H, C.sub.1-4alkyl, and
C.sub.1-4alkoxyl.
[0049] In one example, the compound is according to Formula I,
wherein Z is either --O-- or --NR.sup.5--.
[0050] In another example, the compound is according to Formula I,
wherein Z is either --O-- or --NR.sup.5-- and G is selected from
the following:
##STR00006## ##STR00007## ##STR00008##
wherein Q, R.sup.20, and R.sup.13 are as defined above; each E is
selected from --O--, --N(R.sup.13)--, --CH.sub.2--, and
--S(O).sub.0-2--; M is selected from --O--, --N(R.sup.13)--,
--CH.sub.2--, and --C(.dbd.O)N(R.sup.13)--; each V is independently
either .dbd.N-- or .dbd.C(H)--; each methylene in any of the above
formulae is independently optionally substituted with R.sup.25; and
R.sup.25 is selected from halogen, trihalomethyl, --CN, --NO.sub.2,
--NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl;
two of R.sup.25, together with the carbon or carbons to which they
are attached, can combine to form a three- to seven-membered
alicyclic or heteroalicyclic, two of R.sup.25 on a single carbon
can be oxo.
[0051] In another example, the compound is according to the
preceding paragraph, wherein Ar is according to one of formula Ia,
IIb, and IIIa.
##STR00009##
[0052] In another example, the compound is according to the
preceding paragraph, wherein D is --O-- and R.sup.1 is
--OR.sup.3.
[0053] In another example, the compound is according to the
preceding paragraph, wherein --O--R.sup.50 and R.sup.1 are
interchangeably located at the 6-position and 7-position of the
quinazoline or quinoline according to formula I.
[0054] In another example, the compound is according to the
preceding paragraph, wherein R.sup.1 is --OH or --OC.sub.1-6
alkyl.
[0055] In another example, the compound is according to the
preceding paragraph, wherein A.sup.1 is .dbd.N-- or
.dbd.C(H)--.
[0056] In another example, the compound is according to the
preceding paragraph, wherein G is selected from:
##STR00010## ##STR00011##
wherein Q, R.sup.20, R.sup.13, E, and R.sup.60 are as defined
above; each methylene in any of the above formulae, other than
those in a depicted ring, is independently optionally substituted
with R.sup.25; and R.sup.25 is selected from halogen,
trihalomethyl, oxo, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl;
two of R.sup.25, together with the carbon or carbons to which they
are attached, can combine to form a three- to seven-membered
alicyclic or heteroalicyclic.
[0057] In another example, the compound is according to the
preceding paragraph, wherein Q is selected from:
##STR00012##
wherein R.sup.20 is defined as above, and P is a five- to
seven-membered ring, including the two shared carbons of the
aromatic ring to which P is fused, P optionally containing between
one and three heteroatoms.
[0058] In another example, the compound is according to the
preceding paragraph, wherein Ar is according to formula IIa, and G
is selected from:
##STR00013##
wherein Q, R.sup.20, R.sup.13, E, and R.sup.60 are as defined
above, and each methylene in any of the above formulae, other than
those in a depicted ring, is independently optionally substituted
with R.sup.25; and R.sup.25 is selected from halogen,
trihalomethyl, oxo, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl;
two of R.sup.25, together with the carbon or carbons to which they
are attached, can combine to form a three- to seven-membered
alicyclic or heteroalicyclic.
[0059] In another example, the compound is as defined two
paragraphs above, and G is selected from:
##STR00014##
wherein Q, R.sup.20, R.sup.13, E, and R.sup.60 are as defined
above, and each methylene in any of the above formulae, other than
those depicted in a ring, is independently optionally substituted
with R.sup.25; and R.sup.25 is selected from halogen,
trihalomethyl, oxo, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl;
two of R.sup.25, together with the carbon or carbons to which they
are attached, can combine to form a three- to seven-membered
alicyclic or heteroalicyclic.
[0060] In another example, the compound is according to either of
the two preceding paragraphs, wherein the methylene between the two
carbonyls of the depicted formulae is di-substituted with either
optionally substituted lower alkyl, or an optionally substituted
spirocycle.
[0061] In another example, the compound is as defined three
paragraphs above or as defined two paragraphs above, wherein
R.sup.50 is a heteroalicylic or a
C.sub.1-6alkyl-heteroalicylic.
[0062] In another example, the compound is according to the
preceding paragraph, wherein at least one of R.sup.2 is
halogen.
[0063] In another example, the compound is as defined two
paragraphs above, wherein R.sup.50 is according to formula IV.
[0064] In another example, the compound is according to the
preceding paragraph, wherein the saturated bridged ring system
according to formula IV has a geometry selected from the group
consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0],
[3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2], and
[2.2.1].
[0065] In another example, the compound is according to the
preceding paragraph, wherein Y is selected from
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2--, and absent.
[0066] In another example, the compound is according to the
preceding paragraph, wherein n is 0 and the saturated bridged ring
system according to formula IV has a geometry selected from the
group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0],
[3.2.0], and [3.1.0].
[0067] In another example, the compound is according to the
preceding paragraph, wherein said saturated bridged ring system
contains at least one annular nitrogen or at least one annular
oxygen.
[0068] In another example, the compound is according to the
preceding paragraph, wherein said saturated bridged ring system
contains --NR.sup.8--, wherein R.sup.8 is selected from --H.
optionally substituted lower alkyl, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and --C(O)R.sup.3.
[0069] In another example, the compound is as defined two
paragraphs above, wherein said saturated bridged ring system is of
formula V,
##STR00015##
wherein U.sup.1 is selected from --O--, --S(O).sub.0-2--,
--NR.sup.8--, --CR.sup.6R.sup.7--, and absent; and e is 0 or 1.
[0070] In another example, the compound is according to the
preceding paragraph, wherein Y is --CH.sub.2--.
[0071] In another example, the compound is according to the
preceding paragraph, wherein U.sup.1 is --NR.sup.8--, wherein
R.sup.8 is selected from --H, optionally substituted lower alkyl,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and
--C(O)R.sup.3.
[0072] In another example, the compound is as defined two
paragraphs above, wherein U.sup.1 is --O--.
[0073] In another example, the compound is as defined three
paragraphs above, wherein U.sup.1 is absent.
[0074] In another example, the saturated bridged ring system is
according to formula IV with a geometry selected from the group
consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0],
and [3.1.0] and contains at least one annular nitrogen or at least
one annular oxygen, wherein n is 0 and Y is selected from
--CH.sub.2CH.sub.2--, --CH.sub.2--, and absent.
[0075] In another example, the compound is according to the
preceding paragraph, wherein said saturated bridged ring system is
of formula VI,
##STR00016## [0076] wherein R.sup.9, R.sup.10, and R.sup.11 are
each independently selected from --H, and --OR.sup.12; or [0077]
R.sup.9 is selected from --H, and --OR.sup.12, and R.sup.10 and
R.sup.11, when taken together, are either an optionally substituted
alkylidene or an oxo; [0078] R.sup.12 is selected from --H,
--C(O)R.sup.3, optionally substituted lower alkylidyne, optionally
substituted lower arylalkylidyne, optionally substituted lower
heterocyclylalkylidyne, optionally substituted lower alkylidene,
optionally substituted lower alkylidenearyl, optionally substituted
lower alkylideneheterocyclyl, optionally substituted lower alkyl,
optionally substituted lower alkylaryl, optionally substituted
aryl, optionally substituted lower heterocyclylalkyl, and
optionally substituted heterocyclyl; [0079] or two R.sup.12's, when
taken together, form 1) a corresponding spirocyclic ketal when said
two R.sup.12's stem from R.sup.10 and R.sup.11, or 2) a
corresponding cyclic ketal when said two R.sup.12's stem from
R.sup.9 and one of R.sup.10 and R.sup.11.
[0080] In another example, the compound is according to the
preceding paragraph, wherein one of R.sup.10 and R.sup.11 is
--OR.sup.12, wherein R.sup.12 is selected from --H, --C(O)R.sup.3,
and optionally substituted lower alkyl; and R.sup.9 and the other
of R.sup.10 and R.sup.11 are both --H.
[0081] In another example, the compound is according to the
preceding paragraph, wherein Y is either --CH.sub.2-- or
absent.
[0082] In another example, the compound is according to the
preceding paragraph, wherein R.sup.9 is an alkyl group containing
at least one fluorine substitution thereon.
[0083] In another example, the saturated bridged ring system is of
formula VII, wherein R.sup.8 is selected from --H, optionally
substituted lower alkyl, --CO.sub.2R.sup.3, C(O)NR.sup.3R.sup.3,
--SO.sub.2R.sup.3, and --C(O)R.sup.3.
##STR00017##
[0084] In another example, the compound is according to the
preceding paragraph, wherein Y is either --CH.sub.2-- or
absent.
[0085] In another example, the compound is according to the
preceding paragraph, wherein R.sup.8 is methyl or ethyl.
[0086] In another example, the saturated bridged ring system is of
formula VIII.
##STR00018##
wherein R.sup.8 is selected from --H, optionally substituted lower
alkyl, --CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3,
and --C(O)R.sup.3.
[0087] In another example, the compound is according to the
preceding paragraph, wherein Y is --CH.sub.2--.
[0088] In another example, the compound is according to the
preceding paragraph, wherein R.sup.8 is methyl or ethyl.
[0089] In another example, the said saturated bridged ring system
is of formula IX
##STR00019##
wherein U.sup.2 is selected from --O--, --S(O).sub.0-2--,
--NR.sup.8--, --CR.sup.6R.sup.7--, and absent.
[0090] In another example, the compound is according to the
preceding paragraph, wherein R.sup.3 of formula IX is selected from
--H and optionally substituted alkyl.
[0091] In another example, the compound is according to the
preceding paragraph, wherein U.sup.2 is either --CR.sup.6R.sup.7--
or absent.
[0092] In another example, the compound is according to the
preceding paragraph, wherein U.sup.2 is either --CH.sub.2-- or
absent.
[0093] In another example, the compound is according to the
preceding paragraph, wherein Y is --CH.sub.2--.
[0094] In another example, the saturated bridged ring system is
according to formula X, wherein R.sup.8 is selected from --H,
optionally substituted lower alkyl, --CO.sub.2R.sup.3,
C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and --C(O)R.sup.3.
##STR00020##
[0095] In another example, the compound is according to the
preceding paragraph, wherein R.sup.8 is methyl or ethyl.
[0096] In another example, the compound is selected from Table
1.
TABLE-US-00001 TABLE 1 Entry Name Structure 1 N-[({3-fluoro-4-[(6-
(methyloxy)-7-{[(3aR,6aS)- octahydrocyclopenta[c]pyrrol-
5-ylmethyl]oxy}quinazolin-4- yl)oxy]phenyl}amino) carbonothioyl]-2-
phenylacetamide ##STR00021## 2 N-{[(3-fluoro-4-{[7- ({[(3aR,6aS)-2-
methyloctahydrocyclopenta[c] pyrrol-5-yl]methyl}oxy)-6-
(methyloxy)quinazolin-4- yl]oxy}phenyl)amino] carbonothioyl}-2-
phenylacetamide ##STR00022## 3 N-{[(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3- fluorophenyl)(methyl)amino]
carbonothioyl}-2- phenylacetamide ##STR00023## 4 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)
imidazolidin-2-one ##STR00024## 5 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-3-
(phenylmethyl)imidazolidin- 2-one ##STR00025## 6 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-3-
(phenylacetyl)imidazolidin-2- one ##STR00026## 7 ethyl [(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)
amino](oxo)acetate ##STR00027## 8 N-{[(4-{[6,7-
bis(methyloxy)quinazolin-4- yl]amino}-3-fluorophenyl)
amino]carbonothioyl}-2- phenylacetamide ##STR00028## 9 N'-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N-
methyl-N-(2-phenylethyl) sulfamide ##STR00029## 10 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-3-
(phenylmethyl)-1,2,4- oxadiazol-5-amine ##STR00030## 11 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl) piperidin-2-one
##STR00031## 12 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N'- (phenylmethyl)ethanediamide
##STR00032## 13 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-4- phenyl-1,3-thiazol-2-amine ##STR00033##
14 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N'- (2-phenylethyl)ethanediamide
##STR00034## 15 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-1- phenylmethanesulfonamide ##STR00035## 16
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-2-
phenylethanesulfonamide ##STR00036## 17 4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluoro-N- (phenylmethyl)
benzenesulfonamide ##STR00037## 18 4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluoro-N-methyl-N-
(phenylmethyl) benzenesulfonamide ##STR00038## 19 4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluoro-N-(2- phenylethyl)
benzenesulfonamide ##STR00039## 20 4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluoro-N-methyl-N-
(2-phenylethyl) benzenesulfonamide ##STR00040## 21 4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluoro-N-(3- phenylpropyl)
benzenesulfonamide ##STR00041## 22 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl) pyrrolidin-2-one
##STR00042## 23 4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}phenyl
(phenylmethyl)carbamate ##STR00043## 24 4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl (2- phenylethyl)carbamate
##STR00044## 25 4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluoro-N-methyl-N- (3-phenylpropyl) benzenesulfonamide
##STR00045## 26 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N'- phenylethanediamide ##STR00046## 27
N-{[(3-fluoro-4-{[7-{[(2- methyloctahydrocyclopenta[c]
pyrrol-5-yl)methyl]oxy}-6- (methyloxy)quinolin-4-
yl]oxy}phenyl)amino] carbonothioyl}-2- phenylacetamide ##STR00047##
28 N-[(Z)-[(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl) amino](imino)methyl]-2- phenylacetamide
##STR00048## 29 4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluoro-N-[2- (phenyloxy)ethyl] benzenesulfonamide
##STR00049## 30 N,N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-bis- (3-phenylpropane-1- sulfonamide)
##STR00050## 31 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-3- phenylpropane-1-sulfonamide ##STR00051##
32 N2-[(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-
fluorophenyl)sulfonyl]-N1- phenylglycinamide ##STR00052## 33
N-(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-yl)-2-
phenylacetamide ##STR00053## 34 N-{[(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-
yl)amino]carbonothioyl}-2- phenylacetamide ##STR00054## 35 6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-1,3-benzothiazol-2- amine
##STR00055## 36 6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-fluoro-1,3- benzothiazol-2-amine ##STR00056## 37
N-(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-1,3-
benzothiazol-2-yl)-2- phenylacetamide ##STR00057## 38 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
(2-morpholin-4- ylethyl)ethanediamide ##STR00058## 39
benzyl-{[4-(6,7-dimethoxy- quinolin-4-yloxy)-3-fluoro-
phenylcarbamoyl]-methyl}- carbamic acid tert-butyl ester
##STR00059## 40 N1-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N2- (phenylmethyl)glycinamide ##STR00060##
41 N2-acetyl-N1-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N2- (phenylmethyl)glycinamide ##STR00061##
42 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-1,3-benzothiazol-2- yl)-2-phenylacetamide ##STR00062## 43
benzyl-{[6-(6,7-dimethoxy- quinolin-4-yloxy)-pyridin-3-
ylcarbamoyl]-methyl}- carbamic acid tert-butyl ester ##STR00063##
44 N1-(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-yl)-N2-
(phenylmethyl)glycinamide ##STR00064## 45 N2-acetyl-N1-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-yl)-N2-
(phenylmethyl)glycinamide ##STR00065## 46 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-yl)-3- phenylpropanamide
##STR00066## 47 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}pyridin-3-yl)-4- phenylbutanamide ##STR00067## 48
N1-(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}pyridin-3-yl)-N2-
methyl-N2- (phenylmethyl)glycinamide ##STR00068## 49 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
{2-[4-(methyloxy) phenyl]ethyl}ethanediamide ##STR00069## 50
N1-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N2-
methyl-N2-(phenylmethyl) glycinamide ##STR00070## 51
4-[(2-amino-1,3-benzothiazol- 6-yl)oxy]-6,7-bis(methyloxy)-
1-(2-oxo-2-phenylethyl) quinolinium ##STR00071## 52 N-{[(4-{[6,7-
bis(methyloxy)quinolin-4- yl]amino}phenyl)amino] carbonothioyl}-2-
phenylacetamide ##STR00072## 53 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-1,3-
benzothiazol-2-yl)-3- phenylpropanamide ##STR00073## 54
N-{[(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)amino]carbonothioyl}-2- phenylacetamide ##STR00074## 55
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
(2,3-dihydro-1H-inden-1- yl)ethanediamide ##STR00075## 56
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
(2,3-dihydro-1H-inden-2- yl)ethanediamide ##STR00076## 57
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
(1,2,3,4-tetrahydronaphthalen- 1-yl)ethanediamide ##STR00077## 58
N'-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N-
(2-phenylethyl)-N- (phenylmethyl)sulfamide ##STR00078## 59
N1-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N2-
(trifluoroacetyl)glycinamide ##STR00079## 60 N-{[4-(6,7-dimethoxy-
quinolin-4-yloxy)-3-fluoro- phenylcarbamoyl]-methyl}- benzamide
##STR00080## 61 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}pyridin-3-yl)-N'-(4- fluorophenyl)propanediamide
##STR00081## 62 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N'- [(2S)-1,2,3,4- tetrahydronaphthalen-2-
yl]ethanediamide ##STR00082## 63 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'- [2-(4-
methylphenyl)ethyl] ethanediamide ##STR00083## 64 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
(2-phenylpropyl) ethanediamide ##STR00084## 65 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
[2-(4-chlorophenyl) ethyl]ethanediamide ##STR00085## 66 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N,N'-
bis(phenylmethyl)sulfamide ##STR00086## 67 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N,N'-
bis(2-phenylethyl)sulfamide ##STR00087## 68 ethyl [(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)amino](oxo)acetate ##STR00088## 69 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-N'-(2-phenylethyl) ethanediamide ##STR00089## 70 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-N'-(4-fluorophenyl) propanediamide ##STR00090## 71 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
(1,2,3,4-tetrahydronaphthalen- 2-yl)ethanediamide ##STR00091## 72
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
[2-(1-methylpyrrolidin-2- yl)ethyl]ethanediamide ##STR00092## 73
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
[2-(phenyloxy) ethyl]ethanediamide ##STR00093## 74 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'- [2-hydroxy-1-
(phenylmethyl)ethyl]urea ##STR00094## 75 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-3-
[(4-methylphenyl)sulfonyl]-4- (phenylmethyl)imidazolidin- 2-one
##STR00095## 76 N'-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N- methyl-N-(2-phenylethyl) ethanediamide
##STR00096## 77 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N'- {[3-(trifluoromethyl)
phenyl]methyl}ethanediamide ##STR00097## 78 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
{2-[3-(trifluoromethyl) phenyl]ethyl}ethanediamide ##STR00098## 79
N-(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-3-oxo-4- phenylbutanamide ##STR00099## 80 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-2-[3-(trifluoromethyl) phenyl]acetamide ##STR00100##
81 6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-N-[2-
(phenyloxy)ethyl]-1,3- benzothiazol-2-amine ##STR00101## 82
6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-N-(2-
piperidin-1-ylethyl)-1,3- benzothiazol-2-amine ##STR00102## 83
6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-N-methyl-N-
(2-phenylethyl)-1,3- benzothiazol-2-amine ##STR00103## 84 6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-N-(2-
pyrrolidin-1-ylethyl)-1,3- benzothiazol-2-amine ##STR00104## 85
6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-N-{[3-
(trifluoromethyl)phenyl] methyl}-1,3-benzothiazol-2- amine
##STR00105## 86 6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-fluoro-N-{2-[3- (trifluoromethyl)phenyl]ethyl}-
1,3-benzothiazol-2-amine ##STR00106## 87 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-N'-[3-(trifluoromethyl) phenyl]propanediamide ##STR00107## 88
N-(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-1,3-
benzothiazol-2-yl)-2-[3- (trifluoromethyl)phenyl] acetamide
##STR00108## 89 N1-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N2- {[3-(trifluoromethyl)
phenyl]methyl}glycinamide ##STR00109## 90 N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N2-
(2-phenylethyl)glycinamide ##STR00110## 91 N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N2-
{2-[3-(trifluoromethyl) phenyl]ethyl}glycinamide ##STR00111## 92
benzyl-{[5-chloro-6-(6,7- dimethoxy-quinolin-4-yloxy)-
pyridin-3-ylcarbamoyl]- methyl}-carbamic acid tert- butyl ester
##STR00112## 93 N1-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-chloropyridin-3- yl)-N2-(phenylmethyl) glycinamide
##STR00113## 94 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-fluoro-1,3- benzothiazol-2-yl)-2-[3,5-
bis(trifluoromethyl) phenyl]acetamide ##STR00114## 95 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-1,3-
benzothiazol-2-yl)-2-[2- chloro-5-(trifluoromethyl)
phenyl]acetamide ##STR00115## 96 N-{3-fluoro-4-[(6-
(methyloxy)-7-{[(1- methylpiperidin-4- yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(2- phenylethyl)ethanediamide ##STR00116## 97
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N'-
(1,2,3,4- tetrahydroisoquinolin-1- ylmethyl)ethanediamide
##STR00117## 98 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N'- [(2-methyl-1,2,3,4-
tetrahydroisoquinolin-1- yl)methyl]ethanediamide ##STR00118## 99
N1-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N2-
methyl-N2-{[3- (trifluoromethyl)phenyl] methyl}glycinamide
##STR00119## 100 N1-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)-N2- methyl-N2-{2-[3-
(trifluoromethyl)phenyl] ethyl}glycinamide ##STR00120## 101
N1-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-N2-
methyl-N2-(2- phenylethyl)glycinamide ##STR00121## 102 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-4-
(phenylmethyl)imidazolidin- 2-one ##STR00122## 103 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}pyridazin-3-yl)-N'-(4-
fluorophenyl)propanediamide ##STR00123## 104 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-N'-(2-chlorophenyl) propanediamide ##STR00124## 105 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-N'-(3-chlorophenyl) propanediamide ##STR00125## 106
N1-(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-N2-methyl-N2- (phenylmethyl)glycinamide ##STR00126## 107
N-(6-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-3-
yl)-N'-(4-chlorophenyl) propanediamide ##STR00127## 108
(2E)-N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}phenyl)-2-
[(methyloxy)imino] propanamide ##STR00128## 109 (2E)-N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-2- [(ethyloxy)imino]
propanamide ##STR00129## 110 (2E)-N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-2-
{[(phenylmethyl)oxy]imino} propanamide ##STR00130## 111 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-1-
(phenylmethyl)prolinamide ##STR00131## 112 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-3-[(4-
methylphenyl)sulfonyl]-4- (phenylmethyl)imidazolidin- 2-one
##STR00132## 113 1-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}phenyl)-4- (phenylmethyl)imidazolidin- 2-one ##STR00133##
114 N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}phenyl)-4-
(phenylmethyl)-4,5-dihydro- 1,3-oxazol-2-amine ##STR00134## 115
6,7-bis(methyloxy)-4-({4-[4- (phenylmethyl)piperazin-1-
yl]phenyl}oxy)quinoline ##STR00135## 116 1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-4-
(phenylmethyl)piperazin-2- one ##STR00136## 117 N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N2-
(phenylmethyl)alaninamide ##STR00137## 118 N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N2-methyl-
N2-(phenylmethyl) alaninamide ##STR00138## 119 N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N2-
(phenylmethyl)leucinamide ##STR00139## 120 N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N2-methyl-
N2-(phenylmethyl) leucinamide ##STR00140## 121 N1-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N2-
(phenylmethyl)valinamide ##STR00141## 122
4-(6,7-dimethoxy-quinolin-4- ylamino)-N-(3-phenyl-
propyl)-benzamide ##STR00142## 123 4-benzyl-1-[4-(6,7-
dimethoxy-quinolin-4-yloxy)- phenyl]-tetrahydro-pyrimidin- 2-one
##STR00143## 124 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
phenethyl-oxalamide ##STR00144## 125 2-(Benzyl-methyl-amino)-N-
[4-(6,7-dimethoxy-quinolin-4- yloxy)-phenyl]-3-methyl- butyramide
(note: Alphabetic order of prefixes ignored while selecting parent
chain) ##STR00145## 126 N-[4-(6,7-Dimethoxy-
quinolin-4-yloxy)-phenyl]-2- phenoxyimino-propionamide ##STR00146##
127 2-Benzyloxyimino-N-[4-(6,7- dimethoxy-quinolin-4-yloxy)-
phenyl]-2-phenyl-acetamide ##STR00147## 128
4-[4-(4-Benzyl-piperidin-1- yl)-phenoxy]-6,7-dimethoxy- quinoline
##STR00148## 129 N-[4-(6,7-Dimethoxy- quinolin-4-yloxy)-3-fluoro-
phenyl]-N'-(2-isopropyl- 1,2,3,4-tetrahydro-
isoquinolin-1-ylmethyl)- oxalamide ##STR00149## 130
N-[4-(6,7-Dimethoxy- quinolin-4-yloxy)-3-fluoro-
phenyl]-N'-(2-ethyl-1,2,3,4- tetrahydro-isoquinolin-1-
ylmethyl)-oxalamide ##STR00150## 131 4-(4-{3-Chloro-5-[2-(4-
fluoro-phenylcarbamoyl)- acetylamino]-pyridin-2-
yloxy}-6-methoxy-quinolin-7- yloxymethyl)-piperidine-1- carboxylic
acid tert-butyl ester ##STR00151## 132 N-{5-Chloro-6-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-pyridin-3-
yl}-N'-(4-fluoro-phenyl)- malonamide ##STR00152## 133
N-{5-Chloro-6-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-pyridin-3-yl}-N'-(4-
fluoro-phenyl)-malonamide ##STR00153## 134 N-{4-[7-(3-Diethylamino-
propoxy)-6-methoxy- quinolin-4-yloxy]-3-fluoro-
phenyl}-N'-phenethyl- oxalamide ##STR00154## 135
N-{3-Fluoro-4-[6-methoxy-7- (3-morpholin-4-yl-propoxy)-
quinolin-4-yloxy]-phenyl}-N'- phenethyl-oxalamide ##STR00155## 136
N-{3-Fluoro-4-[6-methoxy-7- (3-piperidin-1-yl-propoxy)-
quinolin-4-yloxy]-phenyl}-N'- phenethyl-oxalamide ##STR00156## 137
N-{4-[7-(2-Diethylamino- ethoxy)-6-methoxy-quinolin-
4-yloxy]-3-fluoro-phenyl}-N'- phenethyl-oxalamide ##STR00157## 138
N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N'-methyl-N'-
phenethyl-oxalamide ##STR00158## 139 N-{3-Fluoro-4-[6-methoxy-7-
(2-methyl-octahydro- cyclopenta[c]pyrrol-5- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-N'-phenethyl- oxalamide ##STR00159## 140
N-{3-Fluoro-4-[6-methoxy-7- (2-methyl-octahydro-
cyclopenta[c]pyrrol-5- ylmethoxy)-quinazolin-4-
yloxy]-phenyl}-N'-phenethyl- oxalamide ##STR00160## 141
2-(3,4-Dihydro-1H- isoquinolin-2-yl)-N-{3-fluoro-
4-[6-methoxy-7-(1-methyl- piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-2- oxo-acetamide ##STR00161## 142
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-2- oxo-2-(3-phenyl-pyrrolidin-1-
yl)-acetamide ##STR00162## 143 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-2-
oxo-2-(2-phenyl-morpholin-4- yl)-acetamide ##STR00163## 144
N-(2-Dimethylamino-2- phenyl-ethyl)-N'-{3-fluoro-4-
[6-methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00164## 145
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2-oxo-2-phenyl-ethyl)- oxalamide
##STR00165## 146 N-[5-Chloro-6-(6,7- dimethoxy-quinolin-4-yloxy)-
pyridin-3-yl]-2,2-difluoro-N'- (4-fluoro-phenyl)-malonamide
##STR00166## 147 N-Benzyl-N'-{3-fluoro-4-[6- methoxy-7-(1-methyl-
piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00167## 148 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
[2-(2-fluoro-phenyl)-ethyl]- oxalamide ##STR00168## 149
N-[2-(3-Chloro-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00169## 150
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(2-methoxy-phenyl)-ethyl]-
oxalamide ##STR00170## 151 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-pyridin-3-yl-ethyl)- oxalamide ##STR00171## 152
N-Benzyl-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00172## 153
N-[2-(2,5-Dimethoxy- phenyl)-ethyl]-N'-{3-fluoro-4-
[6-methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00173##
154 N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(2-trifluoromethyl-phenyl)-
ethyl]-oxalamide ##STR00174## 155 N-[2-(2-Ethoxy-phenyl)-
ethyl]-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00175## 156
N-[2-(2,4-Dimethyl-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00176## 157
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (1S-phenyl-2-p-tolyl-ethyl)-
oxalamide ##STR00177## 158 N-[2-(4-Chloro-phenyl)-
ethyl]-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00178## 159
N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamic acid ##STR00179##
160 N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(3-fluoro-phenyl)-ethyl]-
oxalamide ##STR00180## 161 N-[2-(2-Chloro-phenyl)-
ethyl]-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00181## 162
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(3-methoxy-phenyl)-ethyl]-
oxalamide ##STR00182## 163 N-(1,2-Diphenyl-ethyl)-N'-{3-
fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00183## 164
N-[2-(2,4-Dichloro-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00184## 165 N-[2-(3,4-Dimethoxy-
phenyl)-ethyl]-N'-{3-fluoro-4- [6-methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00185## 166
N-[2-(4-Ethyl-phenyl)-ethyl]- N'-{3-fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00186## 167 N-[2-(4-Ethoxy-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00187## 168 N-[2-(4-Ethoxy-3-methoxy-
phenyl)-ethyl]-N'-{3-fluoro-4- [6-methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00188## 169
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(4-phenoxy-phenyl)-ethyl]-
oxalamide ##STR00189## 170 N-[2-(3-Ethoxy-4-methoxy-
phenyl)-ethyl]-N'-{3-fluoro-4- [6-methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00190## 171
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2-pyridin-2-yl-ethyl)- oxalamide
##STR00191## 172 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-pyridin-4-yl-ethyl)- oxalamide ##STR00192## 173
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(4-fluoro-phenyl)-ethyl]-
oxalamide ##STR00193## 174 N-[2-(2-Bromo-phenyl)-
ethyl]-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00194## 175
N-[2-(2-Chloro-6-fluoro- phenyl)-ethyl]-N'-{3-fluoro-4-
[6-methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00195## 176
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2R-phenyl-propyl)-oxalamide
##STR00196## 177 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
indan-1-yl-oxalamide ##STR00197## 178 N-{3-Fluoro-4-[6-methoxy-7-
(1-methyl-piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-N'-isobutyl- oxalamide ##STR00198## 179
N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N'-(3-methyl-
butyl)-oxalamide ##STR00199## 180 N-{3-Fluoro-4-[6-methoxy-7-
(1-methyl-piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-N'-(2R- phenyl-propyl)-oxalamide ##STR00200## 181
N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N'-(2-phenyl-
propyl)-oxalamide ##STR00201## 182 N-{3-Fluoro-4-[6-methoxy-7-
(1-methyl-piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-N'-indan-2-yl- oxalamide ##STR00202## 183
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (1R-phenyl-ethyl)-oxalamide
##STR00203## 184 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(1S-phenyl-ethyl)-oxalamide ##STR00204## 185 N-[2-(3-Bromo-phenyl)-
ethyl]-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00205## 186
N-[2-(2,6-Dichloro-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00206## 187
N-[2-(2,4-Dichloro-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00207## 188
N-(2-Benzo[1,3]dioxol-5-yl- ethyl)-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00208## 189 N-[2-(3-Bromo-4-methoxy-
phenyl)-ethyl]-N'-{3-fluoro-4- [6-methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00209## 190
N-[2-(3,5-Dimethoxy- phenyl)-ethyl]-N'-{3-fluoro-4-
[6-methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00210## 191
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2-o-tolyl-ethyl)-oxalamide
##STR00211## 192 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-m-tolyl-ethyl)-oxalamide ##STR00212## 193
N-[2-(3-Ethoxy-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00213## 194
N-[2-(3,4-Dimethyl-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00214## 195
N-[2-(2,5-Dimethyl-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00215## 196 N-[2-(3-Chloro-4-propoxy-
phenyl)-ethyl]-N'-{3-fluoro-4- [6-methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00216## 197
N-[2-(4-Butoxy-3-chloro- phenyl)-ethyl]-N'-{3-fluoro-4-
[6-methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00217## 198
N-[2-(4-tert-Butyl-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00218## 199
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(4-sulfamoyl-phenyl)-
ethyl]-oxalamide ##STR00219## 200 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
[2-(4-hydroxy-3-methoxy- phenyl)-ethyl]-oxalamide ##STR00220## 201
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(3-hydroxy-4-methoxy-
phenyl)-ethyl]-oxalamide ##STR00221## 202
N-(2,4-Dichloro-benzyl)-N'- {3-fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00222## 203 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(4-fluoro-2-trifluoromethyl- benzyl)-oxalamide ##STR00223## 204
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (1-p-tolyl-ethyl)-oxalamide
##STR00224## 205 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(3-fluoro-4-trifluoromethyl- benzyl)-oxalamide ##STR00225## 206
N-(3-Chloro-4-fluoro-benzyl)- N'-{3-fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00226## 207 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
[1-(3-methoxy-phenyl)-ethyl]- oxalamide ##STR00227## 208
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (1-naphthalen-2-yl-ethyl)- oxalamide
##STR00228## 209 N-(4-Chloro-3- trifluoromethyl-benzyl)-N'-
{3-fluoro-4-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00229## 210
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (1-p-tolyl-ethyl)-oxalamide
##STR00230## 211 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(6-trifluoromethyl-pyridin-3- ylmethyl)-oxalamide ##STR00231## 212
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2-methyl-benzyl)-oxalamide
##STR00232## 213 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(3-methyl-benzyl)-oxalamide ##STR00233## 214
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (4-fluoro-3-trifluoromethyl-
benzyl)-oxalamide ##STR00234## 215 N-(3,5-Dichloro-benzyl)-N'-
{3-fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00235## 216
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (1R,2,3,4-tetrahydro-
naphthalen-1-yl)-oxalamide ##STR00236## 217
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (1S,2,3,4-tetrahydro-
naphthalen-1-yl)-oxalamide ##STR00237## 218
N-Cyclopentyl-N'-{3-fluoro- 4-[6-methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00238## 219
N-[1-(4-Bromo-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00239## 220
N-(2-Fluoro-benzyl)-N'-{3- fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00240## 221 N-[2-(3,4-Dichloro-phenyl)-
ethyl]-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00241## 222
N-(4-Fluoro-benzyl)-N'-{3- fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00242## 223 N-(2,3-Difluoro-benzyl)-N'-
{3-fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00243## 224
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2-phenoxy-ethyl)-oxalamide
##STR00244## 225 N-(2,2-Diphenyl-ethyl)-N'-{3-
fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00245## 226
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- [2-(4-methoxy-phenyl)-ethyl]-
oxalamide ##STR00246## 227 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-phenyl-propyl)-oxalamide ##STR00247## 228 N-[2-(4-Bromo-phenyl)-
ethyl]-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00248## 229
N-{4-[7-(1-Ethyl-piperidin-4- ylmethoxy)-6-methoxy-
quinolin-4-yloxy]-3-fluoro- phenyl}-2-oxo-2-(2-phenyl-
morpholin-4-yl)-acetamide ##STR00249## 230
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (3-fluoro-5-trifluoromethyl-
benzyl)-oxalamide ##STR00250## 231 N-(3,5-Difluoro-benzyl)-N'-
{3-fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00251## 232
N-(2-Chloro-5- trifluoromethyl-benzyl)-N'-
{3-fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00252## 233
N-[4-(6,7-Dimethoxy- quinolin-4-yloxy)-3-fluoro-
phenyl]-N'-(2-dimethylamino- 2-phenyl-ethyl)-oxalamide ##STR00253##
234 N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (4-methoxy-benzyl)- oxalamide
##STR00254## 235 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(4-trifluoromethyl-benzyl)- oxalamide ##STR00255## 236
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (3-methoxy-benzyl)- oxalamide
##STR00256## 237 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(3-trifluoromethyl-benzyl)- oxalamide ##STR00257## 238
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (3-trifluoromethoxy-benzyl)-
oxalamide ##STR00258## 239 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-methoxy-benzyl)- oxalamide ##STR00259## 240
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2-trifluoromethyl-benzyl)- oxalamide
##STR00260## 241 N-(3-Chloro-benzyl)-N'-{3- fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00261## 242 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-trifluoromethoxy-benzyl)- oxalamide ##STR00262## 243
N-(2-Chloro-benzyl)-N'-{3- fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00263## 244 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(4-trifluoromethoxy-benzyl)- oxalamide ##STR00264## 245
N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N'-(4-
methoxy-benzyl)-oxalamide ##STR00265## 246
N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N'-(4-
trifluoromethyl-benzyl)- oxalamide ##STR00266## 247
N-{4-[7-(Azetidin-3- ylmethoxy)-6-methoxy-
quinolin-4-yloxy]-3-fluoro- phenyl}-N'-phenethyl- oxalamide
##STR00267## 248 N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-azetidin-3-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N'-phenethyl- oxalamide
##STR00268## 249 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-hydroxy-2-phenyl-ethyl)- oxalamide ##STR00269## 250
N-[5-Chloro-6-(6,7- dimethoxy-quinolin-4-yloxy)-
pyridin-3-yl]-N'-(2,4-difluoro- phenyl)-malonamide ##STR00270## 251
N-[5-Chloro-6-(6,7- dimethoxy-quinolin-4-yloxy)-
pyridin-3-yl]-N'-(4-fluoro- phenyl)-N'-methyl- malonamide
##STR00271## 252 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(1R-phenyl-propyl)- oxalamide ##STR00272## 253
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (1R-phenyl-propyl)- oxalamide
##STR00273## 254 N-(3,4-Difluoro-benzyl)-N'-
{3-fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00274## 255
N-(2,6-Difluoro-benzyl)-N'- {3-fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00275## 256 N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N'-[2-(4-
fluoro-phenyl)-ethyl]- oxalamide ##STR00276## 257
N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N'-phenyl- oxalamide
##STR00277## 258 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(3-fluoro-phenyl)-oxalamide ##STR00278## 259 N-(4-Chloro-3-fluoro-
phenyl)-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00279## 260
N-(3,4-Dimethoxy-phenyl)- N'-{3-fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00280## 261 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(3-methyl-butyl)-oxalamide ##STR00281## 262
N-(3,3-Dimethyl-butyl)-N'- {3-fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00282## 263 N-{5-Chloro-6-[6-methoxy-7-
(3-piperidin-1-yl-propoxy)- quinolin-4-yloxy]-pyridin-3-
yl}-N'-(4-fluoro-phenyl)- malonamide ##STR00283## 264
N-{5-Chloro-6-[6-methoxy-7- (3-morpholin-4-yl-propoxy)-
quinolin-4-yloxy]-pyridin-3- yl}-N'-(4-fluoro-phenyl)- malonamide
##STR00284## 265 N-{5-Chloro-6-[7-(3- diethylamino-propoxy)-6-
methoxy-quinolin-4-yloxy]- pyridin-3-yl}-N'-(4-fluoro-
phenyl)-malonamide ##STR00285## 266 N-(4-Chloro-benzyl)-N'-{3-
fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00286## 267
N-(3,5-Dimethoxy-benzyl)- N'-{3-fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00287## 268 N-(4-Butyl-benzyl)-N'-{3- fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00288## 269 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-p-tolyl-ethyl)-oxalamide ##STR00289## 270
N-(3,5-Bis-trifluoromethyl- benzyl)-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00290## 271
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- pyrazin-2-ylmethyl-oxalamide
##STR00291## 272 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
pyridin-2-ylmethyl-oxalamide ##STR00292## 273
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinazolin-4-yloxy]-phenyl}- N'-phenethyl-oxalamide ##STR00293##
274 N-{3-Fluoro-4-[6-methoxy-7- (1-methyl-piperidin-4-
ylmethoxy)-quinazolin-4- yloxy]-phenyl}-N'-phenethyl- oxalamide
##STR00294## 275 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-fluoro-3-trifluoromethyl- benzyl)-oxalamide ##STR00295## 276
N-[2-(2-Bromo-6-methoxy- phenyl)-ethyl]-N'-{3-fluoro-4-
[6-methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00296## 277 N-[2-(3,4-Dimethoxy-
phenyl)-ethyl]-N'-{3-fluoro-4- [6-methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N-methyl- oxalamide
##STR00297## 278 N-[2-(5-Bromo-2-methoxy-
phenyl)-ethyl]-N'-{3-fluoro-4- [6-methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00298## 279
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2-fluoro-5-trifluoromethyl-
benzyl)-oxalamide ##STR00299## 280 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
[1-(4-fluoro-phenyl)-ethyl]- oxalamide ##STR00300## 281
N-(1S-Benzyl-2-oxo-2- pyrrolidin-1-yl-ethyl)-N'-{3-
fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}- oxalamide ##STR00301## 282
N-{3-Fluoro-4-[6-methoxy-7- (octahydro- cyclopenta[c]pyrrol-5-
ylmethoxy)-quinazolin-4- yloxy]-phenyl}-N'-phenethyl- oxalamide
##STR00302## 283 N-[2-(4-Amino-phenyl)- ethyl]-N'-{3-fluoro-4-[6-
methoxy-7-(piperidin-4- ylmethoxy)-quinolin-4-
yloxy]-phenyl}-oxalamide ##STR00303## 284
2-(4-Benzyl-piperidin-1-yl)- N-{3-fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-2- oxo-acetamide
##STR00304## 285 N-[4-(6,7-Dimethoxy- quinolin-4-yloxy)-phenyl]-N'-
(4-fluoro-phenyl)-malonamide ##STR00305## 286 N-[5-Chloro-6-(6,7-
dimethoxy-quinolin-4-yloxy)- pyridin-3-yl]-N'-(3-fluoro-
phenyl)-malonamide ##STR00306## 287 N-[5-Chloro-6-(6,7-
dimethoxy-quinolin-4-yloxy)- pyridin-3-yl]-N'-phenyl- malonamide
##STR00307## 288 N-[5-Chloro-6-(6,7- dimethoxy-quinolin-4-yloxy)-
pyridin-3-yl]-N'-(4-fluoro- phenyl)-2,2-dimethyl- malonamide
##STR00308## 289 N-Ethyl-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00309## 290
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- isopropyl-oxalamide ##STR00310## 291
N-Butyl-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-oxalamide ##STR00311## 292
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-N'- (2-methoxy-ethyl)-oxalamide
##STR00312## 293 N-Cyclopropylmethyl-N'-{3- fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}- oxalamide
##STR00313## 294 N-{3-Fluoro-4-[6-methoxy-7-
(piperidin-4-ylmethoxy)- quinolin-4-yloxy]-phenyl}-N'-
(2-morpholin-4-yl-ethyl)- oxalamide ##STR00314## 295
N-{3-Fluoro-4-[6-methoxy-7- (piperidin-4-ylmethoxy)-
quinolin-4-yloxy]-phenyl}-2- oxo-2-pyrrolidin-1-yl- acetamide
##STR00315## 296 N-Ethyl-N'-{3-fluoro-4-[6- methoxy-7-(piperidin-4-
ylmethoxy)-quinolin-4- yloxy]-phenyl}-N-methyl- oxalamide
##STR00316##
[0097] In another aspect, the invention comprises a compound for
modulating kinase activity of formula A-B-C, or a pharmaceutically
acceptable salt, hydrate, or prodrug thereof, wherein, A is
selected from:
##STR00317##
B is selected from:
##STR00318##
and, C is selected from:
##STR00319##
wherein R.sup.2 is selected from --H, halogen, trihalomethyl, --CN,
--NH.sub.2, --NO.sub.2, --OR.sup.3, --NR.sup.3R.sup.3,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3, and optionally
substituted lower alkyl; q is 0 to 2; each R.sup.3 is independently
selected from --H, optionally substituted lower alkyl, optionally
substituted aryl, optionally substituted arylalkyl, and optionally
substituted heteroarylalkyl; two R.sup.3, together with the
nitrogen to which they are attached, form a four- to seven-membered
heteroalicyclic, said four- to seven-membered heteroalicyclic
optionally containing one additional heteroatom; when one said
additional heteroatom is a nitrogen, then said nitrogen is
optionally substituted with a group selected from --H,
trihalomethyl, --SO.sub.2R.sup.5, --SO.sub.2NR.sup.5R.sup.5,
--CO.sub.2R.sup.5, --C(O)NR.sup.5R.sup.5, --C(O)R.sup.5, and
optionally substituted lower alkyl; each R.sup.35 is independently
selected from --H, --C(.dbd.O)R.sup.3, --C(.dbd.O)OR.sup.3,
--C(.dbd.O)SR.sup.3, --SO.sub.2R.sup.3,
--C(.dbd.O)N(R.sup.3)R.sup.3, and optionally substituted lower
alkyl; two R.sup.35, together with the nitrogen to which they are
attached, can combine to form a heteroalicyclic optionally
substituted with between one and four of R.sup.60, said
heteroalicyclic may have an additional annular heteroatom, and said
heteroalicyclic may have an aryl fused thereto, said aryl
optionally substituted with an additional one to four of R.sup.60;
A.sup.1 is selected from .dbd.N--, .dbd.C(H)--, and .dbd.C(CN)--;
A.sup.2 is either .dbd.N-- or .dbd.C(H)--; R.sup.5 is --H or
optionally substituted lower alkyl; R.sup.8 is selected from
R.sup.3, --SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and --C(O)R.sup.3;
R.sup.9, R.sup.10, and R.sup.11 are each independently selected
from --H, and --OR.sup.12; or R.sup.9 is selected from --H, and
--OR.sup.12, and R.sup.10 and R.sup.11, when taken together, are
either an optionally substituted alkylidene or an oxo; and R.sup.12
is selected from --H, --C(O)R.sup.3, optionally substituted lower
alkylidyne, optionally substituted lower arylalkylidyne, optionally
substituted lower heterocyclylalkylidyne, optionally substituted
lower alkylidene, optionally substituted lower alkylidenearyl,
optionally substituted lower alkylideneheterocyclyl, optionally
substituted lower alkyl, optionally substituted lower alkylaryl,
optionally substituted aryl, optionally substituted lower
heterocyclylalkyl, and optionally substituted heterocyclyl; or two
R.sup.12's, when taken together, form 1) a corresponding
spirocyclic ketal when said two R.sup.12's stem from R.sup.10 and
R.sup.11, or 2) a corresponding cyclic ketal when said two
R.sup.12's stem from R.sup.9 and one of R.sup.10 and R.sup.11;
E.sup.1 is selected from --O--, --CH.sub.2--, --N(R.sup.5)--, and
--S(O).sub.0-2--; Q is a five- to ten-membered ring system,
optionally substituted with between zero and four of R.sup.20;
R.sup.20 is selected from --H, halogen, trihalomethyl, --CN,
--NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.3,
--S(O).sub.0-2R, --SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, and optionally substituted lower alkyl; R.sup.60 is
selected from --H, halogen, trihalomethyl, --CN, --NO.sub.2,
--NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted lower alkyl, optionally
substituted aryl, optionally substituted heteroarylalkyl, and
optionally substituted arylalkyl; two of R.sup.60, when attached to
a non-aromatic carbon, can be oxo; each methylene in any of the
above formulae is independently optionally substituted with
R.sup.25; each R.sup.25 is independently selected from halogen,
trihalomethyl, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
arylalkyl, heteroarylalkyl, and optionally substituted lower alkyl;
two of R.sup.25, together with the carbon or carbons to which they
are attached, can combine to form a three- to seven-membered
alicyclic or heteroalicyclic, two of R.sup.25 on a single carbon
can be oxo; with the proviso that when B is selected from:
##STR00320##
and C contains
##STR00321##
and the remaining portion of C contains one of:
##STR00322##
directly attached to
##STR00323##
then A must be one of:
##STR00324##
and with the proviso that when C contains
##STR00325##
and B is selected from:
##STR00326##
then the portion of C directly attached to
##STR00327##
cannot contain
##STR00328##
when R.sup.70 is selected from --H, C.sub.1-4alkyl, and
C.sub.1-4alkoxyl.
[0098] In another example the compound is according to the
preceding paragraph, wherein Q is selected from phenyl, napthyl,
1,2,3,4-tetrahydronaphthyl, indanyl, benzodioxanyl, benzofuranyl,
phenazinyl, phenothiazinyl, phenoxazinyl, tetrahydroisoquinolyl,
pyrrolyl, pyrazolyl, pyrazolidinyl, imidazolyl, imidazolinyl,
imidazolidinyl, tetrahydropyridinyl, pyridinyl, pyrazinyl,
pyrimidinyl, pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl,
triazolyl, isoxazolyl, isoxazolidinyl, thiazolyl, thiazolinyl,
thiazolidinyl, isothiazolyl, isothiazolidinyl, indolyl, isoindolyl,
indolinyl, isoindolinyl, octahydroindolyl, octahydroisoindolyl,
quinolyl, isoquinolyl, benzimidazolyl, thiadiazolyl, benzopyranyl,
benzothiazolyl, benzoxazolyl, furyl, thienyl, benzothieliyl, and
oxadiazolyl; each optionally substituted with between one and four
of R.sup.20; wherein each R.sup.20 is independently selected from
--H, halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2,
--OR.sup.3, --NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, and optionally substituted lower alkyl.
[0099] In another example the compound is according to the
preceding paragraph, wherein B is either of the following:
##STR00329##
wherein A.sup.1 is either .dbd.N-- or .dbd.C(H)--.
[0100] In another example the compound is according to the
preceding paragraph, wherein B is
##STR00330##
[0101] In another example the compound is according to the
preceding paragraph, wherein C is selected from:
##STR00331## ##STR00332## ##STR00333##
wherein R.sup.2, R.sup.3, R.sup.5, R.sup.20, R.sup.25 and R.sup.60
are as defined above.
[0102] In another example the compound is according to the
preceding paragraph, R.sup.2 is selected from halogen,
trihalomethyl, --CN, --NO.sub.2, --OR.sup.3, --NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3, and optionally
substituted lower alkyl
[0103] In another example the compound is according to the
preceding paragraph, wherein R.sup.2 is halogen.
[0104] In another example the compound is according to the
preceding paragraph, wherein R.sup.2 is either fluorine or
chlorine.
[0105] In another aspect, the invention comprises a compound for
modulating kinase activity according to Formula XI,
##STR00334##
or a pharmaceutically acceptable salt, hydrate, or prodrug thereof,
wherein, each R.sup.1 is independently selected from halogen,
--OR.sup.3, --NO.sub.2, --NH.sub.2, --NR.sup.3R.sup.4, -D-R.sup.5,
and optionally substituted C.sub.1-6alkyl; R.sup.70 is selected
from --H, halogen, --OR.sup.3, --S(O).sub.0-2R.sup.3, --NO.sub.2,
--NH.sub.2, --NR.sup.3R.sup.4, and optionally substituted
C.sub.1-6alkyl; Q is selected from .dbd.N--, .dbd.C(H)--, and
.dbd.C(CN)--; Z is selected from --S(O).sub.0-2--, --O--, and
--NR.sup.5--; Ar is either a five- or six-membered arylene or a
five- or six-membered heteroarylene containing between one and
three heteroatoms; G is either an optionally substituted cycloalkyl
or an optionally substituted heteroalicyclic; each R.sup.2 is
independently selected from halogen, trihalomethyl, --CN,
--NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3, and optionally
substituted C.sub.1-6alkyl; each R.sup.3 is independently --H or
R.sup.4; each R.sup.4 is independently selected from optionally
substituted C.sub.1-6alkyl, optionally substituted aryl, optionally
substituted aryl C.sub.1-6alkyl, optionally substituted
heterocyclyl, and optionally substituted heterocyclyl
C.sub.1-6alkyl; or R.sup.3 and R.sup.4, when taken together with a
common nitrogen to which they are attached, form an optionally
substituted five- to seven-membered heterocyclyl, said optionally
substituted five- to seven-membered heterocyclyl optionally
containing at least one additional annular heteroatom selected from
N, O, S, and P; R.sup.5 is --H or optionally substituted
C.sub.1-6alkyl; each D is independently selected from --O--,
--S(O).sub.0-2--, and --NR.sup.5--; each R.sup.50 is independently
either R.sup.3, or according to formula XII;
##STR00335##
wherein X.sup.1, X.sup.2, and optionally X.sup.3, represent the
atoms of a saturated bridged ring system, said saturated bridged
ring system comprising up to four annular heteroatoms represented
by any of X.sup.1, X.sup.2, and X.sup.3; wherein, [0106] each
X.sup.1 is independently selected from --C(R.sup.6)R.sup.7--,
--O--, --S(O).sub.0-2--, and --NR.sup.8--; [0107] each X.sup.2 is
independently an optionally substituted bridgehead methine or a
bridgehead nitrogen; [0108] each X.sup.3 is independently selected
from --C(R.sup.6)R.sup.7--, --O--, --S(O).sub.0-2--, and
--NR.sup.8--; Y is either: [0109] an optionally substituted lower
alkylene linker, between D and either 1) any annular atom of the
saturated bridged ring system, except X.sup.2 when X.sup.2 is a
bridgehead nitrogen, or 2) any heteroatom, represented by any of
R.sup.6 or R.sup.7; provided there are at least two carbon atoms
between D and any annular heteroatom of the saturated bridged ring
system or any heteroatom represented by any of R.sup.6 or R.sup.7;
[0110] or Y is absent, when Y is absent, said saturated bridged
ring system, is directly attached to D via an annular carbon of
said saturated bridged ring system, unless D is --SO.sub.2--, in
which case said saturated bridged ring system, is directly attached
to D via an any annular atom of said saturated bridged ring system;
m and p are each independently one to four; n is zero to two, when
n equals zero, then there is a single bond between the two
bridgehead X.sup.2's; R.sup.6 and R.sup.7 are each independently
selected from --H, halogen, trihalomethyl, --CN, --NH.sub.2,
--NO.sub.2, --OR.sup.3, --NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.4,
--SO.sub.2NR.sup.3R.sup.4, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.4, --N(R.sup.3)SO.sub.2R.sup.4,
--N(R.sup.3)C(O)R.sup.3, --NCO.sub.2R.sup.3, --C(O)R.sup.3,
optionally substituted C.sub.1-6alkyl, optionally substituted aryl,
optionally substituted aryl C.sub.1-6alkyl, optionally substituted
heterocyclyl, optionally substituted heterocyclyl C.sub.1-6alkyl,
and a bond to either Y or D; or R.sup.6 and R.sup.7, when taken
together are oxo; or R.sup.6 and R.sup.7, when taken together with
a common carbon to which they are attached, form a optionally
substituted three- to seven-membered spirocyclyl, said optionally
substituted three- to seven-membered spirocyclyl optionally
containing at least one additional annular heteroatom selected from
N, O, S, and P; R.sup.8 is selected from --R.sup.3, Y,
--SO.sub.2NR.sup.3R.sup.4, --CO.sub.2R.sup.4,
--C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.4, and --C(O)R.sup.3; and
each R.sup.30 is independently selected from halogen,
trihalomethyl, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, and optionally substituted C.sub.1-6alkyl.
[0111] In one example, the compound is according to Formula XI,
wherein Z is either --O-- or --NR.sup.5--.
[0112] In another example, the compound is according to the
preceding paragraph, wherein at least one of R.sup.1 is
-D-R.sup.50.
[0113] In another example, the compound is according to the
preceding paragraph, wherein D is --O-- and at least one other
R.sup.1 is --OR.sup.3.
[0114] In another example, the compound is according to the
preceding paragraph, of formula XIIIa or XIIIb:
##STR00336##
wherein Q.sup.1 is either .dbd.N-- or .dbd.C(H)--.
[0115] In another example, the compound is according to formula
XIIIa or formula XIIIb, wherein R.sup.50 is selected from
C.sub.1-6alkyl optionally substituted with at least one of
optionally substituted amino, optionally substituted C.sub.1-6alkyl
amino, optionally substituted C.sub.1-6dialkyl amino, optionally
substituted heteroalicylic, and a group of formula XII.
[0116] In another example, the compound is according to the
preceding paragraph, wherein R.sup.3a is C.sub.1-6alkyl.
[0117] In another example, the compound is according to the
preceding paragraph, wherein Z is --O--.
[0118] In another example, the compound is according to the
preceding paragraph, wherein G is selected from cyclopropyl,
aziradine, cyclobutyl, and azetidine, each optionally substituted
with between zero and four of R.sup.30.
[0119] In another example, the compound is according to the
preceding paragraph, wherein Q is either .dbd.N-- or
.dbd.C(H)--.
[0120] In another example, the compound is according to the
preceding paragraph, wherein R.sup.2 is selected from --H, halogen,
C.sub.1-6 alkyl and perfluoro C.sub.1-6 alkyl.
[0121] In another example, the compound is according to the
preceding paragraph, wherein --N(R.sup.3b)R.sup.4 is selected from
the following:
##STR00337##
wherein J, is a five- to ten-membered ring, optionally substituted
with between zero and five of R.sup.20; each R.sup.20 is
independently selected from --H, halogen, trihalomethyl, --CN,
--NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3, --SO.sub.2NR.sup.3R.sup.3,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, optionally substituted
aryl C.sub.1-6alkyl, optionally substituted heterocyclyl, and
optionally substituted heterocyclyl C.sub.1-6alkyl; two of
R.sup.20, together with the atom or atoms to which they are
attached, combine to form an optionally substituted three- to
seven-membered heteroalicyclic, said optionally substituted three-
to seven-membered heteroalicyclic either spiro- to J or fused to J;
E is selected from --O--, --N(R.sup.5)--, --CH.sub.2--, and
--S(O).sub.0-2--; each R.sup.60 is independently selected from
halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.4, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted C.sub.1-6alkyl, optionally
substituted aryl, optionally substituted heteroaryl C.sub.1-6alkyl,
and optionally substituted aryl C.sub.1-6alkyl; each methylene in
any of the above formulae, other than those in a depicted ring, is
independently optionally substituted with R.sup.25; and R.sup.25 is
selected from halogen, trihalomethyl, oxo, --CN, --NO.sub.2,
--NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.4,
--S(O).sub.0-2R.sup.3--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
aryl C.sub.1-6alkyl, heteroaryl C.sub.1-6alkyl, and optionally
substituted C.sub.1-6alkyl; or two of R.sup.25, together with the
carbon or carbons to which they are attached, can combine to form a
three- to seven-membered alicyclic or heteroalicyclic; R.sup.3b is
equivalent to R.sup.3 as defined above; and R.sup.4 and R.sup.5 are
as defined above.
[0122] In another example, the compound is according to the
preceding paragraph, of formula XIVa or XIVb:
##STR00338##
[0123] In another example, the compound is according to the
preceding paragraph, wherein R.sup.50 is C.sub.1-6alkyl optionally
substituted with a group selected from optionally substituted
amino, an optionally substituted alkylamino, optionally substituted
dialkylamino, and optionally substituted heteroalicylic.
[0124] In another example, the compound is according to the
preceding paragraph, wherein the heteroalicyclic portion of
R.sup.50 is selected from the group consisting of piperidine,
piperazine, morpholine, thiomorpholine, thiomorpholine 1-oxide,
thiomorpholine 1,1-dioxide, 2-oxo-morpholine, pyrrolidine, and
azepine.
[0125] In another example, the compound is as defined two
paragraphs above, wherein R.sup.50 is according to formula XII.
[0126] In another example, the compound is according to the
preceding paragraph, wherein the saturated bridged ring system
according to formula XII has a geometry selected from the group
consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0],
[3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2], and
[2.2.1].
[0127] In another example, the compound is according to the
preceding paragraph, wherein Y is selected from
--CH.sub.2CH.sub.2CH.sub.2CH.sub.2--, --CH.sub.2CH.sub.2CH.sub.2--,
--CH.sub.2CH.sub.2--, --CH.sub.2--, and absent.
[0128] In another example, the compound is according to the
preceding paragraph, wherein n is 0 and the saturated bridged ring
system according to formula XII has a geometry selected from the
group consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0],
[3.2.0], and [3.1.0].
[0129] In another example, the compound is according to the
preceding paragraph, wherein said saturated bridged ring system
contains at least one annular nitrogen or at least one annular
oxygen.
[0130] In another example, the compound is according to the
preceding paragraph, wherein said saturated bridged ring system
contains --NR.sup.8--, wherein R.sup.8 is selected from --H,
optionally substituted C.sub.1-6alkyl, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and --C(O)R.sup.3.
[0131] In another example, the compound is as defined two
paragraphs above, wherein said saturated bridged ring system is of
formula XV,
##STR00339##
wherein U.sup.1 is selected from --O--, --S(O).sub.0-2--,
--NR.sup.8--, --CR.sup.6R.sup.7--, and absent; and e is 0 or 1.
[0132] In another example, the compound is according to the
preceding paragraph, wherein Y is --CH.sub.2--.
[0133] In another example, the compound is according to the
preceding paragraph, wherein U.sup.1 is --NR.sup.8--, wherein
R.sup.8 is selected from --H, optionally substituted lower alkyl,
--CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and
--C(O)R.sup.3.
[0134] In another example, the compound is as defined two
paragraphs above, wherein U.sup.1 is --O--.
[0135] In another example, the compound is as defined three
paragraphs above, wherein U.sup.1 is absent.
[0136] In another example, the saturated bridged ring system is
according to formula XII and has a geometry selected from the group
consisting of [4.4.0], [4.3.0], [4.2.0], [4.1.0], [3.3.0], [3.2.0],
[3.1.0], [3.3.3], [3.3.2], [3.3.1], [3.2.2], [3.2.1], [2.2.2], and
[2.2.1], and Y is selected from --CH.sub.2CH.sub.2--, --CH.sub.2--,
and absent.
[0137] In another example, the compound is according to the
preceding paragraph, wherein said saturated bridged ring system is
of formula XVI,
##STR00340##
wherein R.sup.9, R.sup.10, and R.sup.11 are each independently
selected from --H, and --OR.sup.12; or R.sup.9 is selected from
--H, and --OR.sup.2, and R.sup.10 and R.sup.11, when taken
together, are either an optionally substituted alkylidene or an
oxo; R.sup.12 is selected from --H, --C(O)R.sup.3, optionally
substituted lower alkylidyne, optionally substituted lower
arylalkylidyne, optionally substituted lower
heterocyclylalkylidyne, optionally substituted lower alkylidene,
optionally substituted lower alkylidenearyl, optionally substituted
lower alkylideneheterocyclyl, optionally substituted lower alkyl,
optionally substituted lower alkylaryl, optionally substituted
aryl, optionally substituted lower heterocyclylalkyl, and
optionally substituted heterocyclyl; or two R.sup.12's, when taken
together, form 1) a corresponding spirocyclic ketal when said two
R.sup.12's stem from R.sup.10 and R.sup.11, or 2) a corresponding
cyclic ketal when said two R.sup.12's stem from R.sup.9 and one of
R.sup.10 and R.sup.11.
[0138] In another example, the compound is according to the
preceding paragraph, wherein one of R.sup.10 and R.sup.11 is
--OR.sup.12, wherein R.sup.12 is selected from --H, --C(O)R.sup.3,
and optionally substituted lower alkyl; and R.sup.9 and the other
of R.sup.10 and R.sup.11 are both --H.
[0139] In another example, the compound is according to the
preceding paragraph, wherein Y is either --CH.sub.2-- or
absent.
[0140] In another example, the compound is as defined three
paragraphs above, wherein R.sup.9 is an alkyl group containing at
least one fluorine substitution thereon.
[0141] In another example, the compound is as defined eleven
paragraphs above, wherein said saturated bridged ring system is of
formula XVII, wherein R.sup.8 is selected from --H, optionally
substituted C.sub.1-6alkyl, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and --C(O)R.sup.3.
##STR00341##
[0142] In another example, the compound is according to the
preceding paragraph, wherein Y is either --CH.sub.2-- or
absent.
[0143] In another example, the compound is according to the
preceding paragraph, wherein R.sup.8 is methyl or ethyl.
[0144] In another example, the compound is according to the
preceding paragraph, wherein at least one of R.sup.2 is
halogen.
[0145] In another example, the compound is as defined fifteen
paragraphs above, wherein said saturated bridged ring system is of
formula XVIII, wherein R.sup.8 is selected from --H, optionally
substituted C.sub.1-6alkyl, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and --C(O)R.sup.3.
##STR00342##
[0146] In another example, the compound is according to the
preceding paragraph, wherein Y is --CH.sub.2--.
[0147] In another example, the compound is according to the
preceding paragraph, wherein R.sup.8 is methyl or ethyl.
[0148] In another example, the compound is as defined nineteen
paragraphs above, wherein said saturated bridged ring system is of
formula XIX
##STR00343##
wherein U.sup.2 is selected from --O--, --S(O).sub.0-2--,
--NR.sup.8--, --CR.sup.6R.sup.7--, and absent.
[0149] In another example, the compound is according to the
preceding paragraph, wherein R.sup.3 of formula XIX is selected
from --H and optionally substituted alkyl.
[0150] In another example, the compound is according to the
preceding paragraph, wherein U.sup.2 is either --CR.sup.6R.sup.7--
or absent.
[0151] In another example, the compound is according to the
preceding paragraph, wherein U.sup.2 is either --CH.sub.2-- or
absent.
[0152] In another example, the compound is according to the
preceding paragraph, wherein Y is --CH.sub.2--.
[0153] In another example, the compound is as defined above,
wherein said saturated bridged ring system is according to formula
XX, wherein R.sup.8 is selected from --H, optionally substituted
C.sub.1-6alkyl, --CO.sub.2R.sup.3, --C(O)NR.sup.3R.sup.3,
--SO.sub.2R.sup.3, and --C(O)R.sup.3.
##STR00344##
[0154] In another example, the compound is according to the
preceding paragraph, wherein R.sup.8 is methyl or ethyl.
[0155] In another example, the compound is according to formula
XIVa or XIVb, wherein R.sup.2 is selected from C.sub.1-6 alkyl,
perfluoro C.sub.1-6 alkyl, and halogen.
[0156] In another example, the compound is according to the
preceding paragraph, wherein R.sup.2 is selected from perfluoro
C.sub.1-3 alkyl and halogen.
[0157] In another example, the compound is according to formula
XIVa or XIVb, wherein R.sup.20 is selected from halogen, --CN,
--NO.sub.2, --NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.3,
--N(R.sup.3)SO.sub.2R.sup.3, --N(R.sup.3)C(O)R.sup.3,
--N(R.sup.3)CO.sub.2R.sup.3, optionally substituted heterocyclyl,
and optionally substituted heterocyclyl C.sub.1-6alkyl, and (two of
R.sup.20) together with the atom or atoms to which they are
attached, an optionally substituted three- to six-membered
heteroalicyclic, said optionally substituted three- to six-membered
heteroalicyclic fused to the phenyl as in XIVa or XIVb.
[0158] In another example, the compound is according to the
preceding paragraph, wherein R.sup.20 is selected from halogen,
--NR.sup.3R.sup.4, optionally substituted heterocyclyl, and
optionally substituted heterocyclyl C.sub.1-6alkyl, and (two of
R.sup.20) together with the atom or atoms to which they are
attached, an optionally substituted five- to six-membered
heteroalicyclic, said optionally substituted five- to six-membered
heteroalicyclic fused to the phenyl as in XIVa or XIVb.
[0159] In another example, the compound is according to the
preceding paragraph, wherein R.sup.2 is selected from C.sub.1-6
alkyl, perfluoro C.sub.1-6 alkyl, and halogen.
[0160] In another example, the compound is according to the
preceding paragraph, wherein R.sup.2 is selected from perfluoro
C.sub.1-3 alkyl and halogen.
[0161] In another example, the compound is selected from Table
2.
TABLE-US-00002 TABLE 2 Entry Name Structure 1 N-(6-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-chloropyridin-
3-yl)-N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00345## 2 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxyl-5-chloropyridin- 3-yl)-N'-(4-fluorophenyl) cyclobutane-1,1-
dicarboxamide ##STR00346## 3 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-chloropyridin- 3-yl)-N'-(phenylmethyl) cyclopropane-1,1-
dicarboxamide ##STR00347## 4 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-chloropyridin- 3-yl)-N'- phenylcyclopropane-1,1-
dicarboxamide ##STR00348## 5 N-[3-fluoro-4-({6- (methyloxy)-7-[(3 -
morpholin-4-ylpropyl) oxy]quinolin-4-yl}oxy) phenyl]-N'-(4-
fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00349## 6
N-[3-fluoro-4-({6- (methyloxy)-7-[(3- piperidin-1-ylpropyl)
oxy]quinolin-4-yl}oxy) phenyl]-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00350## 7 N-[3-fluoro-4-({6-
(methyloxy)-7-[(3- piperidin-1- ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]-N'-(4- fluorophenyl)cyclobutane- 1,1-dicarboxamide
##STR00351## 8 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-chloropyridin- 3-yl)-N'-(2-phenylethyl) cyclopropane-1,1-
dicarboxamide ##STR00352## 9 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-2-methylpyridin- 3-yl)-N'-(4-fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00353## 10
N-{4-[(7-chloroquinolin- 4-yl)oxy]-3- fluorophenyl}-N'-(4-
fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00354## 11
N-{4-[(7-chloroquinolin- 4-yl)oxy]phenyl}-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00355## 12 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00356## 13 N-(4-{[6,7-
bis(methyloxy)quinazolin- 4-yl]oxy}phenyl)-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00357## 14 N-(4-{[6,7-
bis(methyloxy)quinazolin- 4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00358## 15
N-[3-fluoro-4-({6- (methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinazolin- 4-yl}oxy)phenyl]-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00359## 16 N-{5-chloro-6-[(6-
(methyloxy)-7-{[(1- methylpiperidin-4- yl)methyl]oxy}quinolin-
4-yl)oxy]pyridin-3-yl}- N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00360## 17 N-[5-chloro-6-({6- (methyloxy)-7-
[(piperidin-4- ylmethyl)oxy]quinolin-4- yl}oxy)pyridin-3-yl]-N'-
(4-fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00361## 18
N-[5-chloro-6-({6- (methyloxy)-7- [(phenylmethyl)oxy]quino
lin-4-yl}oxy)pyridin-3- yl]-N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00362## 19 N-(4-{[7-{[2-
(diethylamino)ethyl]oxy}- 6-(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00363## 20 N-(4-{[7-{[2-
(diethylamino)ethyl]oxy}- 6-(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl) cyclobutane-1,1-
dicarboxamide ##STR00364## 21 N-{3-fluoro-4-[(6-
(methyloxy)-7-{[(1- methylpiperidin-4- yl)methyl]oxy}quinazolin-
4-yl)oxy]phenyl}-N'-(4- fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00365## 22 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy)-2-methylphenyl)- N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00366## 23 N-(4-fluorophenyl)-N'-[2-
methyl-6-({6- (methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)pyridin-3- yl]cyclopropane-1,1-
dicarboxamide ##STR00367## 24 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00368## 25 N-(6-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-5-chloro-2- methylpyridin-3-yl)-N'- (4-fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00369## 26 N-[3-fluoro-4-({7-
(methyloxy)-6-[(3- morpholin-4- ylpropyl)oxy]quinazolin-
4-yl}oxy)phenyl]-N'-(4- fluorophenyl)cyclopropane-
1,1-dicarboxamide ##STR00370## 27 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-3,5- difluorophenyl)-N'-(4-
fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00371## 28
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-2,5-
difluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1-
dicarboxarnide ##STR00372## 29 N-[3-fluoro-4-({7-
(methyloxy)-6-[(3- morpholin-4- ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]-N'-(4- fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00373## 30 N-{3-fluoro-4-[(6- (methyloxy)-7-(2-methyl
octahydrocyclo- penta[c]pyrrol-5- ylmethoxy)quinazolin-4-
yl)oxy]phenyl}-N'-(4- fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00374## 31 N-{3-fluoro-4-[(7- (methyloxy)-6-{[(1-
methylpiperidin-4- yl)methyl]oxy}quinazolin-
4-yl)oxy]phenyl}-N'-(4- fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00375## 32 N-[5-fluoro-2-methyl-4-
({6-(methyloxy)-7-[(3- morpholin-4- ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]-N'-(4- fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00376## 33 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-2,3,5- trifluorophenyl)-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00377## 34 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}-5-fluoro-2- methylphenyl)-N'-(4-
fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00378## 35
N-(4-{[6,7- bis(methyloxy)quinolin-4- yl]oxy}-2-chloro-5-
methylphenyl)-N'-(4- fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00379## 36 N-(3-fluoro-4-{[6- hydroxy-7-
(methyloxy)quinolin-4- yl]oxy}phenyl)-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00380## 37
N-(4-fluorophenyl)-N'-[2- methyl-4-({6- (methyloxy)-7-[(3 -
morpholin-4- ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]
cyclopropane-1,1- dicarboxamide ##STR00381## 38 N-[3-fluoro-4-({6-
(methyloxy)-7-[(3 - piperazin-1- ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]-N'-(4- fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00382## 39 N-{3-fluoro-4-[(6- (methyloxy)-7-{[3-(4-
methylpiperazin-1- yl)propyl]oxy}quinolin-4- yl)oxy]phenyl }-N'-(4-
fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00383## 40
N-{3-fluoro-4-[(6- (methyloxy)-7-{[(1- methylpiperidin-4-
yl)methyl]oxy}quinolin- 4-yl)oxy]phenyl}-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00384## 41
N-(4-fluorophenyl)-N'-[4- ({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl] cyclopropane-1,1-
dicarboxamide ##STR00385## 42 N-(4-{[7-{[3-
(diethylamino)propyl]oxy}- 6-(methyloxy)quinolin- 4-yl]oxy}-3-
fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00386## 43 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}-2-chloro-5- fluorophenyl)-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00387## 44 N-(4-{[6,7-
bis(methyloxy)-2- (methylthio)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00388## 45
N-(4-fluorophenyl)-N'-(4- {[2-methyl-6,7- bis(methyloxy)quinazolin-
4-yl]oxy}phenyl) cyclopropane-1,1- dicarboxamide ##STR00389## 46
N-(4-{[2-amino-6,7- bis(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl) cyclopropane-1,1-
dicarboxamide ##STR00390## 47 N-(3-fluoro-4-{[2- (methylamino)-6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00391## 48
(1S,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00392## 49
(1R,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00393## 50 N-(4-{[6-{[3-
(diethylamino)propyl]oxy}- 7-(methyloxy)quinolin- 4-yl]oxy}-3-
fluorophenyl)-N'-(4- fluorophenyl) cyclopropane-1,1- dicarboxamide
##STR00394## 51 N-(4-{[6-{[2- (diethylamino)ethyl]oxy}-
7-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00395## 52
1,1-dimethylethyl 4-(3- {[4-[(2-fluoro-4-{[(1- {[(4-fluorophenyl)
amino]carbonyl}cyclopropyl) carbonyl]amino}phenyl)
oxy]-6-(methyloxy) quinolin-7-yl]oxy}propyl)
piperazine-1-carboxylate ##STR00396## 53 (1R,2R)-N-[3-fluoro-4-
({6-(methyloxy)-7-[(3- morpholin-4- ylpropyl)oxy]quinazolin-
4-yl}oxy)phenyl]-N'-(4- fluorophenyl)-2- methylcyclopropane-1,1-
dicarboxamide ##STR00397## 54 (1R,2R)-N-(4-{[7-{[2-
(diethylamino)ethyl]oxy}- 6-(methyloxy)quinazolin- 4-yl]oxy}-3-
fluorophenyl)-N'-(4- fluorophenyl)-2- methylcyclopropane-1,1-
dicarboxamide ##STR00398## 55 N-(4-{[7-{[3- (diethylamino)propyl]
oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00399## 56
N-(4-{[7-{[3-(4- acetylpiperazin-1- yl)propyl]oxy}-6-
(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00400## 57 1,1-dimethylethyl
4-(3 - {[4-[(2-fluoro-4- {[((1R,2R)-1-{[(4- fluorophenyl)amino]
carbonyl}-2- methylcyclopropyl)carbonyl] amino}phenyl)oxy]-6-
(methyloxy)quinolin-7- yl]oxy}propyl)piperazine- 1-carboxylate
##STR00401## 58 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-(4- fluorophenyl)-1- (phenylmethyl)azetidine-
3,3-dicarboxamide ##STR00402## 59 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxylphenyl)-N'-(4-
fluorophenyl)azetidine- 3,3-dicarboxamide ##STR00403## 60
(1R,2S)-N-{3-fluoro-4- [(6-(methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinolin-4- yl)oxy]phenyl}-N'-(4-
methyleyelopropane-1,1- dicarboxamide ##STR00404## 61
(1R,2R)-N-{3-fluoro-4- [(6-(methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinolin-4- yl)oxy]phenyl}-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00405## 62
(1R,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3- piperazin-1-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00406## 63
N-(3-fluoro-4-{[7-({3-[4- (1-methylethyl)piperazin-
1-yl]propyl}oxy)-6- (methyloxy)quinolin-4- yl]oxy}phenyl)-N'-(4-
fluorophenyl) cyclopropane-1,1- dicarboxamide ##STR00407## 64
N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)
cyclopropane-1,1- dicarboxamide ##STR00408## 65
(1R,2R)-N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2-
methylcycloproparte-1,1- dicarboxamide ##STR00409##
66 (1R,2R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide
##STR00410## 67 (1R,2S)-N-(4-{[7-{[3- (diethylamino)propyl]
oxy}-6-(methyloxy) quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)-2- methylcyclopropane- 1,1- dicarboxamide
##STR00411## 68 (1R,2S)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide
##STR00412## 69 N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinazolin- 4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00413## 70
(1R,2S)-N-[3-fluoro-4- ({6-(methyloxy)-7-{(3- piperazin-1-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00414## 71
(1R,2R,3S)-N-[3-fluoro- 4-({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2,3 -
dimethylcyclopropane- 1,1-dicarboxamide ##STR00415## 72
(1R,2R,3S)-N-{3-fluoro- 4-[(6-(methyloxy)-7-{[3-
(4-methylpiperazin-1- yl)propyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4- fluorophenyl)-2,3- dimethylcyclopropane-
1,1-dicarboxamide ##STR00416## 73 (1R,2R,3S)-N-[3-fluoro-
4-({6-(methyloxy)-7-[(3- morpholin-4- ylpropyl)oxy]quinazolin-
4-yl}oxy)phenyl]-N'-(4- fluorophenyl)-2,3- dimethylcyclopropane-
1,1-dicarboxamide ##STR00417## 74 (1R,2R,3S)-N-{3-fluoro-
4-[(6-(methyloxy)-7-{[3- (4-methylpiperazin-1-
yl)propyl]oxy}quinazolin- 4-yl)oxy]phenyl}-N'-(4-
fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00418## 75 N-[3-fluoro-4-({6 - (methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinazolin- 4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00419## 76
(2R,3R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2,3-
dimethylcyclopropane- 1,1-dicarboxarnide ##STR00420## 77
(2R,3R)-N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2,3 -
dimethylcyclopropane- 1,1-dicarboxamide ##STR00421## 78
N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00422## 79
N-[3-fluoro-4({6- (methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinazolin- 4-yl}oxy)phenyl]-N'-(4- fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00423## 80
(1R,2R,3S)-N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2,3-
dimethylcyclopropane- 1,1-dicarboxarnide ##STR00424## 81
N-(4-{[7-{[2- (diethylamino)ethyl]oxy}- 6-(methyloxy)quinolin-4-
yl]oxy}-3-fluorophenyl)- N'-(4-fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00425## 82
(1R,2R,3S)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00426## 83 N-[3-fluoro-4-({6- (methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinolin-4- yl}oxy)phenyl]-N'-(4- fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00427## 84
N-(4-{[7-{[2- (diethylamino)ethyl]oxy}- 6-(methyloxy)quinazolin-
4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00428## 85
N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2,2-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00429## 86
N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00430## 87
N-{3-fluoro-4-[(6- (methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinazolin- 4-yl)oxylphenyl}-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00431## 88
N-[3-fluoro-4-({6- (methyloxy)-7-[(3- piperazin-1-
ylpropyl)oxy]quinazolin- 4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00432## 89
(2R,3R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3- morpholin-4-
ylpropyl)oxy]quinazolin- 4-yl}oxy)phenyl]-N'-(4- fluorophenyl)-2,3-
dimethylcyclopropane- 1,1-dicarboxamide ##STR00433## 90
N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00434## 91
N-{3-fluoro-4-[(6- (methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinolin-4- yl)oxy]phenyl}-N'-(4-
fluorophenyl)cyclobutane- 1,1-dicarboxamide ##STR00435## 92
(1R,2R)-N-(4-{[7-{[3- (diethylamino)propyl] oxy}-6-(methyloxy)
quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00436## 93
(1R,2R)-N-{3-fluoro-4- [(6-(methyloxy)-7-{[3-(4- methylpiperazin-1-
yl)propyl]oxy}quinazolin- 4-yl)oxy]phenyl}-N'-(4- fluorophenyl)-2-
methylcyclopropane-1,1- dicarboxamide ##STR00437## 94
(2R,3R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinazolin- 4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00438## 95 (2R,3R)-N-(4-{[7-{[3- (diethylamino)propyl]
oxy}-6-(methyloxy) quinazolin-4-yl]oxy}-3- fluorophenyl)-N'-(4-
fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00439## 96 (1R,2R)-N-[3-fluoro-4- ({6-(methyloxy)-7-[(3-
piperazin-1- ylpropyl)oxy]quinazolin- 4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)-2- methylcyclopropane-1,1- dicarboxamide ##STR00440##
97 (2R,3R)-N-(4-{[7-{[2- (diethylamino)ethyl]oxy}-
6-(methyloxy)quinolin-4- yl]oxy}-3-fluorophenyl)-
N'-(4-fluorophenyl)-2,3- dimethylcyclopropane- 1,1-dicarboxamide
##STR00441## 98 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-[(4- fluorophenyl)methyl] cyclopropane-1,1-
dicarboxamide ##STR00442## 99 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-(2- morpholin-4-ylethyl) cyclopropane-1,1-
dicarboxamide ##STR00443## 100 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N'-2-
(piperidin-1-ylmethyl) phenyl]cyclopropane-1,1- dicarboxamide
##STR00444## 101 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-2- (pyrrolidin-1-ylmethyl)
phenyl]cyclopropane-1,1- dicarboxamide ##STR00445## 102 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N'-3-
(morpholin-4-ylmethyl) phenyl]cyclopropane-1,1- dicarboxamide
##STR00446## 103 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-[2- (morpholin-4-ylmethyl)
phenyl]cyclopropane-1,1- dicarboxamide ##STR00447## 104 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxylphenyl)-N'-
phenylcyclopropane-1,1- dicarboxamide ##STR00448## 105 N-[3-
(aminomethyl)phenyl]-N'- (4-{[6,7-bis(methyloxy) quinolin-4-yl]oxy}
phenyl)cyclopropane-1,1- dicarboxamide ##STR00449## 106 N-(4-{[6,7-
bis(methyloxy)quinolin-4- yl]oxy}phenyl)-N'-[3-
(piperidin-1-ylmethyl) phenyl]cyclopropane-1,1- dicarboxamide
##STR00450## 107 N-(4-{[6,7- bis(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-[3- (pyrrolidin-1-ylmethyl)
phenyl]cyclopropane-1,1- dicarboxamide ##STR00451##
[0162] Another aspect of the invention is a pharmaceutical
composition comprising a compound according to the invention and a
pharmaceutically acceptable carrier.
[0163] Another aspect of the invention is a metabolite of the
compound or the pharmaceutical composition according to the
invention.
[0164] Another aspect of the invention is a method of modulating
the in vivo activity of a kinase, the method comprising
administering to a subject an effective amount of the compound or
the pharmaceutical composition according to the invention.
[0165] Another aspect of the invention is the method according to
the preceding paragraph, wherein modulating the in vivo activity of
the kinase comprises inhibition of said kinase.
[0166] Another aspect of the invention is the method according to
the preceding paragraph, wherein the kinase is at least one of
c-Met, KDR, c-Kit, flt-3, and flt-4.
[0167] Another aspect of the invention is the method according to
the preceding paragraph, wherein the kinase is c-Met.
[0168] Another aspect of the invention is a method of treating
diseases or disorders associated with uncontrolled, abnormal,
and/or unwanted cellular activities, the method comprising
administering, to a mammal in need thereof, a therapeutically
effective amount of the compound or the pharmaceutical composition
as described herein.
[0169] Another aspect of the invention is a method of screening for
a modulator of a kinase, said kinase selected from c-Met, KDR,
c-Kit, flt-3, and flt-4, the method comprising combining a compound
according to the invention, and at least one candidate agent and
determining the effect of the candidate agent on the activity of
said kinase.
[0170] Another aspect of the invention is a method of inhibiting
proliferative activity in a cell, the method comprising
administering an effective amount of a composition comprising a
compound according to the invention to a cell or a plurality of
cells.
[0171] As mentioned, although improved quinolines and quinazolines
of the invention can be made via conventional serial methods, due
to their complex structure, more efficient routes are desirable,
particularly convergent syntheses. Thus, the present invention also
comprises a process for preparing a compound of Formula XXI,
##STR00452##
comprising reaction of a compound of Formula XXII, with a compound
of Formula XXIII
##STR00453##
wherein, each R.sup.1 is independently selected from halogen,
--OR.sup.3, --NO.sub.2, --NH.sub.2, --NR.sup.3R.sup.3, -D-R.sup.50
and optionally substituted C.sub.1-6alkyl; R.sup.70 is selected
from --H, halogen, --OR.sup.3, --S(O).sub.02R.sup.3, --NO.sub.2,
--NH.sub.2, --NR.sup.3R.sup.3, and optionally substituted
C.sub.1-6alkyl; J is selected from .dbd.N--, .dbd.C(H)--,
.dbd.C(halogen)-, and .dbd.C(CN)--; Z is selected from
--S(O).sub.0-2--, --O--, and --NR.sup.5--; each R.sup.5 is
independently selected from --H, optionally substituted
C.sub.1-6alkyl, optionally substituted aryl, and optionally
substituted aryl C.sub.1-6alkyl; Ar is either a five- to
ten-membered arylene or a five- to ten-membered heteroarylene
containing between one and three heteroatoms; R.sup.2 is selected
from --H, halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2,
--OR.sup.3, --NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.W,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, and optionally substituted C.sub.1-6alkyl; each
R.sup.3 is independently selected from --H,
--Si(R.sup.5)(R.sup.5)R.sup.5, optionally substituted lower alkyl,
optionally substituted aryl, optionally substituted arylalkyl, and
optionally substituted heteroarylalkyl; two R.sup.3, together with
the nitrogen to which they are attached, form a four- to
seven-membered heteroalicyclic, said four- to seven-membered
heteroalicyclic optionally containing one additional heteroatom;
when one said additional heteroatom is a nitrogen, then said
nitrogen is optionally substituted with a group selected from --H,
trihalomethyl, --SO.sub.2R.sup.5, --SO.sub.2NR.sup.5R.sup.5,
--CO.sub.2R.sup.5, --C(O)NR.sup.5R.sup.5, --C(O)R.sup.5, and
optionally substituted lower alkyl; B is selected from absent,
--N(R.sup.13)--, --N(SO.sub.2R.sup.3)--, --O--, --S(O).sub.0-2--,
and --C(.dbd.O)--; L is selected from absent,
--C(.dbd.S)N(R.sup.13)--, --C(.dbd.NR.sup.14)N(R.sup.13)--,
--SO.sub.2N(R.sup.13)--, --SO.sub.2--, --C(.dbd.O)N(R.sup.13)--,
--N(R.sup.13)--, --C(.dbd.O)C.sub.1-2alkylN(R.sup.13)--,
--N(R.sup.13)C.sub.1-2alkylC(.dbd.O)--,
--C(.dbd.O)C.sub.0-1alkylC(.dbd.O)N(R.sup.13)--, --C(.dbd.O)--,
--C.sub.0-4alkylene-, --C(.dbd.O)C.sub.0-1alkylC(.dbd.O)OR.sup.3--,
--C(.dbd.NR.sup.14)C.sub.0-1alkylC(.dbd.O)--,
--C(.dbd.O)C.sub.0-1alkylC(.dbd.O)--, and an optionally substituted
four- to six-membered heterocyclyl containing between one and three
annular heteroatoms and comprising at least one nitrogen; T is
selected from --H, --R.sup.13, --C.sub.0-4alkyl, --C.sub.0-4alkylQ,
--OC.sub.0-4alkylQ, --C.sub.0-4alkylOQ,
--N(R.sup.13)C.sub.0-4alkylQ, --SO.sub.2C.sub.0-4alkylQ,
--C(.dbd.O)C.sub.0-4alkylQ, --C.sub.0-4alkylN(R.sup.13)Q, and
--C(.dbd.O)N(R.sup.13)C.sub.0-4alkylQ, wherein each of the
aforementioned C.sub.0-4alkyl is optionally substituted; Q is a
five- to ten-membered ring system, optionally substituted with
between zero and four of R.sup.20; each R.sup.20 is independently
selected from --H, halogen, trihalomethyl, --CN, --NO.sub.2,
--NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted C.sub.1-6alkyl, optionally
substituted aryl, optionally substituted aryl C.sub.1-6alkyl,
optionally substituted heterocyclyl, and optionally substituted
heterocyclyl C.sub.1-6alkyl; two of R, together with the atom or
atoms to which they are attached, combine to form an optionally
substituted three- to seven-membered heteroalicyclic, said
optionally substituted three- to seven-membered heteroalicyclic
either spiro- to Q or fused to Q; D is selected from --O--,
--S(O).sub.0-2--, and --NR.sup.15--; R.sup.50 is either R.sup.3, or
according to formula XXIV;
##STR00454##
wherein X.sup.1, X.sup.2, and optionally X.sup.3, represent the
atoms of a saturated bridged ring system, said saturated bridged
ring system comprising up to four annular heteroatoms represented
by any of X.sup.1, X.sup.2, and X.sup.3; wherein, [0172] each
X.sup.1 is independently selected from --C(R.sup.6)R.sup.7--,
--O--, --S(O).sub.0-2, and --NR.sup.8--; [0173] each X.sup.2 is
independently an optionally substituted bridgehead methine or a
bridgehead nitrogen; [0174] each X.sup.3 is independently selected
from --C(R.sup.6)R.sup.7--, --O--, --S(O).sub.0-2--, and
--NR.sup.8--; Y is either: [0175] an optionally substituted
C.sub.1-6alkylene linker, between D and either 1) any annular atom
of the saturated bridged ring system, except X.sup.2 when X.sup.2
is a bridgehead nitrogen, or 2) any heteroatom, represented by any
of R.sup.6 or R.sup.7; provided there are at least two carbon atoms
between D and any annular heteroatom of the saturated bridged ring
system or any heteroatom represented by any of R.sup.6 or R.sup.7;
[0176] or Y is absent, when Y is absent, said saturated bridged
ring system, is directly attached to D via an annular carbon of
said saturated bridged ring system, unless D is --SO.sub.2--, in
which case said saturated bridged ring system, is directly attached
to D via an any annular atom of said saturated bridged ring system;
m and p are each independently one to four; n is zero to two, when
n is zero, then there is a single bond between the two bridgehead
X.sup.2's; R.sup.6 and R.sup.7 are each independently selected from
--H, halogen, trihalomethyl, --CN, --NH.sub.2, --NO.sub.2,
--OR.sup.3, --NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --NCO.sub.2R.sup.3, --C(O)R.sup.3,
optionally substituted C.sub.1-6alkyl, optionally substituted aryl,
optionally substituted aryl C.sub.1-6alkyl, optionally substituted
heterocyclyl, optionally substituted heterocyclyl a C.sub.1-6alkyl,
and a bond to either Y or D; or R.sup.6 and R.sup.7, when taken
together are oxo; or R.sup.6 and R.sup.7, when taken together with
a common carbon to which they are attached, form a optionally
substituted three- to seven-membered spirocyclyl, said optionally
substituted three- to seven-membered spirocyclyl optionally
containing at least one additional annular heteroatom selected from
N, O, S, and P; R.sup.8 is selected from --R.sup.3, Y,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --SO.sub.2R.sup.3, and --C(O)R.sup.3;
R.sup.13 is selected from --H, --C(.dbd.O)R.sup.3,
--C(.dbd.O)OR.sup.3, --C(.dbd.O)SR.sup.3, --SO.sub.2R.sup.3,
--C(.dbd.O)N(R.sup.3)R.sup.3, and optionally substituted
C.sub.1-6alkyl; two R.sup.13, together with the atom or atoms to
which they are attached, can combine to form a heteroalicyclic
optionally substituted with between one and four of R.sup.60, said
heteroalicyclic comprising up to four annular heteroatoms, and said
heteroalicyclic optionally comprising an aryl or heteroaryl fused
thereto, in which case said aryl or heteroaryl is optionally
substituted with an additional one to four of R.sup.60; R.sup.14 is
selected from --H, --NO.sub.2, --NH.sub.2, --N(R.sup.3)R.sup.3,
--CN, --OR.sup.3, optionally substituted C.sub.1-6alkyl, optionally
substituted heteroalicyclyl C.sub.1-6alkyl, optionally substituted
aryl, optionally substituted aryl C.sub.1-6alkyl and optionally
substituted heteroalicyclic; R.sup.15 is a group -M.sup.1-M.sup.2,
wherein M.sup.1 is selected from absent, --C(.dbd.S)N(R.sup.13)--,
--C(.dbd.NR.sup.14)N(R.sup.13)--, --SO.sub.2N(R.sup.13)--,
--SO.sub.2--, --C(.dbd.O)N(R.sup.13)--,
--C(.dbd.O)C(.dbd.O)N(R.sup.13)--, --C.sub.0-4alkylene-,
--C(.dbd.O)--, and an optionally substituted four to six-membered
heterocyclyl containing between one and three heteroatoms but
comprising at least one nitrogen; and M.sup.2 is selected from --H,
--C.sub.0-6alkyl, alkoxy, --C(.dbd.O)C.sub.0-4alkylQ,
--C.sub.0-4alkylQ, --OC.sub.0-4alkylQ-,
--N(R.sup.13)C.sub.0-4alkylQ-, and
--C(.dbd.O)N(R.sup.13)C.sub.0-4alkylQ; R.sup.60 is selected from
--H, halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2,
--OR.sup.3, --NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3, --C(O)R.sup.3
optionally substituted C.sub.1-6alkyl, optionally substituted aryl,
optionally substituted heteroaryl C.sub.1-6alkyl, and optionally
substituted aryl C.sub.1-6alkyl; two of R.sup.60, when attached to
a non-aromatic carbon, can be oxo; P.sup.1 is a suitable leaving
group; and P.sup.2 is selected from --H, a metal, and a group
removed in-situ when combining XXII and XXIII to make XXI.
[0177] In one example, the process is according to the preceding
paragraph, wherein Ar is para-phenylene as defined by the
substitution pattern of -Z- and --B-L-T about said phenylene.
[0178] In another example, the process is according to the
preceding paragraph, wherein Z is either --O-- or --NR.sup.5--.
[0179] In another example, the process is according to the
preceding paragraph, wherein --B-L-T is selected from the
following:
##STR00455## ##STR00456## ##STR00457##
wherein Q, R.sup.20, and R.sup.13 are as defined above; each E is
selected from --O--, --N(R.sup.13)--, --CH.sub.2, and
--S(O).sub.0-2--; M is selected from --O--, --N(R.sup.13)--,
--CH.sub.2--, and --C(.dbd.O)N(R.sup.13)--; each V is independently
either .dbd.N-- or .dbd.C(H)--; each methylene in any of the above
formulae is independently optionally substituted with R.sup.25; and
R.sup.25 is selected from halogen, trihalomethyl, --CN, --NO.sub.2,
--NH.sub.2, --OR.sup.3, --NR.sup.3R.sup.3, --S(O)O-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
aryl C.sub.1-6alkyl, heteroaryl C.sub.1-6alkyl, and optionally
substituted C.sub.1-6alkyl; two of R.sup.25, together with the
carbon or carbons to which they are attached, can combine to form
an optionally substituted three- to seven-membered alicyclic or
heteroalicyclic; two of R.sup.25 on a single carbon can be oxo.
[0180] In another example, the process is according to the
preceding paragraph, wherein there is one of R.sup.1 that is
-D-R.sup.50 and another of R.sup.1 that is --OR.sup.3a.
[0181] In another example, the process is according to the
preceding paragraph, wherein D is --O--.
[0182] In another example, the process is according to the
preceding paragraph, wherein --O--R.sup.50 and --OR.sup.3a are
interchangeably located at the 6-position and 7-position of the
quinazoline or quinoline according to Formula XXI.
[0183] In another example, the process is according to the
preceding paragraph, wherein OR.sup.3a is selected from --OH,
--OSi(R.sup.5)(R.sup.5)R.sup.5, and optionally substituted
--OC.sub.1-6alkyl.
[0184] In another example, the process is according to the
preceding paragraph, wherein J is .dbd.N-- or .dbd.C(H)--.
[0185] In another example, the process is according to the
preceding paragraph, wherein --B-L-T is selected from:
##STR00458## ##STR00459##
wherein Q, R.sup.20, R.sup.13, E, and R.sup.60 are as defined
above; each methylene in any of the above formulae, other than
those in a depicted ring, is independently optionally substituted
with R.sup.25; and R.sup.25 is selected from halogen,
trihalomethyl, oxo, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, optionally substituted aryl, optionally substituted
aryl C.sub.1-6alkyl, heteroaryl C.sub.1-6alkyl, and optionally
substituted C.sub.1-6alkyl; two of R.sup.25, together with the
carbon or carbons to which they are attached, can combine to form a
three- to seven-membered optionally substituted alicyclic or
heteroalicyclic.
[0186] In another example, the process is according to the
preceding paragraph, wherein Q is selected from the following three
formulae:
##STR00460##
wherein R.sup.20 is defined as above, and P is a five- to
seven-membered ring, including the two shared carbons of the
aromatic ring to which P is fused, P optionally containing between
one and three heteroatoms.
[0187] In another example, the process is according to the
preceding paragraph, wherein --B-L-T is either of formula XXV or
formula XXVI,
##STR00461##
wherein R.sup.20 is defined as above; G is either an optionally
substituted cycloalkyl or an optionally substituted
heteroalicyclic; each R.sup.30 is independently selected from
halogen, trihalomethyl, --CN, --NO.sub.2, --NH.sub.2, --OR.sup.3,
--NR.sup.3R.sup.3, --S(O).sub.0-2R.sup.3,
--SO.sub.2NR.sup.3R.sup.3, --CO.sub.2R.sup.3,
--C(O)NR.sup.3R.sup.3, --N(R.sup.3)SO.sub.2R.sup.3,
--N(R.sup.3)C(O)R.sup.3, --N(R.sup.3)CO.sub.2R.sup.3,
--C(O)R.sup.3, and optionally substituted C.sub.1-6alkyl; and
R.sup.3a and R.sup.3b are each independently selected from --H and
optionally substituted C.sub.1-6alkyl.
[0188] In another example, the process is according to the
preceding paragraph, wherein a compound of formula XXIIa is
combined with a compound of formula XXIIIa to make a compound of
formula XXIa,
##STR00462##
wherein --B-L-T, Z, J, R.sup.50, and R.sup.2 are as defined above;
R.sup.70 is selected from --H, --NO.sub.2, --NH.sub.2, and
--NR.sup.3R.sup.3; provided when Z is --N(R.sup.5)-- that R.sup.5
is selected from --H, C.sub.1-3alkyl, and aryl C.sub.1-3alkyl;
P.sup.1 is selected from halogen, optionally substituted
alkyl-S(O).sub.0-2--, optionally substituted arylsulfonate,
optionally substituted alkylsulfonate, a group containing boron, an
azide, a group containing phosphorus, and a metal; and P.sup.2 is
selected from --H and a metal.
[0189] In another example, the process is according to the
preceding paragraph, wherein P.sup.2 is selected from --H, lithium,
sodium, potassium, cesium, copper, palladium, and titanium.
[0190] In another example, the process is according to the
preceding paragraph, wherein Z is --O--.
[0191] In another example, the process is according to the
preceding paragraph, wherein P.sup.1 is selected from chlorine,
bromine, a toluene sulfonate, and trifluoromethansulfonate.
[0192] In another example, the process is according to the
preceding paragraph, wherein R.sup.70 is --H.
[0193] In another example, the process is according to the
preceding paragraph, wherein J is .dbd.C(H)--.
[0194] In another example, the process is according to the
preceding paragraph, wherein R.sup.2 is selected from C.sub.1-6
alkyl, perfluoro C.sub.1-6 alkyl, and halogen.
[0195] In another example, the process is according to the
preceding paragraph, wherein XXIIa and XXIIIa are heated together,
optionally with a base, optionally with microwave radiation, to
form XXIa.
[0196] In another example, the process is according to the
preceding paragraph, wherein the base is selected from an organic
base, an inorganic base, and a combination of an organic base and
an inorganic base.
[0197] In another example, the process is according to the
preceding paragraph, wherein the base is selected from
2,6-lutidine, 4-N,N-dimethylaminopyridine, and a metal
carbonate.
[0198] In another example, the process is according to the
preceding paragraph, wherein XXIIa and XXIIIa are heated together
in a solvent with said base, at between about 40.degree. C. and
200.degree. C. for between about one hour and twenty-four hours to
form XXIa.
[0199] In another example, the process is according to the
preceding paragraph, wherein the solvent is an organic solvent.
[0200] In another example, the process is according to the
preceding paragraph, wherein one molar equivalent of XXIIa is
combined with between about one quarter and four molar equivalents
of XXIIIa.
[0201] In another example, the process is according to the
preceding paragraph, wherein one molar equivalent of XXIIa is
combined with more than one but less than two molar equivalents of
XXIIIa.
[0202] In another example, the process is according to the
preceding paragraph, wherein XXIIa is combined with XXIIIa and said
base in an aromatic solvent to form a mixture, and said mixture is
heated to between about 100.degree. C. and 200.degree. C. for
between about one and ten hours to form Ia.
[0203] In another example, the process is according to the
preceding paragraph, wherein the aromatic solvent is an optionally
substituted benzene.
[0204] In another example, the process is according to the
preceding paragraph, wherein the aromatic solvent is
bromobenzene.
[0205] In another example, the process is according to the
preceding paragraph, wherein the base is
4-N,N-dimethylaminopyridine.
[0206] In another example, the process is according to the
preceding paragraph, wherein said mixture is heated to reflux for
between about three and seven hours.
[0207] In another example, the process is according to the
preceding paragraph, wherein said mixture is heated to reflux for
between about four and six hours.
[0208] In another example, the process is as defined seven
paragraphs above, wherein one molar equivalent of XXIIa is combined
with more than one but less than two molar equivalents of XXIIIa
and said base in a non-aromatic solvent to form a mixture, and said
mixture is heated to between about 40.degree. C. and 100.degree. C.
for between about one and twenty hours to form XXIa.
[0209] In another example, the process is according to the
preceding paragraph, wherein the non-aromatic solvent comprises a
functional group selected from an amide, an ether, a nitrile, a
halide, an ester, an amine, and a ketone.
[0210] In another example, the process is according to the
preceding paragraph, wherein the non-aromatic solvent is
N,N-dimethylacetamide.
[0211] In another example, the process is according to the
preceding paragraph, wherein the base is potassium carbonate.
[0212] In another example, the process is according to the
preceding paragraph, wherein said mixture is heated to about
50.degree. C. between about ten and twenty hours.
[0213] In another example, the process is according to the
preceding paragraph, wherein the aromatic solvent is an optionally
substituted pyridine.
[0214] In another example, the process is according to the
preceding paragraph, wherein the aromatic solvent is
2,6-lutidine.
[0215] In another example, the process is according to the
preceding paragraph, wherein the base is 2,6-lutidine.
[0216] In another example, the process is according to the
preceding paragraph, wherein said mixture is heated to reflux for
between about three and seven hours.
[0217] In another example, the process is according to the
preceding paragraph, wherein said mixture is heated to reflux for
between about four and six hours.
[0218] In another example, the process is as eighteen paragraphs
defined above, wherein one molar equivalent of XXIIIa is combined
with more than one but less than two molar equivalents of
XXIIa.
[0219] In another example, the process is according to the
preceding paragraph, wherein XXIIa is combined with XXIIIa and said
base in an aromatic solvent to form a mixture, and said mixture is
heated to between about 100.degree. C. and 200.degree. C. for
between about ten and twenty hours to form XXIa.
[0220] In another example, the process is according to the
preceding paragraph, wherein the aromatic solvent is an optionally
substituted pyridine.
[0221] In another example, the process is according to the
preceding paragraph, wherein the aromatic solvent is
2,6-lutidine.
[0222] In another example, the process is according to the
preceding paragraph, wherein the base is 2,6-lutidine.
[0223] In another example, the process is according to the
preceding paragraph, wherein said mixture is heated to between
about 150.degree. C. and 200.degree. C. for between about fifteen
and twenty hours.
[0224] In another example, the process is as defined above in any
of the twenty-nine preceding paragraphs, wherein a compound of
formula XXIIb is substituted for the compound of formula XXIIa, and
either a compound of formula XXIIIb or a compound of formula XXIIIc
is substituted for the compound of formula XXIIIa, in order to make
a compound of formula XXIb or a compound of formula XXIc,
respectively,
##STR00463##
wherein J, R.sup.50, R.sup.20 and R.sup.2 are as defined above.
[0225] In another example, the process is according to the
preceding paragraph, wherein R.sup.2, if present, is halogen.
[0226] In another example, the process is according to the
preceding paragraph, wherein R.sup.2, if present, is fluorine.
[0227] In another example, the process is according to the
preceding paragraph, wherein R.sup.2, if present, is up to two
fluorines ortho to the oxygen of the phenylene to which R.sup.2 is
attached.
[0228] In another example, the process is used to make a compound
listed in either Table 1 or Table 2.
[0229] In another example the process is as defined above in any of
the fifty-two preceding paragraphs, further comprising converting
said compound to a pharmaceutically acceptable salt, hydrate, or
prodrug thereof.
DEFINITIONS
[0230] As used in the present specification, the following words
and phrases are generally intended to have the meanings as set
forth below, except to the extent that the context in which they
are used indicates otherwise or they are expressly defined to mean
something different.
[0231] The symbol "--" means a single bond, ".dbd." means a double
bond, ".ident." means a triple bond. The symbol "" refers to a
group on a double-bond as occupying either position on the terminus
of a double bond to which the symbol is attached; that is, the
geometry, E- or Z-, of the double bond is ambiguous. When a group
is depicted removed from its parent formula, the symbol will be
used at the end of the bond which was theoretically cleaved in
order to separate the group from its parent structural formula.
[0232] When chemical structures are depicted or described, unless
explicitly stated otherwise, all carbons are assumed to have
hydrogen substitution to conform to a valence of four. For example,
in the structure on the left-hand side of the schematic below there
are nine hydrogens implied. The nine hydrogens are depicted in the
right-hand structure. Sometimes a particular atom in a structure is
described in textual formula as having a hydrogen or hydrogens as
substitution (expressly defined hydrogen), for example,
--CH.sub.2CH.sub.2--. It is understood by one of ordinary skill in
the art that the aforementioned descriptive techniques are common
in the chemical arts to provide brevity and simplicity to
description of otherwise complex structures.
##STR00464##
[0233] In this application, some ring structures are depicted
generically and will be described textually. For example, in the
schematic below, if in the structure on the left, ring A is used to
describe a "spirocyclyl," then if ring A is cyclopropyl, there are
at most four hydrogens on ring A (when "R" can also be --H). In
another example, as depicted on the right side of the schematic
below, if ring B is used to describe a "phenylene" then there can
be at most four hydrogens on ring B (assuming depicted cleaved
bonds are not C--H bonds).
##STR00465##
[0234] If a group "R" is depicted as "floating" on a ring system,
as for example in the formula:
##STR00466##
then, unless otherwise defined, a substituent "R" may reside on any
atom of the ring system, assuming replacement of a depicted,
implied, or expressly defined hydrogen from one of the ring atoms,
so long as a stable structure is formed.
[0235] If a group "R" is depicted as floating on a fused ring
system, as for example in the formulae:
##STR00467##
then, unless otherwise defined, a substituent "R" may reside on any
atom of the fused ring system, assuming replacement of a depicted
(for example the --NH-- in the formula above), implied (for example
as in the formula above, where the hydrogens are not shown but
understood to be present), or expressly defined hydrogen (for
example where in the formula above, "X" equals .dbd.CH--) from one
of the ring atoms, so long as a stable structure is formed. In the
example depicted, the "R" group may reside on either the 5-membered
or the 6-membered ring of the fused ring system. In the formula
depicted above, when y is 2 for example, then the two "R's" may
reside on any two atoms of the ring system, again assuming each
replaces a depicted, implied, or expressly defined hydrogen on the
ring.
[0236] When there are more than one such depicted "floating"
groups, as for example in the formulae:
##STR00468##
where there are two groups, namely, the "R" and the bond indicating
attachment to a parent structure; then, unless otherwise defined,
the "floating" groups may reside on any atoms of the ring system,
again assuming each replaces a depicted, implied, or expressly
defined hydrogen on the ring.
[0237] When a group "R" is depicted as existing on a ring system
containing saturated carbons, as for example in the formula:
##STR00469##
where, in this example, "y" can be more than one, assuming each
replaces a currently depicted, implied, or expressly defined
hydrogen on the ring; then, unless otherwise defined, where the
resulting structure is stable, two "R's" may reside on the same
carbon. A simple example is when R is a methyl group; there can
exist a geminal dimethyl on a carbon of the depicted ring (an
"annular" carbon). In another example, two R's on the same carbon,
including that carbon, may form a ring, thus creating a spirocyclic
ring (a "spirocyclyl" group) structure with the depicted ring as
for example in the formula:
##STR00470##
[0238] "Alkyl" is intended to include linear, branched, or cyclic
hydrocarbon structures and combinations thereof, inclusively. For
example, "C.sub.8 alkyl" may refer to an n-octyl, iso-octyl,
cyclohexylethyl, and the like. Lower alkyl refers to alkyl groups
of from one to six carbon atoms. Examples of lower alkyl groups
include methyl, ethyl, propyl, isopropyl, butyl, s-butyl, t-butyl,
isobutyl, pentyl, hexyl and the like. Higher alkyl refers to alkyl
groups containing more that eight carbon atoms. Exemplary alkyl
groups are those of C.sub.20 or below. Cycloalkyl is a subset of
alkyl and includes cyclic hydrocarbon groups of from three to
thirteen carbon atoms. Examples of cycloalkyl groups include
c-propyl, c-butyl, c-pentyl, norbornyl, adamantyl and the like. In
this application, alkyl refers to alkanyl, alkenyl, and alkynyl
residues (and combinations thereof); it is intended to include
cyclohexylmethyl, vinyl, allyl, isoprenyl, and the like. Thus when
an alkyl residue having a specific number of carbons is named, all
geometric isomers having that number of carbons are intended to be
encompassed; thus, for example, either "butyl" or "C.sub.4 alkyl"
is meant to include n-butyl, sec-butyl, isobutyl, t-butyl,
isobutenyl and but-2-yne radicals; and for example, "propyl" or
"C.sub.3 alkyl" each include n-propyl, propenyl, and isopropyl.
[0239] "Alkylene" refers to straight or branched chain divalent
radical consisting solely of carbon and hydrogen atoms, containing
no unsaturation and having from one to ten carbon atoms, for
example, methylene, ethylene, propylene, n-butylene and the like.
Alkylene is a subset of alkyl, referring to the same residues as
alkyl, but having two points of attachment and, specifically, fully
saturated. Examples of alkylene include ethylene
(--CH.sub.2CH.sub.2--), propylene (--CH.sub.2CH.sub.2CH.sub.2--),
dimethylpropylene (--CH.sub.2C(CH.sub.3).sub.2CH.sub.2--), and
cyclohexylpropylene (--CH.sub.2CH.sub.2CH(C.sub.6H.sub.13)).
[0240] "Alkylidene" refers to a straight or branched chain
unsaturated divalent radical consisting solely of carbon and
hydrogen atoms, having from two to ten carbon atoms, for example,
ethylidene, propylidene, n-butylidene, and the like. Alkylidene is
a subset of alkyl, referring to the same residues as alkyl, but
having two points of attachment and, specifically, double bond
unsaturation. The unsaturation present includes at least one double
bond.
[0241] "Alkylidyne" refers to a straight or branched chain
unsaturated divalent radical consisting solely of carbon and
hydrogen atoms having from two to ten carbon atoms, for example,
propylid-2-ynyl, n-butylid-1-ynyl, and the like. Alkylidyne is a
subset of alkyl, referring to the same residues as alkyl, but
having two points of attachment and, specifically, triple bond
unsaturation. The unsaturation present includes at least one triple
bond.
[0242] Any of the above radicals, "alkylene," "alkylidene" and
"alkylidyne," when optionally substituted, may contain alkyl
substitution which itself contains unsaturation. For example,
2-(2-phenylethynyl-but-3-enyl)-naphthalene (IUPAC name) contains an
n-butylid-3-ynyl radical with a vinyl substituent at the 2-position
of said radical.
[0243] "Alkoxy" or "alkoxyl" refers to the group --O-alkyl, for
example including from one to eight carbon atoms of a straight,
branched, cyclic configuration, unsaturated chains, and
combinations thereof attached to the parent structure through an
oxygen atom. Examples include methoxy, ethoxy, propoxy, isopropoxy,
cyclopropyloxy, cyclohexyloxy and the like. Lower-alkoxy refers to
groups containing one to six carbons.
[0244] "Substituted alkoxy" refers to the group --O-(substituted
alkyl), the substitution on the alkyl group generally containing
more than only carbon (as defined by alkoxy). One exemplary
substituted alkoxy group is "polyalkoxy" or --O-optionally
substituted alkylene-optionally substituted alkoxy, and includes
groups such as --OCH.sub.2CH.sub.2OCH.sub.3, and glycol ethers such
as polyethyleneglycol and --O(CH.sub.2CH.sub.2O).sub.xCH.sub.3,
where x is an integer of between about two and about twenty, in
another example, between about two and about ten, and in a further
example between about two and about five. Another exemplary
substituted alkoxy group is hydroxyalkoxy or
--OCH.sub.2(CH.sub.2).sub.yOH, where y is for example an integer of
between about one and about ten, in another example y is an integer
of between about one and about four.
[0245] "Acyl" refers to groups of from one to ten carbon atoms of a
straight, branched, cyclic configuration, saturated, unsaturated
and aromatic and combinations thereof, attached to the parent
structure through a carbonyl functionality. One or more carbons in
the acyl residue may be replaced by nitrogen, oxygen or sulfur as
long as the point of attachment to the parent remains at the
carbonyl. Examples include acetyl, benzoyl, propionyl, isobutyryl,
t-butoxycarbonyl, benzyloxycarbonyl and the like. Lower-acyl refers
to groups containing one to six carbons.
[0246] ".alpha.-Amino Acids" refer to naturally occurring and
commercially available amino acids and optical isomers thereof.
Typical natural and commercially available .alpha.-amino acids are
glycine, alanine, serine, homoserine, threonine, valine, norvaline,
leucine, isoleucine, norleucine, aspartic acid, glutamic acid,
lysine, ornithine, histidine, arginine, cysteine, homocysteine,
methionine, phenylalanine, homophenylalanine, phenylglycine,
ortho-tyrosine, meta-tyrosine, para-tyrosine, tryptophan,
glutamine, asparagine, proline and hydroxyproline. A "side chain of
an .alpha.-amino acid" refers to the radical found on the
.alpha.-carbon of an .alpha.-amino acid as defined above, for
example, hydrogen (for glycine), methyl (for alanine), benzyl (for
phenylalanine), and the like.
[0247] "Amino" refers to the group --NH.sub.2. "Substituted amino,"
refers to the group --N(H)R or --N(R)R where each R is
independently selected from the group: optionally substituted
alkyl, optionally substituted alkoxy, optionally substituted aryl,
optionally substituted heterocyclyl, acyl, carboxy, alkoxycarbonyl,
sulfanyl, sulfinyl and sulfonyl, for example, diethylamino,
methylsulfonylamino, furanyl-oxy-sulfonamino.
[0248] "Aryl" refers to aromatic six- to fourteen-membered
carbocyclic ring, for example, benzene, naphthalene, indane,
tetralin, fluorene and the like, univalent radicals. As univalent
radicals, the aforementioned ring examples are named, phenyl,
naphthyl, indanyl, tetralinyl, and fluorenyl.
[0249] "Arylene" generically refers to any aryl that has at least
two groups attached thereto. For a more specific example,
"phenylene" refers to a divalent phenyl ring radical. A phenylene,
thus may have more than two groups attached, but is defined by a
minimum of two non-hydrogen groups attached thereto.
[0250] "Arylalkyl" refers to a residue in which an aryl moiety is
attached to a parent structure via one of an alkylene, alkylidene,
or alkylidyne radical. Examples include benzyl, phenethyl,
phenylvinyl, phenylallyl and the like. Both the aryl, and the
corresponding alkylene, alkylidene, or alkylidyne radical portion
of an arylalkyl group may be optionally substituted. "Lower
arylalkyl" refers to an arylalkyl where the "alkyl" portion of the
group has one to six carbons; this can also be referred to as
C.sub.1-6 arylalkyl.
[0251] "Exo-alkenyl" refers to a double bond that emanates from an
annular carbon, and is not within the ring system, for example the
double bond depicted in the formula below.
##STR00471##
[0252] In some examples, as appreciated by one of ordinary skill in
the art, two adjacent groups on an aromatic system may be fused
together to form a ring structure. The fused ring structure may
contain heteroatoms and may be optionally substituted with one or
more groups. It should additionally be noted that saturated carbons
of such fused groups (i.e. saturated ring structures) can contain
two substitution groups.
[0253] "Fused-polycyclic" or "fused ring system" refers to a
polycyclic ring system that contains bridged or fused rings; that
is, where two rings have more than one shared atom in their ring
structures. In this application, fused-polycyclics and fused ring
systems are not necessarily all aromatic ring systems. Typically,
but not necessarily, fused-polycyclics share a vicinal set of
atoms, for example naphthalene or 1,2,3,4-tetrahydro-naphthalene. A
spiro ring system is not a fused-polycyclic by this definition, but
fused polycyclic ring systems of the invention may themselves have
spiro rings attached thereto via a single ring atom of the
fused-polycyclic.
[0254] "Halogen" or "halo" refers to fluorine, chlorine, bromine or
iodine. "Haloalkyl" and "haloaryl" refer generically to alkyl and
aryl radicals that are substituted with one or more halogens,
respectively. Thus, "dihaloaryl," "dihaloalkyl," "trihaloaryl" etc.
refer to aryl and alkyl substituted with a plurality of halogens,
but not necessarily a plurality of the same halogen; thus
4-chloro-3-fluorophenyl is within the scope of dihaloaryl.
[0255] "Heteroarylene" generically refers to any heteroaryl that
has at least two groups attached thereto. For a more specific
example, "pyridylene" refers to a divalent pyridyl ring radical. A
pyridylene, thus may have more than two groups attached, but is
defined by a minimum of two non-hydrogen groups attached
thereto.
[0256] "Heteroatom" refers to O, S, N, or P.
[0257] "Heterocyclyl" refers to a stable three- to fifteen-membered
ring radical that consists of carbon atoms and from one to five
heteroatoms selected from the group consisting of nitrogen,
phosphorus, oxygen and sulfur. For purposes of this invention, the
heterocyclyl radical may be a monocyclic, bicyclic or tricyclic
ring system, which may include fused or bridged ring systems as
well as spirocyclic systems; and the nitrogen, phosphorus, carbon
or sulfur atoms in the heterocyclyl radical may be optionally
oxidized to various oxidation states. In a specific example, the
group --S(O).sub.0-2--, refers to --S-- (sulfide), --S(O)--
(sulfoxide), and --SO.sub.2-- (sulfone). For convenience,
nitrogens, particularly but not exclusively, those defined as
annular aromatic nitrogens, are meant to include their
corresponding N-oxide form, although not explicitly defined as such
in a particular example. Thus, for a compound of the invention
having, for example, a pyridyl ring; the corresponding
pyridyl-N-oxide is meant to be included as another compound of the
invention. In addition, annular nitrogen atoms may be optionally
quaternized; and the ring radical may be partially or fully
saturated or aromatic. Examples of heterocyclyl radicals include,
but are not limited to, azetidinyl, acridinyl, benzodioxolyl,
benzodioxanyl, benzofuranyl, carbazoyl, cinnolinyl, dioxolanyl,
indolizinyl, naphthyridinyl, perhydroazepinyl, phenazinyl,
phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl,
quinazolinyl, quinoxalinyl, quinolinyl, isoquinolinyl, tetrazoyl,
tetrahydroisoquinolyl, piperidinyl, piperazinyl, 2-oxopiperazinyl,
2-oxopiperidinyl, 2-oxopyrrolidinyl, 2-oxoazepinyl, azepinyl,
pyrrolyl, 4-piperidonyl, pyrrolidinyl, pyrazolyl, pyrazolidinyl,
imidazolyl, imidazolinyl, imidazolidinyl, dihydropyridinyl,
tetrahydropyridinyl, pyridinyl, pyrazinyl, pyrimidinyl,
pyridazinyl, oxazolyl, oxazolinyl, oxazolidinyl, triazolyl,
isoxazolyl, isoxazolidinyl, morpholinyl, thiazolyl, thiazolinyl,
thiazolidinyl, isothiazolyl, quinuclidinyl, isothiazolidinyl,
indolyl, isoindolyl, indolinyl, isoindolinyl, octahydroindolyl,
octahydroisoindolyl, quinolyl, isoquinolyl, decahydroisoquinolyl,
benzimidazolyl, thiadiazolyl, benzopyranyl, benzothiazolyl,
benzoxazolyl, furyl, tetrahydrofuryl, tetrahydropyranyl, thienyl,
benzothieliyl, thiamorpholinyl, thiamorpholinyl sulfoxide,
thiamorpholinyl sulfone, dioxaphospholanyl, and oxadiazolyl.
[0258] "Heteroalicyclic" refers specifically to a non-aromatic
heterocyclyl radical. A heteroalicyclic may contain unsaturation,
but is not aromatic.
[0259] "Heteroaryl" refers specifically to an aromatic heterocyclyl
radical.
[0260] "Heterocyclylalkyl" refers to a residue in which a
heterocyclyl is attached to a parent structure via one of an
alkylene, alkylidene, or alkylidyne radical. Examples include
(4-methylpiperazin-1-yl)methyl, (morpholin-4-yl)methyl,
(pyridine-4-yl)methyl, 2-(oxazolin-2-yl)ethyl,
4-(4-methylpiperazin-1-yl)-2-butenyl, and the like. Both the
heterocyclyl, and the corresponding alkylene, alkylidene, or
alkylidyne radical portion of a heterocyclylalkyl group may be
optionally substituted. "Lower heterocyclylalkyl" refers to a
heterocyclylalkyl where the "alkyl" portion of the group has one to
six carbons. "Heteroalicyclylalkyl" refers specifically to a
heterocyclylalkyl where the heterocyclyl portion of the group is
non-aromatic; and "heteroarylalkyl" refers specifically to a
heterocyclylalkyl where the heterocyclyl portion of the group is
aromatic Such terms may be described in more than one way, for
example, "lower heterocyclylalkyl" and "heterocyclyl
C.sub.1-6alkyl" are equivalent terms.
[0261] "Optional" or "optionally" means that the subsequently
described event or circumstance may or may not occur, and that the
description includes instances where said event or circumstance
occurs and instances in which it does not. One of ordinary skill in
the art would understand that, with respect to any molecule
described as containing one or more optional substituents, that
only sterically practical and/or synthetically feasible compounds
are meant to be included. "Optionally substituted" refers to all
subsequent modifiers in a term, for example in the term "optionally
substituted arylC.sub.1-8 alkyl," optional substitution may occur
on both the "C.sub.1-8alkyl" portion and the "aryl" portion of the
molecule; and for example, optionally substituted alkyl includes
optionally substituted cycloalkyl groups, which in turn are defined
as including optionally substituted alkyl groups, potentially ad
infinitum. A list of exemplary optional substitution are listed
below in the definition of "substituted."
[0262] "Saturated bridged ring system" refers to a bicyclic or
polycyclic ring system that is not aromatic. Such a system may
contain isolated or conjugated unsaturation, but not aromatic or
heteroaromatic rings in its core structure (but may have aromatic
substitution thereon). For example, hexahydro-furo[3,2-b]furan,
2,3,3a,4,7,7a-hexahydro-1H-indene, 7-aza-bicyclo[2.2.1]heptane, and
1,2,3,4,4a,5,8,8a-octahydro-naphthalene are all included in the
class "saturated bridged ring system."
[0263] "Spirocyclyl" or "spirocyclic ring" refers to a ring
originating from a particular annular carbon of another ring. For
example, as depicted below, a ring atom of a saturated bridged ring
system (rings B and B'), but not a bridgehead atom, can be a shared
atom between the saturated bridged ring system and a spirocyclyl
(ring A) attached thereto. A spirocyclyl can be carbocyclic or
heteroalicyclic.
##STR00472##
[0264] "Substituted" alkyl, aryl, and heterocyclyl, refer
respectively to alkyl, aryl, and heterocyclyl, wherein one or more
(for example up to about five, in another example, up to about
three) hydrogen atoms are replaced by a substituent independently
selected from: optionally substituted alkyl (for example,
fluoromethyl), optionally substituted aryl (for example,
4-hydroxyphenyl), optionally substituted arylalkyl (for example,
1-phenyl-ethyl), optionally substituted heterocyclylalkyl (for
example, 1-pyridin-3-yl-ethyl), optionally substituted heterocyclyl
(for example, 5-chloro-pyridin-3-yl or 1-methyl-piperidin-4-yl),
optionally substituted alkoxy, alkylenedioxy (for example
methylenedioxy), optionally substituted amino (for example,
alkylamino and dialkylamino), optionally substituted amidino,
optionally substituted aryloxy (for example, phenoxy), optionally
substituted arylalkyloxy (for example, benzyloxy), carboxy
(--CO.sub.2H), carboalkoxy (that is, acyloxy or --OC(.dbd.O)R),
carboxyalkyl (that is, esters or --CO.sub.2R), carboxamido,
benzyloxycarbonylamino (CBZ-amino), cyano, acyl, halogen, hydroxy,
nitro, sulfanyl, sulfinyl, sulfonyl, thiol, halogen, hydroxy, oxo,
carbamyl, acylamino, and sulfonamido.
[0265] "Suitable leaving group" is defined as the term would be
understood by one of ordinary skill in the art; that is, a carbon
with such a group attached, upon reaction wherein a new bond is to
be formed, loses such a group upon formation of the new bond. The
invention pertains particularly with respect convergent synthesis,
to reactions where such a leaving group is bonded to a reaction
partner that is aromatic, undergoes a bond-forming reaction and
remains aromatic. A typical example of such a reaction is a
nucleophilic aromatic substitution reaction, as would be understood
by one of ordinary skill in the art. However, the invention is not
limited to such mechanistic restrictions; for example, reactions
where there is, for example, an insertion reaction (for example by
a transition metal) into the bond between the aromatic reaction
partner and its leaving group followed by reductive coupling can
also be used within the scope of the invention. Examples of
suitable leaving groups include halogens, optionally substituted
aryl or alkyl sulfonates, phosphonates, azides, RS(O).sub.0-2--
where R is, for example optionally substituted alkyl, optionally
substituted aryl, or optionally substituted heteroaryl.
[0266] "Sulfanyl" refers to the groups: --S-(optionally substituted
alkyl), --S-(optionally substituted aryl), and --S-(optionally
substituted heterocyclyl).
[0267] "Sulfinyl" refers to the groups: --S(O)--H,
--S(O)-(optionally substituted alkyl), --S(O)-optionally
substituted aryl), and --S(O)-(optionally substituted
heterocyclyl).
[0268] "Sulfonyl" refers to the groups: --S(O.sub.2)--H,
--S(O.sub.2)-(optionally substituted alkyl),
--S(O.sub.2)-optionally substituted aryl), --S(O.sub.2)-(optionally
substituted heterocyclyl), --S(O.sub.2)-(optionally substituted
alkoxy), --S(O.sub.2)-optionally substituted aryloxy), and
--S(O.sub.2)-(optionally substituted heterocyclyloxy).
[0269] "Yield" for each of the reactions described herein is
expressed as a percentage of the theoretical yield.
[0270] Some of the compounds of the invention may have imino,
amino, oxo or hydroxy substituents off aromatic heterocyclyl
systems. For purposes of this disclosure, it is understood that
such imino, amino, oxo or hydroxy substituents may exist in their
corresponding tautomeric form, i.e., amino, imino, hydroxy or oxo,
respectively.
[0271] Compounds of the invention are named according to systematic
application of the nomenclature rules agreed upon by the
International Union of Pure and Applied Chemistry (IUPAC),
International Union of Biochemistry and Molecular Biology (IUBMB),
and the Chemical Abstracts Service (CAS).
[0272] The compounds of the invention, or their pharmaceutically
acceptable salts, may have asymmetric carbon atoms, oxidized sulfur
atoms or quaternized nitrogen atoms in their structure.
[0273] The compounds of the invention and their pharmaceutically
acceptable salts may exist as single stereoisomers, racemates, and
as mixtures of enantiomers and diastereomers. The compounds may
also exist as geometric isomers. All such single stereoisomers,
racemates and mixtures thereof, and geometric isomers are intended
to be within the scope of this invention.
[0274] It is assumed that when considering generic descriptions of
compounds of the invention for the purpose of constructing a
compound, such construction results in the creation of a stable
structure. That is, one of ordinary skill in the art would
recognize that there can theoretically be some constructs which
would not normally be considered as stable compounds (that is,
sterically practical and/or synthetically feasible, supra).
[0275] When a particular group with its bonding structure is
denoted as being bonded to two partners; that is, a divalent
radical, for example, --OCH.sub.2--, then it is understood that
either of the two partners may be bound to the particular group at
one end, and the other partner is necessarily bound to the other
end of the particular group, unless stated explicitly otherwise.
Stated another way, divalent radicals are not to be construed as
limited to the depicted orientation, for example "--OCH.sub.2-" is
meant to mean not only "--OCH.sub.2--" as drawn, but also
"--CH.sub.2O--."
[0276] Methods for the preparation and/or separation and isolation
of single stereoisomers from racemic mixtures or non-racemic
mixtures of stereoisomers are well known in the art. For example,
optically active (R)- and (S)-isomers may be prepared using chiral
synthons or chiral reagents, or resolved using conventional
techniques. Enantiomers (R- and S-isomers) may be resolved by
methods known to one of ordinary skill in the art, for example by:
formation of diastereoisomeric salts or complexes which may be
separated, for example, by crystallization; via formation of
diastereoisomeric derivatives which may be separated, for example,
by crystallization, selective reaction of one enantiomer with an
enantiomer-specific reagent, for example enzymatic oxidation or
reduction, followed by separation of the modified and unmodified
enantiomers; or gas-liquid or liquid chromatography in a chiral
environment, for example on a chiral support, such as silica with a
bound chiral ligand or in the presence of a chiral solvent. It will
be appreciated that where a desired enantiomer is converted into
another chemical entity by one of the separation procedures
described above, a further step may be required to liberate the
desired enantiomeric form. Alternatively, specific enantiomer may
be synthesized by asymmetric synthesis using optically active
reagents, substrates, catalysts or solvents, or by converting on
enantiomer to the other by asymmetric transformation. For a mixture
of enantiomers, enriched in a particular enantiomer, the major
component enantiomer may be further enriched (with concomitant loss
in yield) by recrystallization.
[0277] "Patient" for the purposes of the present invention includes
humans and other animals, particularly mammals, and other
organisms. Thus the methods are applicable to both human therapy
and veterinary applications. In a preferred embodiment the patient
is a mammal, and in a most preferred embodiment the patient is
human.
[0278] "Kinase-dependent diseases or conditions" refer to
pathologic conditions that depend on the activity of one or more
protein kinases. Kinases either directly or indirectly participate
in the signal transduction pathways of a variety of cellular
activities including proliferation, adhesion, migration,
differentiation and invasion. Diseases associated with kinase
activities include tumor growth, the pathologic neovascularization
that supports solid tumor growth, and associated with other
diseases where excessive local vascularization is involved such as
ocular diseases (diabetic retinopathy, age-related macular
degeneration, and the like) and inflammation (psoriasis, rheumatoid
arthritis, and the like).
[0279] While not wishing to be bound to theory, phosphatases can
also play a role in "kinase-dependent diseases or conditions" as
cognates of kinases; that is, kinases phosphorylate and
phosphatases dephosphorylate, for example protein substrates.
Therefore compounds of the invention, while modulating kinase
activity as described herein, may also modulate, either directly or
indirectly, phosphatase activity. This additional modulation, if
present, may be synergistic (or not) to activity of compounds of
the invention toward a related or otherwise interdependent kinase
or kinase family. In any case, as stated previously, the compounds
of the invention are useful for treating diseases characterized in
part by abnormal levels of cell proliferation (i.e. tumor growth),
programmed cell death (apoptosis), cell migration and invasion and
angiogenesis associated with tumor growth.
[0280] "Therapeutically effective amount" is an amount of a
compound of the invention, that when administered to a patient,
ameliorates a symptom of the disease. The amount of a compound of
the invention which constitutes a "therapeutically effective
amount" will vary depending on the compound, the disease state and
its severity, the age of the patient to be treated, and the like.
The therapeutically effective amount can be determined routinely by
one of ordinary skill in the art having regard to his own knowledge
and to this disclosure.
[0281] "Cancer" refers to cellular-proliferative disease states,
including but not limited to: Cardiac: sarcoma (angiosarcoma,
fibrosarcoma, rhabdomyosarcoma, liposarcoma), myxoma, rhabdomyoma,
fibroma, lipoma and teratoma; Lung: bronchogenic carcinoma
(squamous cell, undifferentiated small cell, undifferentiated large
cell, adenocarcinoma), alveolar (bronchiolar) carcinoma, bronchial
adenoma, sarcoma, lymphoma, chondromatous hanlartoma,
inesothelioma; Gastrointestinal: esophagus (squamous cell
carcinoma, adenocarcinoma, leiomyosarcoma, lymphoma), stomach
(carcinoma, lymphoma, leiomyosarcoma), pancreas (ductal
adenocarcinoma, insulinorna, glucagonoma, gastrinoma, carcinoid
tumors, vipoma), small bowel (adenocarcinorna, lymphoma, carcinoid
tumors, Karposi's sarcoma, leiomyoma, hemangioma, lipoma,
neurofibroma, fibroma), large bowel (adenocarcinoma, tubular
adenoma, villous adenoma, hamartoma, leiomyoma); Genitourinary
tract: kidney (adenocarcinoma, Wilm's tumor [nephroblastoma],
lymphoma, leukemia), bladder and urethra (squamous cell carcinoma,
transitional cell carcinoma, adenocarcinoma), prostate
(adenocarcinoma, sarcoma), testis (seminoma, teratoma, embryonal
carcinoma, teratocarcinoma, choriocarcinoma, sarcoma, interstitial
cell carcinoma, fibroma, fibroadenoma, adenomatoid tumors, lipoma);
Liver: hepatoma (hepatocellular carcinoma), cholangiocarcinoma,
hepatoblastoma, angiosarcoma, hepatocellular adenoma, hemangioma;
Bone: osteogenic sarcoma (osteosarcoma), fibrosarcoma, malignant
fibrous histiocytoma, chondrosarcoma, Ewing's sarcoma, malignant
lymphoma (reticulum cell sarcoma), multiple myeloma, malignant
giant cell tumor chordoma, osteochronfroma (osteocartilaginous
exostoses), benign chondroma, chondroblastoma, chondromyxofibroma,
osteoid osteoma and giant cell tumors; Nervous system: skull
(osteoma, hemangioma, granuloma, xanthoma, osteitis defomians),
meninges (meningioma, meningiosarcoma, gliomatosis), brain
(astrocytoma, medulloblastoma, glioma, ependymoma, germinoma
[pinealoma], glioblastoma multiform, oligodendroglioma, schwannoma,
retinoblastoma, congenital tumors), spinal cord neurofibroma,
meningioma, glioma, sarcoma); Gynecological: uterus (endometrial
carcinoma), cervix (cervical carcinoma, pre-tumor cervical
dysplasia), ovaries (ovarian carcinoma [serous cystadenocarcinoma,
mucinous cystadenocarcinoma, unclassified carcinoma],
granulosa-thecal cell tumors, SertoliLeydig cell tumors,
dysgerminoma, malignant teratoma), vulva (squamous cell carcinoma,
intraepithelial carcinoma, adenocarcinoma, fibrosarcoma, melanoma),
vagina (clear cell carcinoma, squamous cell carcinoma, botryoid
sarcoma (embryonal rhabdomyosarcoma], fallopian tubes (carcinoma);
Hematologic: blood (myeloid leukemia [acute and chronic], acute
lymphoblastic leukemia, chronic lymphocytic leukemia,
myeloproliferative diseases, multiple myeloma, myelodysplastic
syndrome), Hodgkin's disease, non-Hodgkin's lymphoma [malignant
lymphoma]; Skin: malignant melanoma, basal cell carcinoma, squamous
cell carcinoma, Karposi's sarcoma, moles dysplastic nevi, lipoma,
angioma, dermatofibroma, keloids, psoriasis; and Adrenal lands:
neuroblastoma. Thus, the term "cancerous cell" as provided herein,
includes a cell afflicted by any one of the above-identified
conditions.
[0282] "Pharmaceutically acceptable acid addition salt" refers to
those salts that retain the biological effectiveness of the free
bases and that are not biologically or otherwise undesirable,
formed with inorganic acids such as hydrochloric acid, hydrobromic
acid, sulfuric acid, nitric acid, phosphoric acid, and the like, as
well as organic acids such as acetic acid, trifluoroacetic acid,
propionic acid, glycolic acid, pyruvic acid, oxalic acid, maleic
acid, malonic acid, succinic acid, fumaric acid, tartaric acid,
citric acid, benzoic acid, cinnamic acid, mandelic acid,
methanesulfonic acid, ethanesulfonic acid, p-toluenesulfonic acid,
salicylic acid and the like.
[0283] "Pharmaceutically acceptable base addition salts" include
those derived from inorganic bases such as sodium, potassium,
lithium, ammonium, calcium, magnesium, iron, zinc, copper,
manganese, aluminum salts and the like. Exemplary salts are the
ammonium, potassium, sodium, calcium, and magnesium salts. Salts
derived from pharmaceutically acceptable organic non-toxic bases
include, but are not limited to, salts of primary, secondary, and
tertiary amines, substituted amines including naturally occurring
substituted amines, cyclic amines and basic ion exchange resins,
such as isopropylamine, trimethylamine, diethylamine,
triethylamine, tripropylamine, ethanolamine,
2-dimethylaminoethanol, 2-diethylaminoethanol, dicyclohexylamine,
lysine, arginine, histidine, caffeine, procaine, hydrabamine,
choline, betaine, ethylenediamine, glucosamine, methylglucamine,
theobromine, purines, piperazine, piperidine, N-ethylpiperidine,
polyamine resins, and the like. Exemplary organic bases are
isopropylamine, diethylamine, ethanolamine, trimethylamine,
dicyclohexylamine, choline, and caffeine. (See, for example, S. M.
Berge, et al., "Pharmaceutical Salts," J. Pharm. Sci., 1977;
66:1-19 which is incorporated herein by reference.)
[0284] "Prodrug" refers to compounds that are transformed
(typically rapidly) in vivo to yield the parent compound of the
above formulae, for example, by hydrolysis in blood. Common
examples include, but are not limited to, ester and amide forms of
a compound having an active form bearing a carboxylic acid moiety.
Examples of pharmaceutically acceptable esters of the compounds of
this invention include, but are not limited to, alkyl esters (for
example with between about one and about six carbons) wherein the
alkyl group is a straight or branched chain. Acceptable esters also
include cycloalkyl esters and arylalkyl esters such as, but not
limited to benzyl. Examples of pharmaceutically acceptable amides
of the compounds of this invention include, but are not limited to,
primary amides, and secondary and tertiary alkyl amides (for
example with between about one and about six carbons). Amides and
esters of the compounds of the present invention may be prepared
according to conventional methods. A thorough discussion of
prodrugs is provided in T. Higuchi and V. Stella, "Pro-drugs as
Novel Delivery Systems," Vol 14 of the A.C.S. Symposium Series, and
in Bioreversible Carriers in Drug Design, ed. Edward B. Roche,
American Pharmaceutical Association and Pergamon Press, 1987, both
of which are incorporated herein by reference for all purposes.
[0285] "Metabolite" refers to the break-down or end product of a
compound or its salt produced by metabolism or biotransformation in
the animal or human body; for example, biotransformation to a more
polar molecule such as by oxidation, reduction, or hydrolysis, or
to a conjugate (see Goodman and Gilman, "The Pharmacological Basis
of Therapeutics" 8.sup.th Ed., Pergamon Press, Gilman et al. (eds),
1990 for a discussion of biotransformation). As used herein, the
metabolite of a compound of the invention or its salt may be the
biologically active form of the compound in the body. In one
example, a prodrug may be used such that the biologically active
form, a metabolite, is released in vivo. In another example, a
biologically active metabolite is discovered serendipitously, that
is, no prodrug design per se was undertaken. An assay for activity
of a metabolite of a compound of the present invention is known to
one of skill in the art in light of the present disclosure.
[0286] In addition, the compounds of the present invention can
exist in unsolvated as well as solvated forms with pharmaceutically
acceptable solvents such as water, ethanol, and the like. In
general, the solvated forms are considered equivalent to the
unsolvated forms for the purposes of the present invention.
[0287] In addition, it is intended that the present invention cover
compounds made either using standard organic synthetic techniques,
including combinatorial chemistry or by biological methods, such as
bacterial digestion, metabolism, enzymatic conversion, and the
like.
[0288] "Treating" or "treatment" as used herein covers the
treatment of a disease-state in a human, which disease-state is
characterized by abnormal cellular proliferation, and invasion and
includes at least one of: (i) preventing the disease-state from
occurring in a human, in particular, when such human is predisposed
to the disease-state but has not yet been diagnosed as having it;
(ii) inhibiting the disease-state, i.e., arresting its development;
and (iii) relieving the disease-state, i.e., causing regression of
the disease-state. As is known in the art, adjustments for systemic
versus localized delivery, age, body weight, general health, sex,
diet, time of administration, drug interaction and the severity of
the condition may be necessary, and will be ascertainable with
routine experimentation by one of ordinary skill in the art.
[0289] One of ordinary skill in the art would understand that
certain crystallized, protein-ligand complexes, in particular
c-Met, c-Kit, KDR, flt-3, or flt-4-ligand complexes, and their
corresponding x-ray structure coordinates can be used to reveal new
structural information useful for understanding the biological
activity of kinases as described herein. As well, the key
structural features of the aforementioned proteins, particularly,
the shape of the ligand binding site, are useful in methods for
designing or identifying selective modulators of kinases and in
solving the structures of other proteins with similar features.
Such protein-ligand complexes, having compounds of the invention as
their ligand component, are an aspect of the invention.
[0290] As well, one of ordinary skill in the art would appreciate
that such suitable x-ray quality crystals can be used as part of a
method of identifying a candidate agent capable of binding to and
modulating the activity of kinases. Such methods may be
characterized by the following aspects: a) introducing into a
suitable computer program, information defining a ligand binding
domain of a kinase in a conformation (e.g. as defined by x-ray
structure coordinates obtained from suitable x-ray quality crystals
as described above) wherein the computer program creates a model of
the three dimensional structures of the ligand binding domain, b)
introducing a model of the three dimensional structure of a
candidate agent in the computer program, c) superimposing the model
of the candidate agent on the model of the ligand binding domain,
and d) assessing whether the candidate agent model fits spatially
into the ligand binding domain. Aspects a-d are not necessarily
carried out in the aforementioned order. Such methods may further
entail: performing rational drug design with the model of the
three-dimensional structure, and selecting a potential candidate
agent in conjunction with computer modeling.
[0291] Additionally, one skilled in the art would appreciate that
such methods may further entail: employing a candidate agent,
so-determined to fit spatially into the ligand binding domain, in a
biological activity assay for kinase modulation, and determining
whether said candidate agent modulates kinase activity in the
assay. Such methods may also include administering the candidate
agent, determined to modulate kinase activity, to a mammal
suffering from a condition treatable by kinase modulation, such as
those described above.
[0292] Also, one skilled in the art would appreciate that compounds
of the invention can be used in a method of evaluating the ability
of a test agent to associate with a molecule or molecular complex
comprising a ligand binding domain of a kinase. Such a method may
be characterized by the following aspects: a) creating a computer
model of a kinase binding pocket using structure coordinates
obtained from suitable x-ray quality crystals of the kinase, b)
employing computational algorithms to perform a fitting operation
between the test agent and the computer model of the binding
pocket, and c) analyzing the results of the fitting operation to
quantify the association between the test agent and the computer
model of the binding pocket.
General Administration
[0293] Administration of the compounds of the invention, or their
pharmaceutically acceptable salts, in pure form or in an
appropriate pharmaceutical composition, can be carried out via any
of the accepted modes of administration or agents for serving
similar utilities. Thus, administration can be, for example,
orally, nasally, parenterally (intravenous, intramuscular, or
subcutaneous), topically, transdermally, intravaginally,
intravesically, intracistemally, or rectally, in the form of solid,
semi-solid, lyophilized powder, or liquid dosage forms, such as for
example, tablets, suppositories, pills, soft elastic and hard
gelatin capsules, powders, solutions, suspensions, or aerosols, or
the like, preferably in unit dosage forms suitable for simple
administration of precise dosages.
[0294] The compositions will include a conventional pharmaceutical
carrier or excipient and a compound of the invention as the/an
active agent, and, in addition, may include other medicinal agents,
pharmaceutical agents, carriers, adjuvants, etc. Compositions of
the invention may be used in combination with anticancer or other
agents that are generally administered to a patient being treated
for cancer. Adjuvants include preserving, wetting, suspending,
sweetening, flavoring, perfuming, emulsifying, and dispensing
agents. Prevention of the action of microorganisms can be ensured
by various antibacterial and antifungal agents, for example,
parabens, chlorobutanol, phenol, sorbic acid, and the like. It may
also be desirable to include isotonic agents, for example sugars,
sodium chloride, and the like. Prolonged absorption of the
injectable pharmaceutical form can be brought about by the use of
agents delaying absorption, for example, aluminum monostearate and
gelatin.
[0295] If desired, a pharmaceutical composition of the invention
may also contain minor amounts of auxiliary substances such as
wetting or emulsifying agents, pH buffering agents, antioxidants,
and the like, such as, for example, citric acid, sorbitan
monolaurate, triethanolamine oleate, butylalted hydroxytoluene,
etc.
[0296] Compositions suitable for parenteral injection may comprise
physiologically acceptable sterile aqueous or nonaqueous solutions,
dispersions, suspensions or emulsions, and sterile powders for
reconstitution into sterile injectable solutions or dispersions.
Examples of suitable aqueous and nonaqueous carriers, diluents,
solvents or vehicles include water, ethanol, polyols
(propyleneglycol, polyethyleneglycol, glycerol, and the like),
suitable mixtures thereof, vegetable oils (such as olive oil) and
injectable organic esters such as ethyl oleate. Proper fluidity can
be maintained, for example, by the use of a coating such as
lecithin, by the maintenance of the required particle size in the
case of dispersions and by the use of surfactants.
[0297] One preferable route of administration is oral, using a
convenient daily dosage regimen that can be adjusted according to
the degree of severity of the disease-state to be treated.
[0298] Solid dosage forms for oral administration include capsules,
tablets, pills, powders, and granules. In such solid dosage forms,
the active compound is admixed with at least one inert customary
excipient (or carrier) such as sodium citrate or dicalcium
phosphate or (a) fillers or extenders, as for example, starches,
lactose, sucrose, glucose, mannitol, and silicic acid, (b) binders,
as for example, cellulose derivatives, starch, alignates, gelatin,
polyvinylpyrrolidone, sucrose, and gum acacia, (c) humectants, as
for example, glycerol, (d) disintegrating agents, as for example,
agar-agar, calcium carbonate, potato or tapioca starch, alginic
acid, croscarmellose sodium, complex silicates, and sodium
carbonate, (e) solution retarders, as for example paraffin, (f)
absorption accelerators, as for example, quaternary ammonium
compounds, (g) wetting agents, as for example, cetyl alcohol, and
glycerol monostearate, magnesium stearate and the like (h)
adsorbents, as for example, kaolin and bentonite, and (i)
lubricants, as for example, talc, calcium stearate, magnesium
stearate, solid polyethylene glycols, sodium lauryl sulfate, or
mixtures thereof. In the case of capsules, tablets, and pills, the
dosage forms may also comprise buffering agents.
[0299] Solid dosage forms as described above can be prepared with
coatings and shells, such as enteric coatings and others well known
in the art. They may contain pacifying agents, and can also be of
such composition that they release the active compound or compounds
in a certain part of the intestinal tract in a delayed manner.
Examples of embedded compositions that can be used are polymeric
substances and waxes. The active compounds can also be in
microencapsulated form, if appropriate, with one or more of the
above-mentioned excipients.
[0300] Liquid dosage forms for oral administration include
pharmaceutically acceptable emulsions, solutions, suspensions,
syrups, and elixirs. Such dosage forms are prepared, for example,
by dissolving, dispersing, etc., a compound(s) of the invention, or
a pharmaceutically acceptable salt thereof, and optional
pharmaceutical adjuvants in a carrier, such as, for example, water,
saline, aqueous dextrose, glycerol, ethanol and the like;
solubilizing agents and emulsifiers, as for example, ethyl alcohol,
isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol,
benzyl benzoate, propyleneglycol, 1,3-butyleneglycol,
dimethylformamide; oils, in particular, cottonseed oil, groundnut
oil, corn germ oil, olive oil, castor oil and sesame oil, glycerol,
tetrahydrofurfuryl alcohol, polyethyleneglycols and fatty acid
esters of sorbitan; or mixtures of these substances, and the like,
to thereby form a solution or suspension.
[0301] Suspensions, in addition to the active compounds, may
contain suspending agents, as for example, ethoxylated isostearyl
alcohols, polyoxyethylene sorbitol and sorbitan esters,
microcrystalline cellulose, aluminum metahydroxide, bentonite,
agar-agar and tragacanth, or mixtures of these substances, and the
like.
[0302] Compositions for rectal administrations are, for example,
suppositories that can be prepared by mixing the compounds of the
present invention with for example suitable non-irritating
excipients or carriers such as cocoa butter, polyethyleneglycol or
a suppository wax, which are solid at ordinary temperatures but
liquid at body temperature and therefore, melt while in a suitable
body cavity and release the active component therein.
[0303] Dosage forms for topical administration of a compound of
this invention include ointments, powders, sprays, and inhalants.
The active component is admixed under sterile conditions with a
physiologically acceptable carrier and any preservatives, buffers,
or propellants as may be required. Ophthalmic formulations, eye
ointments, powders, and solutions are also contemplated as being
within the scope of this invention.
[0304] Generally, depending on the intended mode of administration,
the pharmaceutically acceptable compositions will contain about 1%
to about 99% by weight of a compound(s) of the invention, or a
pharmaceutically acceptable salt thereof, and 99% to 1% by weight
of a suitable pharmaceutical excipient. In one example, the
composition will be between about 5% and about 75% by weight of a
compound(s) of the invention, or a pharmaceutically acceptable salt
thereof, with the rest being suitable pharmaceutical
excipients.
[0305] Actual methods of preparing such dosage forms are known, or
will be apparent, to those skilled in this art; for example, see
Remington's Pharmaceutical Sciences, 18th Ed., (Mack Publishing
Company, Easton, Pa., 1990). The composition to be administered
will, in any event, contain a therapeutically effective amount of a
compound of the invention, or a pharmaceutically acceptable salt
thereof, for treatment of a disease-state in accordance with the
teachings of this invention.
[0306] The compounds of the invention, or their pharmaceutically
acceptable salts, are administered in a therapeutically effective
amount which will vary depending upon a variety of factors
including the activity of the specific compound employed, the
metabolic stability and length of action of the compound, the age,
body weight, general health, sex, diet, mode and time of
administration, rate of excretion, drug combination, the severity
of the particular disease-states, and the host undergoing therapy.
The compounds of the present invention can be administered to a
patient at dosage levels in the range of about 0.1 to about 1,000
mg per day. For a normal human adult having a body weight of about
70 kilograms, a dosage in the range of about 0.01 to about 100 mg
per kilogram of body weight per day is an example. The specific
dosage used, however, can vary. For example, the dosage can depend
on a number of factors including the requirements of the patient,
the severity of the condition being treated, and the
pharmacological activity of the compound being used. The
determination of optimum dosages for a particular patient is well
known to one of ordinary skill in the art.
Utility of Compounds of the Invention as Screening Agents
[0307] To employ the compounds of the invention in a method of
screening for candidate agents that bind to, for example c-Met,
KDR, c-Kit, flt-3, or flt-4, the protein is bound to a support, and
a compound of the invention is added to the assay. Alternatively,
the compound of the invention is bound to the support and the
protein is added. Classes of candidate agents among which novel
binding agents may be sought include specific antibodies,
non-natural binding agents identified in screens of chemical
libraries, peptide analogs, etc. Of particular interest are
screening assays for candidate agents that have a low toxicity for
human cells. A wide variety of assays may be used for this purpose,
including labeled in vitro protein-protein binding assays,
electrophoretic mobility shift assays, immunoassays for protein
binding, functional assays (phosphorylation assays, etc.) and the
like.
[0308] The determination of the binding of the candidate agent to,
for example, c-Met, KDR, c-Kit, flt-3, or flt-4 protein may be done
in a number of ways. In one example, the candidate agent (the
compound of the invention) is labeled, for example, with a
fluorescent or radioactive moiety and binding determined directly.
For example, thus may be done by attaching all or a portion of the
c-Met, KDR, c-Kit, flt-3, or flt-4 protein to a solid support,
adding a labeled agent (for example a compound of the invention in
which at least one atom has been replaced by a detectable isotope),
washing off excess reagent, and determining whether the amount of
the label is that present on the solid support. Various blocking
and washing steps may be utilized as is known in the art.
[0309] By "labeled" herein is meant that the compound is either
directly or indirectly labeled with a label which provides a
detectable signal, e.g., radioisotope, fluorescent tag, enzyme,
antibodies, particles such as magnetic particles, chemiluminescent
tag, or specific binding molecules, etc. Specific binding molecules
include pairs, such as biotin and streptavidin, digoxin and
antidigoxin etc. For the specific binding members, the
complementary member would normally be labeled with a molecule
which provides for detection, in accordance with known procedures,
as outlined above. The label can directly or indirectly provide a
detectable signal.
[0310] In some embodiments, only one of the components is labeled.
For example, c-Met, KDR, c-Kit, flt-3, or flt-4 protein may be
labeled at tyrosine positions using .sup.125I, or with
fluorophores. Alternatively, more than one component may be labeled
with different labels; using .sup.125I for the proteins, for
example, and a fluorophore for the candidate agents.
[0311] The compounds of the invention may also be used as
competitors to screen for additional drug candidates. "Candidate
bioactive agent" or "drug candidate" or grammatical equivalents as
used herein describe any molecule, e.g., protein, oligopeptide,
small organic molecule, polysaccharide, polynucleotide, etc., to be
tested for bioactivity. They may be capable of directly or
indirectly altering the cellular proliferation phenotype or the
expression of a cellular proliferation sequence, including both
nucleic acid sequences and protein sequences. In other cases,
alteration of cellular proliferation protein binding and/or
activity is screened. In the case where protein binding or activity
is screened, some embodiments exclude molecules already known to
bind to that particular protein. Exemplary embodiments of assays
described herein include candidate agents, which do not bind the
target protein in its endogenous native state, termed herein as
"exogenous" agents. In one example, exogenous agents further
exclude antibodies to c-Met, KDR, c-Kit, flt-3, or flt-4.
[0312] Candidate agents can encompass numerous chemical classes,
though typically they are organic molecules having a molecular
weight of more than about 100 daltons and less than about 2,500
daltons. Candidate agents comprise functional groups necessary for
structural interaction with proteins, particularly hydrogen bonding
and lipophilic binding, and typically include at least an amine,
carbonyl, hydroxyl, ether, or carboxyl group, for example at least
two of the functional chemical groups. The candidate agents often
comprise cyclical carbon or heterocyclyl structures and/or aromatic
or polyaromatic structures substituted with one or more of the
above functional groups. Candidate agents are also found among
biomolecules including peptides, saccharides, fatty acids,
steroids, purines, pyrimidines, derivatives, structural analogs, or
combinations thereof.
[0313] Candidate agents are obtained from a wide variety of sources
including libraries of synthetic or natural compounds. For example,
numerous means are available for random and directed synthesis of a
wide variety of organic compounds and biomolecules, including
expression of randomized oligonucleotides. Alternatively, libraries
of natural compounds in the form of bacterial, fungal, plant and
animal extracts are available or readily produced. Additionally,
natural or synthetically produced libraries and compounds are
readily modified through conventional chemical, physical and
biochemical means. Known pharmacological agents may be subjected to
directed or random chemical modifications, such as acylation,
alkylation, esterification, amidification to produce structural
analogs.
[0314] In one example, the binding of the candidate agent is
determined through the use of competitive binding assays. In this
example, the competitor is a binding moiety known to bind to c-Met,
KDR, c-Kit, flt-3, or flt-4, such as an antibody, peptide, binding
partner, ligand, etc. Under certain circumstances, there may be
competitive binding as between the candidate agent and the binding
moiety, with the binding moiety displacing the candidate agent.
[0315] In some embodiments, the candidate agent is labeled. Either
the candidate agent, or the competitor, or both, is added first to
for example c-Met, KDR, c-Kit, flt-3, or flt-4 for a time
sufficient to allow binding, if present. Incubations may be
performed at any temperature that facilitates optimal activity,
typically between 4.degree. C. and 40.degree. C. Incubation periods
are selected for optimum activity, but may also be optimized to
facilitate rapid high throughput screening. Typically between 0.1
and 1 hour will be sufficient. Excess reagent is generally removed
or washed away. The second component is then added, and the
presence or absence of the labeled component is followed, to
indicate binding.
[0316] In one example, the competitor is added first, followed by
the candidate agent. Displacement of the competitor is an
indication the candidate agent is binding to c-Met, KDR, c-Kit,
flt-3, or flt-4 and thus is capable of binding to, and potentially
modulating, the activity of the c-Met, KDR, c-Kit, flt-3, or flt-4.
In this embodiment, either component can be labeled. Thus, for
example, if the competitor is labeled, the presence of label in the
wash solution indicates displacement by the agent. Alternatively,
if the candidate agent is labeled, the presence of the label on the
support indicates displacement.
[0317] In an alternative embodiment, the candidate agent is added
first, with incubation and washing, followed by the competitor. The
absence of binding by the competitor may indicate the candidate
agent is bound to c-Met, KDR, c-Kit, flt-3, or flt-4 with a higher
affinity. Thus, if the candidate agent is labeled, the presence of
the label on the support, coupled with a lack of competitor
binding, may indicate the candidate agent is capable of binding to
c-Met, KDR, c-Kit, flt-3, or flt-4.
[0318] It may be of value to identify the binding site of c-Met,
KDR, c-Kit, flt-3, or flt-4. This can be done in a variety of ways.
In one embodiment, once c-Met, KDR, c-Kit, flt-3, or flt-4 has been
identified as binding to the candidate agent, the c-Met, KDR,
c-Kit, flt-3, or flt-4 is fragmented or modified and the assays
repeated to identify the necessary components for binding.
[0319] Modulation is tested by screening for candidate agents
capable of modulating the activity of c-Met, KDR, c-Kit, flt-3, or
flt-4 comprising the steps of combining a candidate agent with
c-Met, KDR, c-Kit, flt-3, or flt-4, as above, and determining an
alteration in the biological activity of the c-Met, KDR, c-Kit,
flt-3, or flt-4. Thus, in this embodiment, the candidate agent
should both bind to (although this may not be necessary), and alter
its biological or biochemical activity as defined herein. The
methods include both in vitro screening methods and in vivo
screening of cells for alterations in cell viability, morphology,
and the like.
[0320] Alternatively, differential screening may be used to
identify drug candidates that bind to native c-Met, KDR, c-Kit,
flt-3, or flt-4, but cannot bind to modified c-Met, KDR, c-Kit,
flt-3, or flt-4.
[0321] Positive controls and negative controls may be used in the
assays. For example, all control and test samples are performed in
at least triplicate to obtain statistically significant results.
Incubation of samples is for a time sufficient for the binding of
the agent to the protein. Following incubation, samples are washed
free of non-specifically bound material and the amount of bound,
generally labeled agent determined. For example, where a radiolabel
is employed, the samples may be counted in a scintillation counter
to determine the amount of bound compound.
[0322] A variety of other reagents may be included in the screening
assays. These include reagents like salts, neutral proteins, e.g.,
albumin, detergents, etc which may be used to facilitate optimal
protein-protein binding and/or reduce non-specific or background
interactions. Also reagents that otherwise improve the efficiency
of the assay, such as protease inhibitors, nuclease inhibitors,
anti-microbial agents, etc., may be used. The mixture of components
may be added in any order that provides for the requisite
binding.
ABBREVIATIONS AND THEIR DEFINITIONS
[0323] The following abbreviations and terms have the indicated
meanings throughout.
TABLE-US-00003 Abbreviation Meaning Ac acetyl ATP adenosine
triphosphate BNB 4-bromomethyl-3-nitrobenzoic acid Boc t-butyloxy
carbonyl br broad Bu butyl .degree. C. degrees Celsius c- cyclo CBZ
CarboBenZoxy = benzyloxycarbonyl d doublet dd doublet of doublet dt
doublet of triplet DBU Diazabicyclo[5.4.0]undec-7-ere DCM
dichloromethane = methylene chloride = CH.sub.2Cl.sub.2 DCE
dichloroethylene DEAD diethyl azodicarboxylate DIC
diisopropylcarbodiimide DIEA N,N-diisopropylethyl amine DMAP
4-N,N-dimethylaminopyridine DMF N,N-dimethylfonnamide DMSO dimethyl
sulfoxide DVB 1,4-divinylbenzene EEDQ
2-ethoxy-1-ethoxycarbonyl-1,2-dihydroquinoline EI Electron Impact
ionization Et ethyl Fmoc 9-fluorenylmethoxycarbonyl g gram(s) GC
gas chromatography h or hr hour(s) HATU
0-(7-Azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium
hexafluorophosphate HMDS hexamethyldisilazane HOAc acetic acid HOBt
hydroxybenzotriazole HPLC high pressure liquid chromatography L
liter(s) M molar or molarity m multiplet Me methyl mesyl
methanesulfonyl mg milligram(s) MHz megahertz (frequency) Min
minute(s) mL milliliter(s) mM millimolar mmol millimole(s) mol
mole(s) MS mass spectral analysis MTBE methyl t-butyl ether N
normal or normality NBS N-bromosuccinimide NCS N-chlorosuccinimide
nM nanomolar NMO N-methylmorpholine oxide NMR nuclear magnetic
resonance spectroscopy PEG polyethylene glycol pEY poly-glutamine,
tyrosine Ph phenyl PhOH phenol PfP pentafluorophenol PfPy
pentafluoropyridine PPTS Pyridinium p-toluenesulfonate Py pyridine
PyBroP bromo-tris-pyrrolidino-phosphonium hexafluorophosphate q
quartet RT Room temperature Sat'd saturated s singlet s- secondary
t- tertiary t or tr triplet TBDMS t-butyldimethylsilyl TES
triethylsilane TFA trifluoroacetic acid THF tetrahydrofuran TMOF
trimethyl orthoformate TMS trimethylsilyl tosyl p-toluenesulfonyl
Trt triphenylmethyl uL microliter(s) uM Micromole(s) or
micromolar
Synthesis of Compounds
[0324] Schemes 1 and 2 depict general synthetic routes for
compounds of the invention and are not intended to be limiting.
More specifically, Scheme 1 depicts synthesis of quinazoline
compounds, and Scheme 2 depicts synthesis of quinoline compounds.
Specific examples are described subsequently to these general
synthetic descriptions so as to allow one skilled in the art to
make and use either quinazolines or quinolines of the
invention.
##STR00473##
[0325] Referring to Scheme 1, a benzoic ester 1, where R is
typically but not necessarily a methyl radical and P is typically
but not necessarily an alkyl group, is O-alkylated at the oxygen
para to the carboxylate group with an electrophile to afford a
substituted derivative 2. P is typically a lower alkyl group, but
may be a protecting group that is removed later in a synthesis.
When P is a lower alkyl group it may possess functionality
initially, or be derivatized to contain such functionality at
various stages of the synthesis. The group, E.sup.1, may represent
either a protecting group, e.g. benzyl, or a group that either has
moieties present in compounds of the invention or possesses
functionality that serve as a precursors to such groups. Aromatic
ring nitration and reduction of the corresponding nitro group are
carried out in a regio- and chemoselective manner by methods well
known in the art to give anthranilate derivative 3. Formation of
quinazolin-4-one 4 is carried out by methods well known in the art,
for example by heating 3 in formamide solution in the presence of
ammonium formate or for example by heating directly with
formamidine hydrochloride. Introduction of 4-position functionality
groups is carried out by methods known in the art. For example,
quinazolin-4-one 4 is converted to an intermediate quinazoline 5,
where "L" represents a leaving group, e.g. chlorine. Quinazoline 5
is then converted to 6 by reaction with a range of nucleophiles,
e.g. amines, alcohols, and thiols. After formation of 6, group "Z"
is either left "as is" or converted at some subsequent stage to a
derivative thereof. For example when Z is --NH--, then the hydrogen
on the nitrogen may optionally be replaced with an alkyl group, or
when Z is sulfur, then that sulfur atom may be oxidized to, for
example, a sulfone. Structure 6 may represent compounds of the
invention or, for example when E.sup.1 serves as a protecting
group, E.sup.1 may be removed to provide phenol 7. Introduction of
a group E.sup.2 is carried out by methods well established in the
art; for example alkylation with an appropriately derivatized alkyl
halide (or mesylate or the like) to give 8 which also represents
compounds of the invention.
##STR00474##
[0326] Scheme 2 shows a general route used to make exemplary
quinolines of the invention. For example, compound 9 contains an
alkyl group, R.sup.1, a protecting group, P. The arrangement of the
protected and alkylated phenolic oxygens may vary from the pattern
depicted in compound 9. Compound 9 is nitrated to provide compound
10. The nitro group of compound 10 is reduced to give aniline 11.
Compound 11 is treated, for example, with ethyl formate under basic
conditions followed by acidification and isolation to form
4-hydroxy quinoline 12. Quinoline 12 may be converted to compounds
of the invention in a number of ways. For example, the 4-oxygen is
used as a nucleophile in a nucleophilic aromatic substitution
reaction to form quinoline-aryl-ether 13. In another example,
compound 13 is further derivatized, via removal of protecting group
P, to afford compound 14. The 7-hydroxy of compound 14 is
alkylated, for example with electrophile E, to provide a compound
of the invention. As discussed in relation to Scheme 1, variations
on any of the above steps are possible, and intermediates in these
schemes, for example compounds 12, 13, and 14 may also be compounds
of the invention according to formula I. Also, for example, the
4-hydroxy quinoline compound 12 are converted to a corresponding
4-nitrogen or 4-sulfur quinoline using chemistry known in the art
to make compounds of the invention, or alternatively the
corresponding 4-nitrogen or 4-sulfur quinolines are made via routes
analogous to that depicted in Schemes 1 and 2.
[0327] Schemes 1 and 2 are illustrative of quinolines and
quinazolines having oxygen substitution at their respective 6- and
7-positions; the invention is not so limited, but rather is
intended to encompass quinolines and quinazolines not necessarily
having substitution, oxygen or otherwise, at their respective 6- or
7-positions.
[0328] Schemes 3 and 4 depict generalized synthetic routes to show
the process of the invention to make compounds of formula XXI and
is not intended to be limiting. More specifically, Schemes 3 and 4
depict convergent syntheses of quinoline and quinazoline compounds
as described herein. Specific examples are described subsequently
to this general synthetic description so as to allow one of
ordinary skill in the art to practice the invention.
[0329] Referring to Scheme 3, a benzoic ester 16 for example, where
R is typically but not necessarily a methyl radical and R.sup.1 is
typically but not necessarily one or more alkoxy or hydroxy groups.
In a typical synthesis, at least one of R.sup.1 within Scheme 3 is
a hydroxyl which is converted (or protected) via one or more steps
to a group important to the activity of the compounds as described
as kinase modulators (in the case that --OH itself is desired in
the final compound, then deprotection affords the --OH, vide
supra). Preferably, but not necessarily, this group is complete
once the synthesis of XXII is complete. By building desired
complexity into XXII prior to combination with XXIII, convergent
syntheses' advantages over serial syntheses are realized more
fully. Regioselective aromatic ring nitration, and reduction of the
corresponding nitro group, are carried out in a regio- and
chemoselective manner by methods well known in the art to give
anthranilate derivative 17. Formation of quinazoline or quinoline
4-one 18 is carried out by methods well known in the art. For
example by heating 17 in formamide solution in the presence of
ammonium formate, or by heating 17 with formamidine hydrochloride,
the quinazoline-4-one analog is made. In another example 17 is
treated, for example, with ethyl formate under basic conditions
followed by acidification and isolation to form the 4-hydroxy
quinoline analog (a tautomer of the 4-one). In this scheme J'
represents either carbon or nitrogen atom with the appropriate
number of hydrogens to fill their respective normal valence bonding
schemes; J' is a precursor to J. Radicals J and R.sup.70 are in
accord with formula XXI. Introduction of 4-position functionality
is carried out by methods known in the art. For example, 4-one 18
is converted to XXII, where "P.sup.1" represents a suitable leaving
group (in accord with formula XXI), e.g. chlorine (via
dehydration/chlorination of 18 to give XXII). In another example, a
4-hydroxy analog is converted to a sulfonyl ester, e.g. the
trifluoromethane sulfonate.
##STR00475##
[0330] Scheme 4 shows a general route used to make compounds of
formula XXIII. For example, aromatic compound 19, where "X" is a
leaving group, such as fluorine and "E" is an electron withdrawing
group such as nitro, is converted to 20 by reaction with a range of
nucleophiles, e.g. amines, alcohols, and thiols (where "Z" is
oxygen, nitrogen (substituted or not), or sulfur). In this case,
"R" represents a removable group, for example benzyl. In a typical
synthesis, after formation of 20, group "E" is either left "as is"
or converted at some subsequent stage to a derivative thereof. In
the example depicted, E is converted to B', a precursor to B in
accord with formula XXI, to make 21. For example if E is a nitro,
then B' could might be an amino group, made via reduction of the
nitro group. Structure 21 may be further derivatized by synthesis
of --B-L-T in accord with formula XXI. In scheme 4, this is
depicted as a serial process whereby L', a precursor to L, is
introduced to give 22, followed by introduction of T' (a precursor
to T) to give 23. In some cases, -L-T is preformed and appended to
B. One of ordinary skill in the art would appreciate that
variations on any of the above steps are possible. Compound 23 is
converted to XXIII via conversion of T' to T and introduction of
P.sup.2 (for example, when R is benzyl, removal of the benzyl after
completion of --B-L-T).
##STR00476##
[0331] As discussed above, one aspect of the invention encompasses
combination of XXII and XXIII to make compounds of formula XXI.
Because of the diversity and complexity of compounds described for
kinase modulation (vide supra), methods of the invention provide
advantages to serial synthesis.
##STR00477##
EXAMPLES
[0332] The following examples serve to more fully describe the
manner of using the above-described invention, as well as to set
forth the best modes contemplated for carrying out various aspects
of the invention. It is understood that these examples in no way
serve to limit the true scope of this invention, but rather are
presented for illustrative purposes. All references cited herein
are incorporated by reference in their entirety. Generally, but not
necessarily, each example set out below describes a multi-step
synthesis as outlined above.
Quinoline and Quinazoline Syntheses
Example 1
##STR00478##
[0334] Synthesis of
1-(4-Benzyloxy-5-methoxy-2-nitro-phenyl)-ethanone.
1-(4-Benzyloxy-3-methoxy-phenyl)-ethanone (200 mmol, 51.3 g)
dissolved in DCM (750 ml) and the mixture cooled to 0.degree. C.
Nitric acid (90%, 300 mmol, 14 ml) was added dropwise to the cooled
solution over 20 minutes. Sulfuric acid (96.2%, 300 mmol, 8.75 ml)
was then added dropwise over 40 minutes at 0.degree. C.
[0335] Additional nitric acid (200 mmol, 9.4 ml) was added dropwise
over 20 minutes. The reaction mixture was diluted with water (300
ml) and wash with water (3.times.200 ml), Sat. NaHCO.sub.3
(4.times.200 ml, or until neutral). The organic layer was dried
over Na.sub.2SO.sub.4 and concentrated.
[0336] The crude mixture was recrystallized with DMF to give 22.5 g
of the nitro product. The DMF layer was concentrated and
recrystallized with ethyl acetate to give additional 8.75 g of the
product. The ethyl acetate layer was concentrated and purified on
silica column using 20% EtOAc/hexanes to gave another 4.75 g of the
product. Total yield is 36 g, (.about.60%). .sup.1H NMR
(CDCl.sub.3): 7.647 (1H, s), 7.446-7.333 (5H, m), 6.745 (1H, s),
5.210 (2H, s), 3.968 (3H, s), 2.487 (3H, s).
Example 2
##STR00479##
[0338] Synthesis of
1-(2-Amino-4-benzyloxy-5-methoxy-phenyl)-ethanone. A Mixture of
iron powder (477 mmol, 27 g), ammonium acetate (500 mmol, 31. g),
1-(4-Benzyloxy-5-methoxy-2-nitro-phenyl)-ethanone (120 mmol, 36 g),
toluene (500 ml) and water (500 ml) was refluxed overnight, or
until completion. The mixture was filtered through celite and
washed with EtOAc. The organic layer was washed with water and Sat.
NaCl, dried over Na.sub.2SO.sub.4, and concentrated to afford the
product, 90%. .sup.1H NMR (CDCl.sub.3): 7.408-7.298 (5H, m), 7.130
(1H, s), 6.155 (2H, br), 6.104 (1H, s), 5.134 (2H, s), 3.834 (3H,
s), 2.507 (3H, s). LC/MS (M+1=272).
Example 3
##STR00480##
[0340] Synthesis of 7-Benzyloxy-6-methoxy-quinolin-4-ol. To a
solution of 1-(2-Amino-4-benzyloxy-5-methoxy-phenyl)-ethanone (108
mmol, 29.3 g) in DME (700 ml) was added sodium methoxide (432 mmol,
23.35 g). The mixture was stirred for 30 minutes. Ethyl formate
(540 mmol, 44 ml) was added and the mixture was stirred overnight.
(Additional sodium methoxide may be needed if reaction is not
complete as monitored by LC/MS.) After the reaction was completion,
the mixture was diluted with water (40 ml) and acidified to neutral
with 1M HCl. The precipitate was filtered and washed with water,
dried in vacuo to afford 22 g (72%) of
7-benzyloxy-6-methoxy-quinolin-4-ol. .sup.1H NMR (CDCl.sub.3): 10.7
(1H, br), 7.703 (1H, s), 7.493-7.461 (1H, t), 7.431-7.413 (2H, br
d), 7.372-7.333 (2H, t), 7.296-7.283 (1H, d), 6.839 (1H, s),
6.212-6.193 (1H, d), 5.212 (2H, s), 3.965 (3H, s). LC/MS
(M+l=282).
Example 4
##STR00481##
[0342]
7-Benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinoline. To a
round bottom flask equipped with a magnetic stir bar was added
7-Benzyloxy-6-methoxy-1H-quinolin-4-one (12.2 g, 43.3 mmol, 1.0
eq.), acetonitrile (150 ml), DMF (150 ml) and cesium carbonate
(28.2 g, 86.5 mmol, 2.0 eq). The mixture was stirred at room
temperature for 30 minutes at which time
1,2-difluoro-4-nitro-benzene (7.57 g, 47.6 mmol, 1.1 eq) was added
over a 10 minute period. After 2 hours the reaction was complete at
which time 75% of the MeCN and DMF was removed and the resulting
solution was poured over into ice water. The solid was filtered and
dried and further columned with a biotage system. The eluent was
1:3 ethyl acetate/hexane. Removal of the solvent afforded
7-Benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinoline as a
pale green solid (7.4 g, 41% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3): 8.53 (d, 1H), 8.42 (dd, 1H), 8.16 (m, 1H), 7.5 (m,
8H), 6.76 (d, 1H), 5.31 (s, 2H), 3.92 (s, 3H); MS (EI) for
C.sub.23H.sub.27FN.sub.2O.sub.5: 421 (MH.sup.+).
Example 5
##STR00482##
[0344] 4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol. To a
round bottom flask equipped with a magnetic stir bar was added
7-benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinoline (2.9
g, 6.9 mmol, 1.0 eq) and 33% HBr in acetic acid (30 ml). The
mixture was stirred at room temperature for 3 hours and diluted
with ether to give a pale white solid. The solid was filtered,
washed with ether and dried to yield
4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol as a pale
white solid (2.74 g, 97.5% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3): 11.89 (bs, 1H), 8.87 (d, 1H), 8.57 (d, 1H), 8.30 (d,
1H), 7.89 (m, 1H), 7.73 (s, 1H), 7.55 (s, 1H), 4.03 (s, 3H); MS
(EI) for C.sub.16H.sub.11FN.sub.2O.sub.5: 421 (M+H.sup.+).
Example 6
##STR00483##
[0346]
5-[4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-yloxymethyl]-h-
exahydro-cyclopenta[c]pyrrole-2-carboxylic acid benzyl ester. To a
round bottom flask equipped with a magnetic stir bar was added
4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-ol (2.74 g, 6.7
mmol, 1.0 eq.), DMA (30 ml) and cesium carbonate (6.6 g, 20.2 mmol,
3.0 eq). The mixture was stirred at room temperature for 30 minutes
at which time
5-methanesulfonyloxymethyl-hexahydro-cyclopenta[c]pyrrole-2-carboxylic
acid benzyl ester (2.6 g, 7.3 mmol, 1.1 eq) was added. The reaction
was heated to 75.degree. C. and allowed to stir overnight. After
allowing the reaction to cool to room temperature the reaction was
poured into water. The solid was filtered and was then dissolved in
EtOAc and washed 2.times. water, 1.times. brine and dried over
NaSO.sub.4. The solvent was removed to yield
5-[4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-yloxymethyl]-hexahyd-
ro-cyclopenta[c]pyrrole-2-carboxylic acid benzyl ester as a cream
solid (3.7 g, 94% yield). .sup.1H NMR (400 MHz, CDCl.sub.3): 8.55
(d, 1H), 8.15 (d, 1H), 8.09 (d, 1H), 7.32 (m, 8H), 6.52 (d, 1H),
5.11 (d, 2H), 4.13 (d, 2H), 3.95 (s, 3H), 3.57 (m, 2H), 3.43 (m,
2H), 2.93 (m, 3H), 2.16 (m, 2H), 1.39 (m, 2H); MS (EI) for
C.sub.32H.sub.30FN.sub.3O.sub.7: 588 (M+H.sup.+).
Example 7
##STR00484##
[0348]
4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-7-(octahydro-cyclopenta[c]py-
rrol-5-ylmethoxy)-quinoline. To a round bottom flask equipped with
a magnetic stir bar was added
5-[4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-yloxymethyl]-hexahyd-
rocyclopenta[c]pyrrole-2-carboxylic acid benzyl ester (2.5 g, 4.1
mmol, 1.0 eq), 33% HBr in acetic acid (5 ml) and acetic acid (5
ml). The mixture was stirred at room temperature for 1 hour and
diluted with EtOAc to give a pale orange solid. The solid was
filtered, washed with EtOAc and dried, giving
4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-7-(octahydro-cyclopenta[c]pyrrol-5-
-ylmethoxy)-quinoline (2.1 g, 95% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3): 8.83 (d, 1H), 8.32 (m, 2H), 8.02 (s, 1H), 7.76 (t,
1H), 7.65 (s, 1H), 6.89 (d, 1H), 5.3 (d, 2H), 4.11 (m, 3H), 3.26
(m, 4H), 2.95 (m, 2H), 2.68 (m, 3H), 2.36 (m, 2H), 1.68 (m, 2H); MS
(EI) for C.sub.24H.sub.24FN.sub.3O.sub.5: 454 (M+H.sup.+).
Example 8
##STR00485##
[0350]
4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-7-(2-methyl-octahydro-cyclop-
enta[c]pyrrol-5-ylmethoxy)-quinoline. To a round bottom flask
equipped with a magnetic stir bar was added
4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-7-(octahydro-cyclopenta[c]pyrrol-5-
-ylmethoxy)-quinoline (2.1 g, 3.9 mmol, 1.0 eq.) and
acetonitrile/water 1:1 (5 ml, 5 ml). The reaction mixture was then
cooled to 0.degree. C. and 37% solution of formaldehyde in water
was added (0.2 g, 7.8 mmol, 2.0 eq). While keeping the temperature
at 0.degree. C. Na(OAc).sub.3BH was added (4.4 g, 20.7 mmol, 3.0
eq). After 1 hour the pH was adjusted to 10 and the aqueous was
extracted 2.times.DCM (100 ml). Removal of the DCM resulted in a
white solid. The compound was further purified with a biotage
system using an eluent EtOAc and 5% MeOH, affording
4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-7-(2-methyl-octahydrocyclopenta[c]-
pyrrol-5-ylmethoxy)-quinoline (0.9 g, 50% yield).). .sup.1H NMR
(400 MHz, CDCl.sub.3): 8.57 (d, 1H), 8.14 (dd, 1H), 8.12 (dd, 1H),
7.41 (s, 2H), 7.34 (t, 1H), 6.54 (d, 1H), 4.19 (d, 2H), 4.01 (s,
3H), 2.61 (m, 4H), 2.43 (m, 1H), 2.33 (s, 3H), 2.11 (m, 4H), 1.32
(m, 2H); MS (EI) for C.sub.25H.sub.26FN.sub.3O.sub.5: 468
(M+H.sup.+).
Example 9
##STR00486##
[0352]
3-Fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-y-
lmethoxy)-quinolin-4-yloxy]-phenylamine. To a par hydrogenation
reaction vessel was added
4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-7-(2-methyl-octahydro-cyclopenta[c-
]pyrrol-5-ylmethoxy)-quinoline (0.800 g, 1.6 mmol, 1.0 eq.), DMF
(50 ml), EtoAc (50 ml), MeOH (50 ml), TEA (5 ml) and 10% Pd/C (200
mg). The vessel was placed on the par hydrogenator at 35 psi
overnight. The Pd was filtered and the solvent removed to give
3-fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-ylmetho-
xy)-quinolin-4-yloxy]-phenylamine as an off yellow solid (0.78 g,
99% yield). .sup.1H NMR (400 MHz, CDCl.sub.3): 8.45 (d, 1H), 7.57
(s, 1H), 7.36 (s, 1H), 7.05 (t, 1H), 6.54 (m, 2H), 6.39 (d, 1H),
4.16 (d, 2H), 4.01 (s, 3H), 3.81 (m, 3H), 2.61 (m, 3H), 2.41 (m,
1H), 2.29 (s, 3H), 2.23 (m, 2H), 1.32 (m, 2H); MS (EI) for
C.sub.25H.sub.28FN.sub.3O.sub.3: 438 (M+H.sup.+).
Example 10
##STR00487##
[0354]
1-{3-Fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol--
5-ylmethoxy)-quinolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea. To
a round bottom flask equipped with a magnetic stir bar was added
3-fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-ylmetho-
xy)-quinolin-4-yloxy]-phenylamine (0.78 mg, 1.7 mmol, 1.0 eq.),
toluene (10 ml), ethanol (10 ml) and phenyl-acetyl isothiocyanate
(1.64 g, 9.2 mmol, 4.5 eq). The reaction mixture was stirred at
room temperature overnight. After removal of the solvent the
product was purified with a biotage system using an eluent EtOAc
and 4% TEA (2 L) then EtOAc, 4% TEA, 1% MeOH (1 L). The solvent was
removed to give
1-{3-fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-ylme-
thoxy)-quinolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea (0.5 g,
50% yield). .sup.1H NMR (400 MHz, DMSO): 8.48 (d, 1H), 7.92 (dd,
1H), 7.53 (s, 1H), 7.40 (m, 4H), 7.33 (d, 2H), 7.23 (m, 2H), 6.54
(d, 2H), 6.39 (d, 1H), 4.21 (d, 2H), 4.02 (s, 3H), 3.81 (m, 3H),
2.87 (d, 2H), 2.73 (m, 4H), 2.53 (m, 1H), 2.27 (m, 2H), 2.01 (s,
3H), 1.36 (m, 2H); MS (EI) for C.sub.34H.sub.35FN.sub.4O.sub.4S:
615 (M+H.sup.+).
Example 11
##STR00488##
[0356]
6-(6,7-Dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-ylamine.
4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenylamine (1.00 g,
3.18 mmol) was dissolved in AcOH (8.0 ml), to which was added
NH.sub.4SCN (486 mg, 6.38 mmol) and the mixture cooled in an ice
bath. Br.sub.2 (0.33 ml, 6.42 mmol) in AcOH (0.33 ml) was added
dropwise with stirring. After addition was complete, the reaction
mixture was stirred at room temperature. After one hour, more
NH.sub.4SCN (1.0 g, 13.1 mmol) was added, followed by more Br.sub.2
(0.33 ml, 6.42 mmol) in AcOH (0.33 ml), dropwise with stirring. The
reaction mixture was then heated to reflux for several minutes.
Upon cooling to room temperature, solids were filtered and washed
with AcOH, followed by H.sub.2O. The volume of the filtrate was
reduced in vacuo and the pH adjusted to pH 9-10 with 1.0N NaOH. The
resulting solids were filtered, washed with H.sub.2O, and dried
under high vacuum to give
6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-ylamine
(568 mg, 48%). .sup.1H-NMR (400 MHz, DMSO): 8.45 (d, 1H), 7.82 (d,
1H), 7.73 (br s, 2H), 7.53 (s, 1H), 7.38 (m, 2H), 6.44 (d, 1H),
3.94 (s, 6H). LC/MS Calcd for [M+H].sup.+ 372.1, found 372.2
Example 12
##STR00489##
[0358]
N-[6-(6,7-Dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-2-
-phenyl-acetamide.
6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-ylamine
(95 mg, 0.25 mmol), Et.sub.3N (0.10 ml, 0.72 mmol), phenylacetyl
chloride (0.044 ml, 0.33 mmol), and THF (1.0 ml) were combined and
stirred at room temperature for 1 hr. Additional phenylacetyl
chloride (0.044 ml, 0.33 mmol) was added and the mixture heated to
reflux for 1-2 hrs. After cooling to room temperature, the reaction
mixture was diluted with 1:1 AcCN:H.sub.2O (1.0 ml) and the
resulting solids filtered, washed with 1:1 AcCN:H.sub.2O and dried
under high vacuum to give
N-[6-(6,7-dimethoxy-quinolin-4-yloxy)-5-fluoro-benzothiazol-2-yl]-2-pheny-
l-acetamide (72 mgs, 59%). .sup.1H-NMR (400 MHz, DMSO): 12.80 (s,
1H), 8.54 (d, 1H), 8.18 (d, 1H), 7.91 (d, 1H), 7.60 (s, 1H), 7.45
(s, 1H), 7.34 (m, 4H), 7.28 (m, 1H), 6.60 (d, 1H), 3.98 (s, 3H),
3.96 (s, 3H), 3.86 (s, 2H). LC/MS Calcd for [M+H].sup.+ 490.1,
found 490.0.
Example 13
##STR00490##
[0360]
5-[4-(4-Amino-2-fluoro-phenoxy)-6-methoxy-quinazolin-7-yloxymethyl]-
-hexahydro-cyclopenta[c]pyrrole-2-carboxylic acid benzyl ester.
4-Amino-2-fluoro-phenol (1.53 g, 12.0 mmol) was dissolved in dry
DMF (30 ml) to which was added 60% NaH (774 mg, 19.3 mmol). After
the mixture was stirred at room temperature for several minutes, a
suspension of
5-(4-chloro-6-methoxy-quinazolin-7-yloxymethyl)-hexahydro-cyclopenta[c]py-
rrole-2-carboxylic acid benzyl ester (4.70 g, 6.7 mmol) in dry DMF
(40 ml) was added. The reaction mixture was stirred at room
temperature for 1-2 hrs, then diluted with EtOAc and washed with
sat'd NaHCO.sub.3 (3.times.), H.sub.2O (1.times.), sat'd NaCl
(1.times.), dried (Na.sub.2SO.sub.4), and concentrated in vacuo to
give crude
5-[4-(4-amino-2-fluoro-phenoxy)-6-methoxy-quinazolin-7-yloxymethyl]-hexah-
ydro-cyclopenta[c]pyrrole-2-carboxylic acid benzyl ester (5.6 g,
100%) which was used in the next reaction without further
purification. .sup.1H-NMR (400 MHz, DMSO): 8.50 (s, 1H), 7.48 (s,
1H), 7.34 (m, 5H), 7.28 (m, 1H), 7.02 (t, 1H), 6.48 (dd, 1H), 6.40
(dd, 1H), 5.40 (br s, 2H), 5.05 (s, 2H), 4.16 (d, 2H), 3.92 (s,
3H), 3.48 (m, 2H), 3.30 (m, 2H), 2.65 (m, 2H), 2.52 (m, 1H), 2.10
(m, 2H), 1.30 (m, 2H). LC/MS Calcd for [M+H].sup.+ 559.2, found
559.4.
Example 14
##STR00491##
[0362]
5-{4-[2-Fluoro-4-(3-phenylacetyl-thioureido)-phenoxy]-6-methoxy-qui-
nazolin-7-yloxymethyl}-hexahydro-cyclopenta[c]pyrrole-2-carboxylic
acid benzyl ester. Phenylacetyl chloride (2.65 ml, 20.0 mmol) and
AgSCN (4.92 g, 29.6 mmol) were combined in dry toluene (50 ml) and
heated to reflux for 2 hrs. The reaction mixture was allowed to
cool to room temperature, the solids were filtered through celite
and the filtrate concentrated in vacuo. The resulting oil was
combined with
5-[4-(4-amino-2-fluoro-phenoxy)-6-methoxy-quinazolin-7-yloxymethyl]-hexah-
ydro-cyclopenta[c]pyrrole-2-carboxylic acid benzyl ester (5.6 g, 10
mmol) in 1:1 EtOH:toluene (100 ml) and the mixture stirred at room
temperature for 1-2 hrs. The reaction mixture was diluted with
EtOAc and washed with sat'd NaHCO.sub.3 (3.times.), H.sub.2O
(1.times.), sat'd NaCl (1.times.), dried (Na.sub.2SO.sub.4), and
concentrated in vacuo. The resulting oil was purified by flash
chromatography (3:1 EtOAc:hexanes) to give
5-{4-[2-fluoro-4-(3-phenylacetyl-thioureido)-phenoxy]-6-methoxy-quinazoli-
n-7-yloxymethyl}-hexahydrocyclopenta[c]pyrrole-2-carboxylic acid
benzyl ester (3.61 g, 49%) as a dark brown foam. .sup.1H-NMR (400
MHz, DMSO): 12.44 (s, 1H), 11.80 (s, 1H), 8.54 (s, 1H), 7.90 (m,
1H), 7.53 (s, 1H), 7.48 (m, 2H), 7.38 (s, 1H), 7.34 (m, 7H), 7.28
(m, 3H), 5.05 (s, 2H), 4.16 (d, 2H), 3.94 (s, 3H), 3.72 (s, 2H),
3.48 (m, 2H), 3.30 (m, 2H), 2.65 (m, 2H), 2.52 (m, 1H), 2.10 (m,
2H), 1.30 (m, 2H). LC/MS Calcd for [M+H].sup.+ 736.2, found
736.0.
Example 15
##STR00492##
[0364]
1-{3-Fluoro-4-[6-methoxy-7-(octahydro-cyclopenta[c]pyrrol-5-ylmetho-
xy)-quinazolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea,
dihydrobromide salt.
5-{4-[2-Fluoro-4-(3-phenylacetyl-thioureido)-phenoxy]-6-methoxy-qui-
nazolin-7-yloxymethyl}-hexahydro-cyclopenta[c]pyrrole-2-carboxylic
acid benzyl ester (3.3 g, 4.5 mmol) was dissolved in AcOH (70 ml)
to which was added 33% HBr in AcOH (12 ml). The reaction mixture
was stirred at room temperature for 1 hr, diluted with Et.sub.2O
(1000 ml) and the resulting solids filtered, washed with Et.sub.2O,
and dried under high vacuum to give the
1-{3-fluoro-4-[6-methoxy-7-(octahydro-cyclopenta[c]pyrrol-5-ylme-
thoxy)-quinazolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea,
dihydrobromide salt (3.4 g, 100%). .sup.1H-NMR (400 MHz, DMSO):
12.42 (s, 1H), 11.80 (s, 1H), 8.84 (br s, 2H), 8.64 (s, 1H), 7.92
(m, 1H), 7.59 (s, 1H), 7.49 (m, 2H), 7.41 (s, 1H), 7.33 (m, 4H),
7.27 (m, 1H), 4.17 (d, 2H), 3.95 (s, 3H), 3.73 (s, 2H), 3.17 (m,
2H), 3.10 (m, 2H), 2.83 (m, 2H), 2.45 (m, 1H), 2.15 (m, 2H), 1.30
(m, 2H). LC/MS Calcd for [M+H].sup.+ 602.2, found 602.1.
Example 16
##STR00493##
[0366]
1-{3-Fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol--
5-ylmethoxy)-quinazolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea.
1-{3-Fluoro-4-[6-methoxy-7-(octahydro-cyclopenta[c]pyrrol-5-ylmethoxy)-qu-
inazolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea, dihydrobromide
salt (3.4 g, 4.5 mmol) was dissolved in a combination of AcCN (100
ml), H.sub.2O (30 ml), and AcOH (2.45 ml). Formaldehyde (37% in
H.sub.2O, 855 ml, 10.5 mmol) was added and the mixture cooled in an
ice bath. Na(OAC).sub.3BH (2.99 g, 14.1 mmol) was added and the
reaction mixture was stirred at 0 C for 1 hr, followed by stirring
at room temperature for 2 hrs. The reaction mixture was neutralized
with the addition of sat'd NaHCO.sub.3 and then concentrated in
vacuo. The resulting aqueous mixture was extracted with
CH.sub.2Cl.sub.2 (3.times.). The combined extractions were washed
with sat'd NaHCO.sub.3 (1.times.), sat'd NaCl (1.times.), dried
(Na.sub.2SO.sub.4), and concentrated in vacuo. The resulting
residue was purified by flash chromatography (100% EtOAc, followed
by 4% Et.sub.3N in EtOAc) to give the free base of
1-{3-fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-ylme-
thoxy)-quinazolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea (1.13 g,
40%). The free base was converted to the HCl salt by dissolving the
free base in a mixture of 1:1 AcCN:H.sub.2O containing 2-3
equivalents of 1 N HCl and lyophilizing to give the HCl salt of
1-{3-fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-ylme-
thoxy)-quinazolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea as a
white solid. .sup.1H-NMR (400 MHz, DMSO): 12.44 (s, 1H), 11.83 (s,
1H), 10.24 (br s, 1H), 8.59 (s, 1H), 7.93 (m, 1H), 7.59 (s, 1H),
7.50 (m, 2H), 7.42 (s, 1H), 7.36 (m, 4H), 7.30 (m, 1H), 4.20 (m,
2H), 3.95 (s, 3H), 3.73 (s, 2H), 3.39 (m, 2H), 3.06 (m, 2H),
2.95-2.77 (m, 5H), 2.35 (m, 1H), 2.15 (m, 2H), 1.45 (m, 2H). LC/MS
Calcd for [M+H].sup.+ 616.2, found 616.2. Alternatively, the free
base was converted to the acetate salt by dissolving the free base
in a mixture of MeOH and CH.sub.2Cl.sub.2 to which was added 3
equivalents of acetic acid. The resulting mixture was concentrated
in vacuo and the resulting residue lyophilized from 1:1
AcCN:H.sub.2O to give the acetate salt of
1-{3-fluoro-4-[6-methoxy-7-(2-methyl-octahydro-cyclopenta[c]pyrrol-5-ylme-
thoxy)-quinazolin-4-yloxy]-phenyl}-3-phenylacetyl-thiourea as a
white solid. .sup.1H-NMR (400 MHz, CDCl.sub.3): d 12.45 (s, 1H),
8.65 (s, 1H), 7.98 (dd, 1H), 7.50 (s, 1H), 7.40 (m, 4H), 7.29 (m,
4H), 4.17 (d, 2H), 4.05 (s, 3H), 3.75 (s, 2H), 2.93 (m, 2H), 2.80
(m, 2H), 2.72 (m, 2H), 2.53 (s, 3H), 2.47 (m, 1H), 2.25 (m, 2H),
2.02 (s, 3H), 1.35 (m, 2H). LC/MS Calcd for [M+H].sup.+ 616.2,
found 616.2.
Example 17
##STR00494##
[0368]
(6,7-Dimethoxy-quinazolin-4-yl)-(2-fluoro-4-nitro-phenyl)-amine. A
mixture of 4-chloro-6,7-dimethoxy-quinazoline (548 mg, 2.4 mmol),
2-fluoro-4-nitro-phenylamine (392 mg, 2.5 mmol), AcCN (10 ml), and
conc'd HCl (0.050 ml) was heated to reflux for several hrs. After
the reaction mixture was allowed to cool to room temperature, the
resulting solids were filtered, washed with AcCN and air-dried to
give
(6,7-dimethoxy-quinazolin-4-yl)-(2-fluoro-4-nitro-phenyl)-amine
(673 mgs, 80%). .sup.1H-NMR (400 MHz, DMSO): 12.18 (br s, 1H), 8.91
(s, 1H), 8.45 (s, 1H), 8.36 (dd, 1H), 8.24 (dd, 1H), 7.91 (dd, 1H),
7.44 (s, 1H), 4.04 (s, 3H), 4.02 (s, 3H). LC/MS Calcd for
[M+H].sup.+ 345.1, found 345.4.
Example 18
##STR00495##
[0370]
N'-(6,7-Dimethoxy-quinazolin-4-yl)-2-fluoro-benzene-1,4-diamine.
(6,7-Dimethoxy-quinazolin-4-yl)-(2-fluoro-4-nitro-phenyl)-amine
(673 mg, 1.95 mmol) was dissolved in a combination of DMF (20 ml)
and MeOH (20 ml), to which was added 10% Pd/C (227 mg). The mixture
was shaken under an atmosphere of H.sub.2 on a Parr hydrogenator at
40 psi for 3 hrs. The reaction mixture was filtered through celite
and the filtrate concentrated in vacuo. The resulting residue was
triturated in EtOAc/Et.sub.2O. The resulting solids were filtered,
washed with Et.sub.2O, and dried under vacuum to give
N.sup.1-(6,7-dimethoxy-quinazolin-4-yl)-2-fluoro-benzene-1,4-diamine
(398 mg, 65%) which was used in the next reaction without further
purification. .sup.1H-NMR (400 MHz, DMSO): 10.80 (br s, 1H), 10.30
(br s, 1H), 8.63 (s, 1H), 8.15 (s, 1H), 7.33 (s, 1H), 7.15 (m, 1H),
6.45 (m, 1H), 3.96 (s, 6H). LC/MS Calcd for [M+H].sup.+ 315.1,
found 315.4.
Example 19
##STR00496##
[0372]
1-[4-(6,7-Dimethoxy-quinazolin-4-ylamino)-3-fluoro-phenyl]-3-phenyl-
acetyl-thiourea. Phenylacetyl chloride (0.18 ml, 1.4 mmol) and
AgSCN (338 mg, 2.0 mmol) were combined in dry toluene (5 ml) and
heated to reflux for 2 hrs. The reaction mixture was allowed to
cool to room temperature, the solids were filtered through celite
and the filtrate concentrated in vacuo. The resulting oil was
combined with
N.sup.1-(6,7-Dimethoxy-quinazolin-4-yl)-2-fluoro-benzene-1,4-diamine
(398 mg, 1.3 mmol) in 1:1:2 EtOH:toluene:MeOH (30 ml) and the
mixture stirred at room temperature overnight. The resulting solids
were filtered and washed with toluene, followed by hexanes. The
solids were dissolved/suspended in a mixture of EtOAc/MeOH.
Insoluble material was filtered and the filtrate concentrated in
vacuo. The resulting solids were once again dissolved/suspended in
a mixture of EtOAc/MeOH. In soluble material was filtered and the
filtrate concentrated in vacuo to give
1-[4-(6,7-dimethoxy-quinazolin-4-ylamino)-3-fluoro-phenyl]-3-phenyla-
cetyl-thiourea (105 mg, 17%). .sup.1H-NMR (400 MHz, DMSO): 12.53
(s, 1H), 11.86 (s, 1H), 11.44 (br s, 1H), 8.81 (s, 1H), 8.25 (s,
1H), 7.94 (dd, 1H), 7.54 (m, 2H), 7.16 (m, 5H), 7.10 (m, 1H), 4.02
(s, 6H), 3.84 (s, 2H). LC/MS Calcd for [M+H].sup.+ 492.1, found
492.4.
Example 20
##STR00497##
[0374] 6,7-Dimethoxy-4-(5-nitro-pyridin-2-yloxy)-quinoline. To a
round bottom flask equipped with a magnetic stir bar was added
6,7-dimethoxy-1H-quinolin-4-one (1.8 g, 8.77 mmol, 1.0 eq.),
anhydrous acetonitrile (90 mL) and Cs.sub.2CO.sub.3 (3.13 g, 9.65
mmole, 1.1 eq.). The reaction mixture was stirred at room
temperature for 5 minutes. Then, 2-C.sub.1-5-nitropyridine (1.53 g,
9.65 mmol, 1.1 eq.) was added. The reaction mixture was stirred at
room temperature for 16 hours. The solids were then filtered off
and the filtrate was concentrated via rotary evaporation. The
resulting material was taken up in EtOAc, and again the solids were
filtered off. The EtOAc filtrate was concentrated. Purification was
done on Biotage with solvent system EtOAc 100%. The collected pure
fractions were concentrated and dried on high vacuum overnight to
give 6,7-dimethoxy-4-(5-nitro-pyridin-2-yloxy)-quinoline as a
yellow foam solid (0.902 g, 31.4% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3): 9.08 (d, 1H), 8.74 (d, 1H), 8.60 (dd, 1H), 7.49 (s,
1H), 7.26 (d, 1H), 7.16 (s, 1H), 7.07 (d, 1H), 4.06 (s, 3H), 3.95
(s, 3H); MS (EI) for C.sub.16H.sub.13N.sub.3O.sub.5: 328
(M+H.sup.+).
Example 21
##STR00498##
[0376] 6-(6,7-Dimethoxy-quinolin-4-yloxy)-pyridin-3-ylamine. To a
round bottom flask equipped with a magnetic stir bar was added
6,7-dimethoxy-4-(5-nitro-pyridin-2-yloxy)-quinoline (0.46 g, 1.41
mmol, 1.0 eq.), and THF (10 mL), MeOH (4 mL), DMF (2 mL), and TEA
(2 mL). The 6,7-Dimethoxy-4-(5-nitro-pyridin-2-yloxy)-quinoline was
dissolved completely in the above solution mixture, and was flushed
with nitrogen for at least 5 minutes. The Pd/C (10% by weight)
(0.090 g, 20% by weight) was then added. A balloon filled with
H.sub.2 was connected to the flask after the nitrogen was vacuumed
out. The reaction mixture was stirred at room temperature for 4
hours. The palladium was filtered out through Celite, and the
filtrated was collected and concentrated via rotary evaporation.
The resulting oil-like product was taken up into 5 mL of water and
1 mL of acetonitrile and lyophilized to yield
6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-ylamine as a light
brown solid (0.411 g, 98.1%). .sup.1H NMR (400 MHz, CDCl.sub.3):
8.54 (d, 1H), 7.85 (d, 1H), 7.53 (s, 1H), 7.41 (s, 1H), 7.18 (dd,
1H), 6.96 (d, 1H), 6.61 (d, 1H), 4.05 (s, 3H), 4.03 (s, 3H), 3.73
(s, 2H); MS (EI) for C.sub.16H.sub.15N.sub.3O.sub.3: 298
(M+H.sup.+).
Example 22
##STR00499##
[0378]
1-[6-(6,7-Dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-3-phenylacetyl--
thiourea. To a round bottom flask equipped with a magnetic stir bar
was added 6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-ylamine (85
mg, 0.0285 mmol, 1.0 eq.), and Phenyl-acetyl isothiocyanate (256
mg, 1.44 mmol, 5.0 eq.) dissolved in EtOAc/MeOH 50:50 (2 mL). The
reaction mixture was stirred at room temperature for 12 hours, and
the solvent was evaporated via rotary evaporation. Purification was
done on Biotage with solvent system 95% EtOAc, 4% TEA and 1% MeOH.
The combined pure fractions were concentrated and dried under
vacuum overnight to yield
1-[6-(6,7-dimethoxy-quinolin-4-yloxy)-pyridin-3-yl]-3-phenylacetyl-thiour-
ea as a light yellow solid (40.4 mg, 29.7%). .sup.1H NMR (400 MHz,
CDCl.sub.3): 8.65 (d, 1H), 8.33 (d, 1H), 8.27 (dd, 1H), 7.35 (m,
7H), 7.15 (d, 1H), 6.92 (d, 1H), 4.05 (s, 3H), 3.99 (s, 3H), 3.76
(s, 2H); MS (EI) for C.sub.25H.sub.22N.sub.4O.sub.4S: 475
(M+H.sup.+).
Example 23
##STR00500##
[0380]
N-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-N'-phenethyl-
-oxalamide. To a solution of
4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenylamine (263 mg,
0.83 mmol) and Et.sub.3N (0.223 ml, 1.67 mmol) in CH.sub.2Cl.sub.2
(10 mL) was added dropwise a solution of ethyl oxalyl chloride in
CH.sub.2Cl.sub.2 (1 mL). The stirring was continued for 0.5 h at
rt. The reaction mixture was then washed with aqueous saturated
NaHCO.sub.3 and dried over NaSO.sub.4. Removal of the solvent gave
the crude oxamate, which was treated with neat phenethylamine (1.0
g, 8.3 mmol) at 80.degree. C. for 3 h. Purification by flash column
chromatography (hexanes:EtOAc=1:3) gave
N-[4-(6,7-dimethoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-N'-phenethyl-oxala-
mide (310 mg, 76%). .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 9.35
(br s, 1H), 8.70 (d, J=6.3 Hz, 1H), 7.83 (dd, J=11.9, 2.5 Hz, 1H),
7.60-7.54 (m, 2H), 7.43 (s, 1H), 7.38-7.32 (m, 3H), 7.30-7.20 (m,
4H), 6.41 (d, J=5.3 Hz, 1H), 4.07 (s, 3H), 4.05 (s, 3H), 3.67 (dt,
J=7.0, 7.0 Hz, 2H), 2.92 (t, J=7.2 Hz, 2H). LC-MS: 490
[M+H].sup.+
Example 24
##STR00501##
[0382]
N-{3-Fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinoli-
n-4-yloxy]-phenyl}-N'-phenethyl-oxalamide. To a flask containing
7-benzyloxy-4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinoline (850
mg, 2.0 mmol) was added 20 mL of 30% HBr in AcOH. The resulted
solution was stirred for 4 h at rt; at this time, a large amount of
precipitate formed. The crude product was filtered, washed with
Et.sub.2O and dried in air, giving
4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-7-hydroxyquinoline (609 mg,
92% yield).
[0383] To a solution of the
4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-7-hydroxyquinoline (609 mg,
1.8 mmol) in DMF (9 mL) was added K.sub.2CO.sub.3 (1.24 g, 9.0
mmol) and N-Boc-4-piperidinemethanol mesylate (732 mg, 2.5 mmol).
The mixture was then stirred at 80.degree. C. for 2.5 h. After it
was cooled to rt, the mixture was loaded directly to a Biotage
column, and eluted with solvents (hexanes:EtOAc=1:3). The resulting
product,
4-[4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-yloxymethyl]-piperid-
ine-1-carboxylic acid tert-butyl ester, was obtained as a solid
(556 mg, 56%).
[0384] To a solution of
4-[4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-quinolin-7-yloxymethyl]-piperid-
ine-1-carboxylic acid tert-butyl ester (305 mg, 0.58 mmol) in
CH.sub.2Cl.sub.2 (1 mL) was added 0.4 mL of TFA. The reaction
mixture was stirred for 1.5 h and the solvents were removed under
reduced pressure. The crude product was treated with
NaBH(OAc).sub.3 (381 mg, 1.80 mmol) and formaldehyde (0.5 mL, 37%
in H.sub.2O). The stirring was continued for 12 h. The reaction was
quenched with sat. aqueous NaHCO.sub.3. 15% NaOH was added until
PH=14. The product was extracted with EtOAc. Removal of the solvent
in vacuo gave the crude product,
4-(2-fluoro-4-nitro-phenoxy)-6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-
-quinoline, (240 mg, 93%), which was used directly in the next
reaction.
[0385] To a solution of
4-(2-Fluoro-4-nitro-phenoxy)-6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-
-quinoline (240 mg, 0.54 mmol) in EtOH (20 mL) was added 10% Pd/C
(50 mg). The mixture was then hydrogenated on a Parr hydrogenator
(40 psi) for 10 h. AcOH was added to dissolve the intermediate
(mostly the hydroxylamine) and the hydrogenation was continued for
additional 12 h. LC-MS was used to monitor the reaction progress.
The solvents were removed under reduced pressure and the resulting
crude product of
3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy-
]-phenylamine (about 220 mg) was used directly in the next
reaction.
[0386] To a 0.degree. C. solution of
3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yloxy-
]-phenylamine (66 mg, 0.13 mmol) and Et.sub.3N (0.34 mL) in
CH.sub.2Cl.sub.2 (6 mL) was added slowly ethyl oxalyl chloride (98
mg). The reaction mixture was stirred at rt for 30 min, then
diluted with CH.sub.2Cl.sub.2 and washed with sat. aqueous
NaHCO.sub.3. After dried over MgSO.sub.4 and concentrated, the
crude ethyl oxamate was reacted with phenethylamine (80 mg, 0.64
mmol) at 80.degree. C. for 2 h. Purification by HPLC gave product,
N-{3-fluoro-4-[6-methoxy-7-(1-methyl-piperidin-4-ylmethoxy)-quinolin-4-yl-
oxy]-phenyl}-N'-phenethyl-oxalamide (52 mg, 68% yield). .sup.1H NMR
(400 MHz) .delta. 9.38 (br s, 1H), 8.48 (d, J=5.2 Hz, 1H), 7.83
(dd, J=11.7, 2.6 Hz, 1H), 7.59 (t, J=6.2 Hz, 1H), 7.55 (s, 1H),
7.40-7.20 (8H), 6.39 (d, J=5.3 Hz, 1H), 4.06 (d, J=6.6 Hz, 2H),
4.04 (s, 3H), 3.67 (q, J=6.8 Hz, 2H), 2.98 (br d, J=11.5 Hz, 2H),
2.92 (t, J=7.0 Hz, 2H), 2.34 (s, 3H), 2.10-1.80 (m, 5H), 1.60-1.54
(m, 2H).
Example 25
##STR00502##
[0388] 1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid.
The title compound was prepared based on a modified procedure of
Shih and Rankin [Synthetic Communications, 1996, 26(4), 833-836]:
To a mixture of cyclopropane-1,1-dicarboxylic acid (21.2 g, 0.163
mol, 1.0 eq.) in anhydrous THF (200 mL) under nitrogen was added
dropwise triethylamine (16.49 g, 0.163 mol, 1.0 eq.) with stirring
for 30 minutes at 0.degree. C., followed by the addition of thionyl
chloride (19.39 g, 0.163 mol, 1.0 eq.) with stirring for another 30
minutes at 0.degree. C. To the resulting mixture under nitrogen was
added dropwise a solution of 4-fluoroaniline (19.92 g, 0.179 mol,
1.1 eq.) in anhydrous THF (100 mL) with stirring for 1.5 hours at
0.degree. C. The reaction mixture was diluted with ethyl acetate
and washed with 1N NaOH. The layers were separated, and the ethyl
acetate layer was concentrated in vacuo to give a brownish solid.
The brownish solid was washed with small amount of cold ethyl
acetate, filtered and dried under vacuum to yield
1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid as a white
solid (23.71 g, 65.18%). .sup.1H NMR (400 MHz, CD.sub.3OD):
7.57-7.53 (m, 2H), 7.05-7.00 (m, 2H) 1.46-1.43 (m, 2H), 1.40-1.37
(m, 2H).
Example 26
##STR00503##
[0390] 1-(4-Fluoro-phenylcarbamoyl)-cyclobutanecarboxylic acid. To
a mixture of cyclobutane-1,1-dicarboxylic acid (10.0 g, 69.4 mmol,
1.0 eq.) in anhydrous THF (100 mL) under nitrogen was added
dropwise triethylamine (7.02 g, 69.4 mmol, 1.0 eq.) with stirring
for 30 minutes at 0.degree. C., followed by the addition of thionyl
chloride (8.25 g, 69.4 mmol, 1.0 eq.) with stirring for another 30
minutes at 0.degree. C. To the resulting mixture under nitrogen was
added dropwise a solution of 4-fluoroaniline (8.48 g, 76.3 mmol,
1.1 eq.) in anhydrous THF (50 mL) with stirring for 1.5 hours at
0.degree. C. The reaction mixture was diluted with ethyl acetate
and extracted with 2N NaOH. The aqueous phase was titrated with 2N
HCl to pH 1-2 and then extracted with ethyl acetate. The organic
phase was dried with sodium sulfate and concentrated in vacuo to
give 1-(4-fluoro-phenylcarbamoyl)-cyclobutanecarboxylic acid as a
light pink solid (5.75 g, 34.9%). .sup.1H NMR (400 MHz, CDCl.sub.3
w/5 drop CD.sub.3OD): 7.53-7.48 (m, 2H), 7.06-7.00 (m, 2H),
2.81-2.63 (m, 4H), 2.14-2.02 (m, 2H).
Example 27
##STR00504##
[0392] 1-Benzylcarbamoyl-cyclopropanecarboxylic acid. The title
compound was prepared based on a modified procedure of Shih and
Rankin [Synthetic Communications, 1996, 26(4), 833-836]: To a
mixture of cyclopropane-1,1-dicarboxylic acid (5.0 g, 38.4 mmol,
1.0 eq.) in anhydrous THF (50 mL) under nitrogen was added dropwise
triethylamine (3.89 g, 38.4 mmol, 1.0 eq.) with stirring for 30
minutes at 0.degree. C., followed by the addition of thionyl
chloride (4.57 g, 38.4 mmol, 1.0 eq.) with stirring for another 30
minutes at 0.degree. C. To the resulting mixture under nitrogen was
added dropwise a solution of benzylamine 5 (4.53 g, 42.3 mmol, 1.1
eq.) in anhydrous THF (25 mL) with stirring for 1.5 hours at
0.degree. C. The reaction mixture was diluted with ethyl acetate
and extracted with 2N NaOH (to pH 10). The aqueous phase was
titrated with 2N HCl to pH 1-2 and then extracted with ethyl
acetate. The organic phase was dried with sodium sulfate and
concentrated in vacuo to give
1-Benzylcarbamoyl-cyclopropanecarboxylic acid as a white solid
(4.39 g, 52.15%). .sup.1H NMR (400 MHz, CDCl.sub.3): 8.44 (br s,
1H), 7.37-7.33 (m, 2H), 7.32-7.26 (m, 3H), 1.82-1.70 (m, 4H).
Example 28
##STR00505##
[0394] 1-Phenylcarbamoyl-cyclopropanecarboxylic acid. To a mixture
of cyclopropane-1,1-dicarboxylic acid (5.29 g, 40.7 mmol, 1.0 eq.)
in anhydrous THF (50 mL) under nitrogen was added dropwise
triethylamine (4.12 g, 40.7 mmol, 1.0 eq.) with stirring for 30
minutes at 0.degree. C., followed by the addition of thionyl
chloride (4.84 g, 40.7 mmol, 1.0 eq.) with stirring for another 30
minutes at 0.degree. C. To the resulting mixture under nitrogen was
added dropwise a solution of phenylamine 9 (4.17 g, 44.8 mmol, 1.1
eq.) in anhydrous THF (25 mL) with stirring for 1.5 hours at
0.degree. C. The reaction mixture was diluted with ethyl acetate
and extracted with 2N NaOH (to pH>10). The aqueous phase was
titrated with 2N HCl to pH 1-2 and then extracted with ethyl
acetate. The organic phase was dried with sodium sulfate and
concentrated in vacuo to give
1-phenylcarbamoyl-cyclopropanecarboxylic acid as a white solid
(5.08 g, 60.8%). .sup.1H NMR (400 MHz, CDCl.sub.3): 10.50 (br s,
1H), 7.56-7.54 (m, 2H), 7.35-7.31 (m, 2H), 7.15-7.10 (m, 1H),
1.94-1.91 (m, 2H), 1.82-1.79 (m, 2H).
Example 29
##STR00506##
[0396] 7-Benzyloxy-4-chloro-6-methoxy-quinoline. Dry DMF (8.0 ml,
103 mmol) was dissolved in dry CHCl.sub.3 (40 ml) and cooled in an
ice bath. Oxalyl chloride (9.0 ml, 105 mmol) in CH.sub.2Cl.sub.2
(10 ml) was added dropwise with stirring at 0.degree. C. When the
bubbling had ceased, this solution was added slowly to an ice-cold
solution of 7-benzyloxy-6-methoxy-3H-quinazolin-4-one (10.0 g, 35.4
mmol) in dry CHCl.sub.3 (60 ml) and the mixture was then heated to
reflux for 2-3 hrs. After cooling to room temperature, H.sub.2O
(100 ml) was added and the phases were separated. The aqueous phase
was further extracted with CHCl.sub.3 (2.times.). The combined
CHCl.sub.3 extractions were washed with sat'd NaCl (1.times.),
dried (Na.sub.2SO.sub.4) and concentrated in vacuo. The resulting
residue was purified by flash chromatography (1:1 hexanes:EtOAc,
followed by 100% EtOAc) to give
7-benzyloxy-4-chloro-6-methoxy-quinoline (5.11 g, 48%). LC/MS Calcd
for [M+H].sup.+ 301.1, found 301.1.
Example 30
##STR00507##
[0398] Cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinolin-4-yloxy)-phenyl]-amide(4-fluoro-
-phenyl)-amide. To a solution of cyclopropane-1,1-dicarboxylic acid
[4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
(4-fluoro-phenyl)-amide (1.18 g, 2.0 mmol) in EtOH (20 mL) was
added 1,4-cyclohexadiene (2.0 mL, 20 mmol) and 10% Pd/C (300 mg).
The reaction mixture was then heated to reflux and the stirring was
continued for 2 h. It was cooled to room temperature, filtered
through celite and washed with MeOH. The MeOH solution was then
concentrated under reduced pressure. The residue was taken into
EtOAc (200 mL). The EtOAc solution was washed with water, and dried
over Na.sub.2SO.sub.4. Removal of the solvent under reduced
pressure gave 900 mg (89%) of the crude product (90% purity by
analytical HPLC), which was used in the next reaction without
further purification.
Example 31
##STR00508##
[0400]
N-(4-{[7-{[2-(Diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]ox-
y}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
To a mixture of cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinolin-4-yloxy)-phenyl]-amide(4-fluoro-
-phenyl)-amide (186 mg, 0.36 mmol) in CH.sub.2Cl.sub.2 (10 mL) was
added 2-(diethylamino)ethanol (63 mg, 0.54 mmol), and PPh.sub.3
(141 mg, 0.54 mmol). DIAD (109 mg, 0.54 mmol) was then added as a
CH.sub.2Cl.sub.2 (1 mL) solution. The resulted solution was stirred
at room temperature for 2 h and the solvent was removed under
reduced pressure. To the residue was added 1 N HCl (50 mL), and it
was washed with EtOAc (50 mL.times.2). The aqueous phase was
basified by adding 15% NaOH aqueous solution until pH=11-13, and
then extracted with ether (50 mL.times.2). The combined organic
layer was dried (MgSO.sub.4), and concentrated in vacuo. The
residue was purified on preparative HPLC to give
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinolin-4-yl]oxy}-3-f-
luorophenyl)-N'-(4-fluoro-phenyl)cyclopropane-1,1-dicarboxamide (74
mg, 34%) as a pale yellow solid. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 10.40 (br s, 1H), 10.02 (br s, 1H), 8.47 (d,
J=5.2 Hz, 1H), 7.91 (br d, J=13.9 Hz, 1H), 7.54-7.52 (m, 2H),
7.55-7.50 (m, 1H), 7.52 (s, 1H), 7.50-7.40 (m, 1H), 7.41 (s, 1H),
7.16 (br t, J=8.7 Hz, 2H), 6.41 (br d, J=4.7 Hz, 1H), 4.18 (t,
J=6.0 Hz, 2H), 3.94 (s, 3H), 2.87 (br t, J=6.3 Hz, 2H), 2.59 (q,
J=7.1 Hz, 4H), 1.47 (br s, 4H), 1.00 (t, J=7.0 Hz, 6H).
Example 32
##STR00509##
[0402] 1-(4-Benzyloxy-3-methoxyphenyl)ethanone. A solution of
4-hydroxy-3-methoxyacetophenone (40 g, 240 mmol), benzyl bromide
(31.4 mL, 260 mmol) and potassium carbonate (99.6 g, 360 mmol) in
DMF (800 mL) was heated to 40.degree. C. overnight. The solution
was cooled to room temperature, poured over ice and the resultant
solid was filtered. This material was washed with water and dried
to give 1-(4-benzyloxy-3-methoxyphenyl)ethanone (61 g, 99%).
[0403] 1-(4-Benzyloxy-5-methoxy-2-nitrophenyl)ethanone. A stirred
solution of 1-(4-benzyloxy-3-methoxyphenyl)ethanone (51.3 g, 200
mmol) in dichloromethane (750 mL) was cooled to 0.degree. C. Nitric
acid (90%, 14 mL, 300 mmol) was added dropwise to the cooled
solution over 20 min. Sulfuric acid (96.2%, 16.3 mL, 300 mmol) was
then added dropwise over 40 min at 0.degree. C. Additional nitric
acid (9.4 mL, 200 mmol) was added dropwise over 20 min. The
reaction mixture was washed with water (3.times.200 mL), and
saturated sodium bicarbonate (4.times.200 mL, or until neutral).
The organic layer was dried over Na.sub.2SO.sub.4 and concentrated.
The crude mixture was recrystallized from DMF to give
1-(4-benzyloxy-5-methoxy-2-nitrophenyl)ethanone (36 g, 60%).
.sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 7.65 (s, 1H), 7.45-7.33
(m, 5H), 6.74 (s, 1H), 5.21 (s, 2H), 3.97 (s, 3H), 2.49 (s,
3H).
[0404] 1-(2-Amino-4-benzyloxy-5-methoxyphenyl)ethanone. A mixture
of iron powder (27 g, 0.48 g atoms), ammonium formate (31 g, 500
mmol), 1-(4-benzyloxy-5-methoxy-2-nitrophenyl)ethanone (36 g, 120
mmol), toluene (500 mL) and water (500 mL) was heated to reflux
overnight. The mixture was filtered through celite and washed with
ethyl acetate. The combined organic layers were washed with water
and brine. The organic layer was dried over Na.sub.2SO.sub.4 and
concentrated to afford
1-(2-amino-4-benzyloxy-5-methoxyphenyl)ethanone (29.3 g, 90%).
.sup.1H NMR (CDCl.sub.3): .delta. 7.41-7.30 (m, 5H), 7.13 (s, 1H),
6.16 (br s, 2H), 6.10 (s, 1H), 5.13 (s, 2H), 3.83 (s, 3H), 2.51 (s,
3H). LC/MS (M+H=272).
[0405] 7-Benzyloxy-6-methoxyquinolin-4-ol. Sodium ethoxide (74.8 g,
1.1 mol) was added to a solution of
1-(2-amino-4-benzyloxy-5-methoxyphenyl)ethanone (29.3 g, 108 mmol)
in DME (700 mL) and stirred for 30 min. Ethyl formate (44 mL, 540
mmol) was added and the mixture was stirred overnight (in case of
incomplete reaction, additional sodium ethoxide can be added and
the reaction monitored by LC/MS). After the reaction was complete,
the mixture was diluted with water (40 mL) and acidified to neutral
pH with 1M HCl. The solid was filtered, washed with water and dried
to afford 7-benzyloxy-6-methoxyquinolin-4-ol (22 g, 72%). .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 10.7 (br s, 1H), 7.70 (s, 1H),
7.49-7.46 (t, 1H), 7.43-7.41 (br d, 2H), 7.37-7.33 (t, 2H),
7.30-7.28 (d, 1H), 6.84 (s, 1H), 6.21-6.19 (d, 1H), 5.21 (s, 2H),
3.96 (s, 3H). LC/MS (M+H=282).
[0406] 7-Benzyloxy-4-chloro-6-methoxyquinoline. Phosphorus
oxychloride (300 mL) was added to
7-benzyloxy-6-methoxyquinolin-4-ol (40 g, 140 mmol) and the mixture
heated to reflux for 2 h. The mixture was carefully poured into a
mixture of ice and sodium carbonate. The solution was adjusted to
pH 8 with the addition of solid sodium bicarbonate and stirred at
room temperature overnight. The solid was filtered and washed with
water and dried to give 7-benzyloxy-4-chloro-6-methoxyquinoline as
a pale brown solid (40.2 g, 95%). .sup.1H NMR (400 MHz,
d.sub.6-DMSO): .delta. 8.61 (s, 1H), 7.57-7.37 (m, 8H), 5.32 (s,
2H), 3.98 (s, 3H); .sup.13C NMR (100 MHz, d.sub.6-DMSO): .delta.
152.4, 151.5, 148.5, 146.2, 139.6, 137.0, 129.2, 128.8, 121.7,
120.4, 110.1, 101.9, 70.8, 56.5; IR (cm.sup.-1): 2359, 2341, 1506,
1456, 1435, 1252, 1227, 1146, 999, 845, 752, 698, 667; LC/MS
(M+H=300).
Example 33
##STR00510##
[0408] Trifluoromethanesulfonic acid
7-benzyloxy-6-methoxy-quinolin-4-yl ester. To a dry 2 L RBF
containing 7-benzyloxy-6-methoxyquinolin-4-ol (75.3 g, 267 mmol)
was added DCM (1 L), 4-dimethylaminopyridine (3.28 g, 26.8 mmol)
and 2,6-lutidine (62 mL, 534 mmol). The mixture was cooled to
-20.degree. C. by controlled addition of dry ice to an acetone
bath. Trifluoromethanesulfonyl chloride (37 mL, 350 mmol) was added
dropwise to the cooled solution with magnetic stirring over 25
minutes. After addition was complete, the mixture was stirred in
bath for 20 minutes, then at room temperature for 3 hours. LCMS
indicated reaction completion. The reaction mixture was
concentrated in vacuo and placed under high vacuum to remove
residual 2,6-lutidine. To the resulting brown solids was added
methanol (3.5 L). The resulting slurry was stirred with mechanical
stirrer for 30 min before adding water (1.5 L). The solids were
isolated by filtration, followed by a water wash. The resulting
solid was dried under high vacuum overnight yielding
trifluoromethanesulfonic acid 7-benzyloxy-6-methoxy-quinolin-4-yl
ester as a light brown solid (92.2 g, 83.8%). .sup.1H NMR (400 MHz,
DMSO, d.sub.6): .delta. 8.82 (d, 1H), 7.67 (s, 1H), 7.59 (d, 1H),
7.54-7.52 (m, 2H), 7.46-7.42 (m, 2H), 7.39-7.36 (m, 1H), 7.23 (s,
1H), 5.35 (s, 2H), 3.97 (s, 3H). LC/MS: M+H=414.
Example 34
##STR00511##
[0410] Trifluoromethanesulfonic acid 6,7-dimethoxyquinolin-4-yl
ester from 6,7-Dimethoxy-quinolin-4-ol. To a dry 1 L RBF containing
6,7-dimethoxy-quinolin-4-ol (20.9 g, 102 mmol), which can be
prepared according to the procedure of Riegel, B. (J. Amer. Chem.
Soc. 1946, 68, 1264), was added DCM (500 mL),
4-dimethylaminopyridine (1.24 g, 10 mmol) and 2,6-lutidine (24 mL,
204 mmol). The mixture was vigorously stirred at RT.
Trifluoromethanesulfonyl chloride (14 mL, 132 mmol) was added
dropwise to the solution. After addition was complete, the mixture
was stirred ice bath for 2 to 3 hrs. On LC/MS indicating the
reaction completion, the reaction mixture was concentrated in vacuo
and placed under high vacuum to remove residual 2,6-lutidine. To
the resulting brown solids was added methanol (250 mL). The
resulting slurry was stirred for 30 min before adding water (1 L).
The solids were isolated by filtration, followed by a water wash.
The resulting solid was dried under high vacuum overnight yielding
trifluoromethanesulfonic acid 6,7-dimethoxy-quinolin-4-yl ester as
a light brown solid (27 g, 80%). .sup.1H NMR (400 MHz, DMSO,
d.sub.6): .delta. 8.82 (d, 1H), 7.59 (m, 2H), 7.20 (s, 1H), 3.97
(d, 6H). LC/MS: M+H=338.
Example 35
##STR00512##
[0412] 1-Benzyloxy-2-fluoro-4-nitrobenzene. A solution of
2-fluoro-4-nitrophenol (50.0 g, 318 mmol), benzyl bromide (42 mL,
350 mmol) and potassium carbonate (66.0 g, 478 mmol) in DMF (200
mL) was heated to 40.degree. C. overnight. The solution was cooled
to room temperature, poured over ice and the resultant solid was
filtered. This material was washed with water and dried to give
1-benzyloxy-2-fluoro-4-nitrobenzene (75.0 g, 95%). .sup.1H NMR (400
MHz, d.sub.6-DMSO): .delta. 8.19-8.11 (m, 2H), 7.53-7.37 (m, 6H),
5.36 (s, 2H); .sup.13C NMR (100 MHz, d.sub.6-DMSO): .delta. 152.8,
152.4, 149.9, 140.9, 136.1, 129.3, 129.1, 128.7, 122.0, 115.2,
112.8, 112.6, 71.6; IR (cm.sup.-1): 1499, 1346, 1279, 1211, 1142,
1072, 986, 885, 812, 789, 754, 742, 700, 648, 577.
[0413] 4-Benzyloxy-3-fluoroaniline. A mixture of iron powder (45.2
g, 0.809 g atoms), ammonium formate (53.6 g, 0.850 mol),
1-benzyloxy-2-fluoro-4-nitrobenzene (50.0 g, 0.200 mol), toluene
(400 mL) and water (400 mL) was heated to reflux overnight. The
mixture was filtered through Celite and washed with hot ethyl
acetate. The combined organic layers were washed with water and
brine, then dried over sodium sulfate and concentrated to afford
4-benzyloxy-3-fluoroaniline (44 g, 100%). .sup.1H NMR (400 MHz,
d.sub.6-DMSO): .delta. 7.43-7.26 (m, 5H), 6.90 (dd, 1H), 6.49 (dd,
1H), 6.34 (m, 1H), 4.99 (br s, 2H), 4.98 (s, 2H); .sup.13C NMR (100
MHz, d.sub.6-DMSO): 6171.1, 155.1, 152.7, 144.9, 138.0, 137.2,
129.6, 129.0, 128.5, 118.9, 110.0, 102.9, 72.5; IR (cm.sup.-1):
1510, 1454, 1277, 1215, 1126, 1007, 957, 843, 800, 789, 739, 694,
604; LC/MS (M+H=218).
[0414] Ethyl [(4-benzyloxy-3-fluorophenyl)amino](oxo)acetate. Ethyl
oxalyl chloride (44 mL, 390 mmol) was added to a solution of
4-benzyloxy-3-fluoroaniline (44 g, 180 mmol) in
diisopropylethylamine (69 mL, 400 mmol) and stirred at room
temperature for 15 min. The mixture was extracted with
dichloromethane and washed with water and brine. The organic layer
was dried over sodium sulfate and concentrated to afford ethyl
[(4-benzyloxy-3-fluorophenyl)amino](oxo)acetate (58.4 g, 100%).
.sup.1H NMR (400 MHz, d.sub.6-DMSO): .delta. 10.87 (s, 1H), 7.73
(d, 1H), 7.69 (d, 1H), 7.53 (d, 1H), 7.46-7.40 (m, 4H), 5.17 (s,
2H), 4.31 (q, 2H), 1.31 (t, 3H); IR (cm.sup.-1): 1732, 1705, 1558,
1541, 1508, 1456, 1273, 1186, 1167, 1101, 999, 858, 741, 694; LC/MS
(M+H=318).
[0415]
N-(4-Benzyloxy-3-fluorophenyl)-N'-(2-phenylethyl)ethanediamide.
Phenethyl-amine (33 mL, 520 mmol) was added to ethyl
[(4-benzyloxy-3-fluorophenyl)amino](oxo)acetate (81 g, 260 mmol)
and the mixture was sonicated at room temperature for 30 min. The
resulting solid was filtered, washed with water and dried to give
N-(4-benzyloxy-3-fluorophenyl)-N'-(2-phenylethyl)ethanediamide (100
g, 99%). .sup.1H NMR (400 MHz, d.sub.6-DMSO): .delta. 10.72 (br s,
1H), 9.05 (m, 1H), 8.78 (m, 1H), 7.77 (m, 1H), 7.59 (m, 1H),
7.46-7.19 (m, 8H), 5.16 (m, 2H), 3.45 (m, 2H), 2.83 (m, 2H); IR
(cm.sup.-1): 2980, 2883, 1653, 1522, 1506, 1441, 1385, 1221, 1122,
951, 808, 746, 696, 584; LC/MS (M+H=393).
[0416]
N-(3-Fluoro-4-hydroxyphenyl)-N'-(2-phenylethyl)ethanediamide. A
mixture of
N-(4-benzyloxy-3-fluorophenyl)-N'-(2-phenylethyl)ethanediamide (40
g, 100 mmol) and 38% hydrobromic acid in acetic acid (250 mL) was
stirred at room temperature overnight. The resulting solid was
filtered, washed with water and dried to give
N-(3-fluoro-4-hydroxyphenyl)-N'-(2-phenylethyl)ethanediamide as a
slightly yellow solid (30.6 g, 99% yield). .sup.1H NMR (400 MHz,
d.sub.6-DMSO): .delta. 10.60 (s, 1H), 9.02 (t, 1H), 7.70 (d, 1H),
7.47 (d, 1H), 7.32-7.20 (m, 3H), 6.91 (t, 1H), 3.43 (m, 2H), 2.81
(m, 2H); .sup.13C NMR (100 MHz, d.sub.6-DMSO): .delta. 160.5,
158.8, 152.0, 149.6, 142.2, 139.8, 130.3, 129.3, 129.0, 126.8,
118.1, 117.4, 109.6, 109.3 IR (cm.sup.-1): 3279, 1653, 1518, 1456,
1279, 1190, 742, 696, 584; LC/MS (M+H=303).
Example 36
##STR00513##
[0418] 1-Benzyloxy-2-fluoro-4-nitro-benzene. To a slurry of sodium
hydride (60% dispersion is oil, 693 mmol, 27.7 g) and
dimethylacetamide (600 ml) was added benzyl alcohol (462 mmol, 48
ml) dropwise with stirring under N.sub.2. The mixture was stirred
for 1 hour at RT and then cooled to 0.degree. C.
3,4-Difluoronitrobenzene (508 mmol, 56.2 ml) was added to the
cooled solution and stirred for 1 hour. Reaction mixture poured
onto saturated ammonium chloride solution (800 ml) and stirred for
30 minutes, filtered and washed with water. The solid was stirred
in ethyl acetate (500 mL), and filtered to give 54 g of product.
The ethyl acetate filtrate, after concentrated in vacuo, was
triturated with diethyl ether (500 mL), sonicated for 2 hours, and
filtered to give another 30 g of product. The ether layer was
concentrated and column purified using 5% EtOAc/hexanes as eluent
to gave additional 15 g of product. The total yield of
1-benzyloxy-2-fluoro-4-nitro-benzene was 95 g (83%). (Note: the
product contains ca. 5% of 3,4-Bis-benzyloxy-nitrobenzene, which is
carried into the next step without further purification.) .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 8.04-8.00 (m, 2H), 7.43-7.37 (m,
5H), 7.08 (t, 1H), 5.26 (s, 2H).
[0419] 4-Benzyloxy-3-fluoro-phenylamine. A mixture of
1-benzyloxy-2-fluoro-4-nitro-benzene (44 g, 178 mmol), toluene (400
ml), ammonium formate (35 g), iron (30 g), and water (400 ml) was
heated to reflux with stirring overnight. The reaction mixture was
filtered through celite and washed with ethyl acetate (400 ml). The
organic layer was separated and washed with brine (300 ml), dried
over sodium sulfate and concentrated to give
4-benzyloxy-3-fluoro-phenylamine as an oil (33.7 g, 87%). .sup.1H
NMR (400 MHz, CDCl.sub.3): .delta. 7.41-7.29 (m, 5H), 6.79 (t, 1H),
6.45 (dd, 1H), 6.14 (dd, 1H), 5.02 (s, 2H), 3.50 (s, 2H). LC/MS:
(M+1) 218.
[0420] Cyclopropane-1,1-dicarboxylic acid
(4-benzyloxy-3-fluoro-phenyl)-amide (4-fluoro-phenyl)-amide. To a
stirred mixture of 4-benzyloxy-3-fluoro-phenylamine (155.3 mmol,
33.7 g), 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid
(170.8 mmol, 38.13 g) and anhydrous dichloromethane (600 ml) was
added EDCI (233.9 mmol, 44.7 g) in portions. After stirring at RT
for 1 hr, the reaction mixture was diluted with saturated sodium
bicarbonate (400 ml) and stirred for 30 minutes. The precipitate
was filtered and air dried to give the 1.sup.st crop of product.
The biphasic filtrate was separated, and the organic phase was
washed with brine (300 ml), dried over sodium sulfate, and
concentrated. The residue was taken up in DCM (100 ml), stirred for
15 minutes, and filtered to give a 2.sup.nd crop of product. The
combined yield of cyclopropane-1,1-dicarboxylic acid
(4-benzyloxy-3-fluoro-phenyl)-amide (4-fluoro-phenyl)-amide was
64.5 g (98%). .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 8.92 (br
s, 1H), 8.88 (br s, 1H), 7.50-7.32 (m, 8H), 7.06-7.02 (m, 3H),
6.97-6.92 (t, 1H), 5.13 (s, 2H), 1.65 (s, 4H). LC/MS: (M+1)
423.
[0421] Cyclopropane-1,1-dicarboxylic acid
(3-fluoro-4-hydroxy-phenyl)-amide (4-fluoro-phenyl)-amide. A
mixture of cyclopropane-1,1-dicarboxylic acid
(4-benzyloxy-3-fluoro-phenyl)-amide (4-fluoro-phenyl)-amide (152.8
mmol, 64.5), ethanol (800 ml), cyclohexadiene (764 mmol, 71 ml),
and 10% Pd/C (2 g) was refluxed for 2 hours. Reaction mixture
cooled and filtered through celite and washed with methanol. The
combined filtrate was concentrated and stirred in 10% EtOAc/ether
(350 ml). The resulting precipitate was filtered and washed with
ether to give a 1.sup.st crop of product. The filtrate was
concentrated and stirred in DCM (150 ml) to give another
precipitate, which was then filtered to give a 2.sup.nd crop of
product. The combined yield of cyclopropane-1,1-dicarboxylic acid
(3-fluoro-4-hydroxy-phenyl)-amide (4-fluoro-phenyl)-amide was 43 g
(85%) in 95% purity by HPLC (UV @254 nm). .sup.1H NMR (400 MHz,
DMSO-D6): .delta. 10.07 (br s, 1H), 9.92 (br s, 1H), 9.64 (br s,
1H), 7.64-7.60 (m, 2H), 7.55-7.51 (m, 1H), 7.17-7.12 (m, 3H),
6.89-6.84 (t, 1H), 1.43 (s, 4H). LC/MS: (M+1) 333.
Example 37
##STR00514##
[0423] Cyclopropane-1,1-dicarboxylic acid
(4-benzyloxy-phenyl)-amide (4-fluoro-phenyl)-amide. To a 0.degree.
C. suspension of 4-benzyloxyaniline hydrochloride (47.0 g, 200
mmol) and 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid
(49.1 g, 220 mmol) in CH.sub.2Cl.sub.2 (400 mL) was added EDCI
(38.2 g, 200 mmol). Stirring was continued at rt for 2-4 h until
the reaction was complete. CH.sub.2Cl.sub.2 was removed under
reduced pressure. H.sub.2O (300 mL) and MeOH (200 mL) were added,
and the resulting mixture was stirred at rt for 30 min. After
filtration and wash with H.sub.2O, the solid was transferred to
another flask containing 300 mL of sat. aqueous NaHCO.sub.3
solution. The mixture was stirred for another 30 min. The solid was
filtered, washed with water, and dried over night on a lyophilizer,
affording cyclopropane-1,1-dicarboxylic acid
(4-benzyloxy-phenyl)-amide (4-fluoro-phenyl)-amide (75.8 g, 95%
yield) as an off-white solid.
[0424] Cyclopropane-1,1-dicarboxylic acid (4-fluoro-phenyl)-amide
(4-hydroxy-phenyl)-amide. To a refluxing mixture of
cyclopropane-1,1-dicarboxylic acid (4-benzyloxy-phenyl)-amide
(4-fluoro-phenyl)-amide (46 g, 113 mmol), 10% Pd/C (2 g) in EtOH
(400 mL) was added dropwise 1,4-cyclohexadiene (62.7 mL, 678 mmol).
Stirring was continued for 2-5 h until the reaction was complete.
The mixture was cooled to rt, filtered through celite, and washed
with EtOH. The solution was then concentrated under reduced
pressure. To the flask containing the crude product was added
CHCl.sub.3 (200 mL). The resulting suspension was stirred for 15
min at rt. The solid was filtered, and dried in the air to give
cyclopropane-1,1-dicarboxylic acid (4-fluoro-phenyl)-amide
(4-hydroxy-phenyl)-amide (34.4 g, 95%, yield).
Example 38
##STR00515##
[0426] Alternate Synthesis of Cyclopropane-1,1-dicarboxylic acid
(4-fluoro-phenyl)-amide (4-hydroxy-phenyl)-amide. To a solution of
4-aminophenol (2.93 g, 26.9 mmol) and
1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid (5.00 g,
22.4 mmol) in DMA (30 mL) was added EDCI (5.15 g, 26.9 mmol). The
mixture was stirred vigorously until the reaction was complete
(.about.3 h). With vigorous stirring, the reaction mixture was then
poured into a flask containing sat. aqueous NaHCO.sub.3 solution
(200 mL). The stirring was continued for 1 h. The resulting
suspension was then filtered. The solid was washed with water (50
mL), chloroform (50 mL) and dried under vacuum, affording
1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid (6.22 g,
88% yield) as a powder (>95% purity by HPLC and .sup.1H
NMR).
Example 39
##STR00516##
[0428]
N-{4-[(7-Benzyloxy-6-methoxyquinolin-4-yl)oxy]-3-fluorophenyl}-N'-(-
2-phenylethyl)ethanediamide. A mixture of
7-benzyloxy-4-chloro-6-methoxyquinoline (30 g, 100 mmol),
N-(3-fluoro-4-hydroxyphenyl)-N'-(2-phenylethyl)ethanediamide (32 g,
106 mmol), DMAP (125 g, 1.02 mol) and bromobenzene (500 mL) was
heated to reflux for 6 h. The mixture was cooled to room
temperature and the bromobenzene was removed under reduced
pressure. Methanol (500 mL) was added to the residue and the
mixture was stirred at room temperature for 2 h. The resulting
solid was filtered, washed with methanol and dried to give
N-{4-[(7-benzyloxy-6-methoxyquinolin-4-yl)oxy]-3-fluorophenyl}-N'-(2-
-phenylethyl)ethanediamide (34 g, 61%). .sup.1H NMR (400 MHz,
d.sub.6-DMSO): .delta. 11.05 (s, 1H), 9.15 (s, 1H), 8.47 (d, 1H),
8.05 (d, 1H), 7.84 (d, 1H), 7.56-6.36 (m, 13H), 6.46 (d, 1H), 5.32
(s, 2H), 3.97 (s, 3H), 3.47 (q, 2H), 2.86 (t, 2H); .sup.13C NMR
(100 MHz, d.sub.6-DMSO): .delta. 160.5, 160.2, 159.9, 159.5, 155.2,
152.7, 152.2, 150.3, 149.6, 146.9, 139.7, 137.4, 137.3, 137.2,
137.1, 129.3, 129.2, 129.1, 129.0, 128.9, 128.7, 128.6, 126.9,
124.8, 117.9, 115.3, 109.9, 102.8, 99.8, 70.6, 56.5, 41.3, 35.2; IR
(cm.sup.-1): 1657, 1510, 1481, 1433, 1416, 1352, 1310, 1252, 1215,
1609, 986, 891, 868, 850, 742, 696; LC/MS (M+H=566).
Example 40
##STR00517##
[0430]
N-{3-Fluoro-4-[(7-hydroxy-6-methoxyquinolin-4-yl)oxy]phenyl}-N'-(2--
phenylethyl)ethanediamide. To a solution of
N-{4-[(7-benzyloxy-6-methoxyquinolin-4-yl)oxy]-3-fluorophenyl}-N'-(2-phen-
ylethyl)ethanediamide (32 g, 56 mmol) in methanol (200 mL), DMF
(100 mL), dichloromethane (100 mL), ethyl acetate (100 mL) and
acetic acid (5 mL) was added palladium hydroxide (4.2 g) and the
mixture was shaken on a Parr hydrogenator under a hydrogen pressure
of 45 psi for 4 h. The resulting suspension was filtered through
celite and the solid residue was washed with boiling
dichloromethane (2 L) and acetone (2 L). The combined filtrates
were evaporated to yield
N-{3-fluoro-4-[(7-hydroxy-6-methoxyquinolin-4-yl)oxy]phenyl}-N'-(2-phenyl-
ethyl)ethanediamide as an off-white solid (25.6 g, 95%). .sup.1H
NMR (400 MHz, d.sub.6-DMSO): .delta. 11.06 (s, 1H), 10.25 (br s,
1H), 9.12 (t, 1H), 8.40 (d, 1H), 8.01 (dd, 1H), 7.50-7.44 (m, 2H),
7.31-7.23 (m, 6H), 6.39 (d, 1H), 3.95 (s, 3H), 2.85 (t, 2H), 2.50
(m, 2H); IR (cm.sup.-1): 1666, 1624, 1585, 1520, 1481, 1427, 1377,
1256, 1211, 1194, 1022, 880, 850, 839, 802, 750, 700; LC/MS
(M+H=476).
Example 41
##STR00518##
[0432]
N-(3-Fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]-
oxy}phenyl)-N'-(2-phenylethyl)ethanediamide. A solution of
N-{3-fluoro-4-[(7-hydroxy-6-methoxyquinolin-4-yl)oxy]phenyl}-N'-(2-phenyl-
ethyl)ethanediamide (25.6 g, 54 mmol), N-(3-chloropropyl)morpholine
hydrochloride (11.7 g, 592 mmol) and potassium carbonate (16.6 g,
120 mmol) in DMF (300 mL) was heated to 80.degree. C. overnight.
Upon cooling, a majority of the DMF (250 mL) was removed on a
rotary evaporator, 5% aqueous LiCl (300 mL) was added and the
mixture was sonicated at room temperature. The solid was filtered,
suspended in 1N HCl and washed with ethyl acetate (2.times.300 mL).
The solution was adjusted to pH 14 using 2N sodium hydroxide and
subsequently extracted with dichloromethane (3.times.200 mL). The
organic layer was dried over sodium sulfate, filtered and
evaporated to give
N-(3-fluoro-4-{[6-methoxy-7-(3-morpholin-4-ylpropoxy)quinolin-4-yl]oxy}ph-
enyl)-N'-(2-phenylethyl)ethanediamide as a yellow solid (24 g,
74%). .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 9.37 (s, 1H), 8.46
(d, 1H), 7.81 (dd, 1H), 7.57 (t, 1H), 7.53 (s, 1H), 7.42 (s, 2H),
7.34-7.20 (m, 6H), 6.39 (d, 1H), 4.27 (t, 2H), 4.03 (s, 3H), 3.71
(m, 4H), 3.65 (q, 2H), 2.91 (t, 2H), 2.56 (br s, 4H), 2.13 (m, 2H);
.sup.13C NMR (100 MHz, d.sub.6-DMSO): .delta. 160.1, 160.0, 159.5,
155.2, 152.7, 152.6, 150.2, 149.5, 147.1, 139.7, 137.3, 137.1,
129.3, 129.1, 126.9, 124.8, 117.9, 115.1, 109.2, 102.7, 99.6, 67.4,
66.9, 56.5, 55.5, 54.1, 41.3, 35.2, 26.4; IR (cm.sup.-1): 1655,
1506, 1483, 1431, 1350, 1302, 1248, 1221, 1176, 1119, 864, 843,
804, 741, 700; LC/MS (M+H=603).
Example 42
##STR00519##
[0434] Cyclopropane-1,1-dicarboxylic acid
[4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
(4-fluoro-phenyl)-amide. To a flask containing
cyclopropane-1,1-dicarboxylic acid
(3-fluoro-4-hydroxy-phenyl)-amide (4-fluoro-phenyl)-amide (2.25 g,
6.7 mmol) and trifluoromethanesulfonic acid
7-benzyloxy-6-methoxy-quinolin-4-yl ester (1.87 g, 4.5 mmol) was
added dry 2,6-lutidine (9 mL). The reaction mixture was heated to
reflux (143.degree. C.) with vigorous stirring. The reaction
progress was monitored by LC-MS. 2,6-Lutidine was removed under
reduced pressure when the reaction was complete (about 6 h). The
residue was treated with charcoal (1.5 g) in refluxing EtOAc (50
mL) for 15 min, and filtered through celite. The volume of the
filtrate was reduced to about 20 mL and was added 20 mL of 1 N HCl.
The crude product precipitated as the HCl salt, which was filtered
and washed with EtOAc and H.sub.2O (88% purity by analytical HPLC).
The HCl salt was free-based with saturated aqueous NaHCO.sub.3
solution. Further purification by column chromatography
(hexans:EtOAc=1:4) gave cyclopropane-1,1-dicarboxylic acid
[4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
(4-fluoro-phenyl)-amide as an off-white solid (1.3 g, 48% yield.
.sup.1H NMR (400 MHz, DMSO, d.sub.6): 10.41 (s, 1H), 10.02 (s, 1H),
8.48 (d, 1H), 7.92 (dd, 1H), 7.65 (m, 2H), 7.54 (m, 5H), 7.41 (m,
4H), 7.17 (m, 2H), 6.43 (d, 1H), 5.32 (s, 2H), 3.97 (s, 3H), 1.48
(m, 4H). LC/MS Calcd for [M+H].sup.+ 596.2, found 596.3.
Example 43
##STR00520##
[0436] Cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide. To a solution of the
cyclopropane-1,1-dicarboxylic acid
[4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-3-fluoro-phenyl]-amide
(4-fluoro-phenyl)-amide (22.4 g, 37.6 mmol) in EtOH (340 mL) was
added 1,4-cyclohexadiene (35 mL, 376 mmol) and 10% Pd/C (2.08 g).
The reaction mixture was then heated at 65.degree. C. with stirring
for 3 h (Caution: H.sub.2 gas is released from the reaction). It
was then allowed to cool to room temperature, and filtered through
celite followed by a MeOH wash. The solution was then concentrated
under reduced pressure. The yellow residue was taken into EtOAc (1
L). The EtOAc solution was washed with water (1.times.), brine
(2.times.), dried over MgSO.sub.4 and concentrated in vacuo.
Cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide was obtained as a yellow solid (17.3 g,
91.1% yield), which were carried on to the next reaction without
further purification. .sup.1H NMR (400 MHz, DMSO, d6): 10.39 (s,
1H), 10.15 (s, 1H), 10.00 (s, 1H), 8.38 (d, 1H), 7.88 (dd, 1H),
7.63 (m, 2H), 7.50 (m, 2H), 7.40 (t, 1H), 7.27 (s, 1H), 7.14 (m,
2H), 6.33 (d, 1H), 3.95 (s, 3H), 1.47 (m, 4H). LC/MS Calcd for
[M+H].sup.+ 506.2, found 506.3. Anal. HPLC: 99.4% pure.
Example 44
##STR00521##
[0438]
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinol-
in-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
To a mechanically stirred slurry of cyclopropane-1,1-dicarboxylic
acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide (16.6 g, 32.8 mmol) and potassium carbonate
(13.6 g, 98.6 mmol) in DMF (250 mL) was added
4-(3-chloropropyl)-morpholine hydrochloride (13, 7.92 g, 39.6
mmol). The resulting mixture was heated at 90.degree. C. for 5
hours (until phenol completely consumed). The reaction mixture was
allowed to cool to room temperature, then dumped into water (900
mL), followed by extraction with EtOAc (3.times.). The combined
extracts were washed with 5% LiCl (aq.) (3.times.) and brine
(1.times.) followed by drying over MgSO.sub.4 and concentration in
vacuo. The crude (1 8.8 g) obtained as brown solid was further
purified by flash chromatography [silica gel, 4-stage gradient
system: 1) EtOAc; 2) EtOAc:MeOH:7N NH.sub.3/MeOH (95:5:0.5); 3)
DCM:MeOH:7N NH.sub.3/MeOH (95:5:0.5); 4) DCM:MeOH: 7N NH.sub.3/MeOH
(93:8:1)], affording
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinolin-4-y-
l}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide was
obtained as an off white solid (15.0 g, 72% yield). .sup.1H NMR
(400 MHz, DMSO-d.sub.6): 10.41 (s, 1H), 10.02 (s, 1H), 8.47 (d,
1H), 7.91 (dd, 1H), 7.65 (m, 2H), 7.53 (m, 2H), 7.42 (t, 1H), 7.40
(s, 1H), 7.16 (m, 2H), 6.42 (d, 1H), 4.20 (t, 2H), 3.96 (s, 3H),
3.59 (t, 4H), 2.47 (t, 2H), 2.39 (br, s, 4H), 1.98 (m, 2H), 1.48
(m, 4H). LC/MS Calcd for [M+H]+ 633.3, found 633.0.
Example 45
##STR00522##
[0440] Cyclopropane-1,1-dicarboxylic acid
[4-(7-benzyloxy-6-methoxy-quinazolin-4-yloxy)-3-fluoro-phenyl]-amide
(4-fluoro-phenyl)-amide: A mixture of
7-benzyloxy-4-chloro-6-methoxy-quinazoline (5 g, 16.67 mmol),
cyclopropane-1,1-dicarboxylic acid
(3-fluoro-4-hydroxy-phenyl)-amide (4-fluoro-phenyl)-amide (8.3 g,
25 mmol), potassium carbonate (125 mmol, 17.25 g), and
dimethylacetamide (125 ml) was heated 50.degree. C. with stirring
for 16 h. Reaction mixture was poured onto ice/water (600 ml) and
stirred for 30 minutes, and filtered. The solid was dissolved in
ethyl acetate and washed with water (1.times.), brine, and
concentrated. The crude was purified on silica get column eluting
with 30% acetone in hexanes to yield cyclopropane-1,1-dicarboxylic
acid
[4-(7-benzyloxy-6-methoxy-quinazolin-4-yloxy)-3-fluoro-phenyl]-amide
(4-fluoro-phenyl)-amide (7.5 g, 76%). .sup.1H NMR (CDCl.sub.3):
8.64 (1H, br. s), 8.55 (1H, s), 8.33 (1H, br. s), 7.74-7.71 (1H,
dd), 7.54 (1H, s), 7.48-7.33 (8H, m), 7.31-7.24 (2H, m), 7.06-7.02
(2H, m), 5.32 (2H, s), 4.06 (3H, s), 1.77-1.74 (2H, m), 1.63-1.61
(2H, m).
Example 46
##STR00523##
[0442] Cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinazolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide. To a mixture of
cyclopropane-1,1-dicarboxylic acid
[4-(7-benzyloxy-6-methoxy-quinazolin-4-yloxy)-3-fluoro-phenyl]-amide
(4-fluoro-phenyl)-amide (7.5 g, 12.6 mmol), acetic acid (few
drops), dichloromethane (50 ml) and methanol (100 ml) was added 10%
Pd/C (700 mg). The mixture was agitated in hydrogen gas (40 psi)
until the reaction was complete (ca. 4 hr). The solution was
filtered through celite and concentrated to give a crude product as
a solid. The crude product was triturated with ether, and filtered.
The filter cake was dried in vacuo to yield
cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinazolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide (6.1 g, 95% yield). .sup.1H NMR (dmso-d6):
10.86 (1H, br. s), 10.34 (1H, br. s), 10.04 (1H, br. s), 8.46 (1H,
s), 7.84-7.80 (1H, dd), 7.66-7.62 (2H, m), 7.55 (1H, s), 7.47-7.45
(1H, m), 7.41-7.37 (1H, m), 7.24 (1H, s), 7.18-7.13 (2H, t), 3.98
(3H, s), 1.46 (4H, s).
Example 47
##STR00524##
[0444]
N-[3-Fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinaz-
olin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
To a mixture of cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinazolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide (1.5 g, 2.96 mmol),
4-(3-hydroxypropyl)morpholine (0.623 mL, 4.5 mmol),
triphenylphosphine (1.18 g, 4.5 mmol), and dichloromethane (50 mL)
was added diisopropyl azodicarboxylate (0.886 mL, 4.5 mmol). The
mixture was stirred at room temperature for 16 h, monitored by
LCMS. After removal of solvent, the crude mixture was separated by
flash column chromatography (silica), eluting with 5% methanol in
dichloromethane to give
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]quinazolin-4-
-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
(890 mg, 47% yield). .sup.1H NMR (400 MHz, DMSO-d.sub.6): .delta.
10.36 (br s, 1H), 10.05 (br s, 1H), 8.55 (s, 1H), 7.83 (m, 1H),
7.64 (m, 2H), 7.57 (s, 1H), 7.44 (m, 3H), 7.18 (t, 2H), 4.27 (m,
2H), 3.99 (s, 3H), 3.61 (m, 6H), 2.40 (m, 4H), 2.01 (m, 2H), 1.47
(m, 4H). LC/MS Calcd for [M+H].sup.+ 634.2, found 634.3.
Example 48
##STR00525##
[0446]
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophen-
yl)cyclopropane-1,1-dicarboxamide. To a solution of
cyclopropane-1,1-dicarboxylic acid (4-fluoro-phenyl)-amide
(4-hydroxy-phenyl)-amide (6.98 g, 22.2 mmol) in anhydrous
2,6-lutidine (50 mL) was added trifluoromethanesulfonic acid
6,7-dimethoxy-quinolin-4-yl ester (5 g, 14.8 mmol). The reaction
mixture was heated at 165.degree. C. in a sealed pressure tube with
stirring for 18 h. The reaction mixture was concentrated on high
vacuum to completely remove lutidine. The resulting solid material
was dissolved in DCM (250 mL), and washed several times with 1 N
sodium hydroxide to remove the excess phenol. The crude mixture was
loaded on a silica gel flash column and eluted with 75%
EtOAc-hexanes, affording
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)cyc-
lopropane-1,1-dicarboxamide (3.2 g, 44%). .sup.1H NMR (400 MHz,
d.sub.6-DMSO): .delta. 10.2 (s, 1H), 10.05 (s, 1H), 8.4 (s, 1H),
7.8 (m, 2H), 7.65 (m, 2H), 7.5 (s, 1H), 7.35 (s, 1H), 7.25 (m, 2H),
7.15 (m, 2H), 6.4 (s, 1H), 4.0 (d, 6H), 1.5 (s, 4H). LC/MS:
M+H=502.
Example 49
##STR00526##
[0448] 4,7-Dichloroquinoline. Phosphorus oxychloride (4 mL, 429
mmol) was added to 7-chloro-4-hydroxyquinoline 2.86 g, 15.9 mmol)
in a round bottom flask equipped with a reflux condenser. The
mixture was heated to reflux for 2 h, then allowed to cool to room
temperature. The solution was concentrated in vacuo to a thick oil,
then dumped over cracked ice. The resulting solution was
neutralized with saturated NaHCO.sub.3 (aq). The slurry was
filtered and washed with water. The solids were dried under vacuum,
afforded 4,7-dichloroquinoline as a white solid (2.79 g, 88.5%
yield).
Example 50
##STR00527##
[0450]
4-[4-(2-Fluoro-4-{[1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarbony-
l]-amino}-phenoxy)-6-methoxy-quinazolin-7-yloxymethyl]-piperidine-1-carbox-
ylic acid tert-butyl ester. Cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinazolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide (325 mg, 0.64 mmol),
4-methanesulfonyloxymethyl-piperidine-1-carboxylic acid tert-butyl
ester (193 mg, 0.66 mmol), K.sub.2CO.sub.3 (181 mg, 1.31 mmol) were
combined in DMF (5 ml) and heated to 80.degree. C. overnight. The
reaction was not complete and more
4-methanesulfonyloxymethyl-piperidine-1-carboxylic acid tert-butyl
ester (90 mg, 0.31 mmol) and K.sub.2CO.sub.3 (90 mg, 0.65 mmol)
were added and heating at 80.degree. C. continued for another
night. The reaction mixture was allowed to cool to room
temperature, then diluted with EtOAc and washed with H.sub.2O
(3.times.), sat'd NaCl (1.times.), dried (Na.sub.2SO.sub.4) and
concentrated in vacuo. The resulting crude material was purified by
flash chromatography (1:1 hexanes:EtOAc, followed by 1:3
hexanes:EtOAc) to give
4-[4-(2-fluoro-4-{[1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarbonyl]-ami-
no}-phenoxy)-6-methoxy-quinazolin-7-yloxymethyl]-piperidine-1-carboxylic
acid tert-butyl ester (273 mg, 60%). LC/MS Calcd for [M+H].sup.+
704.3, found 704.4.
Example 51
##STR00528##
[0452] Cyclopropane-1,1-dicarboxylic acid
{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phen-
yl}-amide (4-fluoro-phenyl)-amide, TFA salt.
4-[4-(2-Fluoro-4-{[1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarbonyl]-ami-
no}-phenoxy)-6-methoxy-quinazolin-7-yloxymethyl]-piperidine-1-carboxylic
acid tert-butyl ester (273 mg, 0.39 mmol) was dissolved in
CH.sub.2Cl.sub.2 (8 ml) to which was added TFA (8 ml) and the
mixture stirred at room temperature for 1 hr. The reaction mixture
was concentrated in vacuo and the resulting oil triturated with
Et.sub.2O. The resulting solids were filtered, washed with
Et.sub.2O and dried under high vacuum to give
cyclopropane-1,1-dicarboxylic acid
{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phen-
yl}-amide (4-fluoro-phenyl)-amide, TFA salt (222 mg, 80%). LC/MS
Calcd for [M+H].sup.+ 604.2, found 604.3.
Example 52
##STR00529##
[0454]
N-{3-Fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]ox-
y}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarbox-
amide. Cyclopropane-1,1-dicarboxylic acid
{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinazolin-4-yloxy]-phen-
yl}-amide (4-fluoro-phenyl)-amide, TFA salt (222 mg, 0.31 mmol),
H.sub.2O (3 ml), 37% formaldehyde in H.sub.2O (0.18 ml) and acetic
acid (27 drops) were combined in acetonitrile (9 ml) to which was
slowly added triacetoxyborohydride (561 mg, 2.65 mmol). The mixture
was stirred at room temperature for 1-2 hr, then diluted with 1N
NaOH and H.sub.2O and extracted with CH.sub.2Cl.sub.2 (3.times.).
The combined CH.sub.2Cl.sub.2 extractions were washed with sat'd
NaCl (1.times.), dried (Na.sub.2SO.sub.4) and concentrated in
vacuo. The resulting residue was dissolved in a minimum of 1:1
dioxane:EtOAc to which was added 4M HCl in dioxane (1-2 ml). The
resulting solids were filtered, washed with EtOAc and dried under
high vacuum to give
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}quin-
azolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,
HCl salt (167 mg, 83%). 1HNMR (400 MHz, DMSO-d.sub.6): .delta.
10.40 (s, 1H), 10.17 (br s, 1H) 10.07 (s, 1H), 8.61 (s, 1H), 7.85
(m, 1H), 7.65 (m, 2H), 7.48 (m, 2H), 7.42 (t, 1H), 7.16 (t, 2H),
4.12 (2, 2H), 4.00 (s, 3H), 3.46 (m, 2H), 2.99 (m, 2H), 2.73 (d,
3H), 2.13 (m, 1H), 2.01 (m, 2H), 1.63 (m, 2H), 1.47 (m, 4H). LC/MS
Calcd for [M+H].sup.+ 618.2, found 618.3.
Synthesis of Bridged Bicyclics
[0455] The following describes synthesis of bridged bicyclics with
appended leaving groups for use as, for example, alkylating agents.
In the context of this invention, these alkylating agents are used,
for example, to alkylate the quinazoline or quinolines on the 6- or
7-oxygens to make compounds of the invention. The invention is not
limited to alkylation chemistry to append such bridged bicyclics,
but rather the aforementioned description is meant only to be
illustrative of an aspect of the invention.
Example 53
1,4:3,6-dianhydro-2-O-methyl-5-O-(methylsulfonyl)-D-glucitol: To a
solution of 1,4:3,6-dianhydro-2-O-methyl-D-glucitol (1.19 g, 7.4
mmol) in dichloromethane was added pyridine (1 mL, 12.36 mmol)
followed by methanesulfonyl chloride (0.69 mL, 8.92 mmol) and the
mixture was allowed to stir at room temperature over 12 hours. The
solvent was removed and the amorphous residue was partitioned with
ethyl acetate and 0.1M aqueous hydrochloric acid. The aqueous phase
was extracted once with additional ethyl acetate and the combined
organic layers were washed with saturated aqueous sodium chloride
then dried over anhydrous magnesium sulfate. Filtration and
concentration followed by drying in vacuo afforded
1,4:3,6-dianhydro-2-O-methyl-5-O-(methylsulfonyl)-D-glucitol (1.67
g, 94% yield) as a colorless oil. GC/MS calculated for
C.sub.8H.sub.14SO.sub.6: 238 (M.sup.+).
Example 54
[0456] 1,4:3,6-dianhydro-5-O-(phenylcarbonyl)-D-fructose ethylene
glycol acetal: A solution of
1,4:3,6-dianhydro-5-O-(phenylcarbonyl)-D-fructose (2.00 g, 8.06
mmol), ethylene glycol (5.00 g, 80.6 mmol), and p-toluenesulfonic
acid (1.53 g, 8.06 mmol) in benzene (100 mL) was refluxed for 90
min using a Dean-Stark Trap apparatus. The reaction mixture was
diluted with ethyl acetate (100 mL), washed with saturated aqueous
sodium bicarbonate (2.times.50 mL) then brine (50 mL), and dried
over anhydrous sodium sulfate. Filtration, concentration and column
chromatography on silica (1:1 hexane/ethyl acetate) provided 1.44 g
(61% yield) of 1,4:3,6-dianhydro-5-O-(phenylcarbonyl)-D-fructose
ethylene glycol acetal as a colorless solid. .sup.1H NMR (400 MHz;
CDCl.sub.3): 8.08 (m, 2H), 7.58 (m, 1H), 7.54 (m, 2H), 5.38 (dd,
1H), 4.97 (t, 1H), 4.21-4.02 (m, 7H), 3.86 (d, 1H), 3.75 (d,
1H).
Example 55
[0457] 1,4:3,6-dianhydro-D-fructose ethylene glycol acetal: To a
solution of 1,4:3,6-dianhydro-5-O-(phenylcarbonyl)-D-fructose
ethylene glycol acetal (1.44 g, 4.93 mmol) in methanol (40 mL) was
added 50% aqueous sodium hydroxide (0.38 g, 4.75 mmol) and the
mixture was stirred at room temperature for 30 minutes.
Neutralization with 1M HCl, followed by concentration and column
chromatography on silica (1:2 hexane/ethyl acetate) provided 0.74 g
(80% yield) of 1,4:3,6-dianhydro-D-fructose ethylene glycol acetal
as a colorless solid. .sup.1H NMR (400 MHz; CDCl.sub.3): 4.60 (t,
1H), 4.32 (m, 1H), 4.14 (d, 1H), 4.05-3.98 (m, 5H), 3.82 (s, 2H),
3.62 (dd, 1H), 2.65 (d, 1H).
[0458] 1,4:3,6-dianhydro-5-O-(methylsulfonyl)-D-fructose ethylene
glycol acetal: To a solution of 1,4:3,6-dianhydro-D-fructose
ethylene glycol acetal (0.74 g, 3.93 mmol) and triethylamine (1.20
g, 11.86 mmol) in dichloromethane (40 mL) was added methanesulfonyl
chloride (0.90 g, 7.88 mmol) at 0.degree. C. under nitrogen. The
solution was warmed to room temperature and stirred for 13 h.
Dichloromethane (50 mL) was added, and the organic layer was washed
with saturated aqueous sodium bicarbonate (30 mL), water (30 mL),
and brine (30 mL) then dried over anhydrous sodium sulfate.
Filtration and concentration provided 1.02 g (97%) of
1,4:3,6-dianhydro-5-O-(methylsulfonyl)-D-fructose ethylene glycol
acetal as a yellow oil. .sup.1H NMR (400 MHz; CDCl.sub.3): 5.08 (m,
1H), 4.82 (t, 1H), 4.13 (dd, 1H), 4.04 (m, 4H), 3.93 (dd, 1H), 3.87
(d, 1H), 3.81 (d, 1H), 3.13 (s, 3H).
Example 56
[0459] 1,4:3,6-dianhydro-2-deoxy-2-methylidene-D-arabino-hexitol:
To a solution of 1,
4:3,6-dianhydro-2-deoxy-2-methylidene-5-O-(phenylcarbonyl)-D-arabino-hexi-
tol (329 mg, 1.34 mmol) in methanol (10 mL) was added 50% aqueous
sodium hydroxide (95 mg, 1.19 mmol) and the mixture was stirred at
room temperature for 30 minutes. Neutralization with 4M hydrogen
chloride in 1,4-dioxane followed by concentration and column
chromatography on silica (1:1 hexane/ethyl acetate) provided 141 mg
(74%) of 1,4:3,6-dianhydro-2-deoxy-2-methylidene-D-arabino-hexitol
as a colorless solid. .sup.1H NMR (400 MHz; CDCl.sub.3): 5.37 (m,
1H), 5.20 (m, 1H), 4.80 (m, 1H), 4.54 (m, 2H), 4.43 (m, 1H), 4.26
(m, 1H), 3.95 (dd, 1H), 3.54 (dd, 1H), 2.70 (d, 1H).
[0460]
1,4:3,6-dianhydro-2-deoxy-2-methylidene-5-O-(methylsulfonyl)-D-arab-
ino-hexitol: To a solution of
1,4:3,6-dianhydro-2-deoxy-2-methylidene-D-arabino-hexitol (135 mg,
0.95 mmol) and triethylamine (288 mg, 2.85 mmol) in dichloromethane
(10 mL) was added methanesulfonyl chloride (222 mg, 1.94 mmol) at
0.degree. C. under nitrogen. The solution was warmed to room
temperature and stirred for 18 h. Dichloromethane (50 mL) was added
and the organic layer was washed with saturated aqueous sodium
bicarbonate (2.times.25 mL), water (25 mL) and brine (25 mL) then
dried over anhydrous sodium sulfate. Filtration and concentration
provided 213 mg (72%) of
1,4:3,6-dianhydro-2-deoxy-2-methylidene-5-O-(methylsulfonyl)-D-arabino-he-
xitol as a yellow oil. .sup.1H NMR (400 MHz; CDCl.sub.3): 5.40 (m,
1H), 5.23 (m, 1H), 5.04 (m, 1H), 4.85 (m, 1H), 4.73 (t, 1H), 4.58
(m, 1H), 4.41 (m, 1H), 4.08 (dd, 1H), 3.86 (dd, 1H), 3.14 (s,
3H).
Example 57
[0461]
1,4:3,6-dianhydro-2-deoxy-5-O-(phenylcarbonyl)-L-arabino-hex-1-enit-
ol: To a mixture of
1,4:3,6-dianhydro-5-O-(phenylcarbonyl)-(D)-glycitol (4.32 g, 17.3
mmol), triethylamine (4.91 mL, 35.3 mmol) and
4-dimethylaminopyridine (0.63 g, 5.2 mmol) in dichloromethane (50
mL) at -10.degree. to -15.degree. was added
trifluoromethanesulfonic anhydride (3.48 mL, 20.7 mmol) dropwise
over ten minutes and the resulting mixture was stirred at this
temperature for 3 hours. The mixture was poured into 100 mL of
ice-water and extracted with dichloromethane (3.times.50 mL). The
combined organic layers were washed with brine, dried over
anhydrous sodium sulfate, filtered then concentrated. The crude
triflate was suspended in toluene (50 mL) followed by addition of
1,8-diazabicyclo[4,5,0]undec-7-ene (5.25 mL, 34.6 mmol) and the
mixture was stirred at room temperature for 18 hours. The reaction
mixture was poured into ice-water and partitioned then the aqueous
portion was extracted with dichloromethane (3.times.50 mL). The
combined organic portion was washed with brine, dried over
anhydrous sodium sulfate, filtered and concentrated. The residue
was purified by flashed chromatography (silica gel, 5-20% ethyl
acetate-hexane) to give
1,4:3,6-dianhydro-2-deoxy-5-O-(phenylcarbonyl)-L-arabino-hex-1-enitol,
as a white solid, 3.10 g, 77% yield. .sup.1H NMR (400 MHz;
CDCl.sub.3): 8.08-8.06 (m, 2H), 7.61-7.57 (m, 1H), 7.56-7.43 (m,
2H), 6.62-6.61 (d, 1H), 5.48-5.46 (m, 1H), 5.32-5.26 (m, 1H),
5.13-5.10 (m, 2H), 4.18-4.14 (tr, 1H), 3.61-3.56 (tr, 1H).
Example 58
[0462] Methyl
3,6-anhydro-5-O-(phenylcarbonyl)-.beta.-L-glucofuranoside: To a
solution of
1,4:3,6-dianhydro-2-deoxy-5-O-(phenylcarbonyl)-L-arabino-hex-1-enitol
(1.00 g, 4.3 mmol) in methanol (17 mL) at -4.degree. C. was added
3-chloroperoxybenzoic acid (85%, 1.35 g, 8.6 mmol), and the
resulting mixture was slowly warmed to room temperature and stirred
for 18 hours. The reaction mixture was concentrated, diluted with
dichloromethane (50 mL), washed with saturated aqueous sodium
bicarbonate solution, dried over sodium sulfate, filtered and
concentrated. The residue was purified by flash chromatography
(silica gel, 25-60% ethyl acetate-hexane) to give methyl
3,6-anhydro-5-O-(phenylcarbonyl)-.beta.-L-glucofuranoside as a
white solid, 1.03 g, 83% yield. .sup.1H NMR (400 MHz; CDCl.sub.3):
8.11-8.08 (d, 2H), 7.61-7.56 (tr, 1H), 7.48-7.44 (m, 2H), 5.24-5.17
(m, 2H), 4.96 (s, 1H), 4.57-4.56 (d, 1H), 4.27 (s, 1H), 4.22-4.18
(dd, 1H), 4.08-4.04 (dd, 1H) 3.36 (s, 3H).
[0463] Methyl
3,6-anhydro-2-O-methyl-5-O-(phenylcarbonyl)-1-L-glucofuranoside: A
mixture of methyl
3,6-anhydro-5-O-(phenylcarbonyl)-.beta.-L-glucofuranoside (1.03 g,
3.7 mmol), silver (I) oxide (0.85 g, 3.7 mmol) and methyl iodide
(0.34 mL, 5.5 mmol) in DMF (2 mL) was heated at 60.degree. C. for 1
hour. After cooling to room temperature the reaction mixture was
diluted with ethyl acetate (50 mL), filtered over celite, adsorbed
on silica gel (10 g) and purified by flash chromatography (silica
gel, 5-30% ethyl acetate-hexane) to give methyl
3,6-anhydro-2-O-methyl-5-O-(phenylcarbonyl)-.beta.-L-glucofuranoside
as a colorless oil, 0.82 g, 76% yield. .sup.1H NMR (400 MHz;
CDCl.sub.3): 8.11-8.09 (d, 2H), 7.60-7.56 (m, 1H), 7.46-7.44 (m,
2H), 5.24-5.20 (m, 1H), 5.18-5.09 (tr, 1H), 4.99 (s, 1H), 4.61-4.60
(d, 1H), 4.21-4.17 (tr, 1H), 4.08-4.03 (tr, 1H), 3.81 (s, 1H), 3.40
(s, 3H), 3.57 (s, 3H).
[0464] Methyl 3,6-anhydro-2-O-methyl-.alpha.-D-idofuranoside: A
solution of methyl
3,6-anhydro-2-O-methyl-5-O-(phenylcarbonyl)-.beta.-L-glucofuran-
oside (820 mg, 3.1 mmol) and 50% sodium hydroxide (248 mg, 3.1
mmol) in methanol (10 mL) was stirred at room temperature for 30
minutes. The material was adsorbed on silica gel (5 g) and passed
through a short column (15% ethyl acetate in hexanes to 5% methanol
in ethyl acetate) to give methyl
3,6-anhydro-2-O-methyl-.alpha.-D-idofuranoside as a colorless oil,
420 mg, 85% yield. .sup.1H NMR (400 MHz; CDCl.sub.3): 5.04 (s, 1H),
5.84-5.81 (tr, 1H), 4.44-4.42 (tr, 1H), 4.25-4.19 (m, 1H),
3.85-3.75 (m, 1H), 3.49 (s, 3H), 3.43 (s, 3H), 2.75-2.72 (d,
1H).
[0465] Methyl
3,6-anhydro-2-O-methyl-5-O-(methylsulfonyl)-.beta.-L-glucofuranoside:
Methyl 3,6-anhydro-2-O-methyl-.alpha.-D-idofuranoside (420 mg, 2.6
mmol) was dissolved in dichloromethane (10 mL) and pyridine (0.36
mL, 3.7 mmol) at 0.degree. C. Methanesulfonyl chloride (0.14 mL,
3.1 mmol) was added and the resulting mixture was stirred at
0.degree. C. for 1 hour then at room temperature for 2 hours. The
reaction mixture was washed with water and saturated aqueous sodium
bicarbonate solution, dried over anhydrous sodium sulfate, filtered
and concentrated to give methyl
3,6-anhydro-2-O-methyl-5-O-(methylsulfonyl)-.beta.-L-glucofuranoside
as a colorless oil, 669 mg, 95% yield, which was used without
further purification.
Example 59
[0466] 3,6-anhydro-5-O-(phenylcarbonyl)-.alpha.-L-glucofuranose: A
mixture of osmium tetroxide (4% in water, 0.25 mL, 0.03 mmol) and
N-methylmorpholine (505 mg, 4.3 mmol) in 3 mL of 50% acetone in
water was warmed to 60.degree. C. A solution of
1,4:3,6-dianhydro-2-deoxy-5-O-(phenylcarbonyl)-L-arabino-hex-1-enitol
(2.00 g, 8.6 mmol) in 6 mL of 50% acetone in water was added over 3
hours. During this time an additional amount of N-methylmorpholine
(1.01 g, 8.6 mmol) was added in small portions periodically. Upon
completion of the addition process the reaction was stirred for
another hour and cooled to room temperature. The crude mixture was
applied to a column of silica gel and flashed (0-6% methanol in 1:1
ethyl acetate:hexane) to give
3,6-anhydro-5-O-(phenylcarbonyl)-.alpha.-L-glucofuranose as a white
solid, 1.5 g, 65% yield. .sup.1H NMR (400 MHz; DMSO-d.sub.6):
8.01-7.95, (m, 2H), 7.68-7.66 (m, 1H), 7.57-7.53 (m, 2H), 5.18-5.11
(m, 2H), 4.85-4.81 (m, 1H, m), 4.37-4.35 (m, 1H), 4.05-3.96 (m,
2H), 3.85-3.83 (m, 1H).
[0467]
3,6-anhydro-2-O-methyl-5-O-(phenylcarbonyl)-.alpha.-L-glucofuranosi-
de: 3,6-Anhydro-5-O-(phenylcarbonyl)-.alpha.-L-glucofuranose (576
mg, 2.2 mmol) was added to a mixture of sodium hydride (60% oil
dispersion, 346 mg, 8.7 mmol) and methyl iodide (0.54 mL, 8.7 mmol)
in 5 mL of DMF at 0.degree. C. and the resulting mixture was
stirred for 1 hour. The reaction mixture was diluted with ethyl
acetate and quenched with water (5 mL). The aqueous portion was
extracted with ethyl acetate (3.times.5 mL). The combined organic
portion was washed with brine, dried over anhydrous sodium sulfate,
filtered, and concentrated. The residue was purified by flashed
chromatography (silica gel, 5-20% ethyl acetate in hexane) to give
3,6-anhydro-2-O-methyl-5-O-(phenylcarbonyl)-.alpha.-L-glucofuranoside
as a white solid, 270 mg, 42% yield. .sup.1H NMR (400 MHz;
CDCl.sub.3): 8.09-8.07 (m, 2H), 7.61-7.57 (m, 1H), 7.48-7.27 (m,
2H), 5.25-5.22 (m, 1H), 5.07-5.06 (d, 1H), 4.94-4.91 (m, 1H),
4.73-4.71 (m, 1H), 4.20-4.16 (m, 1H), 3.96-3.94 (m, 1H), 3.85-3.83
(tr, 1H), 3.50 (s, 3H), 3.42 (s, 3H).
[0468] Methyl
3,6-anhydro-2-O-methyl-5-O-(methylsulfonyl)-.alpha.-L-glucofuranoside:
A solution of methyl
3,6-anhydro-2-O-methyl-5-O-(phenylcarbonyl)-.alpha.-L-glucofuranoside
(230 mg, 0.92 mmol) and 50% sodium hydroxide (74 mg, 0.92 mmol) in
methanol (5 mL) was stirred at room temperature for 30 minutes. The
mixture was adsorbed on silica gel (2 g) and passed through a short
column (15% ethyl acetate in hexanes to 5% methanol in ethyl
acetate) to afford a colorless oil which was employed directly in
the next step, 140 mg, 0.72 mmol, 95% yield. The alcohol was
dissolved in dichloromethane (5 mL) and pyridine (121 .mu.L, 1.03
mmol) was added at 0.degree. C. Methanesulfonyl chloride (27 .mu.L,
0.88 mmol) was added and the resulting mixture was stirred at
0.degree. C. for 1 hour then at room temperature for 2 hours. The
reaction mixture was washed with water and saturated aqueous sodium
bicarbonate solution, dried over sodium sulfate, filtered and
concentrated to give methyl
3,6-anhydro-2-O-methyl-5-O-(methylsulfonyl)-.alpha.-L-glucofuranoside
as a colorless oil, 190 mg, 96% yield.
Example 60
[0469] 3
6-Anhydro-1,2-O-(1-methylethylidene)-5-O-(phenylcarbonyl)-.alpha.-
-L-glucofuranose: A mixture of
3,6-anhydro-5-O-(phenylcarbonyl)-.alpha.-L-glucofuranose (1.00 g),
2,2-dimethoxy propane (0.63 mL), p-toluenesulfonic acid (20 mg) and
benzene (10 mL) was heated at reflux for 3 hours. The reaction
mixture was cooled then adsorbed on silica gel (10 g) and purified
by flash chromatography (silica gel, 5-35% ethyl acetate in
hexanes) to give
3,6-anhydro-1,2-O-(1-methylethylidene)-5-O-(phenylcarbonyl)-.alpha.-L-glu-
cofuranose as colorless oil, 0.85 g, 74% yield. .sup.1H NMR (400
MHz; CDCl.sub.3): 8.08-8.06 (d, 2H), 7.59-7.56 (tr, 1H), 7.46-7.42
(m, 2H), 5.99-5.98 (d, 1H), 5.35-5.31 (tr, 1H), 5.10-5.08 (d, 1H),
4.66-4.65 (d, 1H), 4.61-4.60 (d, 1H), 4.20-4.16 (dd, 1H), 3.91-3.74
(tr, 1H,), 1.50 (s, 3H), 1.34 (s, 3H).
[0470]
3,6-Anhydro-1,2-O-(1-methylethylidene)-5-O-(methylsulfonyl)-.alpha.-
-L-glucofuranose: A solution of
3,6-anhydro-1,2-O-(1-methylethylidene)-5-O-(phenylcarbonyl)-.alpha.-L-glu-
cofuranose (850 mg) and 50% sodium hydroxide (111 mg) in methanol
(10 mL) was stirred at room temperature for 30 minutes. The mixture
was then adsorbed on silica gel (5 g) and passed through a short
column (15% ethyl acetate in hexanes to 5% methanol in ethyl
acetate) and the alcohol intermediate, 390 mg, 70% yield, was used
immediately in the next step. The alcohol was dissolved in
dichloromethane (10 mL) and pyridine (0.32 mL) at 0.degree. C.
Methanesulfonyl chloride (0.12 mL) was added and the resulting
mixture was stirred at 0.degree. C. for 1 hour then at room
temperature for 2 hours. The reaction mixture was washed with water
and saturated aqueous sodium bicarbonate solution, dried over
anhydrous sodium sulfate, filtered and concentrated to give
3,6-anhydro-1,2-O-(1-methylethylidene)-5-O-(methylsulfonyl)-.alpha.-L-glu-
cofuranose as a colorless oil, 485 mg, 90% yield, which was
immediately employed in the next step.
Example 61
[0471]
(3S,8aS)-3-(Chloromethyl)hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine:
(S)-(+)-Prolinol (6.00 g, 59.3 mmol) was added to epichlorohydrin
(47 mL, 600 mmol) at 0.degree. C. The solution was stirred at
40.degree. C. for 0.5 h and then concentrated in vacuo. The
residual oil was cooled in an ice bath and concentrated sulfuric
acid (18 mL) was added dropwise with stirring. The mixture was
heated at 170-180.degree. C. for 1.5 h, poured into ice (300 mL)
and then basified with sodium carbonate to pH.about.8. The mixture
was partitioned with ethyl acetate/hexanes and filtered. The
filtrate was separated and the aqueous portion was extracted twice
with ethyl acetate. The combined organic portion was dried over
sodium sulfate, filtered and concentrated in vacuo to afford oil
that was purified by column chromatography (ethyl acetate for less
polar product and then 30% methanol in ethyl acetate).
(3S,8aS)-3-(Chloromethyl)hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine
(less polar product) (1.87 g, 10.7 mmol, 18% yield): .sup.1H NMR
(400 MHz, CDCl.sub.3): 4.06 (dd, 1H), 3.79-3.71 (m, 1H), 3.60-3.48
(m, 2H), 3.36 (dd, 1H), 3.15 (dd, 1H), 3.13-3.06 (m, 1H), 2.21-2.01
(m, 3H), 1.90-1.68 (m, 3H), 1.39-1.24 (m, 1H); MS (EI) for
C.sub.8H.sub.14NOCl: 176 (MH.sup.+).
(3R,8aS)-3-(Chloromethyl)hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine
(1.54 g, 8.77 mmol, 15% yield): .sup.1H NMR (400 MHz, CDCl.sub.3):
3.94-3.77 (m, 4H), 3.55 (dd, 1H), 3.02-2.93 (m, 2H), 2.45 (dd, 1H),
2.29-2.15 (m, 2H), 1.88-1.64 (m, 3H), 1.49-1.38 (m, 1H); MS (EI)
for C.sub.8H.sub.14NOCl: 176 (MH.sup.+).
[0472] Using the same or analogous synthetic techniques and/or
substituting with alternative starting materials, the following
were prepared:
[0473]
(3R,8aR)-3-(Chloromethyl)hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine:
.sup.1H NMR (400 MHz, CDCl.sub.3): 4.05 (dd, 1H), 3.79-3.70 (m,
1H), 3.61-3.48 (m, 2H), 3.35 (dd, 1H), 3.15 (dd, 1H), 3.13-3.07 (m,
1H), 2.21-2.01 (m, 3H), 1.89-1.67 (m, 3H), 1.39-1.25 (m, 1H); MS
(EI) for C.sub.8H.sub.14NOCl: 176 (MH.sup.+).
[0474]
(3S,8aR)-3-(Chloromethyl)hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine:
.sup.1H NMR (400 MHz, CDCl.sub.3): 3.93-3.77 (m, 4H), 3.55 (dd,
1H), 3.02-2.93 (m, 2H), 2.45 (dd, 1H), 2.30-2.15 (m, 2H), 1.88-1.64
(m, 3H), 1.49-1.37 (m, 1H); MS (EI) for C.sub.8H.sub.14NOCl: 176
(MH.sup.+).
Example 62
[0475] (3S,8aS)-Hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl
acetate:
(3S,8aS)-3-(Chloromethyl)hexahydro-1H-pyrrolo[2,1-c][1,4]oxazine
(2.30 g, 13.1 mmol) and potassium acetate (12.8 g, 131 mmol) were
stirred in dimethylformamide (25 mL) at 140.degree. C. for 20 h.
The mixture was partitioned between ethyl acetate and water. The
organic portion was washed twice with water, then with brine, dried
over sodium sulfate, filtered and concentrated in vacuo to afford
(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl acetate
as a brown oil (2.53 g, 12.7 mmol, 97% yield). .sup.1H NMR (400
MHz, CDCl.sub.3): 4.14-4.02 (m, 3H), 3.81-3.72 (m, 1H), 3.37-3.31
(m, 1H), 3.09 (dt, 1H), 3.00 (dd, 1H), 2.21-2.00 (m, 3H), 2.10 (s,
3H), 1.90-1.67 (m, 3H), 1.39-1.24 (m, 1H); MS (EI) for
C.sub.00H.sub.17NO.sub.3: 200 (MH.sup.+).
[0476] (3S,8aS)-Hexahydro-1H-pyrrolo[2,1-c][41]oxazin-3-ylmethanol:
(3S,8aS)-Hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl acetate
(2.36 g, 11.9 mmol) was treated with sodium methoxide (25 wt %
solution in methanol; 2.7 mL) for 0.5 h. The mixture was cooled in
an ice bath and a solution of 4M HCl in 1,4-dioxane (3 mL, 12.0
mmol) was added slowly. The mixture was stirred at room temperature
for 5 minutes and then was concentrated in vacuo to afford a
suspension which was diluted with dichloromethane, filtered and the
filtrate was concentrated in vacuo to afford
(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethanol as a
brown oil (1.93 g, >100% yield). .sup.1H NMR (400 MHz,
CDCl.sub.3): 4.05 (dd, 1H), 3.73-3.65 (m, 2H), 3.62-3.56 (m, 1H),
3.39-3.34 (m, 1H), 3.10 (dt, 1H), 3.00-2.95 (m, 1H), 2.24-1.98 (m,
4H), 1.97-1.70 (m, 3H), 1.44-1.28 (m, 1H); MS (EI) for
C.sub.8H.sub.15NO.sub.2: 158 (MH.sup.+).
[0477] (3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl
methanesulfonate:
(3S,8aS)-Hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethanol (1.00
g, 6.37 mmol) was dissolved in dichloromethane (10 mL) and
triethylamine (2.4 mL, 17.3 mmol) was added at 0.degree. C.
followed by dropwise addition of methanesulfonyl chloride (0.93 mL,
12.0 mmol). The solution was warmed to room temperature and stirred
for 1.25 h and then was concentrated in vacuo. The residue was
partitioned between ethyl acetate and saturated sodium bicarbonate
solution. The organic portion was washed with saturated sodium
bicarbonate solution. The combined aqueous portion was extracted
with ethyl acetate. The combined organic portion was washed with
brine, dried over sodium sulfate, filtered and concentrated in
vacuo to afford
(3S,8aS)-hexahydro-1H-pyrrolo[2,1-c][1,4]oxazin-3-ylmethyl
methanesulfonate as an orange-brown oil (1.20 g, 5.1 mmol, 80%
yield). MS (EI) for C.sub.9H.sub.17NO.sub.4S: 236 (MH.sup.+).
Example 63
[0478] Octahydro-2H-quinolizin-3-ylmethanol: Ethyl
octahydro-2H-quinolizine-3-carboxylate (2.35 g, 11.1 mmol) was
added dropwise to a stirred suspension of lithium aluminum hydride
(1 M solution in tetrahydrofuran, 33 mL, 33 mmol) in
tetrahydrofuran (50 mL) at 0.degree. C. The reaction was stirred at
room temperature for 3 h. The mixture was cooled in an ice bath and
ethyl acetate (6 mL) was added slowly, followed by water (1.25 mL),
15% aqueous sodium hydroxide solution (5 mL) and water (1.25 mL).
The mixture was filtered through a pad of celite and washed with
ether. The filtrate was concentrated in vacuo and dried rigorously
to afford octahydro-2H-quinolizin-3-ylmethanol as a yellow oil
(1.66 g, 9.82 mmol, 88% yield). MS (EI) for C.sub.10H.sub.19NO: 170
(MH.sup.+).
[0479] Octahydro-2H-quinolizin-3-ylmethyl methanesulfonate:
Octahydro-2H-quinolizin-3-ylmethanol (600 mg, 3.55 mmol) was
dissolved in dichloromethane (8 mL) and triethylamine (1.5 mL, 10.8
mmol) was added at 0.degree. C. followed by dropwise addition of
methanesulfonyl chloride (0.56 mL, 7.16 mmol). The solution was
warmed to room temperature and stirred for 1.25 h and then was
concentrated in vacuo. The residue was partitioned between ethyl
acetate and saturated sodium bicarbonate solution. The aqueous
portion was extracted with ethyl acetate. The combined organic
portion was washed with brine, dried over sodium sulfate, filtered
and concentrated in vacuo to afford
octahydro-2H-quinolizin-3-ylmethyl methanesulfonate as an orange
oil (796 mg, 3.22 mmol, 91% yield). MS (EI) for
C.sub.11H.sub.21NO.sub.3S: 248 (MH.sup.+).
Example 64
[0480]
(3S,8aS)-3-(Hydroxymethyl)hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one:
A solution of methyl
1-[(2S)-3-hydroxy-2-({[(phenylmethyl)oxy]carbonyl}amino)propyl]-L-prolina-
te (3.50 g, 10.4 mmol) in methanol was added to 5% palladium on
carbon (50 wt. % in water) in methanol and treated with hydrogen at
40 psi for 1 h. The mixture was filtered and the filtrate was
brought to reflux briefly and then cooled and concentrated in vacuo
to afford
(3S,8aS)-3-(hydroxymethyl)hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one
as a colorless solid (1.50 g, 8.83 mmol, 85% yield). .sup.1H NMR
(400 MHz, CDCl.sub.3): 7.28-7.22 (m, 1H), 3.83-3.75 (m, 1H), 3.69
(dd, 1H), 3.56 (dd, 1H), 3.31 (t, 1H), 3.08 (dd, 1H), 2.92 (dt,
1H), 2.76-2.70 (m, 1H), 2.66 (dd, 1H), 2.28-2.16 (m, 1H), 2.02-1.73
(m, 3H); MS (EI) for C.sub.8H.sub.14N.sub.2O.sub.2: 171
(MH.sup.+).
[0481] (3S
8aS)-3-({[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}methyl)hexahyd-
ro-pyrrolo[1,2-a]pyrazin-1(2H)-one: To a solution of
(3S,8aS)-3-(hydroxymethyl) hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one
(1.49 g, 8.82 mmol) in dimethylformamide (20 mL) was added
triethylamine (2.45 mL, 17.6 mmol) and 4-dimethylaminopyridine (90
mg, 0.882 mmol). The solution was cooled in an ice bath and
tert-butyldimethylsilyl chloride (2.66 g, 17.6 mmol) was added. The
mixture was warmed to room temperature and stirred for 14 h. The
mixture was concentrated in vacuo and the residue was partitioned
between ethyl acetate and water. The aqueous portion was extracted
twice with ethyl acetate. The combined organic portion was dried
over sodium sulfate, filtered and concentrated in vacuo to afford a
pale brown solid which was triturated with ethyl acetate to afford
(3S,8aS)-3-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)
hexahydropyrrolo[1,2-a]pyrazin-1(2H)-one as an off-white solid
(1.74 g, 5.84 mmol, 66% yield). .sup.1H NMR (400 MHz, CDCl.sub.3):
6.09-5.90 (m, 1H), 3.86-3.76 (m, 1H), 3.63 (dd, 1H), 3.44 (dd, 1H),
3.25 (t, 1H), 3.10 (ddd, 1H), 2.98-2.90 (m, 1H), 2.68-2.60 (m, 1H),
2.52 (dd, 1H), 2.28-2.18 (m, 1H), 2.06-1.95 (m, 1H), 1.93-1.74 (m,
2H), 0.90 (s, 9H), 0.07 (s, 6H); MS (EI) for
C.sub.14H.sub.28N.sub.2O.sub.2Si: 285 (MH.sup.+).
[0482]
(3S,8aS)-3-({[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}methyl)-2-meth-
ylhexahydropyrrolo[1,2-a]pyrazin-1(2H)-one:
(3S,8aS)-3-({[(1,1-Dimethylethyl)(dimethyl)silyl]oxy}methyl)hexahydropyrr-
olo[1,2-a]pyrazin-1(2H)-one (1.51 g, 5.32 mmol) in
dimethylformamide (8 mL) was added to an ice-cooled suspension of
sodium hydride (60 wt. % dispersion in oil; 213 mg, 5.32 mmol) in
dimethylformamide (8 mL). The mixture was stirred at 0.degree. C.
for 0.25 h and then iodomethane (0.332 mL, 5.32 mmol) was added
dropwise. The mixture was stirred at room temperature for 0.5 h and
then was stirred at 70.degree. C. for 2 h. The mixture was
concentrated in vacuo and the residue was partitioned between ethyl
acetate and water. The aqueous portion was extracted with ethyl
acetate. The combined organic portion was dried over sodium
sulfate, filtered and concentrated in vacuo to afford
(3S,8aS)-3-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)-2-methylhexa-
hydropyrrolo[1,2-a]pyrazin-1(2H)-one as a yellow oil (1.552 g, 5.21
mmol) which was dissolved in tetrahydrofuran (20 mL) and treated
with tetrabutylammonium fluoride (1.0M solution in tetrahydrofuran;
10.4 mL, 10.4 mmol) for 2 h at room temperature. The mixture was
concentrated in vacuo and purified by column chromatography (10%
methanol in dichloromethane) to afford
(3S,8aS)-3-(hydroxymethyl)-2-methylhexahydropyrrolo[1,2-a]pyrazin-1(2H)-o-
ne as a yellow oil (496 mg, 2.70 mmol, 51% yield from
(3S,8aS)-3-({[(1,1-dimethylethyl)(dimethyl)silyl]oxy}methyl)hexahydropyrr-
olo[1,2-a]pyrazin-1(2H)-one). .sup.1H NMR (400 MHz, CDCl.sub.3):
3.98-3.93 (m, 1H), 3.86 (dd, 1H), 3.61-3.55 (m, 1H), 3.29-3.25 (m,
1H), 3.09-3.03 (m, 1H), 3.03-2.97 (m, 1H), 3.02 (s, 3H), 2.93 (dd,
1H), 2.87-2.79 (m, 1H), 2.32-2.21 (m, 1H), 2.00-1.86 (m, 2H),
1.83-1.64 (m, 1H); MS (EI) for C.sub.9H.sub.16N.sub.2O.sub.2: 185
(MH.sup.+).
Example 65
[0483]
1,2-Dideoxy-1-[(2S)-2-(methoxycarbonyl)-1-pyrrolidinyl]-2-[[(phenyl-
methoxy) carbonyl]amino]-D-glycero-hexitol: To a solution of
2-deoxy-2-{[(phenylmethyloxy)carbonyl]amino}-D-glycero-hexopyranose
(5.0 g, 0.016 mol) in methanol (500 mL) was added L-proline methyl
ester hydrochloride (2.8 g, 0.022 mol) and sodium cyanoborohydride
(3.4 g, 0.054 mol). The solution was heated to 64.degree. C. for 14
h. After cooling to room temperature, the reaction mixture was
concentrated in vacuo to afford
1,2-dideoxy-1-[(2S)-2-(methoxycarbonyl)-1-pyrrolidinyl]-2-[[(phenylmethox-
y)carbonyl]amino]-D-glycero-hexitol (6.81 g, 100%) as a clear and
colorless oil. MS (EI) for C.sub.20H.sub.31N.sub.2O.sub.8: 427
(MH.sup.+).
Example 66
[0484] Methyl
1-[(2S)-3-hydroxy-2-({[(phenylmethyl)oxy]carbonyl}amino)propyl]-L-prolina-
te:
1,2-dideoxy-1-[(2S)-2-(methoxycarbonyl)-1-pyrrolidinyl]-2-[[(phenylmet-
hoxy)carbonyl]amino]-D-glycero-hexitol (6.81 g, 0.016 mol) was
taken into water (100 mL) and the resulting solution was cooled to
0.degree. C. Sodium periodiate (14.8 g, 0.069 mol) dissolved in
water was added dropwise and the resulting mixture was stirred at
0.degree. C. for 2 h. The reaction mixture was partitioned with
dichloromethane (3.times.100 mL), dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo. The residue was taken
up in methanol (200 mL) and the resulting solution was cooled to
0.degree. C. Sodium borohydride (1.98 g, 0.052 mol) was added and
the reaction mixture was stirred for 1 h at 0.degree. C. The
reaction mixture was concentrated in vacuo and partitioned with
dichloromethane and saturated aqueous ammonium chloride. The
organic layer was dried over anhydrous magnesium sulfate, filtered
and concentrated in vacuo. The resulting crude product was purified
by column chromatography (5% methanol in dichloromethane) to yield
methyl
1-[(2S)-3-hydroxy-2-({[(phenylmethyl)oxy]carbonyl}amino)propyl]-L-prolina-
te (4.9 g, 92%) as a white solid. MS (EI) for
C.sub.17H.sub.25N.sub.2O.sub.5: 337 (MH.sup.+).
[0485] Methyl
1-[(2S)-3-[(methylsulfonyl)oxy]-2-({[(phenylmethyl)oxy]carbonyl}amino)pro-
pyl]-L-prolinate: Methyl
1-[(2S)-3-hydroxy-2-({[(phenylmethyl)oxy]carbonyl}amino)propyl]-L-prolina-
te (200 mg, 0.594 mmol) was dissolved in dichloromethane (5 mL)
followed by the addition of 4-(dimethylamino)pyridine (3.6 mg,
0.039 mmol) and triethylamine (0.125 mL, 0.891 mmol) and the
resulting mixture was cooled to 0.degree. C. Methanesulfonyl
chloride (0.060 mL, 0.773 mmol) was added dropwise and the reaction
mixture was stirred for 1 h at 0.degree. C. The mixture was
partitioned between dichloromethane and saturated aqueous sodium
bicarbonate. The organic layer was dried over anhydrous magnesium
sulfate, filtered and concentrated in vacuo to afford methyl
1-[(2S)-3-[(methylsulfonyl)oxy]-2-({[(phenylmethyl)oxy]carbonyl}amino)pro-
pyl]-L-prolinate (246 mg, 100%) as a clear and colorless oil. MS
(EI) for C.sub.18H.sub.27N.sub.2O.sub.7S: 415 (MH.sup.+).
Example 67
[0486] 1,1-Dimethylethyl
(3aR,6aS)-5-(hydroxymethyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylat-
e: Under a nitrogen atmosphere, borane tetrahydrofuran complex (1M
in THF, 42 mL, 41.9 mmol) was diluted with tetrahydrofuran (42 mL)
and cooled with an ice bath. Neat 2,3-dimethylbut-2-ene (5.0 mL,
41.9 mmol) was added in portions over 0.25 h and the solution was
stirred at 0.degree. C. for 3 h. A solution of 1,1-dimethylethyl
(3aR,6aS)-5-methylidenehexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
(1.98 g, 8.88 mmol) in tetrahydrofuran (10 mL) was added slowly,
and the solution was warmed to room temperature and stirred 12 h.
After cooling to 0.degree. C., 10% aqueous sodium hydroxide (17 mL,
41.7 mmol) was added slowly, followed by 30% aqueous hydrogen
peroxide (13 mL, 128 mmol) and the solution was warmed to room
temperature. The solvent was removed in vacuo and the solution was
partitioned between water and diethyl ether. The layers were
separated and the aqueous layer was further extracted (3.times.50
mL diethyl ether). The combined organic layers were dried over
anhydrous sodium sulfate, filtered and concentrated in vacuo to
provide 2.04 (95%) of 1,1-dimethylethyl
(3aR,6aS)-5-(hydroxymethyl)hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylat-
e, which was used without purification. .sup.1H NMR (400 MHz,
CDCl.sub.3): 8.50 (broad s, 1H), 3.66-3.46 (m, 3H), 3.20-3.00 (m,
2H), 2.70-2.59 (m, 2H), 2.37-2.18 (m, 1H), 2.04 (m, 1H), 1.84
(broad s, 1H), 1.70-1.55 (m, 1H), 1.46 (s, 9H), 1.17 (m, 1H), 0.93
(m, 1H).
[0487] 1,1-Dimethylethyl
(3aR,6aS)-5-{[(methylsulfonyl)oxy]methyl}hexahydrocyclopenta[c]pyrrole-2(-
1H)-carboxylate: Methanesulfonyl chloride (0.2 mL, 2.48 mmol), was
added dropwise to a solution of 1,1-dimethylethyl
(3aR,6aS)-5-(hydroxymethyl)hexahydro
cyclopenta[c]pyrrole-2(1H)-carboxylate (0.40 g, 1.65 mmol) and
triethylamine (0.69 mL, 4.95 mmol) in 20 mL dichloromethane at
0.degree. C. and the reaction mixture was stirred for 1 h at room
temperature. The solvent was evaporated, the resulting crude
mixture was diluted with 100 mL ethyl acetate and washed with water
(30 mL), 1M aqueous sodium hydroxide, brine, 1M aqueous
hydrochloric acid and brine again. The organic layer was dried over
anhydrous sodium sulfate, filtered and concentrated in vacuo. The
resulting 1,1-dimethylethyl
(3aR,6aS)-5-{[(methylsulfonyl)oxy]methyl}hexahydrocyclopenta[c]pyrrole-2(-
1H)-carboxylate was used without further purification. MS (EI) for
C.sub.14H.sub.25NO.sub.5S: 320 (MH.sup.+), 264 (M-tBu).
Example 68
[0488] 1,1-Dimethylethyl
(3aR,6aS)-5-(hydroxy)-hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate:
Sodium borohydride (0.15 g, 4.00 mmol), was added to a solution of
1,1-dimethylethyl
(3aR,6aS)-5-oxo-hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
(0.45 g, 2.00 mmol) in 10 mL methanol at 0.degree. C. and the
reaction mixture was stirred for 1 h at this temperature. The
solvent was evaporated, the crude mixture was diluted with 100 mL
ethyl acetate and washed with water (30 mL), 1M aqueous
hydrochloric acid and brine. The organic layer was dried over
anhydrous sodium sulfate, filtered and concentrated to give
1,1-dimethylethyl
(3aR,6aS)-5-(hydroxy)-hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
(0.44 g, 98%). .sup.1H NMR (400 MHz, d.sub.6-DMSO): 4.08 (m, 1H),
3.40 (m, 2H), 3.30 (m, 2H), 2.50 (m, 2H), 1.98 (m, 2H), 1.40 (s,
9H), 1.30 (m, 2H). MS (EI) for C.sub.12H.sub.21NO.sub.3: 228
(MH.sup.+).
[0489] 1,1-Dimethylethyl
(3aR,6aS)-5-{[(methylsulfonyl)oxy]}hexahydrocyclopenta[c]pyrrole-2(1H)-ca-
rboxylate: Methanesulfonyl chloride (0.18 mL, 2.33 mmol), was added
dropwise to a solution of 1,1-dimethylethyl
(3aR,6aS)-5-(hydroxy)-hexahydrocyclopenta[c]pyrrole-2(1H)-carboxylate
(0.44 g, 1.94 mmol) and triethylamine (0.81 mL, 5.81 mmol) in 10 mL
dichloromethane at 0.degree. C. and the reaction mixture was
stirred for 1 h at room temperature. The solvent was evaporated,
the resulting crude mixture was diluted with 100 mL ethyl acetate
and washed with water (30 mL), brine, 1M aqueous hydrochloric acid
and brine again. The organic layer was dried over anhydrous sodium
sulfate, filtered and concentrated. The resulting crude
1,1-dimethylethyl
(3aR,6aS)-5-{[(methylsulfonyl)oxy]}hexahydrocyclopenta[c]pyrrole-2(1H)-ca-
rboxylate was used without further purification. MS (EI) for
C.sub.13H.sub.23NO.sub.5S: 306 (MH.sup.+).
Example 69
[0490]
3-(Chloromethyl)hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazine: A
solution of (3R)-morpholin-3-ylmethanol (4.21 g, 36.0 mmol) in
2-(chloromethyl)oxirane (28.2 mL, 0.360 mol) was heated to
40.degree. C. for 3 h and then the solution was concentrated in
vacuo. The intermediate was cooled in an ice bath and treated with
30.0 mL of concentrated sulfuric acid. The mixture was heated to
170.degree. C. for 2 h and then allowed to cool to room
temperature. The mixture was poured into ice-water and solid sodium
bicarbonate was carefully added until the solution was basic. 10%
methanol in ethyl acetate was added and the biphasic mixture was
filtered. The layers were separated and the aqueous layer was
extracted (3.times.100 mL 10% methanol in ethyl acetate). The
combined organic layers were dried over anhydrous sodium sulfate,
filtered and concentrated in vacuo. Column chromatography
(SiO.sub.2, 2:5 hexanes:ethyl acetate) provided
3-(chloromethyl)hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazine 2.44 g
(35%) as two separated diastereomers.
(3R,9aS)-3-(chloromethyl)hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazine:
(0.886 g, 13% yield): .sup.1H NMR (400 MHz, CDCl.sub.3): 3.91 (m,
3H), 3.82 (m, 1H), 3.68 (dt, 1H), 3.61 (dd, 1H), 3.47 (dd, 1H),
3.35 (t, 1H), 3.19 (t, 1H), 2.80 (d, 1H), 2.54 (m, 2H), 2.40 (m,
2H); MS (EI) for C.sub.8H.sub.14NO.sub.2Cl: 192 (MH.sup.+).
(3S,9aS)-3-(chloromethyl)hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazine:
(1.55 g, 22% yield): .sup.1H NMR (400 MHz, CDCl.sub.3): 3.85 (m,
2H), 3.73 (m, 3H), 3.50 (m, 2H), 3.29 (t, 1H), 3.18 (t, 1H), 2.85
(dd, 1H), 2.64 (dd, 1H), 2.40 (m, 2H), 2.17 (t, 1H); MS (EI) for
C.sub.8H.sub.14NO.sub.2CI: 192 (MH.sup.+).
[0491] Hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl
acetate: A suspension of
(3R,9aS)-3-(chloromethyl)hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazine
(1.97 g, 10.3 mmol) and potassium acetate (10.1 g, 102 mmol) in DMF
(20.0 mL) was stirred at 140.degree. C. for 16 h, and then at
150.degree. C. for another 12 h. The reaction mixture was
partitioned between water (250 mL) and ethyl acetate (250 mL), the
organic layer was washed with 5% lithium chloride (2.times.100 mL)
and brine (100 mL) then dried over anhydrous sodium sulfate and
concentrated in vacuo. Column chromatography (SiO.sub.2, 1:1
hexane:ethyl acetate, then 100% ethyl acetate) afforded 0.92 g
(42%) of hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl
acetate as a yellow oil. Distinct diastereomers as described above
were converted in this step to give:
(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl
acetate: .sup.1H NMR (400 MHz, CDCl.sub.3): 4.18 (dd, 1H), 4.00 (m,
1H), 3.80 (dd, 1H), 3.68 (dt, 1H), 3.60 (dd, 1H), 3.46 (m, 2H),
3.22 (t, 1H), 2.64 (dd, 1H), 2.53 (m, 2H), 2.43-2.35 (m, 2H), 2.10
(s, 3H), and
(3S,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl
acetate: .sup.1H NMR (400 MHz, CDCl.sub.3): 4.09 (d, 2H), 3.90-3.82
(m, 2H), 3.75-3.64 (m, 3H), 3.27 (t, 1H), 3.18 (t, 1H), 2.69 (dd,
1H), 2.63 (m, 1H), 2.46-2.33 (m, 2H), 2.16 (t, 1H), 2.10 (s,
3H).
[0492]
(3R,9aS)-Hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl
methanesulfonate: To a solution of
(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl
acetate (0.922 g, 4.28 mmol) in methanol (14.0 mL) was added 1.03
mL (4.50 mmol) of sodium methoxide (25% wt. in methanol) dropwise
at room temperature. After 5 min., 1.6 mL (6.43 mmol) of 4.0M
hydrogen chloride in dioxane was added and a pink precipitate
formed. The solution was concentrated in vacuo and the pink solid
was taken up in 30.0 mL dichloromethane. This slurry was cooled in
an ice bath and triethylamine (3.0 mL, 21.5 mmol) was added,
followed by methanesulfonyl chloride (0.37 mL, 4.71 mmol). The
resultant yellow solution was stirred for 30 minutes at room
temperature. The mixture was then partitioned between
dichloromethane and saturated aqueous sodium bicarbonate then the
aqueous layer was extracted (3.times.50 mL dichloromethane). The
combined organic layers were dried over anhydrous sodium sulfate,
filtered and concentrated in vacuo to provide crude
(3R,9aS)-hexahydro-1H-[1,4]oxazino[3,4-c][1,4]oxazin-3-ylmethyl
methanesulfonate which was taken on to the following reaction
without purification.
Example 70
[0493]
(8aR)-6-(Chloromethyl)tetrahydro-1H-[1,3]thiazolo[4,3-c][1,4]oxazin-
e: A solution of (4R)-1,3-thiazolidin-4-ylmethanol (0.300 g, 2.52
mmol) in 2-(chloromethyl)oxirane (2.0 mL, 25.5 mmol) was heated
under nitrogen to 40.degree. C. for 12 h. The solution was then
cooled to room temperature and 2-(chloromethyl)oxirane was removed
in vacuo. The crude intermediate was cooled in ice, and was taken
up in 2.0 mL of concentrated sulfuric acid. The resulting mixture
was heated to 200.degree. C. for 0.5 h then poured carefully onto
wet ice, which was allowed to melt. The aqueous solution was
carefully made basic using solid sodium bicarbonate and the
resulting mixture was filtered using water and 10% methanol in
ethyl acetate as eluent. The layers were separated and the aqueous
layer was extracted with 10% methanol in ethyl acetate. The
combined organic layers were dried over anhydrous sodium sulfate,
filtered, and concentrated in vacuo to give 11.6 mg (2.4% yield) of
crude
(8aR)-6-(chloromethyl)tetrahydro-1H-[1,3]thiazolo[4,3-c][1,4]oxazine
as a mixture of diastereomers which was directly taken on to the
next step.
Example 71
[0494] 1,1-Dimethylethyl
(3-endo)-3-{2-[(methylsulfonyl)oxy]ethyl}-8-azabicyclo[3.2.1]octane-8-car-
boxylate: To a solution of 1,1-dimethylethyl
(3-endo)-3-(2-hydroxyethyl)-8-azabicyclo[3.2.1]octane-8-carboxylate
(30.3 mg, 1.19 mmol) in dichloromethane (4.0 mL), was added
triethylamine (0.5 mL, 3.56 mmol) and the solution was cooled to
0.degree. C. under nitrogen. Methanesulfonyl chloride (0.11 mL,
1.42 mmol) was added slowly and mixture was allowed to warm to room
temperature and stirred for 1 h. The reaction mixture was
partitioned between dichloromethane and water. The aqueous phase
was extracted with dichloromethane (2.times.100 mL). The combined
organic layers were dried over anhydrous sodium sulfate, filtered
and concentrated in vacuo to provide 35.1 mg (89%) of
1,1-dimethylethyl
(3-endo)-3-{2-[(methylsulfonyl)oxy]ethyl}-8-azabicyclo[3.2.1]octane-8-car-
boxylate, which was carried forward for alkylation without
purification.
Example 72
##STR00530##
[0496]
N-[3-Fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4-ylpropyl)oxy]quinaz-
olin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
Crude cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(6-hydroxy-7-methoxy-quinazolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide (333 mg, 0.66 mmol), PS-PPh.sub.3 resin,
(loading=2.33 mmol/g, 797 mg, 1.86 mmol),
3-morpholin-4-yl-propan-1-ol (0.26 ml, 1.88 mmol), and DEAD (0.31
ml, 1.91 mmol) were combined in CH.sub.2Cl.sub.2 (10 ml) and
stirred at room temperature for 1-2 hrs. The reaction mixture was
filtered and the resin thoroughly washed with CH.sub.2Cl.sub.2. The
filtrate was concentrated in vacuo and the resulting residue was
dissolved in EtOAc and washed with H.sub.2O (4.times.) and sat'd
NaCl (1.times.) and then extracted with 1N HCl (3.times.). The
combined 1N HCl extractions were washed with EtOAc (2.times.). The
acidic aqueous phase was then basified with 1N NaOH and extracted
with EtOAc (3.times.). The combined EtOAc extractions were washed
with H.sub.2O (1.times.), sat'd NaCl (1.times.), dried
(Na.sub.2SO.sub.4), and concentrated in vacuo. The resulting
residue was purified by preparative reverse phase HPLC (25 mM
NH.sub.4OAc/acetonitrile) and the pure fractions were lyophilized
to give cyclopropane-1,1-dicarboxylic acid
{3-fluoro-4-[7-methoxy-6-(3-morpholin-4-yl-propoxy)-quinazolin-4-yloxy]-p-
henyl}-amide (4-fluoro-phenyl)-amide (42.6 mg, 10%). .sup.1H NMR
(400 MHz, DMSO-d.sub.6): .delta. 10.37 (br s, 1H), 10.05 (br s,
1H), 8.55 (s, 1H), 7.84 (m, 1H), 7.65 (m, 2H), 7.58 (s, 1H), 7.43
(m, 3H), 7.16 (t, 2H), 4.27 (m, 2H), 4.00 (s, 3H), 3.60 (m, 6H),
2.39 (m, 4H), 1.99 (m, 2H), 1.47 (m, 4H). LC/MS Calcd for
[M+H].sup.+ 634.2, found 634.1.
[0497] Using the same or analogous synthetic techniques and/or
substituting with alternative starting materials, the following
were prepared:
[0498]
N-{3-fluoro-4-[(7-(methyloxy)-6-{[(1-methylpiperidin-4-yl)methyl]ox-
y}quinazolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarbox-
amide: .sup.1H NMR (400 MHz, CDCl.sub.3): .delta. 9.67 (s, 1H),
8.59 (s, 1H), 8.43 (s, 1H), 7.75 (d, 1H), 7.52 (s, 1H), 7.46 (m,
2H), 7.31 (s, 1H), 7.20 (m, 2H), 7.06 (t, 2H), 4.04 (d, 2H), 4.03
(s, 3H), 2.98 (d, 2H), 2.34 (s, 3H), 2.12-2.1.95 (m, 5H), 1.76 (m,
2H), 1.64 (m, 2H), 1.57 (m, 2H).
Example 73
##STR00531##
[0500] Preparation of
1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarbox-
ylic acid. To the cyclopropyl di-carboxylic acid (449 mg, 3.45
mmol) in THF (3.5 mL) was added TEA (485 .mu.L, 3.45 mmol). The
resulting solution was stirred at room temperature under a nitrogen
atmosphere for 40 minutes before adding thionyl chloride (250
.mu.L, 3.44 mmol). The reaction was monitored by LCMS for the
formation of mono acid chloride (quenched the sample with MeOH and
looked for corresponding mono methyl ester). After 3 hours stirring
at room temperature, 4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylamine
(1.02 g, 3.44 mmol) was added as a solid, followed by more THF (1.5
mL). Continued to stir at room temperature for 16 hours. The
resulting thick slurry was diluted with EtOAc (10 mL) and extracted
with 1N NaOH. The biphasic slurry was filtered and the aqueous
phase was acidified with conc. HCl to pH=6 and filtered. Both
solids were combined and washed with EtOAc, then dried under
vacuum. The desired product,
1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarbox-
ylic acid, was obtained (962 mg, 68.7% yield, 97% pure) as a white
solid. .sup.1H NMR (D.sub.2O/NaOH): 7.97 (d, 1H), 7.18 (d, 2H),
6.76 (m, 4H), 6.08 (d, 1H), 3.73 (s, 3H), 3.56 (s, 3H), 1.15 (d,
4H).
Example 74
##STR00532##
[0502]
'N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[(4-fluoroph-
enyl)methyl]cyclopropane-1,1-dicarboxamide. To a solution of
1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarbox-
ylic acid (74.3 mg, 0.182 mmol), 4-Fluoro benzylamine (25 .mu.L,
0.219 mmol), DIEA (90.0 .mu.L, 0.544 mmol) in DMA (1.0 mL) was
added HATU (203 mg, 0.534 mmol). The resulting solution was stirred
at room temperature for 1 hour before adding dropwise to water (10
mL) with stirring. The slurry was sonicated, filtered and the
solids were washed with 1 N NaOH followed by water. After air
drying, the solids were further purified by prep HPLC, affording
'N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[(4-fluorophenyl)m-
ethyl]cyclopropane-1,1-dicarboxamide (33 mg, 35% yield, 98% pure)
as a white solid. .sup.1H NMR (DMSO, d.sub.6): 10.82 (s, 1H), 8.80
(d, 1H), 8.50 (t, 1H), 7.83 (d, 2H), 7.74 (s, 1H), 7.56 (s, 1H),
7.30-7.38 (m, 4H), 7.15 (t, 2H), 6.80 (d, 1H), 4.32 (d, 2H), 4.04
(s, 3H), 4.03 (s, 3H), 1.42 (s, 4H).
[0503] The following compounds were prepared, in a similar manner
as above, from the coupling of
1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropane
carboxylic acid with a corresponding alkylamine or arylamine.
[0504]
N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(piperidin-
-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide. .sup.1H NMR
(DMSO-d.sub.6): 10.62 (s, 1H), 8.79 (d, 1H), 8.24 (t, 1H), 7.83 (d,
2H), 7.72 (s, 1H), 7.58 (s, 1H), 7.37 (d, 2H), 6.76 (d, 1H), 4.04
(s, 3H), 4.03 (s, 3H), 3.98 (m, 2H), 3.66 (m, 2H), 3.49 (m, 4H),
3.25 (t, 2H), 3.13 (br., 2H), 1.42 (d, 4H).
[0505]
N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(piperidin-
-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide. .sup.1H NMR
(DMSO-d.sub.6): 10.78 (s, 1H), 10.53 (s, 1H), 8.43 (d, 1H), 8.12
(d, 1H), 7.82 (d, 2H), 7.49 (s, 1H), 7.37 (s, 1H), 7.20-7.28 (m,
3H), 7.15 (dd, 1H), 7.01 (td, 1H), 6.35 (d, 1H), 3.93 (s, 3H), 3.92
(s, 3H), 3.47 (s, 2H), 2.17 (br., 4H), 1.49 (m, 4H), 1.41 (m, 4H),
1.32 (br., 2H).
[0506]
'N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(pyrrolid-
in-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide. .sup.1H NMR
(DMSO-d.sub.6): 10.98 (s, 1H), 10.56 (s, 1H), 8.42 (d, 1H), 8.10
(dd, 1H), 7.81 (m, 2H), 7.49 (s, 1H), 7.37 (s, 1H), 7.17-7.27 (m,
4H), 7.01 (td, 1H), 6.35 (d, 1H), 3.93 (s, 3H), 3.92 (s, 3H), 3.61
(s, 2H), 2.30 (br., 4H), 1.47 (br., 4H), 1.43 (m, 4H).
[0507]
'N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(morpholi-
n-4-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide. .sup.1H NMR
(DMSO-d.sub.6): 10.12 (s, 1H), 10.03 (s, 1H), 8.44 (d, 1H), 7.74
(d, 2H), 7.57 (s, 1H), 7.53 (d, 1H), 7.48 (s, 1H), 7.37 (s, 1H),
7.21 (m, 3H), 6.98 (d, 1H), 6.40 (d, 1H), 3.93 (s, 3H), 3.92 (s,
3H), 3.56 (t, 4H), 3.41 (s, 2H), 2.34 (br., 4H), 1.48 (s, 4H).
[0508]
'N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[2-(morpholi-
n-4-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide. .sup.1H NMR
(DMSO-d.sub.6): 10.54 (s, 1H), 10.47 (s, 1H), 8.43 (d, 1H), 8.08
(d, 1H), 7.78 (d, 2H), 7.49 (s, 1H), 7.37 (d, 1H), 7.18-7.30 (m,
4H), 7.03 (t, 1H), 6.37 (d, 1H), 3.94 (s, 3H), 3.93 (s, 3H), 3.50
(s, 2H), 3.44 (br., 4H), 2.20 (br., 4H), 1.48 (d, 4H).
[0509]
'N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(piperidi-
n-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide. .sup.1H NMR
(DMSO-d.sub.6): 10.0-10.2 (br., 2H), 8.46 (d, 1H), 7.76 (d, 2H),
7.53 (m, 3H), 7.39 (s, 1H), 7.24 (m, 3H), 6.98 (d, 1H), 6.43 (d,
1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.37 (s, 2H), 2.31 (br., 4H), 1.48
(m, 8H), 1.39 (br., 2H).
[0510]
'N-(4-{[6,7-Bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-[3-(pyrrolid-
in-1-ylmethyl)phenyl]cyclopropane-1,1-dicarboxamide. .sup.1H NMR
(DMSO-d.sub.6): 10.0-10.2 (br., 2H), 8.46 (d, 1H), 7.77 (d, 2H),
7.59 (s, 1H), 7.53 (d, 1H), 7.51 (s, 1H), 7.39 (s, 1H), 7.23 (m,
3H), 6.99 (d, 1H), 6.43 (d, 1H), 3.95 (s, 3H), 3.93 (s, 3H), 3.52
(s, 2H), 2.42 (br., 4H), 1.69 (br, 4H), 1.48 (s, 4H).
Example 75
##STR00533## ##STR00534##
[0512] Synthesis of
N-(4-{[6,7-bis(methyloxy)-2-(methylthio)quinolin-4-yl]oxy}-3-fluorophenyl-
)-N'-(4-fluorophenyl cyclopropane-1,1-dicarboxamide Commercially
available
5-(bis-methylsulfanyl-methylene)-2,2-dimethyl-[1,3]dioxane-4,6-dione
(3.5 g, 14 mmol) and 3,4-dimethoxyoaniline (2.2 g, 14 mmol) were
reflux in EtOH (20 mL) for 2 hours. The EtOH was removed under
reduced pressure and EtOAc was added to the residue. The product
was filtered and washed with cold EtOAc (3.times.).
5-[(3,4-dimethoxy-phenylamino)-methylsulfanyl-methylene]-2,2-dimethyl-[1,-
3]dioxane-4,6-dione was obtained as a white solid (1.7 g, 47%
yield) and used without further purification. LCMS: m/z 352
(M-H).sup.-.
[0513] A mixture of
5-[(3,4-dimethoxy-phenylamino)-methylsulfanyl-methylene]-2,2-dimethyl-[1,-
3]dioxane-4,6-dione (1.7 g, 6.6 mmol) and diphenylether (3.5 g, 21
mmol) were heated at 260.degree. C. for 10 minutes. The mixture was
cooled to room temperature and heptane was added.
6,7-Dimethoxy-2-methylsulfanyl-quinolin-4-ol was filtered and
isolated as an orange solid and used without further purification
(1.4 g, 83% yield). LCMS: m/z 352 (M+H).sup.+.
[0514] A mixture of 6,7-dimethoxy-2-methylsulfanyl-quinolin-4-ol
(1.0 g, 4.0 mmol), 3,4-difluoronitrobenzene (0.48 mL, 4.3 mmol),
cesium carbonate (2.6 g, 8.0 mmol), and DMF (15 mL) was stirred at
room temperature for 12 hours, after which time, the mixture was
filtered. The filtrate was extracted with DCM, washed with 10%
LiCl(aq.), water, (1.times.) and brine (1.times.), followed by
drying over Na.sub.2SO.sub.4 and concentration in vacuo. The crude
solids were purified by flash chromatography (silica gel, 5% MeOH
in DCM), affording the nitroquinoline (1.3 g, 85.8% yield) as an
orange solid. LCMS: m/z 391 (M+H).sup.+. A mixture of
nitroquinoline (0.33 g, 0.85 mmol), 5% Pt/S on carbon (0.050 g),
ammonium formate (0.40 g, 6.3 mmol) in EtOH (5 mL) was heated at
80.degree. C. for 1 hour The mixture was cooled to room temperature
and the solvent removed under reduced pressure. The residue was
dissolved in DCM, the mixture filtered, and the precipitate
discarded. Removal of the organic solvent afforded
4-(6,7-dimethoxy-2-methylsulfanyl-quinolin-4-yloxy)-3-fluoro-phenylamine
as an orange oil (220 mg, 73% yield). LCMS: m/z 361
(M+H).sup.+.
[0515] To a mixture of
4-(6,7-dimethoxy-2-methylsulfanyl-quinolin-4-yloxy)-3-fluoro-phenylamine
(0.22 g, 0.61 mmol) and
1-(4-Fluoro-phenylcarbamoyl)-cyclopropanecarboxylic acid (0.16 g,
0.73 mmol) in DMF (5 mL) was added TEA (0.25 mL, 1.8 mmol) followed
by HATU (0.57 g, 1.5 mmol). The resulting solution was stirred
overnight at room temperature. The reaction mixture was dumped into
water and extracted with DCM (2.times.). The combined extracts were
washed with 5% LiCl(aq) (3.times.), water, (1.times.) and brine
(1.times.), followed by drying over Na.sub.2SO.sub.4 and
concentration in vacuo. The crude solids were purified by
preparatory HPLC with ammonium acetate, affording
N-(4-{[6,7-bis(methyloxy)-2-(methylthio)quinolin-4-yl]oxy}-3-fluorophenyl-
)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide (0.39 g, 11%
yield) as a white solid. .sup.1H NMR (DMSO-d.sub.6) .delta. 10.34
(s, 1H), 9.94 (s, 1H), 7.83 (d, 1H), 7.59 (m, 2H), 7.56 (m, 1H),
7.40 (m, 2H), 7.23 (s, 1H), 7.09 (t, 2H), 6.12 (s, 1H), 3.88 (s,
3H), 3.85 (s, 3H), 2.48 (s, 3H), 1.40 (m, 4H).
Example 76
##STR00535##
[0517] Synthesis of
N-(4-{[2-amino-6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
-fluorophenyl)cyclopropane-1,1-dicarboxamide. A mixture of
5-[(3,4-dimethoxy-phenylamino)-methylsulfanyl-methylene]-2,2-dimethyl-[1,-
3]dioxane-4,6-dione (1.0 g, 2.8 mmol), 30% ammonium hydroxide (8.5
mL), HgCl.sub.2 (0.76 g, 2.8 mmol) in THF (5 mL) was stirred at
room temperature for 30 minutes. The mixture was extracted with DCM
and water (3.times.) and dried with Na.sub.2SO.sub.4. Concentration
in vacuo afforded
5-[amino-(3,4-dimethoxy-phenylamino)-methylene]-2,2-dimethyl-[1,-
3]dioxane-4,6-dione as a white solid (0.90 g, 97% yield) and this
compound was used without further purification. LCMS: m/z 321
(M-H).sup.-.
[0518] A mixture of
5-[amino-(3,4-dimethoxy-phenylamino)-methylene]-2,2-dimethyl-[1,3]dioxane-
-4,6-dione (0.90 g, 2.8 mmol) and diphenylether (3.0 g, 18 mmol)
was heated at 260.degree. C. for 30 minutes. The mixture was cooled
to room temperature and heptane was added. Product
2-amino-6,7-dimethoxy-quinolin-4-ol was filtered and isolated as an
orange solid and used without further purification (0.31 g, 33%
yield). LCMS: m/z 221 (M+H).sup.+.
[0519]
4-(4-Amino-2-fluoro-phenoxy)-6,7-dimethoxy-quinolin-2-ylamine was
synthesized from 2-amino-6,7-dimethoxy-quinolin-4-ol in a similar
manner as
4-(6,7-dimethoxy-2-methylsulfanyl-quinolin-4-yloxy)-3-fluoro-phenylami-
ne, and obtained as a white solid (4.0% yield). LCMS: m/z 330
(M+H).sup.+.
[0520]
N-(4-{[2-amino-6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-
-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide was synthesized
from 4-(4-amino-2-fluoro-phenoxy)-6,7-dimethoxy-quinolin-2-ylamine
in a similar manner as
N-(4-{[6,7-bis(methyloxy)-2-(methylthio)quinolin-4-yl]oxy}-3-fluorophenyl-
)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. It was
purified by preparatory HPLC using ammonium acetate and isolated as
a white solid (4.0% yield). .sup.1H NMR (DMSO-d.sub.6) .delta.
10.34 (s, 1H), 9.95 (s, 1H), 7.82 (d, 1H), 7.58 (m, 2H), 7.44 (d,
1H), 7.33 (t, 1H), 7.25 (s, 1H), 7.09 (t, 2H), 7.07 (s, 1H), 6.17
(br s, 2H), 5.66 (s, 1H), 3.79 (s, 3H), 3.77 (s, 3H), 1.40 (d, 4H).
LCMS: m/z 535 (M+H).sup.+.
Example 77
##STR00536##
[0522] Synthesis of
'N-(3-fluoro-4-{[2-(methylamino)-6,7-bis(methyloxy)quinolin-4-yl]oxy}phen-
yl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide. A mixture of
5-[(3,4-dimethoxy-phenylamino)-methylsulfanyl-methylene]-2,2-dimethyl-[1,-
3]dioxane-4,6-dione (0.50 g, 1.4 mmol), methylamine (2 M in THF,
0.75 mL. 1.5 mmol), HgCl.sub.2 (0.38 g, 1.4 mmol) in THF (5 mL) was
stirred at room temperature for 30 minutes. The mixture was
extracted with DCM and water (3.times.) and dried with
Na.sub.2SO.sub.4. Concentration in vacuo afforded
5-[(3,4-dimethoxy-phenylamino)-methylamino-methylene]-2,2-dimeth-
yl-[1,3]dioxane-4,6-dione as a yellow solid (0.48 g, 99% yield) and
this compound was used without further purification. LCMS: m/z 335
(M-H).sup.-.
[0523] A mixture of
5-[(3,4-dimethoxy-phenylamino)-methylamino-methylene]-2,2-dimethyl-[1,3]d-
ioxane-4,6-dione (0.40 g, 2.8 mmol) and diphenylether (3.0 g, 18
mmol) was heated at 260.degree. C. for 15 minutes. The mixture was
cooled to room temperature and heptane was added. Product
6,7-dimethoxy-2-methylamino-quinolin-4-ol was filtered and isolated
as a tan solid and used without further purification (0.30 g,
quantitative yield). LCMS: m/z 235 (M+H).sup.+.
[0524]
[4-(4-Amino-2-fluoro-phenoxy)-6,7-dimethoxy-quinolin-2-yl]-methyl-a-
mine was synthesized from 6,7-dimethoxy-2-methylamino-quinolin-4-ol
in a similar manner as
4-(4-Amino-2-fluoro-phenoxy)-6,7-dimethoxy-quinolin-2-ylamine, and
isolated as a yellow oil (58% yield). LCMS: m/z 330
(M+H).sup.+.
[0525]
'N-(3-fluoro-4-{[2-(methylamino)-6,7-bis(methyloxy)quinolin-4-yl]ox-
y}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide was
synthesized from
[4-(4-amino-2-fluoro-phenoxy)-6,7-dimethoxy-quinolin-2-yl]-methyl-amine
in a similar manner as
N-(4-{[6,7-bis(methyloxy)-2-(methylthio)quinolin-4-yl]oxy}-3-fluorophenyl-
)-N'-(4-fluoro-phenyl)cyclopropane-1,1-dicarboxamide. It was
purified by preparatory HPLC using ammonium acetate and isolated as
a white solid (6.0 mg, 4.0% yield). .sup.1H NMR (DMSO-d.sub.6)
.delta. 10.42 (s, 1H), 9.91 (s, 1H), 7.88 (dd, 1H), 7.56 (m, 2H),
7.44 (m, 4H), 7.09 (t, 2H), 5.90 (s, 1H), 3.88 (s, 3H), 3.85 (s,
3H), 3.39 (br s, 1H), 2.92 (s, 3H), 1.41 (dt, 4H). LCMS: m/z 535
(M+H).sup.+.
Example 78
##STR00537##
[0527]
'N-(4-{[6-{[3-(diethylamino)propyl]oxy}-7-(methyloxy)quinolin-4-yl]-
oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide.
To a slurry of cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(6-hydroxy-7-methoxy-quinolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide (0.12 g, 0.23 mmol),
hydroxypropyldiethylamine (0.090 mL, 0.61 mmol), triphenylphosphine
(0.20 g, 0.76 mmol) in DCM (10 mL) was added DIAD (0.17 mL, 0.86
mmol). The resulting mixture was stirred at room temperature for 12
hours, after which time, the solvent was removed under reduced
pressure. The residue was extracted with EtOAc and 1N HCl
(6.times.) and brine (1.times.) followed by drying with
Na.sub.2SO.sub.4. Concentration of the organic fraction in vacuo
afforded
'N-(4-{[6-{[3-(diethylamino)propyl]oxy}-7-(methyloxy)quinolin-4-yl]oxy}-3-
-fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide as
a yellow oil (0.18 g, wet, ca 95% purity by analytical HPLC).
Further purification by preparatory HPLC using ammonium acetate
afforded the product in 99% purity by analytical HPLC. LCMS: m/z
619 (M+H).sup.+. .sup.1H NMR (DMSO-d.sub.6) .delta. 10.37 (br s,
1H), 10.00 (s, 1H), 8.44 (d, 1H), 7.87 (d, 1H), 7.62 (m, 2H), 7.49
(m, 2H), 7.41 (m, 2H), 7.13 (t, 2H), 6.40 (d, 1H), 4.17 (t, 2H),
3.93 (s, 3H), 2.59 (t, 2H), 2.49 (m, 6H), 1.91 (m, 4H), 0.94 (t,
6H).
Example 79
##STR00538##
[0529]
'N-(4-fluorophenyl)-N'-(4-{[2-methyl-6,7-bis(methyloxy)quinazolin-4-
-yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide. Commercially
available 2-amino-4,5-dimethoxy-benzoic acid methyl ester (3 g,
0.014 mol) and acetic anhydride (4.03 mL, 0.0426 mol) were heated
in heptane at 100.degree. C. for 3 hours. After removal of heptane
in vaccuo, the crude product of 2-acetylamino-4,5-dimethoxy-benzoic
acid methyl ester was obtained and used without further
purification. LC/MS: m/z 254 (M+H).
[0530] To the crude 2-acetylamino-4,5-dimethoxy-benzoic acid methyl
ester obtained above was added ammonium acetate (7.98 g, 0.104 mol)
and acetic acid (10 mL). The mixture was heated at reflux in a
pressure tube until the formation of the desired cyclization
product, as indicated by LC/MS: m/z 221 (M+H). After cooling to RT,
the reaction mixture was diluted with water, and extracted with
EtOAc 3 times. The combined organic phase was basified with aq.
NaOH solution, and washed 3 times with EtOAc. The aqueous layer was
then acidified with aq. HCl and extracted three times with EtOAc.
The combined organic extract was dried over Na.sub.2SO.sub.4 and
concentrated in vacuo, affording
6,7-dimethoxy-2-methyl-quinazolin-4-ol (0.15 g), which was used
without further purification. LC/MS: m/z 221 (M+H).
[0531] A mixture of 6,7-dimethoxy-2-methyl-quinazolin-4-ol obtained
from previous step (0.15 g, 0.68 mmol) and POCl.sub.3 (1.59 mL,
17.04 mmol) was heated at reflux for 48 hours. The reaction mixture
was poured into ice water, neutralized with NaHCO.sub.3, and
adjusted to basic with K.sub.2CO.sub.3. The mixture was cooled to
0.degree. C. with stirring. The resulting precipitate was filtered,
giving 4-chloro-6,7-dimethoxy-2-methyl-quinazoline (0.094 g), which
was used without further purification.
[0532] A mixture of the chloro quinazoline (0.094 g, 0.397 mmol)
obtained above, 4-nitrophenol (0.11 g, 0.795 mmol) and bromobenzene
(3 mL) was heated at 160.degree. C. for 48 hours. The solvent was
then removed and the reaction was taken up in MeOH. Et.sub.2O was
added and the reaction stirred 30 min and the precipitate was
filtered, affording
6,7-dimethoxy-2-methyl-4-(4-nitro-phenoxy)-quinazoline (0.081 g) as
a very light yellow solid. LC/MS: m/z 342 (M+H).
[0533] A mixture of
6,7-dimethoxy-2-methyl-4-(4-nitro-phenoxy)-quinazoline (0.081 g,
0.236 mmole), Pt/S (0.008 g, 15 mol %), ammonium formate (0.098 g,
1.56 mmol) and EtOH (3 mL) was heated with stirring at 70.degree.
C. for 3 hours. The reaction mixture was then filtered while hot
and washed with hot EtOH. The crude product of
4-(6,7-dimethoxy-2-methyl-quinazolin-4-yloxy)-phenylamine (0.924 g)
was obtained as a yellow solid, which was used in the next reaction
without further purification. LC/MS: m/z 312 (M+H).
[0534] To a mixture of
4-(6,7-dimethoxy-2-methyl-quinazolin-4-yloxy)-phenylamine (0.100 g,
0.321 mmol) and 1-(4-fluoro-phenylcarbamoyl)-cyclopropanecarboxylic
acid (0.056 g, 0.386 mmol) in DMF was added DIEA (0.168 mL, 0.963
mmol), followed by HATU (0.183 g, 0.482 mmol). The reaction mixture
was stirred at RT for 15 hours. The mixture was diluted with EtOAc,
washed with 5% LiCl aq solution three times, dried over
Na.sub.2SO.sub.4, and concentrated in vacuo. The crude product was
purified on preparative HPLC to give
'N-(4-fluorophenyl)-N'-(4-{[2-methyl-6,7-bis(methyloxy)quinazolin-4-yl]ox-
y}phenyl)cyclopropane-1,1-dicarboxamide (3.2 mg) as a white solid.
.sup.1H NMR (DMSO-d.sub.6) 10.15 (bs, 1H), 10.01 (bs, 1H),
7.69-7.75 (m, 2H), 7.61-7.68 (m, 2H), 7.52 (s, 1H), 7.32 (s, 1H),
7.23-7.29 (m, 2H), 7.12-7.19 (m, 2H), 3.93 (d, 6H), 2.43 (s, 3H),
1.53 (s, 4H).
Example 80
##STR00539##
[0536] Preparation of
1-(4-Fluoro-phenylcarbamoyl)-2-methyl-cyclopropanecarboxylic acid.
2-Methylcyclopropane-1,1-dicarboxylic acid methyl ester was
prepared by following the literature procedure (Baldwin, J. E.;
Adlington, R. M.; Rawlings, B. J. Tetrahedron Lett. 1985, 481.) The
carboxylic acid (700 mg, 4.4 mmol) was dissolved in
CH.sub.2Cl.sub.2 (10 mL). To the resulting solution was added
4-fluoroaniline (590 mg, 5.3 mmol), HOBt (890 mg, 6.6 mmol) and
EDCI (2.5 g, 13.2 mmol). The stirring was continued for 3 h at rt.
CH.sub.2Cl.sub.2 (30 mL) was added to the reaction mixture, and the
resulting solution was washed with brine, and dried over
Na.sub.2SO.sub.4. CH.sub.2Cl.sub.2 was removed under reduced
pressure. Further purification by column chromatography gave 635 mg
(57%) of the desired amide.
[0537] The methyl ester obtained above was then treated with
LiOH.H.sub.2O (116 mg, 2.78 mmol, 1.1 eqiv.) in THF (2 mL) and
H.sub.2O (1 mL) for 3 h at rt. THF was removed under reduced
pressure. The aqueous solution was diluted with 20 mL of H.sub.2O,
washed with ether (10 mL), and acidified with 1 N HCl. The solid
was filtered, dissolved in EtOAc, and dried over Na.sub.2SO.sub.4.
Removal of EtOAc gave the crude product of
1-(4-fluoro-phenylcarbamoyl)-2-methyl-cyclopropane-carboxylic acid,
which was used in the next reaction. .sup.1H NMR (400 MHz,
DMSO-d.sub.6) .delta. 12.99 (br s, 1H), 10.33 (br s, 1H), 7.59 (dd,
J=9.0, 5.0 Hz, 2H), 7.11 (dd, J=9.0, 9.0 Hz, 2H), 1.86-1.78 (m,
1H), 1.43 (dd, J=9.0, 4.2 Hz, 1H), 1.30 (dd, J=7.8, 4.3 Hz, 1H),
1.19 (d, J=6.3 Hz, 3H).
Example 81
##STR00540##
[0539] Synthesis of
(1S,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]qui-
nolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicarb-
oxamide. To a solution of
4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-3-fluoro-phenylamine
(150 mg, 0.38 mmol) in CH.sub.2Cl.sub.2 (3 mL) was added DIEA (341
mg, 2.64 mmol),
1-(4-fluoro-phenylcarbamoyl)-2-methyl-cyclopropanecarboxylic acid
(120 mg, 0.49 mmol) and PyBOP (686 mg, 1.32 mmol). The reaction
mixture was stirred at rt for 6 h. After standard workup, the crude
product was purified by column chromatography.
[0540] The coupling product (130 mg, 0.21 mmol) obtained above was
dissolved in EtOH (2 mL). 1,4-cyclohexadiene (170 mg, 2.1 mmol) and
10% Pd/C (10 mg) were added. The mixture was stirred for 2 h under
reflux. After cooling, the mixture was filtered through Celite, and
washed with MeOH. Removal of the solvents gave the crude product
(136 mg), which was used in the next reaction.
[0541] To a solution of the 7-hydroxyquinoline (136 mg, 0.26 mmol)
in DMF (2 mL) was added 4-(3-chloropropyl)morpholine hydrochloride
(70 mg, 0.35 mmol) and K.sub.2CO.sub.3 (69 mg, 0.50 mmol). The
reaction mixture was then stirred at 80.degree. C. for 5 h. After
cooling, EtOAc (20 mL) was added. The EtOAc solution was washed
twice with brine, and dried over Na.sub.2SO.sub.4. Removal of EtOAc
and purification by column chromatography (CH.sub.2Cl.sub.2:
MeOH=10:1) gave
'(1S,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]qu-
inolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicar-
boxamide. The product was then dissolved in ethyl ether, and
treated with 1.5 equiv. of 1 N HCl/ether. Filtration and
lyophilization gave the HCl salt of
'(1S,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropy-
l)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1-
,1-dicarboxamide: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.49
(br s, 1H), 10.26 (br s, 1H), 10.15 (br s, 1H), 8.74 (br s, 1H),
7.95 (br d, J=13.2 Hz, 1H), 7.8-7.5 (m, 6H), 7.16 (t, J=8.9 Hz,
2H), 6.82 (br s, 1H), 4.34 (t, J=5.9 Hz, 2H), 4.02 (s, 3H), 3.99
(br s, 2H), 3.77 (br t, J=12.0 Hz, 2H), 3.56-3.30 (m, 4H),
3.17-3.07 (m, 2H), 2.40-2.30 (m, 2H), 2.04-1.95 (m, 1H), 1.45 (dd,
J=7.2, 4.7 Hz, 1H), 1.36 (dd, J=8.5, 4.5 Hz, 1H), 1.09 (d, J=6.2
Hz, 3H).
Example 82
##STR00541##
[0543] Synthesis of
(1R,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-qu-
inolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicar-
boxamide. To a solution of
4-(7-benzyloxy-6-methoxy-quinolin-4-yloxy)-3-fluoro-phenylamine
(322 mg, 0.82 mmol) and 2-Methyl-cyclopropane-1,1-dicarboxylic acid
methyl ester (195 mg, 1.23 mmol) in CH.sub.2Cl.sub.2 (4 mL) was
added HOBt (61 mg, 0.32 mmol) and EDCI (211 mg, 1.64 mmol). The
stirring was continued for 12 h at rt. The reaction mixture was
then diluted with EtOAc and washed with brine. Removal of organic
solvents in vacuo and further purification by column chromatography
gave the desired coupling product (153 mg).
[0544] The product (153 mg, 0.29 mmol) obtained above was treated
with LiOH.H.sub.2O (15 mg, 0.35 mmol) in THF (1 mL) and H.sub.2O (1
mL) for 2 h. THF was removed. 10 mL of H.sub.2O was added to the
mixture. The aqueous solution was washed with ether, and acidified
with 1 N HCl. The solid was then filtered and dried under
vacuum.
[0545] The crude carboxylic acid (118 mg, 0.23 mmol) and
4-fluoroaniline (111 mg, 0.27 mmol) were dissolved in DMF (2 mL).
To this solution was added DIEA (178 mg, 1.38 mmol) and PyBOP (358
mg, 0.69 mmol). The mixture was stirred overnight at rt. It was
then diluted with EtOAc, washed twice with brine. Removal of EtOAc
and column chromatography gave the desired product.
[0546] The product (66 mg, 0.11 mmol) obtained above was dissolved
in EtOH (2 mL). 1,4-cyclohexadiene (80 mg, 1.1 mmol) and 10% Pd/C
(10 mg) were added. The mixture was stirred for 2 h under reflux.
After cooling, the mixture was filtered through Celite, and washed
with MeOH. Removal of the solvents gave the crude product (70 mg),
which was used in the next reaction.
[0547] To a solution of the 7-hydroxyquinoline (80 mg, 0.15 mmol)
in DMF (2 mL) was added 4-(3-chloropropyl)morpholine hydrochloride
(62 mg, 0.31 mmol) and K.sub.2CO.sub.3 (64 mg, 0.46 mmol). The
reaction mixture was then stirred at 80.degree. C. for 5 h. After
cooling, EtOAc (20 mL) was added. The EtOAc solution was washed
twice with brine, and dried over Na.sub.2SO.sub.4. Removal of EtOAc
and purification by column chromatography (CH.sub.2Cl.sub.2:
MeOH=10:1) gave
'(1R,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]qu-
inolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1,1-dicar-
boxamide. The product was then dissolved in ethyl ether, and
treated with 1.5 equiv. of 1 N HCl/ether. Filtration and
lyophilization gave the HCl salt of
'(1R,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropy-
l)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-methylcyclopropane-1-
,1-dicarboxamide: .sup.1H NMR (400 MHz, DMSO-d.sub.6) .delta. 10.65
(br s, 1H), 10.54 (br s, 1H), 9.74 (s, 1H), 8.75 (br s, 1H), 8.01
(br d, J=12.9 Hz, 1H), 7.80-7.50 (m, 6H), 7.20-7.10 (m, 2H), 6.84
(br s, 1H), 4.34 (br t, J=5 Hz, 2H), 4.04 (s, 3H), 4.05-3.95 (m,
2H), 3.77 (br t, J=11 Hz, 2H), 3.52 (br d, J=12.7 Hz, 4H), 3.12 (br
q, J=9.0 Hz, 2H), 2.40-2.30 (m, 2H), 2.10-1.95 (m, 1H), 1.40-1.30
(m, 2H), 1.10 (d, J=6.2 Hz, 3H).
Example 83
##STR00542##
[0549] Synthesis of
'(2R,3R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]-q-
uinolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1--
dicarboxamide. 2,3-trans-Dimethyl-cyclopropane-1,1-dicarboxylic
acid diethyl ester was prepared by following the literature
procedure. (Ohishi, J. Synthesis, 1980, 690.) To a solution of
2,3-trans-dimethyl-cyclopropane-1,1-dicarboxylic acid diethyl ester
(6.75 g, 31.5 mmol) in MeOH (30 mL) was added 33 mL of 1 N NaOH
aqueous solution. The mixture was stirred at 85.degree. C. for 5 h.
MeOH was removed under reduced pressure; the residue was diluted
with 40 mL of H.sub.2O. The aqueous solution was washed with 20 mL
of ether, and acidified with 1 N HCl. Filtration and drying under
vacuum gave 4.72 g 80%) of the desired carboxylic acid.
[0550] The aniline (1.08 g, 2.78 mmol) and the carboxylic acid (518
mg, 2.78 mmol) prepared above were dissolved in CH.sub.2Cl.sub.2
(15 mL). HATU (2.11 g, 5.56 mmol) and DIEA (1.8 mL, 11.1 mmol) were
added. The reaction mixture was stirred at rt overnight. It was
then concentrated and diluted with EtOAc. The EtOAc solution was
then washed with 5% NaOH and brine. Removal of EtOAc gave the crude
coupling product, which was hydrolyzed to the corresponding
carboxylic acid by treatment with LiOH.H.sub.2O (175 mg, 4.17 mmol)
in THF (100 mL)-H.sub.2O (50 mL) at 60.degree. C. for 10 h.
[0551] The carboxylic acid (850 mg, 1.60 mmol) and 4-fluoroaniline
(355 mg, 3.20 mmol) were dissolved in DMF (8 mL). HATU (3.89 g, 3.2
mmol) and DIEA (1.1 ml, 6.4 mmol) were added. The reaction mixture
was stirred at rt overnight. H.sub.2O (10 mL) was added to the
reaction, and a precipitate formed. The solid was filtered, washed
with aqueous sat. Na.sub.2CO.sub.3 and ether. Further purification
by column chromatography gave 596 mg (60%) of the desired product.
Debenzylation was done by following the standard procedure.
[0552] To a solution of the 7-hydroxyquinoline (261 mg, 0.49 mmol)
in DMF (5 mL) was added 4-(3-chloropropyl)morpholine hydrochloride
(195 mg, 0.98 mmol) and K.sub.2CO.sub.3 (202 mg, 1.46 mmol). The
reaction mixture was then stirred at 80.degree. C. for 4 h. After
cooling, EtOAc (20 mL) was added. The EtOAc solution was washed
twice with brine, and dried over Na.sub.2SO.sub.4. Removal of EtOAc
and purification by column chromatography (CH.sub.2Cl.sub.2:
MeOH=10:1) gave 122 mg (37%) of
'(2R,3R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4-ylpropyl)oxy]qu-
inolin-4-yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-dimethyl-cyclopropane-1,1--
dicarboxamide. .sup.1H NMR (400 MHz, CDCl.sub.3) .delta. 8.44 (d,
J=5.1 Hz, 1H), 8.11 (br s, 1H), 7.77-7.70 (m, 2H), 7.53 (s, 1H),
7.50-7.44 (m, 2H), 7.40 (s, 1H), 7.22-7.16 (m, 2H), 7.06-6.98 (m,
2H), 6.36 (br d, J=5.1 Hz, 1H), 4.26 (t, J=7.0 Hz, 2H), 4.02 (s,
3H), 3.72 (t, J=4.4 Hz, 4H), 2.57 (t, J=7.3 Hz, 2H), 2.50-2.42 (m,
4H), 2.18-2.10 (m, 2H), 1.80-1.66 (m, 2H), 1.30-1.24 (m, 6H).
Example 84
##STR00543##
[0554] Synthesis of
'N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)-1-
-(phenylmethyl)azetidine-3,3-dicarboxamide.
1-Benzyl-azetidine-3,3-dicarboxylic acid was prepared by following
the literature procedure (Miller, R. A.; et al. Syn. Comm. 2003,
33, 3347). To a solution of
4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylamine (4.2 mmol, 1 equiv.)
and 4-fluoroaniline (4.2 mmol, 1 equiv.) in DMF (20 mL) was charged
with DIEA (12.6 mmol, 3 equiv.) and a solution of
1-benzyl-azetidine-3,3-dicarboxylic acid (4.2 mmol, 1 equiv.) in
DMF (10 mL). The reaction mixture was allowed to stir at RT and
monitored by LCMS. The reaction was complete in 6 h. The reaction
mixture was diluted with ethyl acetate and washed with 10% LiCl
(3.times.), brine (3.times.), dried with sodium sulfate, filtered
and the solvent was reduced in vacuo. The crude product was
purified by silica gel chromatography eluting with 2% of MeOH in
EtOAc. The fractions containing the desired product were further
purified using preparative HPLC to give
'N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)-1-
-(phenylmethyl)azetidine-3,3-dicarboxamide (300 mg, 12% yield) as a
white solid. .sup.1HNMR (DMSO-d.sub.6): 10.0 (s, 1H), 9.90 (s, 1H),
8.45 (d, 1H), 7.80 (d, 2H), 7.70 (m, 2H), 7.50 (s, 1H), 7.40 (s,
1H), 7.48-7.15 (m, 9H), 3.95 (s, 6H), 3.70 (s, 4H), 3.60 (s, 2H).
LCMS (POS): 607.2 (M+H).
[0555]
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophen-
yl) azetidine-3,3-dicarboxamide. To a solution of
'N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)-1-
-(phenylmethyl)azetidine-3,3-dicarboxamide (300 mg, 0.5 mmol) in
MeOH (50 mL) was charged with Pd/C (50% wet, 10% mmol, 265 mg) and
acetic acid (2 mL). The reaction mixture was subjected to
hydrogenolysis condition under H2 (50 psi) on a Parr Hydrogenator
for 16 hr. The reaction mixture was filtered through celite and
washed with MeOH. After removal of solvent in vacuo, the crude
product was purified using preparative HPLC (solvent system:
MeCN/H.sub.2O/NH.sub.4OAc), affording
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-fluorophenyl)
azetidine-3,3-dicarboxamide (82 mg, 32% yield) as a white solid.
.sup.1HNMR (DMSO-d.sub.6): 8.46 (d, 1H), 7.84 (d, 2H), 7.70 (m,
2H), 7.50 (s, 1H), 7.40 (s, 1H), 7.24 (d, 2H), 7.20 (t, 2H), 6.44
(d, 1H), 4.03 (s, 4H), 3.95 (s, 6H), 1.90 (s, 3H, acetate salt).
LCMS (POS): 517.3 (M+H).
Example 85
##STR00544##
[0557]
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]ox-
y}quinolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxam-
ide. To a solution of cyclopropane-1,1-dicarboxylic acid
{3-fluoro-4-[6-methoxy-7-(piperidin-4-ylmethoxy)-quinolin-4-yloxy]-phenyl-
}-amide (4-fluoro-phenyl)-amide, TFA salt (.about.500 mg, 0.71
mmol) in ClCH.sub.2H.sub.2Cl (8 mL) were added 30% formaldehyde (4
mL) and NaBH(OAc).sub.3 (752 mg, 3.55 mmol). The reaction mixture
was stirred overnight. It was then quenched with aqueous sat.
NaHCO.sub.3, extracted with EtOAc. The organic phase was washed
with brine and dried over Na.sub.2SO.sub.4. Drying salts were
filtered, washed with EtOAc and the filtrate concentrated in vacuo
to give 21 0 mgs of crude product. The resulting residue was
redissolved in EtOAc and any insoluble material filtered. To the
filtrate was added 4M HCl in dioxane (200 .mu.l) and the mixture
was stirred at room temperature for 1 hour. Solids were filtered,
washed with EtOAc, dried under high vacuum, dissolved in 50%
aqueous AcCN and lyophilized to give
'N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin-4-yl)methyl]oxy}qui-
nolin-4-yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide,
HCl salt (113 mg, 25% yield). .sup.1HNMR (400 MHz, DMSO-d.sub.6):
.delta. 10.51 (s, 1H), 10.30 (br. s, 1H), 10.04 (s, 1H), 8.80 (d,
1H), 7.99 (dd, 1H), 7.55 (m, 2H), 7.67-7.53 (m, 4H), 7.16 (t, 2H),
6.89 (d, 1H), 4.13 (d, 2H), 4.05 (s, 3H), 3.47 (m, 2H), 3.00 (m,
2H), 2.74 (d, 3H), 2.17 (m, 1H), 2.03 (m, 2H), 1.68 (m, 2H), 1.49
(m, 4H). LC/MS Calcd for [M+H].sup.+ 617.3, found 617.4. Anal. HPLC
(8 min gradient): 98% pure, 3.11 min.
Example 86
##STR00545##
[0559]
(1R,2R,3S)--N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quin-
olin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopropan-
e-1,1-dicarboxamide. 2,3-Dimethyl-cyclopropane-1,1-dicarboxylic
acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide (210 mg, 0.39 mmol), DMA (2 mls),
(2-chloro-ethyl)-diethyl-amine, HCl salt (73 mg, 0.42 mmol) and
K.sub.2CO.sub.3 (136 mg, 0.98 mmol) were combined and heated at 80
C overnight. The reaction mixture was then diluted with H.sub.2O
and sonicated. The resulting solids were filtered, washed with
H.sub.2O and dried under high vacuum. The crude product was then
purified by preparative HPLC using an ammonium acetate buffer
system and lyophilized to give
'(1R,2R,3S)--N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)q-
uinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,3-dimethylcyclopro-
pane-1,1-dicarboxamide (39 mg, 16% yield). .sup.1HNMR (400 MHz,
DMSO-d.sub.6): .delta. 10.14 (s, 1H), 9.61 (s, 1H), 8.46 (d, 1H),
7.87 (dd, 1H), 7.67 (m, 2H), 7.57 (m, 1H), 7.51 (s, 1H), 7.42 (s,
1H), 7.39 (m, 1H), 7.15 (t, 2H), 6.41 (d, 1H), 4.20 (m, 2H), 3.94
(s, 3H), 2.87 (m, 2H), 2.60 (m, 4H), 1.80 (m, 2H), 1.18 (s, 3H),
1.17 (s, 3H), 1.01 (m, 6H). Note: 0.5 eq of AcOH is present by NMR.
LC/MS Calcd for [M+H].sup.+ 633.3, found 633.4. Anal. HPLC (25 min
gradient): 96% pure, 18.52 min.
Example 87
##STR00546##
[0561]
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]-
oxy}-3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1-dica-
rboxamide. 2,2-Dimethyl-cyclopropane-1,1-dicarboxylic acid
[3-fluoro-4-(7-hydroxy-6-methoxy-quinazolin-4-yloxy)-phenyl]-amide
(4-fluoro-phenyl)-amide (203 mg, 0.38 mmol), DMA (2 mls),
(2-chloro-ethyl)-diethyl-amine, HCl salt (73 mg, 0.42 mmol) and
K.sub.2CO.sub.3 (146 mg, 1.05 mmol) were combined and heated at 80
C overnight. The reaction mixture was then diluted with H.sub.2O
and extracted with CH.sub.2Cl.sub.2 (3.times.). The combined
CH.sub.2Cl.sub.2 extractions were washed with sat'd NaHCO.sub.3
(1.times.), sat'd NaCl (1.times.), dried (Na.sub.2SO.sub.4), and
concentrated in vacuo. The resulting crude product was purified by
flash chromatography (Silica Gel 60, 100% EtOAc, followed by 10%
MeOH, 1% triethylamine in EtOAc), then dissolved in 50% aqueous
AcCN and lyophilized to give
'N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6-(methyloxy)quinazolin-4-yl]oxy}--
3-fluorophenyl)-N'-(4-fluorophenyl)-2,2-dimethyl-cyclopropane-1,1-dicarbox-
amide (70 mg, 29% yield). .sup.1H NMR (400 MHz, DMSO): .delta.
10.24 (s, 1H), 10.00 (s, 1H), 8.54 (s, 1H), 7.84 (dd, 1H), 7.66 (m,
2H), 7.56 (s, 1H), 7.51 (m, 1H), 7.43 (m, 2H), 7.18 (t, 2H), 4.26
(m, 2H), 3.98 (s, 3H), 2.88 (m, 2H), 2.59 (m, 4H), 1.58 (m, 2H),
1.18 (s, 6H), 1.00 (t, 6H). LC/MS Calcd for [M+H].sup.+ 634.3,
found 634.4. Anal. HPLC (25 min gradient): 94% pure, 24.08 min.
Example 88
##STR00547##
[0563] Synthesis of
'N-[3-(aminomethyl)phenyl]-N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}ph-
enyl)cyclopropane-1,1-dicarboxamide. (4-Nitro-benzyl)-carbamic acid
tert-butyl ester. 4-Nitro-benzylamine, HCl salt (5.19 g, 27.5 mmol)
was dissolved in dioxane (100 mls). NaOH (3.4 g, 85.0 mmol) in
H.sub.2O (20 mls) was added, followed by Boc anhydride (7.6 g, 34.8
mmol). The mixture was stirred at room temperature. After 3 hrs,
the reaction mixture was diluted with EtOAc and washed with
H.sub.2O (3.times.), sat'd NaCl (1.times.), dried
(Na.sub.2SO.sub.4), and concentrated in vacuo. The resulting
residue was triturated with hexanes, the resulting solids filtered,
washed with hexanes and dried under vacuum to give
(4-nitro-benzyl)-carbamic acid tert-butyl ester (6.34 g, 91%
yield). LC/MS Calcd for [M+H].sup.+ 253.1, found 197.0 (minus
t-butyl).
[0564] (4-Amino-benzyl)-carbamic acid tert-butyl ester.
(4-Nitro-benzyl)-carbamic acid tert-butyl ester (6.34 g, 25.1
mmol), iron powder (6.5 g, 116 mmol), ammonium formate (13.0 g, 206
mmol), H.sub.2O (75 mls), and toluene (75 mls) were combined and
heated to reflux. After 3 hrs the reaction mixture was allowed to
cool and filtered through Celite with thorough washing with EtOAc.
The filtrate was transferred to a separatory funnel and the phases
separated. The organic phase was further washed with H.sub.2O
(1.times.), sat'd NaCl (1.times.), dried (Na.sub.2SO.sub.4), and
concentrated in vacuo to give (4-amino-benzyl)-carbamic acid
tert-butyl ester (5.02 g, 90% yield). LC/MS Calcd for [M+H].sup.+
223.1, found 167.1 (minus t-butyl).
[0565]
[3-({1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopr-
opane-carbonyl}-amino)-benzyl]-carbamic acid tert-butyl ester.
1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanecarbox-
ylic acid (254 mg, 0.62 mmol), (4-amino-benzyl)-carbamic acid
tert-butyl ester (164 mg, 0.74 mmol), dry DMA (10 mls), HATU (714
mg, 1.88 mmol), and DIEA (325 ml, 1.86 mmol) were combined and
stirred at room temperature. After 2 hrs, the reaction mixture is
diluted with H.sub.2O and the resulting solids are filtered, washed
with H.sub.2O, followed by sat'd NaHCO.sub.3, and dried under high
vacuum to give crude
[3-({1-[4-(6,7-dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanec-
arbonyl}-amino)-benzyl]-carbamic acid tert-butyl ester (301 mg, 79%
yield) which was used in the next reaction without further
purification. LC/MS Calcd for [M+H].sup.+ 613.3, found 613.1.
[0566]
N-[3-(Aminomethyl)phenyl]-N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]o-
xy}phenyl)cyclopropane-1,1-dicarboxamide, TFA salt.
[3-({1-[4-(6,7-Dimethoxy-quinolin-4-yloxy)-phenylcarbamoyl]-cyclopropanec-
arbonyl}-amino)-benzyl]-carbamic acid tert-butyl ester (50 mg,
0.081 mmol) was dissolved in 50% TFA in CH.sub.2Cl.sub.2 (10 mls)
and stirred at room temperature. After 2 hrs, the reaction mixture
was concentrated in vacuo and the resulting residue was triturated
with Et.sub.2O. The resulting solids were filtered, washed with
Et.sub.2O and dried under high vacuum to give
'N-[3-(aminomethyl)phenyl]-N'-(4-{[6,7-bis(methyloxy)quinolin-4-y-
l]oxy}phenyl)cyclopropane-1,1-dicarboxamide as the TFA salt (54 mg,
100%). .sup.1HNMR (400 MHz, DMSO-d.sub.6): .delta. 10.28 (s, 1H),
10.19 (s, 1H), 8.77 (m, 1H), 8.21 (m, 3H), 7.84 (m, 2H), 7.76 (m,
1H), 7.71 (m, 1H), 7.58 (m, 2H), 7.38 (m, 3H), 7.19 (m, 1H), 6.76
(m, 1H), 4.03 (s, 6H), 3.39 (m, 2H), 1.53 (m, 4H). Note: all peaks
are very broad and unresolved. LC/MS Calcd for [M+H].sup.+ 513.2,
found 513.4. Anal. HPLC (25 min gradient): 88% pure, 12.39 min.
[0567] Table 3 contains .sup.1H-NMR data for selected compounds of
the invention.
TABLE-US-00004 TABLE 3 Entry Name .sup.1H-NMR 1
N-[3-fluoro-4-({6-(methyloxy)- 1H NMR (DMSO-d6): 10.52 (s, 1H),
10.02 (s, 7-[(3-piperazin-1- 1H), 9.38 (br., 3H), 8.79 (d, 1H),
7.98 (dd, 1H), ylpropyl)oxy]quinolin-4- 7.74 (s, 1H), 7.65 (m, 3H),
7.54 (m, 2H), yl}oxy)phenyl]-N'-(4- 7.15 (t, 2H), 6.86 (d, 1H),
4.33 (t, 2H), 4.04 (s, 3H), fluorophenyl)cyclopropane-1,1-
3.17-3.50 (m, 9H), 2.27 (br., 2H), 1.79 (m, 1H), dicarboxamide 1.48
(m, 4H). Note: The peak at .delta.9.38 includes 2 TFA equivalents.
2 N-{3-fluoro-4-[(6-(methyloxy)- 1H NMR (DMSO-d6): 10.41 (s, 1H),
10.03 (s, 7-{[3-(4-methylpiperazin-1- 1H), 8.47 (d, 1H), 7.90 (dd,
1H), 7.64 (m, 2H), yl)propyl]oxy}quinolin-4- 7.52 (s, 2H), 7.42 (t,
1H), 7.39 (s, 1H), 7.16 (t, yl)oxy]phenyl}-N'-(4- 2H), 6.41 (d,
1H), 4.18 (t, 2H), 3.95 (s, 3H), fluorophenyl)cyclopropane-1,1-
2.47 (t, 2H), 2.6-2.8 (br., 8H), 2.17 (s, 3H), dicarboxamide 1.97
(m, 2H), 1.48 (s, 4H). 3 N-{3-fluoro-4-[(6-(methyloxy)- 1H NMR (400
MHz, DMSO-d6): d 10.51 (s, 7-{[(1-methylpiperidin-4- 1H), 10.30
(br. s, 1H), 10.04 (s, 1H), 8.80 (d, yl)methyl]oxy}quinolin-4- 1H),
7.99 (dd, 1H), 7.55 (m, 2H), 7.67-7.53 (m, yl)oxy]phenyl}-N'-(4-
4H), 7.16 (t, 2H), 6.89 (d, 1H), 4.13 (d, 2H),
fluorophenyl)cyclopropane-1,1- 4.05 (s, 3H), 3.47 (m, 2H), 3.00 (m,
2H), dicarboxamide 2.74 (d, 3H), 2.17 (m, 1H), 2.03 (m, 2H), 1.68
(m, 2H), 1.49 (m, 4H). 4 N-(4-fluorophenyl)-N'-[4-({6- .sup.1H NMR
(400 MHz, DMSO-d6): 8.47 (d, 1H), (methyloxy)-7-[(3-morpholin-4-
8.30 (m, 1H), 8.15 (m, 1H), 7.8 (m, 2H), ylpropyl)oxy]quinolin-4-
7.62 (s, 1H), 7.45 (m, 2H), 7.2 (m, 3H), 7.10 (m,
yl}oxy)phenyl]cyclopropane- 2H), 6.7 (d, 1H), 4.5 (m, 2H), 4.3 (m,
2H), 1,1-dicarboxamide 4.01 (s, 3H), 3.5 (br, 2H), 3.3 (m, 2H), 3.1
(m, 2H), 2.51 (m, 2H), 1.9 (m, 2H) 1.6 (m, 4H). 5 N-(4-{[7-{[3-
.sup.1H NMR (400 MHz, DMSO-d6): 10.58 (s, 1H),
(diethylamino)propyl]oxy}-6- 10.31 (bs, 1H), 10.04 (s, 1H), 8.75
(d, 1H), (methyloxy)quinolin-4-yl]oxy}- 7.99 (d, 1H), 7.74 (s, 1H),
7.63 (m, 4H), 3-fluorophenyl)-N'-(4- 7.19 (t, 2H), 6.91 (m, 1H),
4.39 (t, 2H), 4.19 (s, 3H), fluorophenyl)cyclopropane-1,1- 3.21 (m,
7H), 2.29 (m, 2H), 1.46 (d, 4H), dicarboxamide 1.15 (t, 6H). 6
N-(4-{[6,7- 1H NMR (DMSO-d6): 11.56 (s, 1H), 9.77 (s,
bis(methyloxy)quinolin-4- 1H), 8.50 (d, 1H), 8.32 (d, 1H), 7.82 (d,
1H), yl]oxy}-2-chloro-5- 7.59 (m, 2H), 7.51 (s, 1H), 7.42 (s, 1H),
7.20 (t, fluorophenyl)-N'-(4- 2H), 6.55 (d, 1H), 3.95 (s, 3H), 3.94
(s, 3H), fluorophenyl)cyclopropane-1,1- 1.73 (m, 2H), 3.65 (m, 2H).
dicarboxamide 7 N-(4-{[6,7-bis(methyloxy)-2- .sup.1H NMR
(DMSO-d.sub.6) d 10.34 (s, 1H), 9.94 (s,
(methylthio)quinolin-4-yl]oxy}- 1H), 7.83 (d, 1H), 7.59 (m, 2H),
7.56 (m, 1H), 3-fluorophenyl)-N'-(4- 7.40 (m, 2H), 7.23 (s, 1H),
7.09 (t, 2H), 6.12 (s, fluorophenyl)cyclopropane-1,1- 1H), 3.88 (s,
3H), 3.85 (s, 3H), 2.48 (s, 3H), dicarboxamide 1.40 (m, 4H). 8
N-(4-fluorophenyl)-N'-(4-{[2- .sup.1H NMR (DMSO-d.sub.6) 10.15 (bs,
1H), 10.01 (bs, methyl-6,7-bis(methyloxy)quinazolin- 1H), 7.69-7.75
(m, 2H), 7.61-7.68 (m, 2H), 4-yl]oxy}phenyl)cyclopropane- 7.52 (s,
1H), 7.32 (s, 1H), 7.23-7.29 (m, 2H), 1,1- 7.12-7.19 (m, 2H), 3.93
(d, 6H), 2.43 (s, 3H), dicarboxamide 1.53 (s, 4H). 9
N-(4-{[2-amino-6,7- 1H NMR (DMSO-d6) d 10.34 (s, 1H), 9.95 (s,
bis(methyloxy)quinolin-4- 1H), 7.82 (d, 1H), 7.58 (m, 2H), 7.44 (d,
1H), yl]oxy}-3-fluorophenyl)-N'-(4- 7.33 (t, 1H), 7.25 (s, 1H),
7.09 (t, 2H), 7.07 (s, fluorophenyl)cyclopropane-1,1- 1H), 6.17 (br
s, 2H), 5.66 (s, 1H), 3.79 (s, 3H), dicarboxamide 3.77 (s, 3H),
1.40 (d, 4H). 10 N-(3-fluoro-4-{[2- .sup.1H NMR (DMSO-d.sub.6) d
10.42 (s, 1H), 9.91 (s, (methylamino)-6,7- 1H), 7.88 (dd, 1H), 7.56
(m, 2H), 7.44 (m, 4H), bis(methyloxy)quinolin-4- 7.09 (t, 2H), 5.90
(s, 1H), 3.88 (s, 3H), 3.85 (s, yl]oxy}phenyl)-N'-(4- 3H), 3.39 (br
s, 1H), 2.92 (s, 3H), 1.41 (dt, 4H). fluorophenyl)cyclopropane-1,1-
dicarboxamide 11 (1S,2R)--N-[3-fluoro-4-({6- .sup.1H NMR (400 MHz,
DMSO-d.sub.6) d 10.49 (br s, (methyloxy)-7-[(3-morpholin-4- 1 H),
10.26 (br s, 1 H), 10.15 (br s, 1 H), ylpropyl)oxy]quinolin-4- 8.74
(br s, 1 H), 7.95 (br d, J = 13.2 Hz, 1 H), yl}oxy)phenyl]-N'-(4-
7.8-7.5 (m, 6 H), 7.16 (t, J = 8.9 Hz, 2 H), 6.82 (br
fluorophenyl)-2- s, 1 H), 4.34 (t, J = 5.9 Hz, 2 H), 4.02 (s, 3 H),
methylcyclopropane-1,1- 3.99 (br s, 2 H), 3.77 (br t, J = 12.0 Hz,
2 H), dicarboxamide 3.56-3.30 (m, 4 H), 3.17-3.07 (m, 2 H),
2.40-2.30 (m, 2 H), 2.04-1.95 (m, 1 H), 1.45 (dd, J = 7.2, 4.7 Hz,
1 H), 1.36 (dd, J = 8.5, 4.5 Hz, 1 H), 1.09 (d, J = 6.2 Hz, 3 H).
12 (1R,2R)--N-[3-fluoro-4-({6- .sup.1H NMR (400 MHz, DMSO-d.sub.6)
d 10.65 (br s, (methyloxy)-7-[(3-morpholin-4- 1 H), 10.54 (br s, 1
H), 9.74 (s, 1 H), 8.75 (br s, ylpropyl)oxy]quinolin-4- 1 H), 8.01
(br d, J = 12.9 Hz, 1 H), yl}oxy)phenyl]-N'-(4- 7.80-7.50 (m, 6 H),
7.20-7.10 (m, 2 H), 6.84 (br s, 1 H), fluorophenyl)-2- 4.34 (br t,
J = 5 Hz, 2 H), 4.04 (s, 3 H), methylcyclopropane-1,1- 4.05-3.95
(m, 2 H), 3.77 (br t, J = 11 Hz, 2 H), dicarboxamide 3.52 (br d, J
= 12.7 Hz, 4 H), 3.12 (br q, J = 9.0 Hz, 2 H), 2.40-2.30 (m, 2 H),
2.10-1.95 (m, 1 H), 1.40-1.30 (m, 2 H), 1.10 (d, J = 6.2 Hz, 3 H).
13 N-(4-{[6-{[3- .sup.1H NMR (DMSO-d.sub.6) d 10.37 (br s, 1H),
(diethylamino)propyl]oxy}-7- 10.00 (s, 1H), 8.44 (d, 1H), 7.87 (d,
1H), 7.62 (m, (methyloxy)quinolin-4-yl]oxy}- 2H), 7.49 (m, 2H),
7.41 (m, 2H), 7.13 (t, 2H), 3-fluorophenyl)-N'-(4- 6.40 (d, 1H),
4.17 (t, 2H), 3.93 (s, 3H), 2.59 (t, fluorophenyl)cyclopropane-1,1-
2H), 2.49 (m, 6H), 1.91 (m, 4H), 0.94 (t, 6H). dicarboxamide 14
N-(4-{[6-{[2- .sup.1H NMR (DMSO-d.sub.6) d 10.36 (br s, 1H),
(diethylamino)ethyl]oxy}-7- 9.99 (s, 1H), 8.44 (d, 1H), 7.88 (dd,
1H), 7.62 (m, (methyloxy)quinolin-4-yl]oxy}- 2H), 7.57 (m, 2H),
7.41 (m, 2H), 7.13 (t, 2H), 3-fluorophenyl)-N'-(4- 6.40 (d, 1H),
4.17 (t, 2H), 3.93 (s, 3H), 2.85 (t, fluorophenyl)cyclopropane-1,1-
2H), 2.56 (q, 4H), 2.49 (m, 4H), 0.98 (t, 6H). dicarboxamide 15
1,1-dimethylethyl 4-(3-{[4-[(2- .sup.1H NMR (400 MHz, CDCl.sub.3):
10.05 (s, 1H), fluoro-4-{[(1-{[(4- 8.49-8.27 (t, 1H), 7.79-7.76 (d,
1H), 7.57 (s,
fluorophenyl)amino]carbonyl}cyclopropyl)carbonyl]amino}phenyl)oxy]-
1H), 7.47-7.43 (m, 3H), 7.27-7.20 (m, 1H), 6-(methyloxy)quinolin-
7.09-7.04 (m, 2H), 6.40-6.39 (d, 1H), 7-yl]oxy}propyl)piperazine-
4.28-4.25 (t, 2H), 3.50 (s, 3H), 3.47-3.44, (t, 4H), 1-carboxylate
2.62-2.59 (t, 2H), 2.46-2.44 (t, 4H), 2.18-2.11 (m, 2H), 2.09 (s,
1H), 1.83-1.81 (t, 2H), 1.64-1.61 (t, 2H), 1.47 (s, 9H). 16
(1R,2R)--N-[3-fluoro-4-({6- .sup.1H NMR (DMSO-d.sub.6) d 10.40 (s,
1H), 9.65 (s, (methyloxy)-7-[(3-morpholin-4- 1H), 8.45 (s, 1H),
7.79 (dd, 1H), 7.53 (m, 2H), ylpropyl)oxy]quinazolin-4- 7.47 (s,
1H), 7.36 (m, 1H), 7.31 (m, 2H), yl}oxy)phenyl]-N'-(4- 7.05 (t,
2H), 4.17 (t, 2H), 3.91 (s, 3H), 3.51 (t, 4H), fluorophenyl)-2-
2.40 (t, 2H), 2.36 (m, 4H), 1.90 (m, 3H), methylcyclopropane-1,1-
1.30 (m, 2H), 1.02 (d, 3H). dicarboxamide 17 (1R,2R)--N-(4-{[7-{[2-
.sup.1H NMR (DMSO-d.sub.6) d 10.49 (s, 1H), 9.73 (s,
(diethylamino)ethyl]oxy}-6- 1H), 8.52 (s, 1H), 7.85 (dd, 1H), 7.61
(m, 2H), (methyloxy)quinazolin-4- 7.54 (s, 1H), 7.41 (m, 3H), 7.12
(t, 2H), 7.23 (t, yl]oxy}-3-fluorophenyl)-N'-(4- 2H), 3.96 (s, 3H),
2.86 (t, 2H), 2.56 (q, 4H), fluorophenyl)-2- 1.98 (m, 1H), 1.34 (m,
2H), 1.07 (d, 3H), methylcyclopropane-1,1- 0.97 (t, 6H).
dicarboxamide 18 N-(4-{[7-{[3- 1H NMR (DMSO-d6) 8.51 (s, 1H),
(diethylamino)propyl]oxy}-6- 7.78-7.84 (m, 1H), 7.58-7.64 (m, 2H),
7.53 (s, 1H), (methyloxy)quinazolin-4- 7.34-7.48 (m, 3H), 7.13 (t,
2H), 4.22 (t, 2H), 3.98 (s, yl]oxy}-3-fluorophenyl)-N'-(4- 3H),
2.84 (t, 2H), 2.55 (q, 4H), 1.48 (s, 4H),
fluorophenyl)cyclopropane-1,1- 1.39 (t, 6H). dicarboxamide 19
N-(4-{[7-{[3-(4-acetylpiperazin- .sup.1H NMR (400 MHz, CDCl.sub.3):
10.04 (s, 1H), 1-yl)propyl]oxy}-6- 8.48-8.47 (d, 1H), 8.21 (s, 1H),
7.79-7.76 (d, (methyloxy)quinolin-4-yl]oxy}- 1H), 7.57 (s, 1H),
7.52-7.44 (m, 3H), 3-fluorophenyl)-N'-(4- 7.28-7.20 (m, 2H),
7.09-7.05 (t, 2H), 6.40-6.39 (d, 1H),
fluorophenyl)cyclopropane-1,1- 4.30-4.26 (t, 2H), 4.04 (s, 3H),
3.64-3.62 (t, dicarboxamide 2H), 3.49-3.47 (t, 2H), 2.62-2.58 (t,
2H), 2.50-2.44 (m, 4H), 2.17-2.12 (m, 2H), 2.10 (s, 3H), 1.84-1.81
(t, 2H), 1.64-1.61 (t, 2H). 20 1,1-dimethylethyl 4-(3-{[4-[(2-
.sup.1H NMR (400 MHz, DMSO-d.sub.6): 10.54 (s, 1H),
fluoro-4-{[((1R,2R)-1-{[(4- 9.72 (s, 1H), 8.47-8.46 (d, 1H),
7.96-7.93 (dd, fluorophenyl)amino]carbonyl}- 1H), 7.63-7.61 (m,
2H), 7.52 (br s, 2H),
2-methylcyclopropyl)carbonyl]amino}phenyl)oxy]- 7.42-7.40 (d, 2H),
7.17-7.12 (t, 2H), 6.44-6.42 (d, 6- 1H), 4.22-4.18 (t, 2H), 3.95
(s, 3H), (methyloxy)quinolin-7- 3.42-3.40 (m, 2H), 2.36-2.26 (m,
8H), 2.00-1.98 (m, yl]oxy}propyl)piperazine-1- 3H), 1.58-1.54 (m,
2H), 1.40 (s, 9H), 1.10-1.09 (d, carboxylate 3H). 21 N-(4-{[6,7- 1H
NMR (DMSO-d6): 10.0 (s, 1H), 9.9 (s, bis(methyloxy)quinolin-4- 1H),
8.45 (d, 1H), 7.8 (d, 2H), 7.7 (m, 2H), yl]oxy}phenyl)-N'-(4- 7.5
(s, 1H), 7.4 (s, 1H), 7.48-7.15 (m, 9H), 3.95 (s, fluorophenyl)-1-
6H), 3.7 (s, 4H), 3.6 (s, 2H). (phenylmethyl)azetidine-3,3-
dicarboxamide 22 N-(4-{[6,7- 1H NMR (DMSO-d6): 8.46 (d, 1H), 7.84
(d, bis(methyloxy)quinolin-4- 2H), 7.70 (m, 2H), 7.50 (s, 1H), 7.40
(s, 1H), yl]oxy}phenyl)-N'-(4- 7.24 (d, 2H), 7.20 (t, 2H), 6.44 (d,
1H), 4.03 (s, fluorophenyl)azetidine-3,3- 4H), 3.95 (s, 6H), 1.90
(s, 3H, acetate salt). dicarboxamide 23 (1R,2S)--N-{3-fluoro-4-[(6-
.sup.1H NMR (400 MHz, DMSO-d.sub.6): 10.26 (s, 1H),
(methyloxy)-7-{[3-(4- 9.75 (s, 1H), 8.47-8.46 (d, 1H), 7.91-7.87
(dd, methylpiperazin-1- 1H), 7.70-7.66 (m, 2H), 7.56-7.51 (m, 2H),
yl)propyl]oxy}quinolin-4- 7.43-7.38 (m, 2H), 6.42-6.41 (d, 1H),
yl)oxy]phenyl}-N'-(4- 4.20-4.16 (t, 2H), 3.95 (s, 3H), 2.47-2.43
(m, 2H), fluorophenyl)-2- 2.40-2.24 (m, 5H), 2.14 (s, 3H),
2.03-1.93 (m, 3H), methylcyclopropane-1,1- 1.89 (s, 3H), 1.45-1.42
(m, 1H), 1.38-1.35 (m, dicarboxamide 1H), 1.10-1.08 (d, 3H). 24
(1R,2R)--N-{3-fluoro-4-[(6- .sup.1H NMR (400 MHz, DMSO-d.sub.6):
10.56 (s, 1H), (methyloxy)-7-{[3-(4- 9.75 (s, 1H), 8.47-8.46 (d,
1H), 7.96-7.93 (d, methylpiperazin-1- 1H), 7.68-7.61 (m, 2H),
7.53-7.52 (m, 2H), yl)propyl]oxy}quinolin-4- 7.44-7.39 (m, 2H),
7.18-7.12 (m, 2H), yl)oxy]phenyl}-N'-(4- 6.44-6.42 (d, 1H),
4.20-4.17 (t, 2H), 3.95 (s, 3H), fluorophenyl)-2- 3.42-3.30 (m,
3H), 2.46-2.44 (m, 2H), 2.33 (br methylcyclopropane-1,1- s, 2H),
2.15 (s, 3H), 2.05-1.94 (m, 2H), 1.89 (s, dicarboxamide 5H),
1.40-1.35 (m, 1H), 1.10-1.09 (m, 3H). 25
(1R,2R)--N-[3-fluoro-4-({6- .sup.1H NMR (400 MHz, DMSO-d.sub.6):
10.55 (s, 1H), (methyloxy)-7-[(3-piperazin-1- 9.72 (s, 1H),
8.47-8.46 (d, 1H), 7.96-7.93 (d, ylpropyl)oxy]quinolin-4- 1H),
7.68-7.61 (m, 2H), 7.52 (br s, 2H), yl}oxy)phenyl]-N'-(4- 7.44-7.40
(m, 2H), 7.17-7.12 (m, 2H), 6.44-6.43 (d, fluorophenyl)-2- 1H),
4.21-4.18 (t, 2H), 3.95 (s, 3H), 2.79 (br s,
methylcyclopropane-1,1- 4H), 2.47-2.44 (t, 2H), 2.38 (br s, 3H),
dicarboxamide 2.04-1.95 (m, 3H), 1.40-1.35 (m, 2H), 1.11-1.09 (m,
5H). 26 N-(3-fluoro-4-{[7-({3-[4-(1- .sup.1H NMR (400 MHz,
DMSO-d.sub.6): 10.40 (s, 1H), methylethyl)piperazin-1- 10.02 (s,
1H), 8.47-8.46 (d, 1H), 7.92-7.89 (d, yl]propyl}oxy)-6- 1H),
7.66-7.63 (m, 2H), 7.52-7.51 (d, 2H), (methyloxy)quinolin-4-
7.44-7.39 (m, 2H), 7.19-7.14 (m, 2H), yl]oxy}phenyl)-N'-(4-
6.42-6.41 (d, 1H), 4.20-4.17 (t, 2H), 3.95 (s, 3H),
fluorophenyl)cyclopropane-1,1- 2.70-2.68 (m, 1H), 2.62-2.55 (m,
2H), dicarboxamide 2.46-2.33 (m, 8H), 1.99-1.94 (m, 2H), 1.47 (s,
4H), 1.00-0.95 (m, 6H). 27 N-(4-{[7-{[3- .sup.1H NMR
(DMSO-d.sub.6)10.34 (s, 1H), 10.01 (s, (diethylamino)propyl]oxy}-6-
1H), 8.50 (s, 1H), 7.81 (dd, 1H), 7.55-7.68 (m,
(methyloxy)quinazolin-4- 2H), 7.51-7.55 (m, 2H), 7.33-7.48 (m, 3H),
yl]oxy}-3-fluorophenyl)-N'-(4- 7.12 (t, 2H), 4.22 (t, 2H), 3.94 (s,
3H), fluorophenyl)cyclopropane-1,1- 2.52-2.61 (m, 2H), 2.49-2.51
(m, 4H), 1.83-1.94 (m, dicarboxamide 2H), 1.42 (s, 4H), 0.95 (t,
6H). 28 (1R,2R)--N-(4-{[7-{[3- .sup.1H NMR (DMSO-d.sub.6) d 10.52
(s, 1H), 9.70 (s, (diethylamino)propyl]oxy}-6- 1H), 8.44 (d, 1H),
7.92 (dd, 1H), 7.61 (m, 2H), (methyloxy)quinolin-4-yl]oxy}- 7.50
(m, 2H), 7.43 (m, 2H), 7.12 (t, 2H), 3-fluorophenyl)-N'-(4- 6.41
(d, 1H), 4.17 (t, 2H), 3.93 (s, 3H), 2.55 (m, fluorophenyl)-2- 2H),
2.31 (m, 4H), 1.98 (m, 1H), 1.88 (m, 2H), methylcyclopropane-1,1-
1.35 (m, 2H), 1.07 (d, 3H), 0.94 (t, 6H). dicarboxamide 29
(1R,2R)--N-(4-{[7-{[2- .sup.1H NMR (DMSO-d.sub.6) d 10.52 (s, 1H),
9.70 (s, (diethylamino)ethyl]oxy}-6- 1H), 8.44 (d, 1H), 7.78 (dd,
1H), 7.61 (m, 2H), (methyloxy)quinolin-4-yl]oxy}- 7.51 (m, 2H),
7.41 (m, 2H), 7.12 (t, 2H), 3-fluorophenyl)-N'-(4- 6.41 (d, 1H),
4.17 (t, 2H), 3.93 (s, 3H), 2.85 (t, 2H), fluorophenyl)-2- 2.57 (q,
4H), 1.98 (m, 1H), 1.34 (m, 2H), methylcyclopropane-1,1- 1.07 (d,
3H), 0.98 (t, 6H). dicarboxamide 30 (1R,2S)--N-(4-{[7-{[3- .sup.1H
NMR (DMSO-d.sub.6) d 10.17 (s, 1H), 9.97 (s,
(diethylamino)propyl]oxy}-6- 1H), 8.39 (d, 1H), 7.80 (dd, 1H), 7.62
(m, 2H), (methyloxy)quinolin-4-yl]oxy}- 7.45 (m, 2H), 7.31 (m, 2H),
7.09 (t, 2H), 3-fluorophenyl)-N'-(4- 6.34 (d, 1H), 4.12 (t, 2H),
3.88 (s, 3H), 2.46 (m, fluorophenyl)-2- 2H), 2.40 (m, 4H), 1.92 (m,
1H), 1.84 (m, 2H), methylcyclopropane-1,1- 1.37 (m, 1H), 1.29 (m,
1H), 1.01 (d, 3H), dicarboxamide 0.89 (t, 6H). 31
(1R,2S)--N-(4-{[7-{[2- .sup.1H NMR (DMSO-d.sub.6) d 10.22 (s, 1H),
10.01 (s, (diethylamino)ethyl]oxy}-6- 1H), 8.44 (d, 1H), 7.86 (dd,
1H), 7.66 (m, 2H), (methyloxy)quinolin-4-yl]oxy}- 7.49 (m, 2H),
7.39 (m, 2H), 7.14 (m, 2H), 3-fluorophenyl)-N'-(4- 6.39 (d, 1H),
4.18 (m, 2H), 3.92 (s, 3H), 2.85 (t, fluorophenyl)-2- 2H), 2.57 (q,
4H), 1.97 (m, 1H), 1.42 (m, 1H), methylcyclopropane-1,1- 1.35 (m,
1H), 1.06 (d, 3H), 0.98 (t, 6H). dicarboxamide 32 N-(4-{[7-{[2-
.sup.1H NMR (CDCl.sub.3) 8.57 (s, 1H), 8.12 (s, 1H),
(diethylamino)ethyl]oxy}-6- 7.73-7.81 (m, 2H), 7.48-7.53 (m, 2H),
7.32 (s, (methyloxy)quinazolin-4- 1H), 6.98-7.08 (m, 3H), 4.28 (t,
2H), 4.04 (s, yl]oxy}-3-fluorophenyl)-N'-(4- 3H), 3.25 (t, 2H),
2.76 (q, 4H), 2.67 (q, 4H), fluorophenyl)cyclobutane-1,1- 2.01-2.15
(m, 2H), 1.10 (t, 6H). dicarboxamide 33 (1R,2S)--N-[3-fluoro-4-({6-
.sup.1H NMR (400 MHz, DMSO-d.sub.6): 10.28 (s, 1H),
(methyloxy)-7-[(3-piperazin-1- 9.80 (s, 1H) 8.47-8.46 (d, 1H),
7.90-7.88 (d, ylpropyl)oxy]quinolin-4- 1H), 7.70-7.62 (m, 2H),
7.56-7.52 (m, 2H), yl}oxy)phenyl]-N'-(4- 7.44-7.39 (m, 2H),
7.18-7.12 (m, 2H), fluorophenyl)-2- 6.44-6.41 (t, 1H), 4.20-4.17
(t, 2H), 3.95 (s, 3H), methylcyclopropane-1,1- 2.74-2.72 (t, 3H),
2.46-2.42 (m, 1H), 2.35 (br s, dicarboxamide 3H), 2.03-1.93 (m,
3H), 1.87 (s, 4H), 1.43-1.35 (m, 2H), 1.09-1.08 (m, 3H). 34
(1r,2R,3S)--N-[3-fluoro-4-({6- 1H NMR (DMSO-d6): 1H (10.12 ppm, s),
1H (methyloxy)-7-[(3-morpholin-4- (9.6 ppm, s), 1H (8.46 ppm, d),
1H (7.88 ppm, ylpropyl)oxy]quinolin-4- dd), 2H (7.68 ppm, m), 1H
(7.56 ppm, d), 1H yl}oxy)phenyl]-N'-(4- (7.51 ppm, s), 2H (7.4 ppm,
m), 2H (7.13 ppm, fluorophenyl)-2,3- t), 1H (6.4 ppm, d), 2H (4.2
ppm, t), 3H (3.94 ppm, dimethylcyclopropane-1,1- s), 4H (3.6 ppm,
t), 2H (2.45 ppm, t), 4H dicarboxamide (2.37 ppm, m), 2H (1.97 ppm,
t), 2H (1.8 ppm, m), 6 H (1.28 ppm, d). 35
(1r,2R,3S)--N-{3-fluoro-4-[(6- 1H NMR (DMSO-d6): 1H (10.12 ppm, s),
1H (methyloxy)-7-{[3-(4- (9.6 ppm, s), 1H (8.46 ppm, d), 1H (7.88
ppm, methylpiperazin-1- dd), 2H (7.69 ppm, m), 1H (7.58 ppm, d), 1H
yl)propyl]oxy}quinolin-4- (7.51 ppm, s), 2H (7.4 ppm, m), 2H (7.13
ppm, yl)oxy]phenyl}-N'-(4- t), 1H (6.4 ppm, d), 2H (4.2 ppm, t), 3H
(3.95 ppm, fluorophenyl)-2,3- s), 10H (2.35 ppm, m), 3H (2.14 ppm,
s), dimethylcyclopropane-1,1- 2H (1.97 ppm, t), 2H (1.8 ppm, m), 6H
(1.28 ppm, dicarboxamide d). 36 N-[3-fluoro-4-({6-(methyloxy)-
.sup.1H NMR (400 MHz, DMSO-d6): 8.45 (d, 2 H), 7-[(3-morpholin-4-
8.15 (d, 1H), 7.8 (d, 1H), 7.45 (m, 3H), ylpropyl)oxy]quinazolin-4-
7.25 (m, 3H), 7.0 (m, 2H), 4.20 (t, 2H), 4.0 (s, 3H),
yl}oxy)phenyl]-N'-(4- 3.7 (m, 4H), 2.67 (m, 4H), 2.45 (m, 6H),
fluorophenyl)cyclobutane-1,1- 2.0 (m, 4H). dicarboxamide 37
(2R,3R)--N-[3-fluoro-4-({6- .sup.1H NMR (400 MHz, CDCl.sub.3) d
8.44 (d, J = 5.1 Hz, (methyloxy)-7-[(3-morpholin-4- 1 H), 8.11 (br
s, 1 H), 7.77-7.70 (m, 2 H), ylpropyl)oxy]quinolin-4- 7.53 (s, 1
H), 7.50-7.44 (m, 2 H), 7.40 (s, 1 H), yl}oxy)phenyl]-N'-(4-
7.22-7.16 (m, 2 H), 7.06-6.98 (m, 2H), fluorophenyl)-2,3- 6.36 (br
d, J = 5.1 Hz, 1 H), 4.26 (t, J = 7.0 Hz, 2 H),
dimethylcyclopropane-1,1- 4.02 (s, 3 H), 3.72 (t, J = 4.4 Hz, 4 H),
2.57 (t, dicarboxamide J = 7.3 Hz, 2 H), 2.50-2.42 (m, 4 H),
2.18-2.10 (m, 2 H), 1.80-1.66 (m, 2 H), 1.30-1.24 (m, 6 H). 38
(2R,3R)--N-(4-{[7-{[3- .sup.1H NMR (400 MHz, DMSO-d.sub.6) d 10.34
(s, 1 (diethylamino)propyl]oxy}-6- H), 10.05 (s, 1 H), 8.46 (br s,
1 H), 7.93 (br d, (methyloxy)quinolin-4-yl]oxy}- J = 4.7 Hz, 1 H),
7.54-7.52 (m, 2 H), 3-fluorophenyl)-N'-(4- 7.52-7.50 (m, 2 H),
7.50-7.30 (m, 2 H), 7.20-7.10 (m, 2 fluorophenyl)-2,3- H), 6.47 (br
s, 1 H), 4.30-4.20 (m, 2 H), 3.95 (s, dimethylcyclopropane-1,1- 3
H), 3.40-3.10 (m, 6H), 2.60-2.40 (m, 2 H), dicarboxamide 1.90-1.80
(m, 2 H), 1.30-1.10 (m, 12 H). 39 N-(4-{[7-{[3- 1H NMR (400 MHz,
DMSO-d6): d 10.47 (s, (diethylamino)propyl]oxy}-6- 1H), 10.16 (s,
1H), 8.43 (d, 1H), 7.92 (dd, 1H), (methyloxy)quinolin-4-yl]oxy}-
7.67 (m, 2H), 7.58 (m, 1H), 7.52 (s, 1H), 3-fluorophenyl)-N'-(4-
7.41 (m, 2H), 7.15 (t, 2H), 6.44 (d, 1H), 4.25 (t, 2H),
fluorophenyl)-2,2- 3.95 (s, 3H), 3.10 (m, 6H), 2.17 (m, 2H),
dimethylcyclopropane-1,1- 1.91 (s, 3H, acetate salt), 1.52 (m, 2H),
1.18 (m, dicarboxamide 12H). 40 N-[3-fluoro-4-({6-(methyloxy)- 1H
NMR (400 MHz, DMSO-d6): d 10.21 (s, 7-[(3-morpholin-4- 1H), 9.97
(s, 1H), 8.51 (s, 1H), 7.81 (dd, 1H), ylpropyl)oxy]quinazolin-4-
7.64 (m, 2H), 7.54 (s, 1H), 7.48 (m, 1H), yl}oxy)phenyl]-N'-(4-
7.41 (m, 1H), 7.38 (s, 1H), 7.15 (t, 2H), 4.24 (t, 2H),
fluorophenyl)-2,2- 3.97 (s, 3H), 3.58 (m, 4H), 2.45 (t, 2H),
dimethylcyclopropane-1,1- 2.38 (m, 4H), 1.97 (m, 2H), 1.58 (m, 2H),
1.18 (s, dicarboxamide 3H), 1.17 (s, 3H). 41
(1R,2R,3S)--N-(4-{[7-{[2- 1H NMR (400 MHz, DMSO-d6): d 10.14 (s,
(diethylamino)ethyl]oxy}-6- 1H), 9.61 (s, 1H), 8.46 (d, 1H), 7.87
(dd, 1H), (methyloxy)quinolin-4-yl]oxy}- 7.67 (m, 2H), 7.57 (m,
1H), 7.51 (s, 1H), 3-fluorophenyl)-N'-(4- 7.42 (s, 1H), 7.39 (m,
1H), 7.15 (t, 2H), 6.41 (d, fluorophenyl)-2,3- 1H), 4.20 (m, 2H),
3.94 (s, 3H), 2.87 (m, 2H), dimethylcyclopropane-1,1- 2.60 (m, 4H),
1.80 (m, 2H), 1.18 (s, 3H), dicarboxamide 1.17 (s, 3H), 1.01 (m,
6H). Note: 0.5eq of AcOH is present by NMR. 42 N-(4-{[7-{[2- 1H NMR
(400 MHz, DMSO): d 10.24 (s, 1H), (diethylamino)ethyl]oxy}-6- 10.00
(s, 1H), 8.54 (s, 1H), 7.84 (dd, 1H), (methyloxy)quinazolin-4- 7.66
(m, 2H), 7.56 (s, 1H), 7.51 (m, 1H), 7.43 (m,
yl]oxy}-3-fluorophenyl)-N'-(4- 2H), 7.18 (t, 2H), 4.26 (m, 2H),
3.98 (s, 3H), fluorophenyl)-2,2- 2.88 (m, 2H), 2.59 (m, 4H), 1.58
(m, 2H), dimethylcyclopropane-1,1- 1.18 (s, 6H), 1.00 (t, 6H).
dicarboxamide 43 N-(4-{[7-{[3- 1H NMR (400 MHz, DMSO-d6): d 10.21
(s, (diethylamino)propyl]oxy}-6- 1H), 9.97 (s, 1H), 8.51 (s, 1H),
7.82 (dd, 1H), (methyloxy)quinazolin-4- 7.64 (m, 2H), 7.54 (s, 1H),
7.48 (m, 1H), yl]oxy}-3-fluorophenyl)-N'-(4- 7.41 (m, 1H), 7.37 (s,
1H), 7.15 (t, 2H), 4.23 (t, 2H), fluorophenyl)-2,2- 3.97 (s, 3H),
2.56 (m, 2H), 2.46 (m, 4H), dimethylcyclopropane-1,1- 1.91 (m, 2H),
1.58 (m, 2H), 1.18 (s, 6H), 0.96 (t, dicarboxamide 6H). 44
N-(4-{[7-{[3- 1H NMR (CDCl3): 8.57 (s, 1H), 8.50 (s, 1H),
(diethylamino)propyl]oxy}-6- 8.11 (s, 1H), 7.81 (dd, 1H), 7.53 (m,
3H), (methyloxy)quinazolin-4- 7.28 (m, 4H), 7.04 (t, 2H), 4.24 (t,
2H), 4.04 (s, 3H), yl]oxy}-3-fluorophenyl)-N'-(4- 2.95 (t, 2H),
2.84 (q, 4H), 2.75 (m, 4H), fluorophenyl)cyclobutane-1,1- 2.21 (m,
2H), 2.02 (m, 2H), 1.18 (t, 6H). dicarboxamide 45
N-{3-fluoro-4-[(6-(methyloxy)- 1H NMR (CDCL3): 8.57 (s, 1H), 8.49
(s, 1H), 7-{[3-(4-methylpiperazin-1- 8.10 (s, 1H), 7.80 (d, 1H),
7.70 (br., 1H), yl)propyl]oxy}quinazolin-4- 7.52 (m, 3H), 7.31 (m,
3H), 7.04 (t, 2H), 4.26 (t, yl)oxy]phenyl}-N'-(4- 2H), 4.04 (s,
3H), 2.62-2.77 (m, 14H), 2.40 (s, fluorophenyl)cyclobutane-1,1-
3H), 2.13 (m, 2H), 2.01 (m, 2H). dicarboxamide 46
(2R,3R)--N-[3-fluoro-4-({6- .sup.1H NMR (400 MHz, CDCl.sub.3) d
8.59 (s, 1 H), (methyloxy)-7-[(3-morpholin-4- 8.11 (br s, 1 H),
7.80-7.76 (m, 2 H), 7.53 (s, 1 ylpropyl)oxy]quinazolin-4- H),
7.50-7.46 (m, 2 H), 7.34 (s, 1 H), yl}oxy)phenyl]-N'-(4- 7.26-7.24
(m, 2 H), 7.06-7.00 (m, 2 H), 4.28 (t, fluorophenyl)-2,3- J = 6.6
Hz, 2 H), 4.05 (s, 3 H), 3.73 (br t, J = 4.4 Hz, 4
dimethylcyclopropane-1,1- H), 2.57 (t, J = 7.0 Hz, 2 H), 2.52-2.45
(m, 4 dicarboxamide H), 2.18-2.10 (m, 2 H), 1.80-1.68 (m, 2 H),
1.28-1.20 (m, 6 H). 47 N-(4-{[7-{[3- .sup.1H NMR (400 MHz,
DMSO-d.sub.6): 9.98 (s, 1H), (diethylamino)propyl]oxy}-6- 9.72 (s,
1H), 8.45-8.43 (d, 1H), 7.97-7.94 (dd,
(methyloxy)quinolin-4-yl]oxy}- 1H), 7.73-7.69 (m, 2H), 7.65-7.52
(m, 3H), 3-fluorophenyl)-N'-(4- 7.44-7.39 (m, 1H), 7.18-7.14 (m,
2H), fluorophenyl)cyclobutane-1,1- 6.43-6.42 (d, 1H), 4.20-4.19 (t,
2H), 3.95 (s, 3H), dicarboxamide 2.70-2.66 (m, 6H), 2.45 (br s,
2H), 1.91-1.84 (m, 6H), 0.98 (br s, 6H). 48
N-{3-fluoro-4-[(6-(methyloxy)- .sup.1H NMR (400 MHz, DMSO-d.sub.6):
9.99 (s, 1H), 7-{[3-(4-methylpiperazin-1- 9.73 (s, 1H), 8.45-8.43
(d, 1H), 7.97-7.93 (dd, yl)propyl]oxy}quinolin-4- 1H), 7.73-7.69
(m, 2H), 7.65-7.52 (m, 2H), yl)oxy]phenyl}-N'-(4- 7.44-7.38 (m,
2H), 7.18-7.14 (m, 2H), fluorophenyl)cyclobutane-1,1- 6.43-6.42 (d,
1H), 4.19-4.16 (t, 3H), 3.95 (s, 3H), dicarboxamide 2.70-2.66 (m,
4H), 2.47-2.33 (m, 8H), 2.15 (s, 3H), 1.98-1.94 (m, 2H), 1.90-1.84
(m, 4H). 49 (2R,3R)--N-(4-{[7-{[2- .sup.1H NMR (400 MHz,
CDCl.sub.3) d 8.59 (br s, 1 H), (diethylamino)ethyl]oxy}-6- 8.29
(br s, 1 H), 7.93 (s, 1 H), 7.77 (d, J = 10.8 Hz,
(methyloxy)quinazolin-4- 1 H), 7.53 (s, 1 H), 7.50-7.45 (m, 2 H),
yl]oxy}-3-fluorophenyl)-N'-(4- 7.32 (s, 1 H), 7.26-7.22 (m, 2 H),
7.05-6.99 (m, fluorophenyl)-2,3- 2 H), 4.27 (t, J = 6.6 Hz, 2 H),
4.04 (s, 3 H), dimethylcyclopropane-1,1- 3.03 (t, J = 6.5 Hz, 2 H),
2.67 (q, J = 7.0 Hz, 4 dicarboxamide H), 1.80-1.70 (m, 2 H), 1.22
(br t, J = 5.3 Hz, 6 H), 1.09 (br t, J = 7.2 Hz, 6 H). 50
(2R,3R)--N-(4-{[7-{[3- .sup.1H NMR (400 MHz, CDCl.sub.3) d 8.58 (s,
1 H), (diethylamino)propyl]oxy}-6- 8.40-8.36 (m, 1 H), 8.02-7.96
(m, 1 H), (methyloxy)quinazolin-4- 7.80-7.75 (m, 1 H), 7.53 (s, 1
H), 7.52-7.50 (m, 2 yl]oxy}-3-fluorophenyl)-N'-(4- H), 7.31 (s, 1
H), 7.28-7.20 (m, 2 H), 7.02 (t, J = 8.5 Hz, fluorophenyl)-2,3- 2
H), 4.25 (t, J = 6.3 Hz, 2 H), dimethylcyclopropane-1,1- 4.04 (s, 3
H), 3.00-2.90 (m, 2 H), 2.88-2.80 (m, 4 dicarboxamide H), 2.30-2.20
(m, 2 H), 1.76-1.68 (m, 2 H), 1.25-1.15 (m, 12 H). 51
(2R,3R)--N-(4-{[7-{[2- .sup.1H NMR (400 MHz, CDCl.sub.3) d 8.47 (d,
J = 5.2 Hz, (diethylamino)ethyl]oxy}-6- 1 H), 8.17 (br s, 1 H),
7.80-7.74 (m, 2 H), (methyloxy)quinolin-4-yl]oxy}- 7.55 (s, 1 H),
7.52-7.46 (m, 2 H), 7.42 (s, 1 H), 3-fluorophenyl)-N'-(4- 7.24-7.20
(m, 2 H), 7.05 (t, J = 8.6 Hz, 2 H), fluorophenyl)-2,3- 6.38 (br d,
J = 5.4 Hz, 1 H), 4.27 (t, J = 6.4 Hz, dimethylcyclopropane-1,1- 2
H), 4.03 (s, 3 H), 3.04 (br t, J = 7.2 Hz, 2 H), dicarboxamide 2.68
(q, J = 6.8 Hz, 4 H), 1.80-1.68 (m, 2 H), 1.26 (d, J = 6.4 Hz, 6
H), 1.09 (br t, J = 7.2 Hz,
6 H). 52 N-(4-{[6,7- 1H NMR (DMSO-d6): 10.82 (s, 1H), 8.80 (d,
bis(methyloxy)quinolin-4- 1H), 8.50 (t, 1H), 7.83 (d, 2H), 7.74 (s,
1H), yl]oxy}phenyl)-N'-[(4- 7.56 (s, 1H), 7.30-7.38 (m, 4H), 7.15
(t, 2H), fluorophenyl)methyl] 6.80 (d, 1H), 4.32 (d, 2H), 4.04 (s,
3H), 4.03 (s, cyclopropane-1,1- 3H), 1.42 (s, 4H). dicarboxamide 53
N-(4-{[6,7- 1H NMR (DMSO-d6): 10.62 (s, 1H), 8.79 (d,
bis(methyloxy)quinolin-4- 1H), 8.24 (t, 1H), 7.83 (d, 2H), 7.72 (s,
1H), yl]oxy}phenyl)-N'-(2- 7.58 (s, 1H), 7.37 (d, 2H), 6.76 (d,
1H), 4.04 (s, morpholin-4- 3H), 4.03 (s, 3H), 3.98 (m, 2H), 3.66
(m, 2H), ylethyl)cyclopropane-1,1- 3.49 (m, 4H), 3.25 (t, 2H), 3.13
(br., 2H), dicarboxamide 1.42 (d, 4H). 54 N-(4-{[6,7- 1H NMR
(DMSO-d6): 10.78 (s, 1H), 10.53 (s, bis(methyloxy)quinolin-4- 1H),
8.43 (d, 1H), 8.12 (d, 1H), 7.82 (d, 2H), yl]oxy}phenyl)-N'-[2-
7.49 (s, 1H), 7.37 (s, 1H), 7.20-7.28 (m, 3H), (piperidin-1- 7.15
(dd, 1H), 7.01 (td, 1H), 6.35 (d, 1H),
ylmethyl)phenyl]cyclopropane- 3.93 (s, 3H), 3.92 (s, 3H), 3.47 (s,
2H), 2.17 (br., 1,1-dicarboxamide 4H), 1.49 (m, 4H), 1.41 (m, 4H),
1.32 (br., 2H). 55 N-(4-{[6,7- 1H NMR (DMSO-d6): 10.98 (s, 1H),
10.56 (s, bis(methyloxy)quinolin-4- 1H), 8.42 (d, 1H), 8.10 (dd,
1H), 7.81 (m, 2H), yl]oxy}phenyl)-N'-[2- 7.49 (s, 1H), 7.37 (s,
1H), 7.17-7.27 (m, 4H), (pyrrolidin-1- 7.01 (td, 1H), 6.35 (d, 1H),
3.93 (s, 3H), ylmethyl)phenyl]cyclopropane- 3.92 (s, 3H), 3.61 (s,
2H), 2.30 (br., 4H), 1.47 (br., 1,1-dicarboxamide 4H), 1.43 (m,
4H). 56 N-(4-{[6,7- 1H NMR (DMSO-d6): 10.12 (s, 1H), 10.03 (s,
bis(methyloxy)quinolin-4- 1H), 8.44 (d, 1H), 7.74 (d, 2H), 7.57 (s,
1H), yl]oxy}phenyl)-N'-[3- 7.53 (d, 1H), 7.48 (s, 1H), 7.37 (s,
1H), (morpholin-4- 7.21 (m, 3H), 6.98 (d, 1H), 6.40 (d, 1H), 3.93
(s, ylmethyl)phenyl]cyclopropane- 3H), 3.92 (s, 3H), 3.56 (t, 4H),
3.41 (s, 2H), 1,1-dicarboxamide 2.34 (br., 4H), 1.48 (s, 4H). 57
N-(4-{[6,7- 1H NMR (DMSO-d6): 10.54 (s, 1H), 10.47 (s,
bis(methyloxy)quinolin-4- 1H), 8.43 (d, 1H), 8.08 (d, 1H), 7.78 (d,
2H), yl]oxy}phenyl)-N'-[2- 7.49 (s, 1H), 7.37 (d, 1H), 7.18-7.30
(m, 4H), (morpholin-4- 7.03 (t, 1H), 6.37 (d, 1H), 3.94 (s, 3H),
3.93 (s, ylmethyl)phenyl]cyclopropane- 3H), 3.50 (s, 2H), 3.44
(br., 4H), 2.20 (br., 4H), 1,1-dicarboxamide 1.48 (d, 4H). 58
N-(4-{[6,7- 1H NMR (DMSO-d6): 10.14 (s, 1H), 10.03 (s,
bis(methyloxy)quinolin-4- 1H), 8.44 (d, 1H), 7.74 (d, 2H), 7.62 (d,
2H), yl]oxy}phenyl)-N'- 7.48 (s, 1H), 7.37 (s, 1H), 7.27-7.31 (m,
2H), phenylcyclopropane-1,1- 7.19-7.23 (m, 2H), 7.05 (t, 1H), 6.41
(d, 1H), dicarboxamide 3.93 (s, 6H), 3.92 (s, 3H), 1.48 (s, 4H). 59
N-[3-(aminomethyl)phenyl]-N'- 1H NMR (400 MHz, DMSO-d6): d 10.28
(s, (4-{[6,7-bis(methyloxy) 1H), 10.19 (s, 1H), 8.77 (m, 1H), 8.21
(m, 3H), quinolin-4-yl]oxy}phenyl) 7.84 (m, 2H), 7.76 (m, 1H), 7.71
(m, 1H), cyclopropane-1,1- 7.58 (m, 2H), 7.38 (m, 3H), 7.19 (m,
1H), 6.76 (m, dicarboxamide 1H), 4.03 (s, 6H), 3.39 (m, 2H), 1.53
(m, 4H). Note: all peaks are very broad and unresolved. 60
N-(4-{[6,7- 1H NMR (DMSO-d6): 10.0-10.2 (br., 2H),
bis(methyloxy)quinolin-4- 8.46 (d, 1H), 7.76 (d, 2H), 7.53 (m, 3H),
yl]oxy}phenyl)-N'-[3- 7.39 (s, 1H), 7.24 (m, 3H), 6.98 (d, 1H),
6.43 (d, (piperidin-1-ylmethyl) 1H), 3.95 (s, 3H), 3.93 (s, 3H),
3.37 (s, 2H), phenyl]cyclopropane-1,1- 2.31 (br., 4H), 1.48 (m,
8H), 1.39 (br., 2H). dicarboxamide 61 N-(4-{[6,7- 1H NMR (DMSO-d6):
10.0-10.2 (br., 2H), bis(methyloxy)quinolin-4- 8.46 (d, 1H), 7.77
(d, 2H), 7.59 (s, 1H), 7.53 (d, yl]oxy}phenyl)-N'-[3- 1H), 7.51 (s,
1H), 7.39 (s, 1H), 7.23 (m, 3H), (pyrrolidin-1-ylmethyl) 6.99 (d,
1H), 6.43 (d, 1H), 3.95 (s, 3H), 3.93 (s, phenyl]cyclopropane-1,1-
3H), 3.52 (s, 2H), 2.42 (br., 4H), 1.69 (br, 4H), dicarboxamide
1.48 (s, 4H).
Assays
[0568] Kinase assays were performed by measurement of incorporation
of .gamma.-.sup.33P ATP into immobilized myelin basic protein
(MBP). High binding white 384 well plates (Greiner) were coated
with MBP (Sigma #M-1891) by incubation of 60 ul/well of 20 .mu.g/ml
MBP in Tris-buffered saline (TBS; 50 mM Tris pH 8.0, 138 mM NaCl,
2.7 mM KCl) for 24 hours at 4.degree. C. Plates were washed
3.times. with 100 .mu.l TBS. Kinase reactions were carried out in a
total volume of 34 .mu.l in kinase buffer (5 mM Hepes pH 7.6, 15 mM
NaCl, 0.01% bovine gamma globulin (Sigma #I-5506), 10 mM
MgCl.sub.2, 1 mM DTT, 0.02% TritonX-100). Compound dilutions were
performed in DMSO and added to assay wells to a final DMSO
concentration of 1%. Each data point was measured in duplicate, and
at least two duplicate assays were performed for each individual
compound determination. Enzyme was added to final concentrations of
10 nM or 20 nM, for example. A mixture of unlabeled ATP and
.gamma.-.sup.33P ATP was added to start the reaction
(2.times.10.sup.6 cpm of .gamma.-.sup.33P ATP per well (3000
Ci/mmole) and either 10 .mu.M or 30CM unlabeled ATP, typically. The
reactions were carried out for 1 hour at room temperature with
shaking. Plates were washed 7.times. with TBS, followed by the
addition of 50 .mu.l/well scintillation fluid (Wallac). Plates were
read using a Wallac Trilux counter. This is only one format of such
assays, various other formats are possible, as known to one skilled
in the art.
[0569] The above assay procedure can be used to determine the
IC.sub.50 for inhibition and/or the inhibition constant, K.sub.i.
The IC.sub.50 is defined as the concentration of compound required
to reduce the enzyme activity by 50% under the conditions of the
assay. Exemplary compositions have IC.sub.50's of, for example,
less than about 100 .mu.M, less than about 10 .mu.M, less than
about 1 .mu.M, and further for example having IC.sub.50's of less
than about 100 nM, and still further, for example, less than about
10 nM. The K.sub.i for a compound may be determined from the
IC.sub.50 based on three assumptions. First, only one compound
molecule binds to the enzyme and there is no cooperativity. Second,
the concentrations of active enzyme and the compound tested are
known (i.e., there are no significant amounts of impurities or
inactive forms in the preparations). Third, the enzymatic rate of
the enzyme-inhibitor complex is zero. The rate (i.e., compound
concentration) data are fitted to the equation:
V = V max E 0 [ I - ( E 0 + I 0 + K d ) - ( E 0 + I 0 + K d ) 2 - 4
E 0 I 0 2 E 0 ] ##EQU00001##
where V is the observed rate, V.sub.max, is the rate of the free
enzyme, I.sub.0 is the inhibitor concentration, E.sub.0 is the
enzyme concentration, and K.sub.d is the dissociation constant of
the enzyme-inhibitor complex.
Kinase Specificity Assays:
[0570] Kinase activity and compound inhibition are investigated
using one or more of the three assay formats described below. The
ATP concentrations for each assay are selected to be close to the
Michaelis-Menten constant (KM) for each individual kinase.
Dose-response experiments are performed at 10 different inhibitor
concentrations in a 384-well plate format. The data are fitted to
the following four-parameter equation:
Y=Min+(Max-Min)/(1+(X/IC.sub.50) H)
where Y is the observed signal, X is the inhibitor concentration,
Min is the background signal in the absence of enzyme (0% enzyme
activity), Max is the signal in the absence of inhibitor (100%
enzyme activity), IC.sub.50 is the inhibitor concentration at 50%
enzyme inhibition and H represents the empirical Hill's slope to
measure the cooperativity. Typically H is close to unity. c-Met
Assay
[0571] c-Met biochemical activity was assessed using a
Luciferase-Coupled Chemiluminescent Kinase assay (LCCA) format as
described above. Again, kinase activity was measured as the percent
ATP remaining following the kinase reaction. Remaining ATP was
detected by luciferase-luciferin-coupled chemiluminescence.
Specifically, the reaction was initiated by mixing test compounds,
1 .mu.M ATP, 1 .mu.M poly-EY and 1 0 nM c-Met (baculovirus
expressed human c-Met kinase domain P948-S1343) in a 20 uL assay
buffer (20 mM Tris-HCL pH7.5, 10 mM MgCl.sub.2, 0.02% Triton X-100,
100 mM DTT, 2 mM MnCl.sub.2). The mixture is incubated at ambient
temperature for 2 hours after which 20 uL luciferase-luciferin mix
is added and the chemiluminescent signal read using a Wallac
Victor.sup.2 reader. The luciferase-luciferin mix consists of 50 mM
HEPES, pH 7.8, 8.5 ug/mL oxalic acid (pH 7.8), 5 (or 50) mM DTT,
0.4% Triton X-100, 0.25 mg/mL coenzyme A, 63 uM AMP, 28 ug/mL
luciferin and 40,000 units of light/mL luciferase.
KDR Assay
[0572] KDR biochemical activity was assessed using a
Luciferase-Coupled Chemiluminescent Kinase assay (LCCA) format.
Kinase activity was measured as the percent ATP remaining following
the kinase reaction. Remaining ATP was detected by
luciferase-luciferin-coupled chemiluminescence. Specifically, the
reaction was initiated by mixing test compounds, 3 .mu.M ATP, 1.6
.mu.M poly-EY and 5 nM KDR (baculovirus expressed human KDR kinase
domain D807-V1356) in a 20 uL assay buffer (20 mM Tris-HCL pH7.5,
10 mM MgCl.sub.2, 0.01% Triton X-100, 1 mM DTT, 3 mM MnCl.sub.2).
The mixture is incubated at ambient temperature for 4 hours after
which 20 uL luciferase-luciferin mix is added and the
chemiluminescent signal read using a Wallac Victor.sup.2 reader.
The luciferase-luciferin mix consists of 50 mM HEPES, pH 7.8, 8.5
ug/mL oxalic acid (pH 7.8), 5 (or 50) mM DTT, 0.4% Triton X-100,
0.25 mg/mL coenzyme A, 63 uM AMP, 28 ug/mL luciferin and 40,000
units of light/mL luciferase. [0573] flt-4 Assay
[0574] Biochemical activity for flt-4 was assessed using an
Alphascreen Tyrosine Kinase protocol. AlphaScreen.TM. (Perkin
Elmer) technology is a proximity assay employing microparticles.
Singlet oxygen derived from a donor bead following laser excitation
results in chemiluminescence when in proximity (100 .ANG.) to an
acceptor bead due to biomolecular interactions. For the Flt-4
assay, donor beads coated with streptavidin and acceptor beads
coated with PY100 anti-phosphotyrosine antibody were used (Perkin
Elmer). Biotinylated poly(Glu,Tyr) 4:1 (Perkin Elmer) was used as
the substrate. Substrate phosphorylation was measured by addition
of donor/acceptor beads by chemiluminescence following
donor-acceptor bead complex formation. Test compounds, 5 .mu.M ATP,
3 nM biotinylated poly(Glu, Tyr) and 1 nM Flt-4 (baculovirus
expressed human Flt-4 kinase domain D725-R1298) were combined in a
volume of 20 .mu.L in a 384-well white, medium binding microtiter
plate (Greiner). Reaction mixtures were incubated for 1 hr at
ambient temperature. Reactions were quenched by addition of 10 uL
of 15-30 mg/mL AlphaScreen bead suspension containing 75 mM Hepes,
pH 7.4, 300 mM NaCl, 120 mM EDTA, 0.3% BSA and 0.03% Tween-20.
After 2-16 hr incubation at ambient temperature plates were read
using an AlphaQuest reader (Perkin Elmer). IC.sub.50 values
correlate well with those determined by radiometric assays.
flt-3 Assay
[0575] Biochemical activity for flt-3 was assessed using a
Luciferase-Coupled Chemiluminescent Kinase assay (LCCA) format.
Kinase activity was measured as the percent ATP remaining following
the kinase reaction. Remaining ATP was detected by
luciferase-luciferin-coupled chemiluminescence. Specifically, the
reaction was initiated by mixing test compounds, 5 .mu.M ATP, 3
.mu.M poly-EY and 5 nM Flt-3 (baculovirus expressed human Flt-3
kinase domain R571-S993) in a 20 uL assay buffer (20 mM Tris-HCL
pH7.5, 10 mM MgCl.sub.2, 0.01% Triton X-100, 1 mM DTT, 2 mM
MnCl.sub.2). The mixture is incubated at ambient temperature for 3
hours after which 20 uL luciferase-luciferin mix is added and the
chemiluminescent signal read using a Wallac Victor.sup.2 reader.
The luciferase-luciferin mix consists of 50 mM HEPES, pH 7.8, 8.5
ug/mL oxalic acid (pH 7.8), 5 (or 50) mM DTT, 0.4% Triton X-100,
0.25 mg/mL coenzyme A, 63 uM AMP, 28 ug/mL luciferin and 40,000
units of light/mL luciferase.
c-Kit Assay
[0576] c-Kit biochemical activity was assessed using
AlphaScreen.TM. (Perkin Elmer) technology, described above. Test
compounds, ATP, biotinylated poly(Glu, Tyr) and c-Kit kinase were
combined in a volume of 20 .mu.L in a 384-well white, medium
binding microtiter plate (Greiner). Reaction mixtures were
incubated for 1 hr at ambient temperature. Reactions were quenched
by addition of 10 uL of 15-30 mg/mL AlphaScreen bead suspension
containing 75 mM Hepes, pH 7.4, 300 mM NaCl, 120 mM EDTA, 0.3% BSA
and 0.03% Tween-20. After 16 hr incubation at ambient temperature
plates were read using an AlphaQuest reader (Perkin Elmer).
Structure Activity Relationships
[0577] Table 4 shows structure activity relationship data for
selected compounds of the invention. Inhibition is indicated as
IC.sub.50 with the following key: A=IC.sub.50 less than 50 nM,
B=IC.sub.50 greater than 50 nM, but less than 500 nM,
C.dbd.IC.sub.50 greater than 500 nM, but less than 5000 nM, and
D=IC.sub.50 greater than 5,000 nM. Depending upon the functionality
about the quinazoline or quinoline, exemplary compounds of the
invention exhibit selectivity for any of c-Met, KDR, c-Kit, flt-3,
and flt-4. Abbreviations for enzymes listed in Tables 2-3 are
defined as follows: c-Met refers to hepatocyte growth factor
receptor kinase; KDR refers to kinase insert domain receptor
tyrosine kinase; flt-4, fms-like tyrosine kinase-4, representative
of the FLK family of receptor tyrosine kinases; c-Kit, also called
stem cell factor receptor or steel factor receptor; and flt-3,
fms-like tyrosine kinase-3. Empty cells in the tables indicate lack
of data only.
TABLE-US-00005 TABLE 4 Entry Name c-Met KDR c-Kit flt3 flt4 1
N-[({3-fluoro-4-[(6-(methyloxy)-7-{[(3aR,6aS)- A A
octahydrocyclopenta[c]pyrrol-5- ylmethyl]oxy}quinazolin-4-
yl)oxy]phenyl}amino)carbonothioyl]-2- phenylacetamide 2
N-{[(3-fluoro-4-{[7-({[(3aR,6aS)-2- A A A A
methyloctahydrocyclopenta[c]pyrrol-5-
yl]methyl}oxy)-6-(methyloxy)quinazolin-4-
yl]oxy}phenyl)amino]carbonothioyl}-2- phenylacetamide 3
N-{[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)(methyl)amino]carbonothioyl}-2- phenylacetamide 4
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C C C
fluorophenyl)imidazolidin-2-one 5
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C B C
fluorophenyl)-3-(phenylmethyl)imidazolidin-2-one 6
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B
fluorophenyl)-3-(phenylacetyl)imidazolidin-2-one 7 ethyl
[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B C B
fluorophenyl)amino](oxo)acetate 8
N-{[(4-{[6,7-bis(methyloxy)quinazolin-4-yl]amino}-3- A B C B
fluorophenyl)amino]carbonothioyl}-2- phenylacetamide 9
N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N-methyl-N-(2-phenylethyl)sulfamide 10
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C B C
fluorophenyl)-3-(phenylmethyl)-1,2,4-oxadiazol-5- amine 11
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C C C
fluorophenyl)piperidin-2-one 12
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B B C B
fluorophenyl)-N'-(phenylmethyl)ethanediamide 13
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C C B
fluorophenyl)-4-phenyl-1,3-thiazol-2-amine 14
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- A A A C A
fluorophenyl)-N'-(2-phenylethyl)ethanediamide 15
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C C B
fluorophenyl)-1-phenylmethanesulfonamide 16
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C C C
fluorophenyl)-2-phenylethanesulfonamide 17
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N- C C C
(phenylmethyl)benzenesulfonamide 18
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N- C C C
methyl-N-(phenylmethyl)benzenesulfonamide 19
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N- C C C
(2-phenylethyl)benzenesulfonamide 20
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N- C C C
methyl-N-(2-phenylethyl)benzenesulfonamide 21
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N- C
(3-phenylpropyl)benzenesulfonamide 22
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C C B
fluorophenyl)pyrrolidin-2-one 23
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl C
(phenylmethyl)carbamate 24
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl (2- C
phenylethyl)carbamate 25
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N- C
methyl-N-(3-phenylpropyl)benzenesulfonamide 26
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B D C C
fluorophenyl)-N'-phenylethanediamide 27
4-{[6,7-bis(methyloxy)quinolin-4-yl]amino}-N-(3- C
phenylpropyl)benzamide 28 N-{[(3-fluoro-4-{[7-{[(2- A A A A A
methyloctahydrocyclopenta[c]pyrrol-5-
yl)methyl]oxy}-6-(methyloxy)quinolin-4-
yl]oxy}phenyl)amino]carbonothioyl}-2- phenylacetamide 29
N-[(Z)-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)amino](imino)methyl]-2- phenylacetamide 30
4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-fluoro-N- C
[2-(phenyloxy)ethyl]benzenesulfonamide 31 This type of
multiplicative nomenclature is not C supported in current version!
32 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-3-phenylpropane-1-sulfonamide 33
N~2~-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)sulfonyl]-N-phenylglycinamide 34
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin- C
3-yl)-2-phenylacetamide 35 N-{[(6-{[6,7-bis(methyloxy)quinolin-4- A
C D C yl]oxy}pyridin-3-yl)amino]carbonothioyl}-2- phenylacetamide
36 6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-1,3- C C C
benzothiazol-2-amine 37
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro- C C C
1,3-benzothiazol-2-amine 38
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- B C D B
fluoro-1,3-benzothiazol-2-yl)-2-phenylacetamide 39
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C B B
fluorophenyl)-N'-(2-morpholin-4- ylethyl)ethanediamide 40
1,1-dimethylethyl {2-[(4-{[6,7- C
bis(methyloxy)quinolin-4-yl]oxy}-3- fluorophenyl)amino]-2-
oxoethyl}(phenylmethyl)carbamate 41
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B
fluorophenyl)-N~2~-(phenylmethyl)glycinamide 42
N~2~-acetyl-N-(4-{[6,7-bis(methyloxy)quinolin-4- C
yl]oxy}-3-fluorophenyl)-N~2~- (phenylmethyl)glycinamide 43
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-1,3- B
benzothiazol-2-yl)-2-phenylacetamide 44 1,1-dimethylethyl
{2-[(6-{[6,7- C
bis(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)amino]-
2-oxoethyl}(phenylmethyl)carbamate 45
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin- C
3-yl)-N~2~-(phenylmethyl)glycinamide 46
N~2~-acetyl-N-(6-{[6,7-bis(methyloxy)quinolin-4- C
yl]oxy}pyridin-3-yl)-N~2~- (phenylmethyl)glycinamide 47
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin- C
3-yl)-3-phenylpropanamide 48
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin- C
3-yl)-4-phenylbutanamide 49
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin- C
3-yl)-N~2~-methyl-N~2~-(phenylmethyl)glycinamide 50
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C C C
fluorophenyl)-N'-{2-[4- (methyloxy)phenyl]ethyl}ethanediamide 51
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B A B B A
fluorophenyl)-N~2~-methyl-N~2~- (phenylmethyl)glycinamide 52
N-{[(4-{[6,7-bis(methyloxy)quinolin-4- A B B C A
yl]amino}phenyl)amino]carbonothioyl}-2- phenylacetamide 53
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
fluoro-1,3-benzothiazol-2-yl)-3-phenylpropanamide 54
N-{[(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A B C B
chloropyridin-3-yl)amino]carbonothioyl}-2- phenylacetamide 55
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- A B B B
fluorophenyl)-N'-(2,3-dihydro-1H-inden-1- yl)ethanediamide 56
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N'-(2,3-dihydro-1H-inden-2- yl)ethanediamide 57
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B C C
fluorophenyl)-N'-(1,2,3,4-tetrahydronaphthalen-1- yl)ethanediamide
58 N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- 1470.06
fluorophenyl)-N-(2-phenylethyl)-N- (phenylmethyl)sulfamide 59
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B C B B
fluorophenyl)-N~2~-(trifluoroacetyl)glycinamide 60
N-{2-[(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B A A A A
fluorophenyl)amino]-2-oxoethyl}benzamide 61
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}pyridin- A B B B
3-yl)-N'-(4-fluorophenyl)propanediamide 62
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N'-[(2S)-1,2,3,4-tetrahydronaphthalen-2-
yl]ethanediamide 63 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3-
C C C fluorophenyl)-N'-[2-(4- methylphenyl)ethyl]ethanediamide 64
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B A B B B
fluorophenyl)-N'-(2-phenylpropyl)ethanediamide 65
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- A C B C C
fluorophenyl)-N'-[2-(4- chlorophenyl)ethyl]ethanediamide 66
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N,N'-bis(phenylmethyl)sulfamide 67
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N,N'-bis(2-phenylethyl)sulfamide 68 ethyl
[(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
chloropyridin-3-yl)amino](oxo)acetate 69
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
chloropyridin-3-yl)-N'-(2-phenylethyl)ethanediamide 70
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A B B C
chloropyridin-3-yl)-N'-(4- fluorophenyl)propanediamide 71
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B D B C
fluorophenyl)-N'-[(2R)-1,2,3,4-tetrahydronaphthalen-
2-yl]ethanediamide 72
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C C C
fluorophenyl)-N'-[2-(1-methylpyrrolidin-2- yl)ethyl]ethanediamide
73 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B B C
fluorophenyl)-N'-[2-(phenyloxy)ethyl]ethanediamide 74
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B
fluorophenyl)-N'-[2-hydroxy-1- (phenylmethyl)ethyl]urea 75
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B B B B
fluorophenyl)-3-[(4-methylphenyl)sulfonyl]-4-
(phenylmethyl)imidazolidin-2-one 76
N'-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- A B B B B
fluorophenyl)-N-methyl-N-(2- phenylethyl)ethanediamide 77
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B B
fluorophenyl)-N'-{[3- (trifluoromethyl)phenyl]methyl}ethanediamide
78 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C A B
fluorophenyl)-N'-{2-[3- (trifluoromethyl)phenyl]ethyl}ethanediamide
79 N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
chloropyridin-3-yl)-3-oxo-4-phenylbutanamide 80
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
chloropyridin-3-yl)-2-[3- (trifluoromethyl)phenyl]acetamide 81
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N- B
[2-(phenyloxy)ethyl]-1,3-benzothiazol-2-amine 82
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N- C
(2-piperidin-1-ylethyl)-1,3-benzothiazol-2-amine 83
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N- C
methyl-N-(2-phenylethyl)-1,3-benzothiazol-2-amine 84
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N- C
(2-pyrrolidin-1-ylethyl)-1,3-benzothiazol-2-amine 85
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N- C
{[3-(trifluoromethyl)phenyl]methyl}-1,3-benzothiazol- 2-amine 86
6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5-fluoro-N- C
{2-[3-(trifluoromethyl)phenyl]ethyl}-1,3-benzothiazol- 2-amine 87
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
chloropyridin-3-yl)-N'-[3- (trifluoromethyl)phenyl]propanediamide
88 N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C A B B B
fluoro-1,3-benzothiazol-2-yl)-2-[3-
(trifluoromethyl)phenyl]acetamide 89
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B A B B A
fluorophenyl)-N~2~-{[3- (trifluoromethyl)phenyl]methyl}glycinamide
90 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B
fluorophenyl)-N~2~-(2-phenylethyl)glycinamide 91
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B B B A
fluorophenyl)-N~2~-{2-[3- (trifluoromethyl)phenyl]ethyl}glycinamide
92 1,1-dimethylethyl {2-[(6-{[6,7- C
bis(methyloxy)quinolin-4-yl]oxy}-5-chloropyridin-3-
yl)amino]-2-oxoethyl}(phenylmethyl)carbamate 93
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
chloropyridin-3-yl)-N~2~-(phenylmethyl)glycinamide 94
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C B B D C
fluoro-1,3-benzothiazol-2-yl)-2-[3,5-
bis(trifluoromethyl)phenyl]acetamide 95
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A A B B B
fluoro-1,3-benzothiazol-2-yl)-2-[2-chloro-5-
(trifluoromethyl)phenyl]acetamide 96
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A A A A A
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(2-phenylethyl)ethanediamide 97
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N'-(1,2,3,4-tetrahydroisoquinolin-1-
ylmethyl)ethanediamide
98 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B B A B
fluorophenyl)-N'-[(2-methyl-1,2,3,4-
tetrahydroisoquinolin-1-yl)methyl]ethanediamide 99
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N~2~-methyl-N~2~-{[3-
(trifluoromethyl)phenyl]methyl}glycinamide 100
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N~2~-methyl-N~2~-{2-[3-
(trifluoromethyl)phenyl]ethyl}glycinamide 101
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- C
fluorophenyl)-N~2~-methyl-N~2~-(2- phenylethyl)glycinamide 102
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B B B C
fluorophenyl)-4-(phenylmethyl)imidazolidin-2-one 103
N-(6-{[6,7-bis(methyloxy)quinolin-4- A C B A C
yl]oxy}pyridazin-3-yl)-N'-(4- fluorophenyl)propanediamide 104
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- B
chloropyridin-3-yl)-N'-(2- chlorophenyl)propanediamide 105
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
chloropyridin-3-yl)-N'-(3- chlorophenyl)propanediamide 106
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C
chloropyridin-3-yl)-N~2~-methyl-N~2~- (phenylmethyl)glycinamide 107
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- B
chloropyridin-3-yl)-N'-(4- chlorophenyl)propanediamide 108
(2E)--N-(4-{[6,7-bis(methyloxy)quinolin-4- B B
yl]oxy}phenyl)-2-[(methyloxy)imino]propanamide 109
(2E)--N-(4-{[6,7-bis(methyloxy)quinolin-4- B A
yl]oxy}phenyl)-2-[(ethyloxy)imino]propanamide 110
(2E)--N-(4-{[6,7-bis(methyloxy)quinolin-4- B B yl]oxy}phenyl)-2-
{[(phenylmethyl)oxy]imino}propanamide 111
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
1-(phenylmethyl)prolinamide 112
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- B C B C C
3-[(4-methylphenyl)sulfonyl]-4- (phenylmethyl)imidazolidin-2-one
113 1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
4-(phenylmethyl)imidazolidin-2-one 114
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C B
4-(phenylmethyl)-4,5-dihydro-1,3-oxazol-2-amine 115
6,7-bis(methyloxy)-4-({4-[4-(phenylmethyl)piperazin- C C
1-yl]phenyl}oxy)quinoline 116
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
4-(phenylmethyl)piperazin-2-one 117
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
N~2~-(phenylmethyl)alaninamide 118
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
N~2~-methyl-N~2~-(phenylmethyl)alaninamide 119
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
N~2~-(phenylmethyl)leucinamide 120
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
N~2~-methyl-N~2~-(phenylmethyl)leucinamide 121
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
N~2~-(phenylmethyl)valinamide 122
N-[5-chloro-6-({6-(methyloxy)-4-[(piperidin-4- C C
ylmethyl)oxy]quinolin-7-yl}oxy)pyridin-3-yl]-N'-(4-
fluorophenyl)propanediamide 123
1-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
4-(phenylmethyl)tetrahydropyrimidin-2(1H)-one 124
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
phenylethyl)ethanediamide 125
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A A B A B
chloropyridin-3-yl)-N'-(4-fluorophenyl)cyclopropane-
1,1-dicarboxamide 126
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C C
chloropyridin-3-yl)-N'-(4-fluorophenyl)cyclobutane-
1,1-dicarboxamide 127
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C C
N~2~-methyl-N~2~-(phenylmethyl)valinamide 128
(2E)--N-(4-{[6,7-bis(methyloxy)quinolin-4- C A
yl]oxy}phenyl)-2-[(phenyloxy)imino]propanamide 129
(2E)--N-(4-{[6,7-bis(methyloxy)quinolin-4- B C
yl]oxy}phenyl)-2-phenyl-2- {[(phenylmethyl)oxy]imino}ethanamide 130
6,7-bis(methyloxy)-4-({4-[4-(phenylmethyl)piperidin- C C
1-yl]phenyl}oxy)quinoline 131
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B
fluorophenyl)-N'-{[2-(1-methylethyl)-1,2,3,4-
tetrahydroisoquinolin-1-yl]methyl}ethanediamide 132
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B C
fluorophenyl)-N'-[(2-ethyl-1,2,3,4-
tetrahydroisoquinolin-1-yl)methyl]ethanediamide 133
1,1-dimethylethyl 4-({[4-{[3-chloro-5-({3-[(4- B C
fluorophenyl)amino]-3-oxopropanoyl}amino)pyridin-
2-yl]oxy}-6-(methyloxy)quinolin-7-
yl]oxy}methyl)piperidine-1-carboxylate 134
N-[5-chloro-6-({6-(methyloxy)-7-[(piperidin-4- A B B A
ylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-N'-(4-
fluorophenyl)propanediamide 135
N-{5-chloro-6-[(6-(methyloxy)-7-{[(1- A B B A
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]pyridin-3-yl}-N'-(4- fluorophenyl)propanediamide 136
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A A B A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-
phenylethyl)ethanediamide 137
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4- A A A B A
ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
phenylethyl)ethanediamide 138
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1- A A A A
ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
phenylethyl)ethanediamide 139
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-
phenylethyl)ethanediamide 140
N'-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A A B
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N-methyl-N-(2- phenylethyl)ethanediamide 141
N-(3-fluoro-4-{[7-({[(3aR,5r,6aS)-2- A A A A A
methyloctahydrocyclopenta[c]pyrrol-5-
yl]methyl}oxy)-6-(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-(2-phenylethyl)ethanediamide 142
N-(3-fluoro-4-{[7-({[(3aR,6aS)-2- A A A A A
methyloctahydrocyclopenta[c]pyrrol-5-
yl]methyl}oxy)-6-(methyloxy)quinazolin-4-
yl]oxy}phenyl)-N'-(2-phenylethyl)ethanediamide 143
2-(3,4-dihydroisoquinolin-2(1H)-yl)-N-{3-fluoro-4- A A
[(6-(methyloxy)-7-{[(1-methylpiperidin-4-
yl)methyl]oxy}quinolin-4-yl)oxy]phenyl}-2- oxoacetamide 144
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-2-oxo-2-(3-
phenylpyrrolidin-1-yl)acetamide 145
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-2-oxo-2-(2-
phenylmorpholin-4-yl)acetamide 146
N-[2-(dimethylamino)-2-phenylethyl]-N'-[3-fluoro-4- A A B A
({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 147
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-oxo-2-
phenylethyl)ethanediamide 148
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C C
chloropyridin-3-yl)-2,2-difluoro-N'-(4- fluorophenyl)propanediamide
149 N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A A A B A
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(phenylmethyl)ethanediamide 150
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[2-(2-
fluorophenyl)ethyl]ethanediamide 151
N-[2-(3-chlorophenyl)ethyl]-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 152
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{2-[2-
(methyloxy)phenyl]ethyl}ethanediamide 153
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
pyridin-3-ylethyl)ethanediamide 154
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A B A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-
(phenylmethyl)ethanediamide 155
N-{2-[2,5-bis(methyloxy)phenyl]ethyl}-N'-[3-fluoro- A A A A A
4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 156
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{2-[2-
(trifluoromethyl)phenyl]ethyl}ethanediamide 157
N-{2-[2-(ethyloxy)phenyl]ethyl}-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 158
N-[2-(2,4-dimethylphenyl)ethyl]-N'-[3-fluoro-4-({6- A B B A B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 159
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- B C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1S)-2-
(4-methylphenyl)-1-phenylethyl]ethanediamide 160
N-[2-(4-chlorophenyl)ethyl]-N'-[3-fluoro-4-({6- A A A A B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 161
({3-fluoro-4-[(6-(methyloxy)-7-{[(1-methylpiperidin- B C
4-yl)methyl]oxy}quinolin-4- yl)oxy]phenyl}amino)(oxo)acetic acid
162 N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[2-(3-
fluorophenyl)ethyl]ethanediamide 163
N-[2-(2-chlorophenyl)ethyl]-N'-[3-fluoro-4-({6- A A A B A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 164
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{2-[3-
(methyloxy)phenyl]ethyl}ethanediamide 165
N-(1,2-diphenylethyl)-N'-[3-fluoro-4-({6-(methyloxy)- A A B B C
7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 166
N-[2-(2,4-dichlorophenyl)ethyl]-N'-[3-fluoro-4-({6- A B B A B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 167
N-{2-[3,4-bis(methyloxy)phenyl]ethyl}-N'-[3-fluoro- A B B B
4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 168
N-[2-(4-ethylphenyl)ethyl]-N'-[3-fluoro-4-({6- A B B B C
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 169
N-{2-[4-(ethyloxy)phenyl]ethyl}-N'-[3-fluoro-4-({6- B C B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 170
N-{2-[4-(ethyloxy)-3-(methyloxy)phenyl]ethyl}-N'-[3- A B C B
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 171
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- B C C C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{2-[4-
(phenyloxy)phenyl]ethyl}ethanediamide 172
N-{2-[3-(ethyloxy)-4-(methyloxy)phenyl]ethyl}-N'-[3- A C B B
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 173
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
pyridin-2-ylethyl)ethanediamide 174
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
pyridin-4-ylethyl)ethanediamide 175
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[2-(4-
fluorophenyl)ethyl]ethanediamide 176
N-[2-(2-bromophenyl)ethyl]-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 177
N-[2-(2-chloro-6-fluorophenyl)ethyl]-N'-[3-fluoro-4- A A A B A
({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 178
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A B A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(2R)-2-
phenylpropyl]ethanediamide 179
N-(2,3-dihydro-1H-inden-1-yl)-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 180
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A B B B
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(2-methylpropyl)ethanediamide 181
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A B B B B
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(3-methylbutyl)ethanediamide 182
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A A A A A
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-[(2R)-2- phenylpropyl]ethanediamide 183
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A A A A A
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(2-phenylpropyl)ethanediamide 184
N-(2,3-dihydro-1H-inden-2-yl)-N'-{3-fluoro-4-[(6- A A A B A
(methyloxy)-7-{[(1-methylpiperidin-4- yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}ethanediamide 185
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1R)-1-
phenylethyl]ethanediamide 186
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B A B C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1S)-1-
phenylethyl]ethanediamide 187
N-[2-(3-bromophenyl)ethyl]-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 188
N-[2-(2,6-dichlorophenyl)ethyl]-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 189
N-[2-(1,3-benzodioxol-5-yl)ethyl]-N'-[3-fluoro-4-({6- A A B A B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 190
N-{5-chloro-6-[(6-(methyloxy)-7-{[(1- A A B A A
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]pyridin-3-yl}-N'-(4-fluorophenyl)cyclopropane-
1,1-dicarboxamide 191
N-{2-[3-bromo-4-(methyloxy)phenyl]ethyl}-N'-[3- A A B B B
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 192
N-{2-[3,5-bis(methyloxy)phenyl]ethyl}-N'-[3-fluoro- A A A B B
4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 193
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A B A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[2-(2-
methylphenyl)ethyl]ethanediamide 194
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[2-(3-
methylphenyl)ethyl]ethanediamide 195
N-{2-[3-(ethyloxy)phenyl]ethyl}-N'-[3-fluoro-4-({6- A A B B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 196
N-[2-(3,4-dimethylphenyl)ethyl]-N'-[3-fluoro-4-({6- A A B B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 197
N-[2-(2,5-dimethylphenyl)ethyl]-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 198
N-{2-[3-chloro-4-(propyloxy)phenyl]ethyl}-N'-[3- B C
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 199
N-{2-[4-(butyloxy)-3-chlorophenyl]ethyl}-N'-[3- B C
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 200
N-{2-[4-(1,1-dimethylethyl)phenyl]ethyl}-N'-[3- B C
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 201
N-{2-[4-(aminosulfonyl)phenyl]ethyl}-N'-[3-fluoro-4- A B B B B
({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 202
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{2-[4-
hydroxy-3-(methyloxy)phenyl]ethyl}ethanediamide 203
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{2-[3-
hydroxy-4-(methyloxy)phenyl]ethyl}ethanediamide 204
N-[(2,4-dichlorophenyl)methyl]-N'-[3-fluoro-4-({6- A A A A B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 205
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A B A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[4- fluoro-2-
(trifluoromethyl)phenyl]methyl}ethanediamide 206
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1R)-1-
(4-methylphenyl)ethyl]ethanediamide 207
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[3- fluoro-4-
(trifluoromethyl)phenyl]methyl}ethanediamide 208
N-[(3-chloro-4-fluorophenyl)methyl]-N'-[3-fluoro-4- A A A A B
({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 209
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{(1S)-1-
[3-(methyloxy)phenyl]ethyl}ethanediamide 210
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1R)-1-
naphthalen-2-ylethyl]ethanediamide 211
N-{[4-chloro-3-(trifluoromethyl)phenyl]methyl}-N'- A A A A A
[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 212
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B C B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1S)-1-
(4-methylphenyl)ethyl]ethanediamide 213
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B C B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[6-
(trifluoromethyl)pyridin-3-yl]methyl}ethanediamide 214
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(2-
methylphenyl)methyl]ethanediamide 215
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A B A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(3-
methylphenyl)methyl]ethanediamide 216
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A B A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[4- fluoro-3-
(trifluoromethyl)phenyl]methyl}ethanediamide 217
N-[(3,5-dichlorophenyl)methyl]-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 218
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1R)-
1,2,3,4-tetrahydronaphthalen-1-yl]ethanediamide 219
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1S)-
1,2,3,4-tetrahydronaphthalen-1-yl]ethanediamide 220
N-cyclopentyl-N'-[3-fluoro-4-({6-(methyloxy)-7- A B B B B
[(piperidin-4-ylmethyl)oxy]quinolin-4- yl}oxy)phenyl]ethanediamide
221 N-[1-(4-bromophenyl)ethyl]-N'-[3-fluoro-4-({6- A B B B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 222
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A B B A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(2-
fluorophenyl)methyl]ethanediamide 223
N-[2-(3,4-dichlorophenyl)ethyl]-N'-[3-fluoro-4-({6- A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 224
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(4-
fluorophenyl)methyl]ethanediamide 225
N-[(2,3-difluorophenyl)methyl]-N'-[3-fluoro-4-({6- A A B B A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 226
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[2-
(phenyloxy)ethyl]ethanediamide 227
N-(2,2-diphenylethyl)-N'-[3-fluoro-4-({6-(methyloxy)- A B B A B
7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 228
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{2-[4-
(methyloxy)phenyl]ethyl}ethanediamide 229
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
phenylpropyl)ethanediamide 230
N-[2-(4-bromophenyl)ethyl]-N'-[3-fluoro-4-({6- A A B B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 231
N-(4-{[7-{[(1-ethylpiperidin-4-yl)methyl]oxy}-6- A B B B B
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-2-oxo-
2-(2-phenylmorpholin-4-yl)acetamide 232
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A B A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[3- fluoro-5-
(trifluoromethyl)phenyl]methyl}ethanediamide 233
N-[(3,5-difluorophenyl)methyl]-N'-[3-fluoro-4-({6- A A A B A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 234
N-{[2-chloro-5-(trifluoromethyl)phenyl]methyl}-N'- A A B A B
[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 235
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- B B B A
fluorophenyl)-N'-[2-(dimethylamino)-2- phenylethyl]ethanediamide
236 N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[4-
(methyloxy)phenyl]methyl}ethanediamide 237
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[4-
(trifluoromethyl)phenyl]methyl}ethanediamide 238
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[3-
(methyloxy)phenyl]methyl}ethanediamide 239
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[3-
(trifluoromethyl)phenyl]methyl}ethanediamide 240
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-({3-
[(trifluoromethyl)oxy]phenyl}methyl)ethanediamide 241
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[2-
(methyloxy)phenyl]methyl}ethanediamide 242
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[2-
(trifluoromethyl)phenyl]methyl}ethanediamide 243
N-[(3-chlorophenyl)methyl]-N'-[3-fluoro-4-({6- A A A B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 244
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-({2-
[(trifluoromethyl)oxy]phenyl}methyl)ethanediamide 245
N-[(2-chlorophenyl)methyl]-N'-[3-fluoro-4-({6- A A A A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 246
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-({4-
[(trifluoromethyl)oxy]phenyl}methyl)ethanediamide 247
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A B A B
methylpiperidin-4-yl)methyl]oxy}quinolin-4- yl)oxy]phenyl}-N'-{[4-
(methyloxy)phenyl]methyl}ethanediamide 248
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A B B B B
methylpiperidin-4-yl)methyl]oxy}quinolin-4- yl)oxy]phenyl}-N'-{[4-
(trifluoromethyl)phenyl]methyl}ethanediamide 249
N-(4-{[7-[(azetidin-3-ylmethyl)oxy]-6- A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(2-
phenylethyl)ethanediamide 250
N-(3-fluoro-4-{[7-{[(1-methylazetidin-3- A A A A A
yl)methyl]oxy}-6-(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-(2-phenylethyl)ethanediamide 251
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
hydroxy-2-phenylethyl)ethanediamide 252
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A C
chloropyridin-3-yl)-N'-(2,4- difluorophenyl)propanediamide 253
N'-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- B C
chloropyridin-3-yl)-N-(4-fluorophenyl)-N- methylpropanediamide 254
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1R)-1-
phenylpropyl]ethanediamide 255
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B C B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1S)-1-
phenylpropyl]ethanediamide 256
N-[(3,4-difluorophenyl)methyl]-N'-[3-fluoro-4-({6- A A A B A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 257
N-[(2,6-difluorophenyl)methyl]-N'-[3-fluoro-4-({6- A A A B A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 258
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A A A A A
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-[2-(4- fluorophenyl)ethyl]ethanediamide 259
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A B C C B
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-phenylethanediamide 260
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A C B C C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(3-
fluorophenyl)ethanediamide 261
N-(3-chloro-4-fluorophenyl)-N'-[3-fluoro-4-({6- A C C B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 262
N-[3,4-bis(methyloxy)phenyl]-N'-[3-fluoro-4-({6- A C C B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 263
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B A B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(3-
methylbutyl)ethanediamide 264
N-(3,3-dimethylbutyl)-N'-[3-fluoro-4-({6-(methyloxy)- A A A A B
7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 265
N-[5-chloro-6-({6-(methyloxy)-7-[(3-piperidin-1- A B B A B
ylpropyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-N'-(4-
fluorophenyl)propanediamide 266
N-[5-chloro-6-({6-(methyloxy)-7-[(3-morpholin-4- A B B A B
ylpropyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-N'-(4-
fluorophenyl)propanediamide 267
N-(5-chloro-6-{[7-{[3-(diethylamino)propyl]oxy}-6- A B B A B
(methyloxy)quinolin-4-yl]oxy}pyridin-3-yl)-N'-(4-
fluorophenyl)propanediamide 268
N-[(4-chlorophenyl)methyl]-N'-[3-fluoro-4-({6- A A
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 269
N-{[3,5-bis(methyloxy)phenyl]methyl}-N'-[3-fluoro-4- A A A
({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 270
N-[(4-butylphenyl)methyl]-N'-[3-fluoro-4-({6- A B B B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 271
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[2-(4-
methylphenyl)ethyl]ethanediamide 272
N-{[3,5-bis(trifluoromethyl)phenyl]methyl}-N'-[3- A A C B
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 273
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- B C C B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(pyrazin-
2-ylmethyl)ethanediamide 274
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(pyridin-
2-ylmethyl)ethanediamide 275
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(2-
phenylethyl)ethanediamide 276 N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1-
A A A A A methylpiperidin-4-yl)methyl]oxy}quinazolin-4-
yl)oxy]phenyl}-N'-(2-phenylethyl)ethanediamide 277
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[2- fluoro-3-
(trifluoromethyl)phenyl]methyl}ethanediamide 278
N-{2-[2-bromo-6-(methyloxy)phenyl]ethyl}-N'-[3- A A A A A
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 279
N-{2-[3,4-bis(methyloxy)phenyl]ethyl}-N'-[3-fluoro- B B B A B
4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N- methylethanediamide 280
N-{2-[5-bromo-2-(methyloxy)phenyl]ethyl}-N'-[3- A A A A A
fluoro-4-({6-(methyloxy)-7-[(piperidin-4-
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]ethanediamide 281
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A B A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-{[2- fluoro-5-
(trifluoromethyl)phenyl]methyl}ethanediamide 282
N-[5-chloro-6-({6-(methyloxy)-7-[(piperidin-4- A A A A A
ylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 283
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A B A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[1-(4-
fluorophenyl)ethyl]ethanediamide 284
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A C B B C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[(1S)-2-
oxo-1-(phenylmethyl)-2-pyrrolidin-1- ylethyl]ethanediamide 285
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(3aR,6aS)- A A A A A
octahydrocyclopenta[c]pyrrol-5-
ylmethyl]oxy}quinazolin-4-yl)oxy]phenyl}-N'-(2-
phenylethyl)ethanediamide 286
N-[2-(4-aminophenyl)ethyl]-N'-[3-fluoro-4-({6- A B B B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 287
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A A B A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-2-oxo-2-[4-
(phenylmethyl)piperidin-1-yl]acetamide 288
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- A A A A A
N'-(4-fluorophenyl)propanediamide 289
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- A A A A 5.581
N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 290
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- B C
chloropyridin-3-yl)-N'-(3- fluorophenyl)propanediamide 291
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A C B A C
chloropyridin-3-yl)-N'-phenylpropanediamide 292
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- B B B A B
chloropyridin-3-yl)-N'-(4-fluorophenyl)-2,2- dimethylpropanediamide
293 N-ethyl-N'-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin- A B B B B
4-ylmethyl)oxy]quinolin-4- yl}oxy)phenyl]ethanediamide 294
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(1-
methylethyl)ethanediamide 295
N-butyl-N'-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin- A B B B B
4-ylmethyl)oxy]quinolin-4- yl}oxy)phenyl]ethanediamide 296
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- B B B B C
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-[2-
(methyloxy)ethyl]ethanediamide 297
N-(cyclopropylmethyl)-N'-[3-fluoro-4-({6- A B B B B
(methyloxy)-7-[(piperidin-4-ylmethyl)oxy]quinolin-4-
yl}oxy)phenyl]ethanediamide 298
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- B A B A B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(2-
morpholin-4-ylethyl)ethanediamide 299
N-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin-4- A B B B B
ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-2-oxo-2-
pyrrolidin-1-ylacetamide 300
N-ethyl-N'-[3-fluoro-4-({6-(methyloxy)-7-[(piperidin- A B C B B
4-ylmethyl)oxy]quinolin-4-yl}oxy)phenyl]-N- methylethanediamide 301
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A C B B B
chloropyridin-3-yl)-N'-(phenylmethyl)cyclopropane-
1,1-dicarboxamide 302
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- C C
chloropyridin-3-yl)-N'-(2-phenylethyl)cyclopropane-
1,1-dicarboxamide 303
N-{4-[(7-chloroquinolin-4-yl)oxy]-3-fluorophenyl}- A A C C B
N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 304
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 305
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A B B A
chloropyridin-3-yl)-N'-phenylcyclopropane-1,1- dicarboxamide 306
N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2- A B B C B
methylpyridin-3-yl)-N'-(4-fluorophenyl)cyclopropane-
1,1-dicarboxamide 307 N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A
A B A (methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclobutane-1,1-dicarboxamide 308
N-{4-[(7-chloroquinolin-4-yl)oxy]phenyl}-N'-(4- A A B C B
fluorophenyl)cyclopropane-1,1-dicarboxamide 309
N-[5-chloro-6-({6-(methyloxy)-7- A C C B C
[(phenylmethyl)oxy]quinolin-4-yl}oxy)pyridin-3-yl]-
N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 310
N-(4-{[6,7-bis(methyloxy)quinazolin-4- A A A A A
yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
311 N-(4-{[6,7-bis(methyloxy)quinazolin-4-yl]oxy}-3- A A B A A
fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
312 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4- A A A A A
ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 313
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1- A A A A A
ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 314
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperidin-1- A A A B A
ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclobutane-1,1-dicarboxamide 315
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4- A A A A A
ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 316
N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A A A A A
methylpiperidin-4-yl)methyl]oxy}quinazolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
317 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2- A A A C A
methylphenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
318 N-(4-fluorophenyl)-N'-[2-methyl-6-({6-(methyloxy)-7- A A B B B
[(3-morpholin-4-ylpropyl)oxy]quinolin-4-
yl}oxy)pyridin-3-yl]cyclopropane-1,1-dicarboxamide 319
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3- A A A A A
fluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
320 N-(6-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A C C B C
chloro-2-methylpyridin-3-yl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 321
N-[3-fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4- A A B A A
ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 322
N-[3-fluoro-4-({7-(methyloxy)-6-[(3-morpholin-4- A A A A A
ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 323
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-3,5- A A B A A
difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
324 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2,5- A A A A A
difluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
325 N-{3-fluoro-4-[(7-(methyloxy)-6-{[(1- A A B A A
methylpiperidin-4-yl)methyl]oxy}quinazolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
326 N-[5-fluoro-2-methyl-4-({6-(methyloxy)-7-[(3- A A B B B
morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-
N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 327
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2,3,5- A A B B B
trifluorophenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
328 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-5- A B B C C
fluoro-2-methylphenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 329
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2- A B B C B
chloro-5-methylphenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 330
N-(3-fluoro-4-{[6-hydroxy-7-(methyloxy)quinolin-4- A A A A A
yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
331 N-(4-fluorophenyl)-N'-[2-methyl-4-({6-(methyloxy)-7- A A A B A
[(3-morpholin-4-ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide 332
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1- A A A A A
ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 333
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4- A A A A A
methylpiperazin-1-yl)propyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
334 N-{3-fluoro-4-[(6-(methyloxy)-7-{[(1- A A A A A
methylpiperidin-4-yl)methyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
335 N-(4-fluorophenyl)-N'-[4-({6-(methyloxy)-7-[(3- A A A A A
morpholin-4-ylpropyl)oxy]quinolin-4-
yl}oxy)phenyl]cyclopropane-1,1-dicarboxamide 336
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 337
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}-2- A B B C C
chloro-5-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 338
N-(4-{[6,7-bis(methyloxy)-2-(methylthio)quinolin-4- C C
yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 339
N-(4-fluorophenyl)-N'-(4-{[2-methyl-6,7- C C
bis(methyloxy)quinazolin-4-
yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide 340
N-(4-{[2-amino-6,7-bis(methyloxy)quinolin-4- C C
yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 341
N-(3-fluoro-4-{[2-(methylamino)-6,7- C C
bis(methyloxy)quinolin-4-yl]oxy}phenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 342
(1S,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A A B A A
morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-
N'-(4-fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 343
(1R,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A A A A A
morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-
N'-(4-fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 344
N-(4-{[6-{[3-(diethylamino)propyl]oxy}-7- A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 345
N-(4-{[6-{[2-(diethylamino)ethyl]oxy}-7- A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 346 1,1-dimethylethyl
4-(3-{[4-[(2-fluoro-4-{[(1-{[(4- A A B
fluorophenyl)amino]carbonyl}cyclopropyl)carbonyl]amino}phenyl)oxy]-
6-(methyloxy)quinolin-7- yl]oxy}propyl)piperazine-1-carboxylate
347 (1R,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A A
morpholin-4-ylpropyl)oxy]quinazolin-4-
yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-
methylcyclopropane-1,1-dicarboxamide 348
(1R,2R)--N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A B
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 349
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A A
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 350
N-(4-{[7-{[3-(4-acetylpiperazin-1-yl)propyl]oxy}-6- A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclopropane-1,1-dicarboxamide 351 1,1-dimethylethyl
4-(3-{[4-[(2-fluoro-4-{[((1R,2R)-1- A A B
{[(4-fluorophenyl)amino]carbonyl}-2-
methylcyclopropyl)carbonyl]amino}phenyl)oxy]-6-
(methyloxy)quinolin-7-yl]oxy}propyl)piperazine-1- carboxylate 352
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- A C C
N'-(4-fluorophenyl)-1-(phenylmethyl)azetidine-3,3- dicarboxamide
353 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- B C C
N'-(4-fluorophenyl)azetidine-3,3-dicarboxamide 354
(1R,2S)--N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4- A A A
methylpiperazin-1-yl)propyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-
methylcyclopropane-1,1-dicarboxamide 355
(1R,2R)--N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4- A A A
methylpiperazin-1-yl)propyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-
methylcyclopropane-1,1-dicarboxamide 356
(1R,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A A A
piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-
N'-(4-fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 357
N-(3-fluoro-4-{[7-({3-[4-(1-methylethyl)piperazin-1- A A A
yl]propyl}oxy)-6-(methyloxy)quinolin-4-
yl]oxy}phenyl)-N'-(4-fluorophenyl)cyclopropane-1,1- dicarboxamide
358 N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A A
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)cyclopropane-1,1-dicarboxamide 359
(1R,2R)--N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 360
(1R,2R)--N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 361
(1R,2S)--N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 362
(1R,2S)--N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A A
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 363
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)cyclobutane-1,1-dicarboxamide 364
(1R,2S)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A A A
piperazin-1-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-
N'-(4-fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 365
(1r,2R,3S)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A B B
morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-
N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1- dicarboxamide 366
(1r,2R,3S)--N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4- A B B
methylpiperazin-1-yl)propyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)-2,3-
dimethylcyclopropane-1,1-dicarboxamide 367
(1r,2R,3S)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- B A B
morpholin-4-ylpropyl)oxy]quinazolin-4-
yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-
dimethylcyclopropane-1,1-dicarboxamide 368
(1r,2R,3S)--N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4- A A B
methylpiperazin-1-yl)propyl]oxy}quinazolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)-2,3-
dimethylcyclopropane-1,1-dicarboxamide 369
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4- B A B
ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclobutane-1,1-dicarboxamide 370
(2R,3R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A A B
morpholin-4-ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-
N'-(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1- dicarboxamide 371
(2R,3R)--N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A B
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2,3-dimethylcyclopropane-1,1- dicarboxamide 372
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A B
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2,2-dimethylcyclopropane-1,1- dicarboxamide 373
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4- A A C
ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)-2,2-dimethylcyclopropane-1,1- dicarboxamide 374
(1r,2R,3S)--N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A B B
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2,3-dimethylcyclopropane-1,1- dicarboxamide 375
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A C
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2,2-dimethylcyclopropane-1,1- dicarboxamide 376
(1r,2R,3S)--N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A B B
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2,3-dimethylcyclopropane-1,1- dicarboxamide 377
N-[3-fluoro-4-({6-(methyloxy)-7-[(3-morpholin-4- A A B
ylpropyl)oxy]quinolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)-2,2-dimethylcyclopropane-1,1- dicarboxamide 378
N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A B C
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1- dicarboxamide 379
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A C
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)-2,2-dimethylcyclopropane-1,1- dicarboxamide 380
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A B
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)cyclobutane-1,1-dicarboxamide 381
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4- A A B
methylpiperazin-1-yl)propyl]oxy}quinazolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclobutane-1,1- dicarboxamide
382 N-[3-fluoro-4-({6-(methyloxy)-7-[(3-piperazin-1- A A B
ylpropyl)oxy]quinazolin-4-yl}oxy)phenyl]-N'-(4-
fluorophenyl)cyclobutane-1,1-dicarboxamide 383
(2R,3R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A A C
morpholin-4-ylpropyl)oxy]quinazolin-4-
yl}oxy)phenyl]-N'-(4-fluorophenyl)-2,3-
dimethylcyclopropane-1,1-dicarboxamide 384
N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A C
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)cyclobutane-1,1-dicarboxamide 385
N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4- A A C
methylpiperazin-1-yl)propyl]oxy}quinolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)cyclobutane-1,1- dicarboxamide
386 (1R,2R)--N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A A
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)-2-methylcyclopropane-1,1- dicarboxamide 387
(1R,2R)--N-{3-fluoro-4-[(6-(methyloxy)-7-{[3-(4- A A A
methylpiperazin-1-yl)propyl]oxy}quinazolin-4-
yl)oxy]phenyl}-N'-(4-fluorophenyl)-2-
methylcyclopropane-1,1-dicarboxamide 388
(2R,3R)--N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- B A C
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1- dicarboxamide 389
(2R,3R)--N-(4-{[7-{[3-(diethylamino)propyl]oxy}-6- A A B
(methyloxy)quinazolin-4-yl]oxy}-3-fluorophenyl)-N'-
(4-fluorophenyl)-2,3-dimethylcyclopropane-1,1- dicarboxamide 390
(1R,2R)--N-[3-fluoro-4-({6-(methyloxy)-7-[(3- A A A
piperazin-1-ylpropyl)oxy]quinazolin-4-
yl}oxy)phenyl]-N'-(4-fluorophenyl)-2-
methylcyclopropane-1,1-dicarboxamide 391
(2R,3R)--N-(4-{[7-{[2-(diethylamino)ethyl]oxy}-6- A A B
(methyloxy)quinolin-4-yl]oxy}-3-fluorophenyl)-N'-(4-
fluorophenyl)-2,3-dimethylcyclopropane-1,1- dicarboxamide 392
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- B B A
N'-[(4-fluorophenyl)methyl]cyclopropane-1,1- dicarboxamide 393
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- C D B
N'-(2-morpholin-4-ylethyl)cyclopropane-1,1- dicarboxamide 394
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- B D B
N'-[2-(piperidin-1-ylmethyl)phenyl]cyclopropane-1,1- dicarboxamide
395 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- B C B
N'-[2-(pyrrolidin-1-ylmethyl)phenyl]cyclopropane-1,1- dicarboxamide
396 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- B A A
N'-[3-(morpholin-4-ylmethyl)phenyl]cyclopropane- 1,1-dicarboxamide
397 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- B C B
N'-[2-(morpholin-4-ylmethyl)phenyl]cyclopropane- 1,1-dicarboxamide
398 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- A A A
N'-phenylcyclopropane-1,1-dicarboxamide 399
N-[3-(aminomethyl)phenyl]-N'-(4-{[6,7- B A B
bis(methyloxy)quinolin-4-
yl]oxy}phenyl)cyclopropane-1,1-dicarboxamide 400
N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- B A
N'-[3-(piperidin-1-ylmethyl)phenyl]cyclopropane-1,1- dicarboxamide
401 N-(4-{[6,7-bis(methyloxy)quinolin-4-yl]oxy}phenyl)- A A
N'-[3-(pyrrolidin-1-ylmethyl)phenyl]cyclopropane-1,1-
dicarboxamide
* * * * *